0001200375-19-000005.txt : 20190301 0001200375-19-000005.hdr.sgml : 20190301 20190301164032 ACCESSION NUMBER: 0001200375-19-000005 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20181231 FILED AS OF DATE: 20190301 DATE AS OF CHANGE: 20190301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CODEXIS INC CENTRAL INDEX KEY: 0001200375 STANDARD INDUSTRIAL CLASSIFICATION: INDUSTRIAL ORGANIC CHEMICALS [2860] IRS NUMBER: 710872999 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34705 FILM NUMBER: 19650068 BUSINESS ADDRESS: STREET 1: 200 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-421-8100 MAIL ADDRESS: STREET 1: 200 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 10-K 1 cdxs-20181231x10k.htm 10-K 2018 ANNUAL REPORT Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________ 
FORM 10-K
(Mark One)
ý
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended: December 31, 2018
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to             .
Commission File No.: 001-34705
______________________________________ 
Codexis, Inc.
(Exact name of Registrant as specified in its charter)
______________________________________ 
Delaware
 
71-0872999
(State or other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
 
200 Penobscot Drive,
Redwood City, California
 
94063
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s telephone number, including area code: (650) 421-8100
Securities Registered Pursuant to Section 12(b) of the Act:
Title of Each Class:
 
Name of Each Exchange on which Registered:
Common Stock, par value $0.0001 per share
 
The Nasdaq Global Select Market
Securities Registered Pursuant to Section 12(g) of the Act: None.
 _______________________________________
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    Yes  ¨    No  ý
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    Yes  ¨    No  ý
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ý    No  ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ý    No  ¨
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.  ý
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer
ý
 
Accelerated filer
¨
Non-accelerated filer
¨
 
Smaller reporting company
¨
 
Emerging growth company
¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ¨                 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    Yes  ¨  No  ý
The aggregate market value of voting common stock held by non-affiliates of Codexis as of June 30, 2018 was approximately $731.5 million based upon the closing price reported for such date on the Nasdaq Global Select Market.
As of February 22, 2019, there were 54,158,617 shares of the registrant’s Common Stock, par value $0.0001 per share, outstanding.
______________________________________ 
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s Definitive Proxy Statement to be filed with the Commission pursuant to Regulation 14A in connection with the registrant’s 2019 Annual Meeting of Stockholders, to be filed subsequent to the date hereof, are incorporated by reference into Part III of this Report. Such Definitive Proxy Statement will be filed with the Securities and Exchange Commission not later than 120 days after the conclusion of the registrant’s fiscal year ended December 31, 2018. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.
 





Codexis, Inc.
Annual Report on Form 10-K
For The Year Ended December 31, 2018
INDEX
 
PART I
 
Item 1
 
Item 1A
 
Item 1B
 
Item 2
 
Item 3
 
Item 4
 
PART II
 
Item 5
 
Item 6
 
Item 7
 
Item 7A
 
Item 8
 
Item 9
 
Item 9A
 
Item 9B
 
PART III
 
Item 10
 
Item 11
 
Item 12
 
Item 13
 
Item 14
 
PART IV
 
Item 15
 

2



SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (“the Exchange Act”), particularly in Part I, Item 1: “Business,” Part I, Item 1A: “Risk Factors” and Part 2, Item 7: “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate” or “continue,” and similar expressions or variations. All statements other than statements of historical fact could be deemed forward-looking, including, but not limited to: any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, technology developments, our products, product sales, expenses, liquidity, cash flow, market growth rates or enforceability of our intellectual property rights and related litigation expenses; and any statements of assumptions underlying any of the foregoing. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Accordingly, we caution you not to place undue reliance on these statements. For a discussion of some of the factors that could cause actual results to differ materially from our forward-looking statements, see the discussion on risk factors that appear in Part I, Item 1A: “Risk Factors” of this Annual Report on Form 10-K and other risks and uncertainties detailed in this and our other reports and filings with the Securities and Exchange Commission (“SEC”). The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.

 


3



PART I
ITEM 1. BUSINESS
COMPANY OVERVIEW
We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which we have been continuously improving over our sixteen-year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.
We are a pioneer in the harnessing of computational technologies to drive biology advancements. Since our inception in 2002, we have made substantial investments in the development of our CodeEvolver® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development, which are all coordinated to create our novel protein innovations.
Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design using our CodeEvolver® protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.
The successful embodiment of our CodeEvolver® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver® protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.
We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances and agricultural chemicals.
We have also begun using the CodeEvolver® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement (the "Nestlé Agreement") with Nestec Ltd. ("Nestlé Health Science") to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114.
In April 2018, we entered into a strategic agreement (the "Porton Agreement") with Porton Pharma Solutions, Ltd. ("Porton") to license key elements of our platform technology to Porton’s global custom intermediate and active pharmaceutical ingredients ("API") development and manufacturing business. This gives us access to a wide variety of small and medium-sized pharmaceutical customers.

4



We are also using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. Our first enzyme is a ligase which we began marketing to customers in 2018.
BUSINESS SEGMENTS
We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. See Note 15, "Segment, Geographical and Other Revenue Information" in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.

Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. In April 2018, we entered into the Porton Agreement related to our strategic collaboration with Porton to license key elements of our world-leading biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business.
Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.
OUR STRATEGY
Our strategy is to grow our revenues, profits, and stockholder value by leveraging our CodeEvolver® protein engineering technology platform in the following ways:
Licensing our CodeEvolver® protein engineering technology platform. We intend to continue to pursue opportunities to license our CodeEvolver® protein engineering technology platform to third parties so they can create cost-saving protein catalyst solutions utilizing their own in-house protein engineering capability.
Growing our pharmaceutical protein catalysts business. We intend to continue to pursue opportunities in the pharmaceutical market to use our protein catalysis products and services to reduce the costs for manufacturing small

5



molecule drugs. We intend to increase the number of pharmaceutical customers and processes that utilize and benefit from our novel, cost-saving protein catalyst solutions.
Creating and advancing novel biotherapeutic drug candidates. We intend to continue to pursue opportunities to apply our protein engineering capabilities to the creation and development of novel biotherapeutic drug candidates, both in partnership with customers and as proprietary Codexis drug candidates. We have also invested in research and development in an effort to generate additional early stage novel biotherapeutic candidates.
Growing our fine chemicals protein catalysts business. We intend to continue to pursue opportunities in the fine chemicals market to use protein catalysis products and services to reduce the costs for manufacturing in adjacent markets like food and food ingredients. We intend to increase the number of fine chemical customers and processes who utilize and benefit from our novel, cost-saving protein catalyst solutions.
Developing high-performance enzymes for use in diagnostic applications. We intend to offer high-performance enzymes to customers using NGS and PCR/qPCR for in vitro molecular diagnostic applications.
In this Annual Report, the “Company,” “we,” “us” and “our” refer to Codexis, Inc. and its subsidiaries on a consolidated basis.
OUR MARKET OPPORTUNITIES
Pharmaceutical Market
We believe the pharmaceutical industry represents a significant market opportunity for us and is our primary business focus. Pharmaceutical companies are in constant search for new drugs to offer to their customers, and are under significant competitive pressure both to reduce costs and to increase the speed to market for their products. To meet these pressures, pharmaceutical companies are discovering and developing novel protein-based drug products, as well as seeking manufacturing processes for their new and existing drugs that reduce overall costs, simplify production and increase efficiency and product yield, while not affecting drug safety and efficacy. Cost reduction is even more important to developers (known as innovators) of patent-protected pharmaceutical products when the patents for those products expire and such innovators are forced to compete with manufacturers of generic drugs.
The pharmaceutical product lifecycle begins with the discovery of new chemical entities and continues through preclinical and clinical development, regulatory review and approval, commercial scale-up, product launch, and, ultimately, patent expiration and the transition from branded to generic products. As innovators develop, produce and then market products, manufacturing priorities and processes evolve. Historically, innovators have focused on production cost reduction in the later stages of clinical development and have been reluctant to make process changes after a product has been launched. However, as pressures to reduce costs have increased, innovators have pursued cost reduction measures much earlier in the pharmaceutical product lifecycle and are increasingly looking for opportunities to improve their operating margins, including making manufacturing process changes for marketed products after the products have been launched if these changes can result in significant cost reductions. As a result, innovators are investing in new technologies, including our CodeEvolver® protein engineering technology platform, to improve their manufacturing productivity and efficiency or outsourcing the manufacture of their intermediates and APIs.
Our Solutions for the Pharmaceutical Market
Small Molecule Manufacturing Cost Reduction
Our pharmaceutical customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. Our CodeEvolver® protein engineering technology platform enables us to deliver solutions to our customers in this market by developing and delivering optimized protein catalysts that perform chemical transformations at a lower cost and improve the efficiency and productivity of manufacturing processes. We provide value throughout the pharmaceutical product lifecycle. Our products and services allow us to provide benefits to our pharmaceutical customers in a number of cost saving ways, including any - and sometimes all - of the following:
reducing the use of raw materials and reagents;
eliminating multiple steps in the manufacturing process;
improving purity, productivity and yield;
using water as a primary solvent;
eliminating hazardous inputs;
enabling the use of simple equipment and reducing the need for capital expenditure;
reducing energy requirements;

6



reducing the generation of chemical byproducts or waste; and
reducing the need for late-stage purifications.
Early in a pharmaceutical product’s lifecycle, pharmaceutical manufacturers can use our protein catalyst products and services to reduce manufacturing costs. If an innovator incorporates our products or processes into an approved product, we expect the innovator to continue to use our products or processes at least over the patent life of the marketed drug.
Pharmaceutical manufacturers can also use our products and services to reduce manufacturing costs after a product is launched. At this stage, changes in the manufacturing process originally approved by the drug regulator may require additional regulatory review. Typically, pharmaceutical companies will only seek regulatory approval for a manufacturing change if substantial cost savings are realizable. We believe that the cost savings associated with our products may lead our customers to change their manufacturing processes for approved products and, if necessary, seek regulatory approval of the new processes which incorporate our proteins. Moreover, we believe these cost savings are attractive to generics manufacturers, who compete primarily on price.
In addition, manufacturing processes that utilize our protein catalysts can frequently enable processes that are more sustainable and environmentally friendly compared to alternative, traditional manufacturing approaches. This has led us to earn three U.S. EPA Presidential Green Chemistry Challenge awards for improved pharmaceutical manufacturing processes since we were founded. All three of these awards were associated with blockbuster drug products.
Discovery and Development of Biotherapeutic Drug Candidates
We are also targeting new opportunities in the pharmaceutical industry to discover or improve biotherapeutic drug candidates for our customers. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity.
We approach biopharmaceutical companies to collaborate and utilize our platform technology for the discovery of specific novel biotherapeutic candidates. We currently have one such biotherapeutic discovery partnership in progress under the strategic collaboration agreement with Nestlé Health Science. We continue to pursue other customers who could benefit by applying our CodeEvolver® protein engineering platform technology to improve the discovery and/or development of other biotherapeutics in partnership with us.
Biotherapeutic Product Discovery and Development
We are also using our platform technology to self-fund the development of our own early stage, novel enzyme therapeutic product candidates. The lead product candidate is CDX-6114, an enzyme which we have engineered to be orally administered and is being developed as a potential treatment of PKU in humans. PKU is an inborn metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. As a result, phenylalanine accumulates to toxic levels in the brain, causing serious neurological problems including intellectual disability, seizures and cognitive and behavioral problems. To avoid toxic levels of phenylalanine in their blood, individuals with PKU must follow a strict, life-long diet that is low in phenylalanine and supplement their diet with a synthetic phenylalanine-free formula to provide them with sufficient nutrients. Maintaining a strict, life-long diet can be challenging for individuals with PKU. There are an estimated 50,000 people with PKU in the developed world.
In addition to the PKU program, we have focused our self-funded biotherapeutic investments with aim to discover therapeutic solutions for four additional rare disease conditions. Two of those programs are targeting potential enzyme replacement treatments for patients with inborn errors of amino acid metabolism diseases. The other two programs are targeting potential treatments for patients with lysosomal storage diseases. We expect to continue to make additional investments with the aim of generating additional product candidates targeting these, and potentially other therapeutic areas.
Nestlé Health Science
On October 12, 2017 (the “Effective Date”), we entered into a Global Development, Option and License Agreement (the “Nestlé Agreement”) with Nestlé Health Science and, solely for the purpose of the integration and the dispute resolution clauses of the Nestlé Agreement, Nestlé Health Science S.A., pursuant to which we granted to Nestlé Health Science, under certain of our patent rights and know-how: (i) an option to obtain an exclusive, worldwide, royalty-bearing, sublicenseable license to develop and commercialize certain products (each, a “Product”) based on CDX-6114 and our other therapeutic enzyme product candidates covered by specified patent applications for the treatment of hyperphenylalaninemia (“HPA”), and (ii) an exclusive right of first negotiation (the “Right of First Negotiation”) for a period of five years to obtain an exclusive worldwide license to develop and commercialize up to two enzymes discovered by us for use in the field of the prevention, diagnosis, treatment and

7



management of inborn errors of amino acid metabolism. We are not under any obligation to undertake any research and development activities relating to inborn errors of amino acid metabolism. HPA (also referred to as PKU) is a medical condition characterized by elevated concentrations of the amino acid phenylalanine in the blood. PKU can result in severe HPA. 
In February 2019, Nestlé Health Science exercised its option to receive an exclusive license to further develop and commercialize CDX-6114 and our other therapeutic enzyme product candidates covered by specified patent applications for the treatment of PKU (each, a “Compound”). Under the terms of the Nestlé Agreement, upon option exercise, Nestlé Health Science received a license to the Compound, other than any enzyme that has other clinically significant, specified activity against another molecule, unless that enzyme’s specified activity against phenylalanine is ten times greater than its activity against such other molecule (in which case it is not excluded). Furthermore, we generally will retain the right to use any enzyme as a biocatalyst, provided that preclinical development of such enzyme has not commenced. The first Compound to be developed under the Nestlé Agreement was our enzyme CDX-6114.
The Nestlé Agreement also sets forth the parties’ respective obligations for development, commercialization, regulatory and manufacturing and supply activities for CDX-6114 and Product containing CDX-6114. Prior to Nestlé Health Science exercising its option to receive an exclusive license to CDX-6114, we were generally responsible for development activities, including conducting a Phase 1a clinical study. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. Our development activities were governed by a development plan and overseen by a joint steering committee. The parties established a patent committee to discuss strategies and coordinate activities for the patents related to CDX-6114 and Product containing CDX-6114, and we will jointly own all inventions and information that result from each party’s activities performed under the Nestlé Agreement. The Nestlé Agreement also contains customary representations and warranties by the parties, intellectual property protection provisions, certain indemnification rights in favor of each party and customary confidentiality provisions and limitations of liability.
Nestlé Health Science paid us an upfront cash payment of $14.0 million in the fourth quarter of 2017. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license for the global development and commercialization of CDX-6114 for the management of PKU. The exercise of the option triggers a $3 million milestone payment. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
Other potential payments from Nestlé Health Science to us under the Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of products containing an enzyme covered by the agreement as its sole active ingredient.
In addition to the Nestlé Agreement, we and Nestlé Health Science concurrently entered into a strategic collaboration agreement pursuant to which we and Nestlé Health Science are collaborating to leverage the CodeEvolver® platform technology to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas.
Fine Chemicals and Industrial Enzyme Markets
Beyond the pharmaceutical industry, our CodeEvolver® protein engineering platform technology has enabled cost-savings for our partners in the fine chemicals markets, and the food industry in particular. In November 2016, we entered into an exclusive agreement with Tate & Lyle, a market-leading food ingredients company, to supply a proprietary enzyme for use in Tate & Lyle’s food ingredient production. In March 2017, we announced a second multi-year research and development services agreement with Tate & Lyle for the development of a second ingredient for the food ingredient industry. We engineered a suite of enzymes that enable Tate & Lyle’s novel bioconversion route for the manufacture of their newly-launched zero-calorie TASTEVA® M Stevia sweetener.
We are seeking to expand our enzyme offerings in the fine chemical and industrial enzyme markets within and beyond the food industry, including, for example, to the animal feed, agricultural chemicals and flavors and fragrances markets.

8



Molecular Biology and In Vitro Diagnostic Enzymes
We believe that our Codexis protein engineering capability can also be deployed to commercialize novel enzymes as improvements to enzymes consumed by customers in many industrial sectors. As our first effort in this strategy, we have developed an enzyme for customers using NGS and PCR/qPCR for in vitro molecular diagnostic applications. Our first proprietary enzyme for this market targets improved library preparation for NGS users and is currently being beta tested. We are also currently working on a second enzyme, a DNA polymerase, which is being prepared for beta testing.
Licensing Our CodeEvolver® Protein Engineering Technology Platform
Our CodeEvolver® protein engineering technology platform enables rapid development of custom-designed enzymes that are highly optimized for efficient manufacturing processes. We intend to continue to enter into license arrangements with third parties that will allow them to use our CodeEvolver® protein engineering technology platform to discover and develop novel proteins for their internal use. To date, we have entered into platform technology licensing agreements with each of GlaxoSmithKline and Merck.
GlaxoSmithKline
We entered into our first CodeEvolver® protein engineering Platform Technology Transfer, Collaboration and License Agreement (“GSK CodeEvolver® Agreement”) on July 10, 2014 with GlaxoSmithKline Intellectual Property Development Limited, a subsidiary of GlaxoSmithKline plc (collectively, “GSK”), pursuant to which we granted GSK a non-exclusive, worldwide license to use our CodeEvolver® protein engineering technology platform in the field of human healthcare for its internal development purposes.
Under the GSK CodeEvolver® Agreement, we transferred our CodeEvolver® protein engineering technology platform to GSK over a twenty-one-month period that began on July 10, 2014. As a part of this technology transfer, we provided to GSK our proprietary enzymes, proprietary protein engineering protocols and methods, and proprietary software algorithms. In addition, teams of our and GSK scientists participated in technology training sessions and collaborative research projects at our laboratories in Redwood City, California and at GSK’s laboratories in Upper Merion, Pennsylvania. The technology transfer was completed in April 2016 and our CodeEvolver® protein engineering technology platform has been installed at GSK’s Upper Merion, Pennsylvania site. We have the potential to receive additional contingent payments that range from $5.75 million to $38.5 million per project based on GSK's successful application of the licensed technology.
We are also eligible to receive royalties based on net sales, if any, of a limited set of products developed by GSK using the CodeEvolver® protein engineering technology platform.
The licenses to GSK were granted under certain patents, patent applications and know-how that we owned or controlled as of the effective date of the GSK CodeEvolver® Agreement and that cover our CodeEvolver® protein engineering technology platform and certain enzymes useful in the Field. Any improvements to our CodeEvolver® protein engineering technology platform during the technology transfer period were included in the license grants from us to GSK.
Under the GSK CodeEvolver® Agreement, GSK owns (the “GSK-Owned Technology”) (a) any enzyme technology that was developed during a project under the GSK CodeEvolver® Agreement that used our CodeEvolver® protein engineering technology platform during the technology transfer period and (b) the methods of use of any Project Enzyme in compound synthesis that were developed during the technology transfer period. GSK granted to us a worldwide, non-exclusive, fully paid-up, royalty-free license, with the right to grant sublicenses, to use outside of the GSK Exclusive Field, the GSK-Owned Technology that was developed during the technology transfer period.
Until July 10, 2019 (the “Embargo Period”), GSK is prohibited from using the CodeEvolver® protein engineering technology platform for the use, research or development (whether in vitro or in vivo) or commercialization of any enzyme or enzyme fusion protein that (a) effects a chemical transformation in humans or (b) facilitates, assists, transports or enables the action, dispersion, absorption or bioavailability of a molecule, biologic agent, drug product, therapeutic agent or other compound in humans (the “Embargo Field”). GSK is permitted to use our CodeEvolver® protein engineering technology platform during the Embargo Period to develop and use an enzyme or enzyme fusion protein that (x) is used by GSK solely as a research reagent or a research tool within the Embargo Field, (y) is used to synthesize a small-molecule compound owned or controlled by GSK or (z) facilitates, assists, transports or enables the action, dispersion, absorption or bioavailability of a small-molecule compound that is owned or controlled by GSK.
The term of the GSK CodeEvolver® Agreement continues, unless earlier terminated, until the expiration of all payment obligations under the GSK CodeEvolver® Agreement. GSK can terminate the GSK CodeEvolver® Agreement by providing 90 days written notice to us.

9



Merck
On August 3, 2015, we entered into a CodeEvolver® platform technology transfer and license agreement (the “Merck CodeEvolver® Agreement”) with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (collectively, “Merck”).
The Merck CodeEvolver® Agreement allows Merck to use our proprietary CodeEvolver® protein engineering platform technology in the field of human and animal healthcare.
Under the terms of the Merck CodeEvolver® Agreement, we granted to Merck a non-exclusive worldwide license to use the CodeEvolver® protein engineering technology platform to research, develop and manufacture novel enzymes for use by Merck in its internal research programs (“Merck Non-Exclusive Field”). The license to Merck is exclusive for the research, development and manufacture of novel enzymes for use by Merck in the chemical synthesis of therapeutic products owned or controlled by Merck (“Merck Exclusive Field”). Merck has the right to grant sublicenses to affiliates of Merck and, in certain limited circumstances, to third parties. We also granted to Merck a license to make or have made products manufactured using the CodeEvolver® protein engineering technology platform with a right to grant sublicenses solely to affiliates of Merck, contract manufacturing organizations and contract research organizations. The manufacturing license is exclusive in the Merck Exclusive Field and non-exclusive in the Merck Non-Exclusive Field. The licenses are subject to certain limitations based on pre-existing contractual obligations that apply to the technology and intellectual property that are the subject of the license grants. The licenses do not permit the use of the CodeEvolver® protein engineering technology platform to discover any therapeutic enzyme, diagnostic product or vaccine. In addition, Merck is prohibited from using the CodeEvolver® protein engineering technology platform to develop or produce enzymes or any other compounds for or on behalf of any third parties except in a very limited manner when Merck divests a therapeutic product that is manufactured using an enzyme developed using the CodeEvolver® protein engineering technology platform.
Under the terms of the Merck CodeEvolver® Agreement, Merck paid us $18.0 million comprised of up-front technology transfer and license fees and milestone payments over the technology transfer period of 15 months from August 3, 2015, the effective date of the Merck CodeEvolver® Agreement. We also have the potential to receive product-related payments of up to $15.0 million for each API that is manufactured by Merck using one or more enzymes that have been developed or are in development using the CodeEvolver® protein engineering technology platform during the 10-year period that begins on the conclusion of the 15-month technology transfer period. These product-related payments, if any, will be paid by Merck to us for each quarter that Merck manufactures API using a CodeEvolver®-developed enzyme. The payments will be based on the total volume of API produced using the CodeEvolver®-developed enzyme. We have the right to conduct an annual audit to confirm that all payments that are owed to us have been paid in full and on time.
Under the Merck CodeEvolver® Agreement, we transferred the CodeEvolver® protein engineering technology platform to Merck over the period from August 2015 through September 2016. As part of this technology transfer, we provided to Merck our proprietary enzymes, proprietary protein engineering protocols and methods, and proprietary software algorithms. We provided additional enzyme evolution services to Merck at our laboratories in Redwood City through November 2016. The remaining deferred revenue relating to the upfront payment was recognized upon completion of the additional enzyme evolution services.
The licenses to Merck are granted under patents, patent applications and know-how that we owned or controlled as of the effective date of the Merck CodeEvolver® Agreement and that cover the CodeEvolver® protein engineering technology platform. Any improvements to the CodeEvolver® protein engineering technology platform during the technology transfer period are also included in the license grants from Codexis to Merck. Following the technology transfer period, Merck can exercise annual options that, upon payment of certain option fees, would extend Merck’s license to include certain improvements to the CodeEvolver® protein engineering technology platform that arise during the three-year period that begins at the end of the technology transfer period.
Under the Merck CodeEvolver® Agreement, we own any improvements to our protein engineering methods, processes and algorithms that arose and any enzyme technology or process technology that are developed during an evolution program or additional services. Merck owns (the “Merck-Owned Technology”) (a) any enzyme technology that is developed solely by Merck under the Merck CodeEvolver® Agreement using the CodeEvolver® protein engineering technology platform (a “Project Enzyme”) and (b) the methods of use of any Project Enzyme or any enzyme developed jointly by Merck and us using the CodeEvolver® protein engineering technology platform. Merck granted to us a worldwide, non-exclusive, fully paid-up, royalty-free license, with the right to grant sublicenses, to use the Merck-Owned Technology outside of the Merck Exclusive Field.

10



For each API that Merck manufactures using an enzyme developed with the CodeEvolver® protein engineering technology platform, we will have a right of first refusal to supply Merck with the enzyme used to manufacture the API if Merck outsources the supply of the enzyme. Our right of first refusal applies during the period that begins on the completion of a phase III clinical trial for the product containing the API and ends five years following regulatory approval for such product.
The Merck CodeEvolver® Agreement has a term that continues, unless earlier terminated, until the expiration of all payment obligations under the agreement. Merck may terminate the Merck CodeEvolver® Agreement by providing 90 days written notice to us. We can terminate the Merck CodeEvolver® Agreement by providing 30 days written notice to Merck if we determine, pursuant to our contractual audit rights under the Merck CodeEvolver® Agreement, that Merck has repeatedly failed to make required payments to us and/or materially underpaid us an amount due under the Merck CodeEvolver® Agreement. In the event the Merck CodeEvolver® Agreement is terminated earlier by Merck, or by us due to an uncured material breach by Merck, or if Merck sells or transfers to a third party any Merck business or facility that includes any of our proprietary materials, information or technology, we have the right to conduct an audit of Merck’s facilities to confirm that all of our proprietary materials, information and technology have been destroyed. The Merck CodeEvolver® Agreement contains indemnification provisions under which Merck and we have agreed to indemnify each other against certain third party claims.
In September 2016, we completed the full transfer of the engineering platform technology and earned milestone revenue of $8.0 million. We received the $8.0 million milestone payment in the fourth quarter of 2016. In October 2018, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we amended certain licensing provisions and one exhibit. In January 2019, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we will install certain CodeEvolver® protein engineering technology upgrades into Merck’s platform license installation and maintain those upgrades for a multi-year term.
Protein Catalyst Products and Services
Our protein catalyst products and services can deliver value to our customers in multiple potential ways:
manufacture their products at lower cost;
manufacture their products with lower fixed capital investment;
reduce the cost of development of complex chemical synthesis processes;
enable their products to achieve higher product purity;
reduce the risk of adverse effects arising from product impurities;
allow the removal of entire steps from chemical production; and
provide flexibility to apply at any point across their product’s lifecycle.
Our products include protein catalysts, chemical intermediates and Codex® Biocatalyst Panels and Kits. We sell our products worldwide primarily through our direct sales and business development force in the United States and Europe.
In addition to products, we also offer research and development services to our customers. These research and development service agreements often contain service fee payments and intellectual property provisions under which we screen and/or engineer protein catalysts for customers in connection with their process development efforts. In these collaborations, we typically receive consideration in the form of one or more of the following: up-front payments, milestone payments, payments for screening and engineering services, licensing fees and royalties.
Protein Catalysts
We often sell protein catalysts (also referred to as biocatalysts or enzymes), by the gram or kilogram, that have already been engineered, scaled up, and installed in a customer’s commercial process. For example, we sell protein catalysts to Merck for their manufacture of Sitagliptin, the active ingredient in Januvia®. We also sell protein catalysts which are in developmental stages. These are enzymes that are sold in batches or by the gram or kilogram that are in the process of being engineered or scaled up by Codexis, or are in the process of being trialed or approved for use in the customer’s process. We may sell batches of specific protein catalysts that are in the middle of our protein engineering efforts to test their performance at a larger customer scale. We also may sell batches of specific protein catalysts for use in a customer’s developmental products (for example, to trial in a customer’s Phase II drug candidate process). Finally, we may sell batches of specific protein catalysts as a customer performs trials for approval in their commercial manufacturing operations.
Chemical Intermediates
In some cases, we sell intermediate chemicals products that are produced in a process that uses our protein catalysts. These chemical intermediates are then used by our customer for further chemical processing.

11



Codex® Biocatalyst Panels and Kits
We sell kits and panels of our protein catalysts. These kits and panels assemble a relevant subset of our engineered enzymes to enable customers to perform chemistry screening on their own. These kits and panels are organized by specific types of chemical reactions that are widely applicable in the pharmaceutical and fine chemical markets.
Protein Catalyst Screening Services
If a customer prefers, rather than purchasing our Codex® Biocatalyst Panels or Kits to use for its own screening, it may send us its starting materials and desired chemical reaction, and we will test against our existing libraries of enzymes on a research and development service fee basis. If we detect desired activity in a specific enzyme, we can supply the customer with this enzyme or perform engineering services to improve the performance of the enzyme.
Protein Engineering Services
We work with our customers throughout their product development lifecycle to optimize enzymes that have been engineered specifically to perform a desired process according to a highly selective set of specifications. We typically charge customers for research and development services by project or project-month. These are typically larger research and development service fees than screening services.
The protein engineering process starts by identifying genes that code for enzymes known to have the general type of catalytic reactivity for a desired chemical reaction. Typically, we identify gene sequences from our extensive in-house collection or from published databases and then synthesize candidate genes having those sequences. Using a variety of biotechnology tools, we diversify these genes by introducing mutations, giving rise to changes in the enzymes for which they encode. The methods for diversifying these genes, and types of diversity being tested, often vary over the course of a protein engineering program. For finding initial diversity, methods typically include random mutagenesis and site-directed (included computational structure-guided) mutagenesis. We also test mutational variations from related enzymes found in different organisms.
Once we have identified potentially beneficial mutations, we create libraries of thousands of variants with combinations of these mutations. With our proprietary genetic manipulation tools, we generate libraries of genes that have programmed and random combinations of the mutations for testing. The pool of genes is used to transform host cells, which entails introducing the various genes into host cells. These cells are then grown into colonies. Cells from individual colonies are cultured in high throughput to produce the enzyme encoded by the genetic variant in those cells. The enzymes expressed by these cells are then screened in high throughput using test conditions relevant to the desired process. The screening results allow us to identify and catalog individual genes that produce improved enzymes with beneficial mutations as well as enzymes having detrimental ones. Using specifically developed test conditions and analytical methods, we can identify variant enzymes that exhibit various improved performance characteristics, such as stability, activity and selectivity, under conditions relevant to the desired chemical process.
In the next step in our optimization process, we use our proprietary bioinformatics software to analyze protein sequence-activity relationships. Our software and algorithms relate the screening results to the mutations and rank the individual and interacting protein sequence mutations with regard to their degree of benefit or detriment, relative to the process parameter(s) tested. Using this information, we can create a select pool of mutational diversity in the next iteration to further the accumulation of beneficial diversity and cancel out detrimental diversity in the individual genes in the resulting library. The gene that codes for the best performing enzyme in one iteration is used as the starting gene for the next iteration of recombination and screening. As the enzymes improve over these iterations, the screening conditions are made increasingly more stringent. In this way, the protein catalyst is rapidly optimized until all in-process performance requirements have been achieved and the economic objectives for the desired process have been met.
INTELLECTUAL PROPERTY
Our success depends in large part on our ability to protect our proprietary products and technology under patent, copyright, trademark and trade secret laws. We also rely heavily on confidential disclosure agreements for further protection of our proprietary products and technologies. Protection of our technologies is important for us to offer our customers and partners proprietary services and products that are not available from our competitors, and to exclude our competitors from practicing technology that we have developed or exclusively licensed from other parties. For example, our ability to supply innovator pharmaceutical manufacturers depends on our ability to supply proprietary enzymes or methods for making pharmaceutical intermediates or APIs that are not available from our competitors. Likewise, in the generic pharmaceutical area, proprietary protection, through patent, trade secret or other protection of our enzymes and methods of producing a pharmaceutical product is important for us and our customers to maintain a lower cost production advantage over competitors.

12



As of December 31, 2018, we owned or controlled approximately 1,100 issued patents and pending patent applications in the United States and in various foreign jurisdictions. These patents and patent applications include many that are directed to our enabling technologies and specific methods and products that support our business in the pharmaceutical markets. In addition, our portfolio includes applications and patents that support our businesses in the biotherapeutics, molecular diagnostics, food and other markets. Our current intellectual property rights have terms that expire between 2019 and 2039. Our United States intellectual property rights directed to the CodeEvolver® proprietary enabling technology platform developed internally by us have terms that expire between 2029 to 2034. Our current intellectual property rights also include patents, trademarks, copyrights, software and certain assumed contracts that we acquired from Maxygen, Inc. (“Maxygen”) in October 2010, which are associated with directed evolution technology, known as the MolecularBreeding™ technology platform developed by Maxygen. The intellectual property rights and assets that we acquired from Maxygen continue to be subject to existing exclusive and non-exclusive license rights granted by Maxygen to third parties. We continue to file new patent applications, for which terms generally extend 20 years from the non-provisional filing date in the United States.
As of December 31, 2018, we owned and used the following registered, pending, and common law trademarks in the United States, with some trademarks also registered or pending in foreign jurisdictions: Codexis®, Codex®, CodeEvolver®, Mosaic®, Sage®, Microcyp®, MCYP®, ProSAR®, Unlock the Power of Proteins®, Codexis Protein Engineering Experts™, and a Codexis design mark (i.e., the Codexis logo).
COMPETITION
We face differing forms of competition in the small molecule pharmaceuticals, biotherapeutics, and fine chemicals markets, as set forth below.
Small Molecule Pharmaceuticals

We market our protein catalyst products and services to manufacturers of small molecule pharmaceutical intermediates and APIs. Our primary competitors in that market are companies marketing either conventional, non-enzymatic catalysts or alternative protein catalyst products and services. We also face competition sometimes from existing in-house technologies (both biocatalysts and conventional catalysts) within our client and potential client companies. The principal methods of competition and competitive differentiation in this market are price, product quality and performance, including manufacturing yield, safety and environmental benefits and speed of delivery of product. Pharmaceutical manufacturers that use biocatalytic processes can face increased competition from manufacturers that use more conventional processes and/or manufacturers that are based in regions (such as India and China) with lower regulatory, safety and environmental costs.

The market for the manufacture and supply of APIs and intermediates is large with many established companies. These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Pfizer, Bristol Myers Squibb and Teva Pharmaceutical Industries Ltd., which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermediates. The processes used by these companies include classical conventional organic chemistry reactions, chemo catalytic reactions, biocatalytic reactions or combinations thereof. Our protein catalyst based manufacturing processes must compete with these internally developed routes.
Companies developing and marketing conventional catalysts include Solvias AG, BASF, Johnson-Mathey, and Takasago International Corporation.

The market for supplying enzymes for use in pharmaceutical manufacturing is quite fragmented. There is competition from large industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger contract research/contract manufacturing organizations (“CRO/CMO”), such as Royal DSM N.V. (“DSM”), Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several smaller companies, such as BRAIN AG, Arzeda, c-LEcta GmbH and Evocatal GmbH.
We believe that our principal advantage is our ability to rapidly deliver customized protein catalysts for existing and new intermediates and APIs in the pharmaceutical manufacturing market. This capability has allowed us to create a breadth of protein catalysts with improved performance characteristics including, for example, better activity, stability, and activity on a range of substrates, compared to traditional chemistry-based manufacturing processes and naturally occurring (and thus not optimized) biocatalysts. We believe that our CodeEvolver® protein engineering platform technology provides substantially superior results, in shorter time frames, than companies offering competing biocatalyst development services.

13



Biotherapeutics
There are other companies that participate in the biotherapeutics market generally and the PKU market specifically. Many of these companies are large, successful and well-capitalized. BioMarin Pharmaceutical Inc. (“BioMarin”) and Daiichi Sankyo Company market Kuvan® in the United States, Europe and Japan for the treatment of a certain type of PKU. In addition, BioMarin gained US FDA approval in 2018 and began commercial sales of PalynziqTM as an injectable enzyme substitution therapy for the potential treatment of PKU. Synlogic is developing SYNB1618 as a potential treatment for PKU, and in 2018, they completed a phase 1/2a clinical trial using SYNB1618. Takeda (who recently acquired Shire Plc), Genzyme / Sanofi S.A. and other companies market or are actively developing new enzyme therapeutics. There are numerous companies that are developing other forms of therapeutics, such as small molecules and gene therapy, which could compete with biotherapeutics.
Fine Chemicals
We entered the fine chemicals market in 2013 by applying our protein engineering technology in the food market. We face similar forms of competition in this market as in the small molecule pharmaceutical markets, with the exception that the risk of losing opportunities to larger competitors in fine chemicals is greater given the larger scale of opportunities available in the fine chemicals market compared to the pharmaceutical market. Our significant competitors in the fine chemicals markets include companies that have been in these marketplaces for many years, such as DuPont Industrial Biosciences (DuPont Genencor), DSM, Novozymes and A.B. Enzymes. These companies have greater resources in these markets than we do and have long-term supply arrangements already in place with customers. Our ability to compete in these markets may be limited by our relatively late entrance. We also face competition in both the fine chemicals and small molecule pharmaceutical markets from emerging companies, like Zymergen and Gingko Bioworks who offer engineered microbe metabolic pathway approaches to these markets.
Core Technology
We are a leader in the field of protein engineering to create novel biocatalysts. Both our pharmaceuticals and fine chemicals businesses rely on our core technology. We are aware that other companies, organizations and persons have developed technologies that appear to have some similarities to our patented proprietary technologies. For example, we are aware that other companies, including DSM and BASF, have alternative methods for obtaining and generating genetic diversity or use mutagenesis techniques to produce genetic diversity. In addition, academic institutions such as the California Institute of Technology, the Max Planck Institute and the Austrian Centre of Industrial Biotechnology are also working in this field. This field is highly competitive with companies and academic and research institutions actively seeking to develop technologies that could be competitive with our technologies.
Technological developments by others may result in our products and technologies, as well as products manufactured by our customers using our biocatalysts, becoming obsolete. We monitor publications and patents that relate to directed molecular evolution to be aware of developments in the field and evaluate appropriate courses of action in relation to these developments.
Many of our competitors have substantially greater manufacturing, financial, research and development, personnel and marketing resources than we do. As a result, our competitors may be able to develop competing and/or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors.
OPERATIONS
Our corporate headquarters are located in Redwood City, California and provide general administrative support to our business and are the center of our research, development and business operations. We have limited internal manufacturing capacity at our headquarters in Redwood City. We expect to rely on third-party manufacturers for commercial production of our biocatalysts for the foreseeable future. Our in-house manufacturing is dedicated to producing both Codex® Biocatalyst Panels and Kits and enzymes for use by our customers in pilot scale production. We also supply initial commercial quantities of biocatalysts for use by our collaborators to produce pharmaceutical intermediates and manufacture biocatalysts that we sell. Please see Note 15 in the notes to our Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for a description of our revenues and long-lived assets both within and outside of the United States.
Our research and development operations include efforts directed towards engineering protein catalysts, bioprocess development, cellular engineering, biocatalyst screening, metabolites, strain improvement, fermentation development and process engineering. We conduct enzyme evolution, enzyme production development, microbial bioprocess development, cellular engineering, microbial evolution and process engineering evaluations and design primarily at our headquarters in Redwood City, California. For more information on our research and development expenditures, see Item 8 of this Annual

14



Report on Form 10-K. Manufacturing of our enzymes is conducted primarily in three locations, at our in-house facility in Redwood City, California and at third-party contract manufacturing organizations, Lactosan, GmbH & Co. KG (“Lactosan”) in Kapfenberg, Austria and DPhar SpA (“DPhar”) in Agnani, Italy. Generally, we perform smaller scale manufacturing in-house and outsource the larger scale manufacturing and a large percentage of our production of novel enzymes to contract manufacturing organizations.
GOVERNMENT REGULATION
In the United States, the FDA regulates drug and biologic products under the Federal Food, Drug and Cosmetic Act, its implementing regulations and other laws, including, in the case of biologics, the Public Health Service Act. Our biotherapeutic product candidates are subject to regulation by the FDA as biologics. Biologics require the submission of a biologics license application (“BLA”) and licensure, which constitutes approval, by the FDA before being marketed in the United States. If we or our development partners fail to comply with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval, we may become subject to administrative or judicial sanctions.

The process required by the FDA before our biologic product candidates may be marketed in the United States generally involves the following:
completion of preclinical laboratory tests and animal studies performed in accordance with the FDA’s good laboratory practice (“GLP”) regulations;
submission to the FDA of an IND, which must become effective before clinical trials in the United States may begin;
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, conducted in accordance with the FDA’s good clinical practice (“GCP”) regulations;
submission to the FDA of a BLA;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with current good manufacturing (“cGMP”) regulations; and
FDA review and approval of the BLA prior to any commercial marketing, sale or distribution of the product.
The testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if at all.
Preclinical and Clinical Trials
Once a product candidate is identified for development, it enters the preclinical testing stage. Preclinical studies include laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, which must be conducted in accordance with GLP requirements. The results of preclinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks, and imposes a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development, and the FDA must grant permission, either explicitly or implicitly by not objecting, before each clinical trial can begin.
Clinical trials involve the administration of the product candidate to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial and the parameters and criteria to be used in monitoring safety and evaluating effectiveness. Each protocol must be submitted to the FDA as part of the IND. An independent institutional review board (“IRB”) for each investigator site proposing to participate in a clinical trial must also review and approve the clinical trial before it can begin at that site, and the IRB must monitor the clinical trial until it is completed. The FDA, the IRB, or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP requirements, including requirements for informed consent.
For purposes of BLA approval, clinical trials are typically conducted in three sequential phases, which may overlap or be combined.
Phase 1-Phase 1 clinical trials involve initial introduction of the investigational product into healthy human subjects or patients with the target disease or condition. These studies are typically designed to test the safety,

15



dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence of effectiveness.
Phase 2-Phase 2 clinical trials typically involve administration of the investigational product to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosage and dosing schedule and to identify possible adverse side effects and safety risks.
Phase 3-Phase 3 clinical trials typically involve administration of the investigational product to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval and physician labeling.
In some cases, the FDA may condition approval of a BLA on the sponsor’s agreement to conduct additional clinical trials to further assess the biologic’s safety and effectiveness after BLA approval. Such post-approval clinical trials are typically referred to as Phase 4 clinical trials.
Although most clinical research performed in the United States in support of a BLA must be authorized in advance by the FDA, under the IND regulations and procedures described above, there are certain circumstances under which clinical trials can be conducted without submission of an IND. For example, a sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND.
Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events, findings from other studies that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious adverse reaction over that listed in the protocol or investigator brochure.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the biologic and finalize a process for manufacturing the biologic in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and manufacturers must develop, among other things, methods for testing the identity, strength, quality and purity of the final biological product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.
BLA Submission and FDA Review
The results of preclinical studies and clinical trials, together with other detailed information, including extensive manufacturing information and information on the composition of the biologic, are submitted to the FDA in the form of a BLA requesting approval to market the biologic for one or more specified indications. The submission of a BLA requires payment of a substantial user fee unless a waiver is granted. Each BLA submitted to the FDA is reviewed for administrative completeness and reviewability within 60 days of the FDA’s receipt of the application. If the BLA is found to be complete, the FDA will file the BLA, triggering a full substantive review of the application. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission.
Once a BLA has been accepted for filing, by law the FDA has 180 days to review the application and respond to the applicant. However, the review process is often significantly longer. Under the Prescription Drug User Fee Act, the FDA has a goal of reviewing BLAs within ten months of the 60-day filing date for standard review or six months for priority review, but the overall timeframe is often extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether the biological product is safe, pure and potent and whether the facility or facilities in which it is manufactured meet standards designed to assure the product’s continued safety, purity and potency. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.
Before approving a BLA, the FDA will inspect the facility or the facilities at which the biologic product is manufactured, and will not license the product unless cGMP compliance is satisfactory. The FDA may also inspect the sites at which the clinical trials were conducted to assess their compliance with GCP requirements.
The FDA may deny approval of a BLA if the applicable statutory and regulatory criteria are not satisfied, or it may require additional preclinical or clinical data. Even if such data are submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than sponsors. Once the FDA approves a BLA, such approval defines the indicated uses for which the biologic may be

16



marketed. The FDA may also require implementation of a Risk Evaluation and Mitigation Strategy, or REMS, which can include a medication guide, communication plan, or elements to assure safe use, such as restricted distribution methods, physician training, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling claims or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the market. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product’s safety and effectiveness after commercialization, and it may limit further marketing based on the results of these post-marketing studies. After approval, certain changes to the approved biologic, such as adding new indications, manufacturing changes or additional labeling claims, are subject to further FDA review and approval. Depending on the nature of the proposed change, a BLA supplement must be filed and approved before the change may be implemented.
Post-Approval Requirements
Licensed biologics that are manufactured and distributed in the United States are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product distribution, advertising and promotion and reporting of adverse experiences with the product. There is also a continuing, annual prescription drug program user fee.
Any biologics manufactured or distributed by us, our partners or our contract manufacturers pursuant to FDA approvals would be subject to ongoing regulation by the FDA. Manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose extensive procedural and documentation requirements. Failure to comply with statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, product seizures, injunctions, civil penalties or criminal prosecution.
Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, requirements for post-market studies or clinical trials to assess new safety risks, imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
fines, warning letters or holds on post-approval clinical trials;
refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of product approvals;
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet and social media. A company can make only those claims relating to safety and efficacy that are approved by the FDA. Physicians may prescribe legally available biologics for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the FDA. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, impose stringent restrictions on manufacturers’ communications regarding off-label use. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties.
Biosimilars and Regulatory Exclusivity
As part of the Patient Protection and Affordable Care Act enacted in 2010, as amended by the Health Care and Education Reconciliation Act of 2010, the Biologics Price Competition and Innovation Act (“BPCIA”) established an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The abbreviated regulatory pathway provides legal authority for the FDA to review and approve biosimilar biologics based on their similarity to an existing brand product, referred to as a reference product, including the possible designation of a biosimilar as interchangeable with a brand product. Under the BPCIA, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. Moreover, the extent to which a biosimilar, once approved, will be substituted for a reference product in a way that is similar to traditional generic substitution for non-biological drug products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing. The BPCIA is complex and continues

17



to be interpreted and implemented by the FDA. As a result, its ultimate implementation and impact are subject to uncertainty. In addition, the period of exclusivity provided by the BPCIA only operates against third parties seeking approval via the abbreviated pathway, but would not prevent third parties from pursuing approval via the traditional BLA approval pathway.
CUSTOMERS
We rely on a limited number of key customers for the majority of our revenues. Customers that provided 10% or more of our total revenues in any of the past three fiscal years consist of the following:
 
Percentage of Total Revenues
For The Years Ended December 31,
 
2018
 
2017
 
2016
Customers:
 
 
 
 
 
Merck
29
%
 
28
%
 
47
%
Nestlé Health Science
22
%
 
15
%
 
*

Tate & Lyle
13
%
 
11
%
 
*

Novartis
*

 
14
%
 
*

GSK
*

 
*

 
22
%
* Percentage was less than 10%
EMPLOYEES
As of December 31, 2018, we had 132 full-time employees and part-time employees worldwide. Of these employees, 77 were engaged in research and development, 18 were engaged in operations and quality control, and 37 were engaged in selling, general and administrative activities. None of our employees is represented by a labor union, and we consider our employee relations to be good.
CORPORATE & AVAILABLE INFORMATION
Our principal corporate offices are located at 200 Penobscot Drive, Redwood City, California 94063 and our telephone number is (650) 421-8100. We were incorporated in Delaware in January 2002. Our internet address is www.codexis.com. The information on, or that can be accessed through, our website is not incorporated by reference into this Annual Report on Form 10-K or any other filings we make with the U.S. Securities and Exchange Commission (the “SEC”).
We make available on or through our website certain reports and amendments to those reports that we file with, or furnish to, the SEC in accordance with the Exchange Act. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available on or through our website free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. Copies of this information may be obtained at the SEC website at www.sec.gov. The contents of these websites are not incorporated into this filing. Further, the references to website URLs are intended to be inactive textual references only.

18



ITEM 1A. RISK FACTORS
You should carefully consider the risks described below together with the other information set forth in this Annual Report on Form 10-K, which could materially affect our business, financial condition or future results. The risks described below are not the only risks facing our company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.
Risks Relating to Our Business and Strategy
During our operating history, the markets in which we have participated have changed significantly, which may make it difficult to evaluate our current business and predict our future performance.
Our company has been in existence since January 2002. From 2002 until 2005, our operations focused on organizing and staffing our company and developing our technology platform. In 2005, we recognized our first revenues from product sales. From 2006 to August 2012, a major portion of our business revolved around our research and development collaboration with Shell with respect to advanced biofuels. The Shell collaboration was terminated in August 2012 and did not contribute to our revenues after the termination. As a result of the termination of the Shell collaboration, we undertook a significant restructuring of our operations and refocused our business on the biocatalysis market. In November 2013, we announced that we had begun to wind down our CodeXyme® cellulase enzymes program, and that we had stopped further development of our CodeXol® detergent alcohols program in the third quarter of 2013. Our Novel Biotherapeutics business is relatively new to Codexis. As a result of these changes in our business and any changes to our business focus that we may make as we move forward, our operating history in past periods may not provide a basis to evaluate our current business or be indicative of our future performance. We have encountered and will continue to encounter risks and difficulties frequently experienced by young companies in rapidly changing industries. If we do not address these risks successfully, our business will be harmed.
Our quarterly or annual operating results may fluctuate in the future. As a result, we may fail to meet or exceed the expectations of research analysts or investors, which could cause our stock price to decline.
Our financial condition and operating results have varied significantly in the past and may continue to fluctuate from quarter to quarter and year to year in the future due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contribute to these fluctuations include the following factors, as well as other factors described elsewhere in this report:
our ability to achieve or maintain profitability;
our relationships with, and dependence on, collaborators in our principal markets;
our dependence on a limited number of customers;
our dependence on a limited number of products in our biocatalysis business;
our reliance on a limited number of contract manufacturers for large scale production of substantially all of our enzyme products;
our ability to develop and successfully commercialize new products for the biocatalysis market(s);
our ability to obtain additional development partners for our biotherapeutic programs;
potential of Nestlé Health Science terminating any development program under its license agreement with us;
our ability to deploy our technology platform in the fine chemicals market;
the success of our customers’ pharmaceutical products in the market and the ability of such customers to obtain regulatory approvals for products and processes;
our or our customers’ ability to obtain regulatory approval for the sale and manufacturing of food products using our enzymes;
our ability to deploy our technology platform in the in vitro molecular diagnostics market;
our ability to successfully achieve domestic and foreign regulatory approval for product candidates;
our ability to successfully design and execute clinical testing at a reasonable cost and on an acceptable time-frame;
our dependence on product candidates which could unexpectedly fail at any stage of preclinical or clinical development;
our dependence on product candidates which may lack the ability to work as intended or cause undesirable side effects;
our dependency on third parties to conduct clinical trials, research, and preclinical studies;

19



our ability to successfully prosecute and protect our intellectual property;
our ability to compete if we do not adequately protect our proprietary technologies or if we lose some of our intellectual property rights;
our ability to avoid infringing the intellectual property rights of third parties;
our involvement in lawsuits to protect or enforce our patents or other intellectual property rights;
our ability to enforce our intellectual property rights throughout the world;
our dependence on, and the need to attract and retain, key management and other personnel;
our ability to prevent the theft or misappropriation of our biocatalysts, the genes that code for our biocatalysts, know-how or technologies;
our ability to protect our trade secrets and other proprietary information from disclosure by employees and others;
our ability to obtain substantial additional capital that may be necessary to expand our business;
our ability to comply with the terms of our credit facility;
our ability to timely pay debt service obligations;
our customers’ ability to pay amounts owed to us in a timely manner;
our ability to avoid charges to earnings as a result of any impairment of goodwill, intangible assets or other long-lived assets;
changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported results of operations;
our ability to maintain effective internal control over financial reporting;
our dependency on information technology systems, infrastructure and data;
our ability to control and to improve product gross margins;
our ability to protect against risks associated with the international aspects of our business;
the cost of compliance with European Union chemical regulations;
potential advantages that our competitors and potential competitors may have in securing funding or developing products;
our ability to accurately report our financial results in a timely manner;
results of regulatory tax examinations;
business interruptions, such as earthquakes and other natural disasters;
public concerns about the ethical, legal and social ramifications of genetically engineered products and processes;
our ability to integrate our current business with any businesses that we may acquire in the future;
our ability to properly handle and dispose of hazardous materials in our business;
potential product liability claims;
uncertainties in the interpretation and application of the 2017 Tax Cuts and Jobs Act and related regulations could materially affect our tax obligations and effective tax rate; and
our ability to use our net operating loss carryforwards to offset future taxable income.
Due to the various factors mentioned above, and others, the results of any prior quarterly or annual periods should not be relied upon as indications of our future operating performance.
We have a history of net losses and we may not achieve or maintain profitability.
We have incurred net losses since our inception, including losses of $10.9 million in 2018, $23.0 million in 2017 and $8.6 million in 2016. As of December 31, 2018 and 2017, we had an accumulated deficit of $330.5 million and $315.1 million, respectively. If we are unable to expand our biocatalysis business, through new or expanded collaborations, development of new products or services, or increased sales of existing products and services, our net losses may increase and we may never achieve profitability. In addition, some of our collaboration agreements, including our collaboration with Nestlé Health Science, provide for milestone payments and/or future royalty payments, which we will only receive if we and our collaborators develop and commercialize products. We also may fund development of additional proprietary biocatalysis and/or biotherapeutic products. There can be no assurance that any of these products will become commercially viable or that we will ever achieve profitability on a quarterly or annual basis. If we fail to achieve profitability, or if the time required to achieve profitability is longer than we anticipate, we may not be able to continue our business. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis.

20



We are dependent on our collaborators, and our failure to successfully manage these relationships could prevent us from developing and commercializing many of our products and achieving or sustaining profitability, and could lead to disagreements with our current or former collaborators.
Our ability to maintain and manage collaborations in our markets is fundamental to the success of our business. We currently have license agreements, research and development agreements, supply agreements and/or distribution agreements with various collaborators. For example, we have ongoing collaborations with GSK, Merck and Nestlé Health Science that are important to our business and financial results. We may have limited or no control over the amount or timing of resources that any collaborator is able or willing to devote to our partnered products or collaborative efforts. Any of our collaborators may fail to perform its obligations. These collaborators may breach or terminate their agreements with us or otherwise fail to conduct their collaborative activities successfully and in a timely manner. Further, our collaborators may not develop products arising out of our collaborative arrangements or devote sufficient resources to the development, manufacture, marketing or sale of these products. Moreover, disagreements with a collaborator could develop, and any conflict with a collaborator could lead to litigation and could reduce our ability to enter into future collaboration agreements and negatively impact our relationships with one or more existing collaborators. If any of these events occur, especially if they occur in our collaborations with GSK, Merck or Nestlé Health Science, or if we fail to maintain our agreements with our collaborators, we may not be able to commercialize our existing and potential products or grow our business or generate sufficient revenues to support our operations, we may not receive contemplated milestone payments and royalties under the collaboration, and we may be involved in litigation. Our collaboration opportunities could be harmed and our financial condition and results of operations could be negatively affected if:
we do not achieve our research and development objectives under our collaboration agreements in a timely manner or at all;
we develop products and processes or enter into additional collaborations that conflict with the business objectives of our other collaborators;
we, our collaborators and/or our contract manufacturers do not receive the required regulatory and other approvals necessary for the commercialization of the applicable product;
we disagree with our collaborators as to rights to intellectual property that are developed during the collaboration, or their research programs or commercialization activities;
we are unable to manage multiple simultaneous collaborations;
our collaborators or licensees are unable or unwilling to implement or use the technology or products that we provide or license to them;
our collaborators become competitors of ours or enter into agreements with our competitors;
our collaborators become unable or less willing to expend their resources on research and development or commercialization efforts due to general market conditions, their financial condition or other circumstances beyond our control; or
our collaborators experience business difficulties, which could eliminate or impair their ability to effectively perform under our agreements.
Even after collaboration relationships expire or terminate, some elements of the collaboration may survive. For instance, certain rights, licenses and obligations of each party with respect to intellectual property and program materials may survive the expiration or termination of the collaboration. Disagreements or conflicts between and among the parties could develop even though the collaboration has ended. These disagreements or conflicts could result in expensive arbitration or litigation, which may not be resolved in our favor.
Finally, our business could be negatively affected if any of our collaborators or suppliers undergoes a change of control or were to otherwise assign the rights or obligations under any of our agreements.
We are dependent on a limited number of customers.
Our current revenues are derived from a limited number of key customers. For the year ended December 31, 2018 and 2017, customers that each individually contributed 10% or more of our total revenue accounted for 64% and 68% of our total revenues in 2018 and 2017, respectively. We expect a limited number of customers to continue to account for a significant portion of our revenues for the foreseeable future. This customer concentration increases the risk of quarterly fluctuations in our revenues and operating results. The loss or reduction of business from one or a combination of our significant customers could, materially adversely affect our revenues, financial condition and results of operations.
We are dependent on a limited number of products in our protein catalysts business.

21



Our current product sales are derived from a limited number of protein catalyst products. We expect a limited number of protein catalyst products to continue to account for a significant portion of our product sales for the foreseeable future. This product concentration increases the risk of quarterly fluctuations in our revenues and operating results. The loss or reduction of business of one or a combination of our significant products could materially adversely affect our revenues, financial condition and results of operations.
We are dependent on a limited number of contract manufacturers for large scale production of substantially all of our enzymes.
Manufacturing of our enzymes is conducted primarily in three locations: our in-house facility in Redwood City, California, and at two third-party contract manufacturing organizations, Lactosan, GmbH & Co. KG ("Lactosan"), in Kapfenberg, Austria, and DPhar SpA (“DPhar”), in Agnani, Italy. Generally, we perform smaller scale manufacturing in-house and outsource the larger scale manufacturing to these contract manufacturers. We have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third-party manufacturers for the larger scale manufacturing of the enzymes used in our pharmaceutical and fine chemicals business.
Accordingly, we face risks of difficulties with, and interruptions in, performance by third party manufacturers, the occurrence of which could adversely impact the availability, launch and/or sales of our enzymes in the future. Manufacturing delays at a contract manufacturer could negatively affect our business, reputation, results of operations and financial condition. The failure of any contract manufacturer to supply us enzymes on a timely basis, or to manufacture our enzymes in compliance with our specifications or applicable quality requirements or in volumes sufficient to meet demand, would adversely affect our ability to sell pharmaceutical and fine and complex chemicals products, could harm our relationships with our collaborators or customers and could negatively affect our revenues and operating results. We may be forced to secure alternative sources of supply, which may be unavailable on commercially acceptable terms, and could cause delays in our ability to deliver products to our customers, increase our costs and decrease our profit margins.
We currently have supply agreements in place with Lactosan and DPhar. In the absence of a supply agreement, a contract manufacturer will be under no obligation to manufacture our enzymes and could elect to discontinue their manufacture at any time. If we require additional manufacturing capacity and are unable to obtain it in sufficient quantity, we may not be able to increase our product sales, or we may be required to make substantial capital investments to build that capacity or to contract with other manufacturers on terms that may be less favorable than the terms we currently have with our suppliers. If we choose to build our own additional manufacturing facility, it could take two years or longer before our facility is able to produce commercial volumes of our enzymes. Any resources we expend on acquiring or building internal manufacturing capabilities could be at the expense of other potentially more profitable opportunities. In addition, if we contract with other manufacturers, we may experience delays of several months in qualifying them, which could harm our relationships with our collaborators or customers and could negatively affect our revenues or operating results.
If we are unable to develop and commercialize new products for the pharmaceutical, fine chemicals, biotherapeutics and molecular diagnostics markets, our business and prospects will be harmed.
We plan to launch new products for the pharmaceutical, fine chemicals, therapeutics and molecular diagnostics markets. These efforts are subject to numerous risks, including the following:
customers in these markets may be reluctant to adopt new manufacturing processes that use our enzymes;
we may be unable to successfully develop the enzymes or manufacturing processes for our products in a timely and cost-effective manner, if at all;
we may face difficulties in transferring the developed technologies to our customers and the contract manufacturers that we may use for commercial scale production of intermediates and enzymes in these markets;
the contract manufacturers that we may use may be unable to scale their manufacturing operations to meet the demand for these products and we may be unable to secure additional manufacturing capacity;
customers may not be willing to purchase these products for these markets from us on favorable terms, if at all;
we may face product liability litigation, unexpected safety or efficacy concerns and product recalls or withdrawals;
changes in laws or regulations relating to the pharmaceutical industry or the industries into which we sell our fine chemicals products, including the food industry, could cause us to incur increased costs of compliance or otherwise harm our business;
our customers’ products may experience adverse events or face competition from new products, which would reduce demand for our products;

22



we may face pressure from existing or new competitive products; and
we may face pricing pressures from existing or new competitors, some of which may benefit from government subsidies or other incentives.
Our biotherapeutic programs are early stage, highly regulated and expensive. Our ability to obtain additional development partners for the programs, to advance our product candidates to clinical trials and to ultimately receive regulatory approvals is highly uncertain.
We are developing and have developed novel biotherapeutic candidates, including CDX-6114, our novel oral enzyme product candidate for the treatment of PKU. The successful development of biotherapeutic candidates involves many risks and uncertainties, requires long timelines and may lead to uncertain results. In addition, drug development is highly regulated and requires areas of expertise and capital resources we do not currently possess. In order to market a drug product in the United States, we must undergo the following process required by the FDA:
completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with GLP requirements;
submission to the FDA of an IND, which must become effective before human clinical studies may begin in the United States;
approval by an independent IRB representing each clinical site before the clinical study may be initiated at the site;
performance of adequate and well-controlled human clinical studies (generally divided into three phases) in accordance with GCP requirements to establish the safety and efficacy of the product candidate for each proposed indication;
preparation of and submission to the FDA of a BLA after completion of all clinical studies;
potential review of the product candidate by an FDA advisory committee;
satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the product candidate is produced to assess compliance with cGMP requirements; and
FDA review and approval of a BLA prior to any commercial marketing or sale of the product in the United States.
If we fail to comply with applicable FDA or other regulatory requirements at any time during the drug development process, clinical testing, the approval process or after approval, we may become subject to administrative or judicial penalties, including the FDA’s refusal to approve a pending application, withdrawal of an approval, warning letters, product recalls, and additional enforcement actions.
In October 2017, we entered into a Global Development, Option and License Agreement with Nestlé Health Science (“Nestlé Agreement”) pursuant to which we granted to Nestlé Health Science an option to obtain an exclusive, worldwide, royalty-bearing, sublicenseable license to develop and commercialize certain products based on our therapeutic enzyme product candidates for the treatment of hyperphenylalaninemia (“HPA”), including CDX-6114, as well as an exclusive right of first negotiation to obtain an exclusive worldwide license to develop and commercialize any enzyme discovered by us for use in the field of the prevention, diagnosis, treatment and management of inborn errors of amino acid metabolism. HPA is a medical condition characterized by mildly or strongly elevated concentrations of the amino acid phenylalanine in the blood. PKU can result in severe HPA. In February 2019, Nestlé Health Science exercised its option to receive an exclusive license to further develop and commercialize CDX-6114 and our other therapeutic enzyme product candidates covered by specified patent applications for the treatment of PKU.
Our efforts to advance our biotherapeutic candidates that we develop are subject to numerous risks, including the following:
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and the results are inherently unpredictable. If we are ultimately unable to obtain regulatory approval for biotherapeutic product candidates, our business will be harmed. To obtain regulatory approval to market any product candidate, preclinical studies and costly and lengthy clinical trials are required, and the results of the studies and trials are highly uncertain. A failure of one or more pre-clinical or clinical trials can occur at any stage, and many companies that have believed their drug candidates performed satisfactorily in pre-clinical and clinical testing have nonetheless failed to obtain marketing approval of their product candidates.
We may find it difficult to enroll patients in our clinical trials for product candidates. Any enrollment difficulties could delay clinical trials and any potential product approval.
We may experience difficulty or delay in obtaining the FDA’s acceptance of an IND for product candidates we may seek to enter into clinical development, which would delay initiation of Phase 1 clinical testing. Delays in the

23



commencement or completion of clinical testing could significantly affect our product development costs or the product development costs of our present and any future collaborators. We do not know whether planned clinical trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical trials can be delayed for a number of reasons. For example, a clinical trial may be suspended or terminated by us, by the IRB of the institution in which such trial is being conducted, or by the FDA due to a number of factors, including unforeseen safety issues, changes in governmental regulations or lack of adequate funding to continue the clinical trial.
We have limited experience in drug development or regulatory matters related to drug development. As a result, we rely or will rely on third parties to conduct our pre-clinical and clinical studies, assist us with drug manufacturing and formulation and perform other tasks for us. If these third parties do not successfully carry out their responsibilities or comply with regulatory requirements, we may receive lower quality products or services, suffer reputational harm and not be able to obtain regulatory approval for product candidates.
Our efforts to use CodeEvolver® protein engineering technology platform to generate new lead biotherapeutic candidates, whether under our collaboration with Nestlé Health Science or otherwise, may not be successful in creating candidates of value.
We will be exposed to potential product liability risks through the testing of experimental therapeutics in humans, which may expose us to substantial uninsured liabilities.
Third parties may develop intellectual property that could limit our ability to develop, market and commercialize product candidates.
Changes in methods of treatment of disease, such as gene therapy, could cause us to stop development of our product candidate or reduce or eliminate potential demand for CDX-6114, if approved, or any other product candidates that we may develop in the future.

If Nestlé Health Science terminates its development program under its license agreement with us, any potential revenue from that license agreement will be significantly reduced or non-existent, and our results of operations and financial condition will be materially and adversely affected.
We have invested significant time and financial resources in the development of CDX-6114 and other product candidates for the treatment of HPA now included in the Nestlé Agreement (each a “Compound”).
In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
Under the Nestlé Agreement, we are eligible to receive from Nestlé Health Science development and approval milestones of up to $86.0 million, sales-based milestones of up to $250.0 million, and tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of products containing a licensed Compound as its sole active ingredient. We have received milestone payments under the Nestlé Agreement to date. However, there is no guarantee that we will receive further milestone payments under the Nestlé Agreement.
Nestlé Health Science may terminate the entire agreement in the event of serious safety issues related to any Compound or product subject to the agreement and at its convenience. We may terminate the Nestlé Agreement if Nestlé Health Science challenges the validity or enforceability of any of our patents covering the Compound. Either party may terminate the agreement in the event of the other party’s uncured material breach or insolvency. Depending on the timing of any such termination, we may not be entitled to receive potential milestone payments, as these payments terminate with termination of the Nestlé Agreement.
If Nestlé Health Science terminates its rights and obligations with respect to the Nestlé Agreement, then depending on the timing of such event:
the development of our product candidates subject to the agreement may be terminated or significantly delayed;
our cash expenditures could increase significantly if it is necessary for us to hire additional employees and allocate scarce resources to the development and commercialization of product candidates;

24



we would bear all of the risks and costs related to the further development and commercialization of product candidates that were previously the subject of the Nestlé Agreement, including the reimbursement of third parties; and
in order to fund further development and commercialization of new product candidates or programs, we may need to seek out and establish alternative collaboration arrangements with third-party partners; this may not be possible, or we may not be able to do so on terms which are acceptable to us, in which case it may be necessary for us to limit the size or scope of one or more of our programs or increase our expenditures and seek additional funding by other means.
Our efforts to deploy our technology platform in the fine chemicals market may fail.
We have recently begun to use our CodeEvolver® protein engineering technology platform to develop new products in the fine chemicals markets. We do not know if we can successfully compete in this new market. This new market is well established and consists of numerous large, well-funded entrenched market participants who have long and established track records and customer relationships. We have currently developed products in the food sector of this market and these products, or any other products that we may develop in the future for the fine chemicals market may not succeed in displacing current products. If we succeed in commercializing new products for the fine chemicals market, we may not generate significant revenues and cash flows from these activities. The failure to successfully deploy products in the fine chemicals space may limit our growth and have a material adverse effect on our financial condition, operating results and business prospects.
Our business could be adversely affected if our customers’ products are not received well in the market, if their products, or the processes used by our customers to manufacture their final products, fail to be approved, or if our customers discontinue their development activities for any reason.
Our enzymes are used by our pharmaceutical customers in the manufacture of intermediates and APIs which are then used in the manufacture of final pharmaceutical products by our existing and potential branded and generic drug customers, and by our fine chemicals customers to manufacture food ingredients. Our business could be adversely affected if these final products do not perform in the market as well as expected, or if our customers encounter competition from new entrants into the market with competing, and possibly superior, products. Additionally, many of these pharmaceutical and food products must be reviewed and approved by the FDA in the United States and similar regulatory bodies in other markets prior to commercialization. If our customers who sell branded drugs, which we refer to as innovators, fail to receive regulatory approval for the drugs, fail to receive regulatory approval for new manufacturing processes for previously approved drugs, or decide for business or other reasons to discontinue their drug development activities, our revenues and prospects will be negatively impacted. The process of producing these drugs, and their generic equivalents, is also subject to regulation by the FDA in the United States and equivalent regulatory bodies in other markets. Similarly, if our food ingredient product and other fine chemical customers were to delay or discontinue development on their products, our revenues and prospects will be negatively impacted. If any pharmaceutical or food manufacturing process that uses our enzymes or enzyme technology does not receive required approval by the appropriate regulatory body or if customers decide not to pursue approval, our business could be adversely affected.
We or our customers may not be able to obtain regulatory approval for the use of our products in food and food ingredients, if required, and, even if approvals are obtained, complying on an ongoing basis with the numerous regulatory requirements applicable to these products will be time-consuming and costly.
The products that we develop for our food and food ingredient customers are, and any other products that we may develop for the food and food ingredients market will likely be, subject to regulation by various government agencies, including the FDA, state and local agencies and similar agencies outside the United States, as well as religious compliance certifying organizations. Food ingredients are regulated by the FDA either as food additives or as substances generally recognized as safe (“GRAS”). A substance can be listed or affirmed as GRAS by the FDA or self-affirmed by its manufacturer upon determination that independent qualified experts would generally agree that the substance is GRAS for a particular use. While we generally self-affirm GRAS status for the products that we develop for the food market, our customer(s) will need to submit a GRAS Notice of Determination for its final commercial product. There can be no assurance that our customer(s) will not receive any objections from the FDA to their Notice of Determination. If the FDA were to disagree with our customer’s determination, they could ask our customer to voluntarily withdraw the final commercial product from the market or could initiate legal action to halt its sale. Such actions by the FDA could have an adverse effect on our business, financial condition, and results of our operations. Food ingredients that are not GRAS are regulated as food additives and require FDA approval prior to commercialization. The food additive petition process is generally expensive and time consuming, with approval, if secured, potentially taking years.

25



Changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.
We expect to encounter regulations in most if not all of the countries in which we may seek to sell our products which are used in food and food ingredients, and we cannot be sure that we or our customers will be able to obtain necessary approvals in a timely manner or at all. If our existing and future products which are used in food and food ingredients do not meet applicable regulatory requirements in a particular country or at all, then we may not be able to commercialize them and our business will be adversely affected. The various regulatory schemes applicable to our products which are used in food and food ingredients will continue to apply following initial approval for sale, including FDA requirements for food safety, mandatory labeling, and certain nutrient content or health claims made about the product. Monitoring regulatory changes and ensuring our ongoing compliance with applicable requirements will be time-consuming and may affect our results of operations. If we fail to comply with such requirements on an ongoing basis, we may be subject to fines or other penalties, or may be prevented from selling our products which are used in food and food ingredients and our business may be harmed.
Our efforts to deploy our technology in the in vitro molecular diagnostics market may fail.
We have recently begun to use our CodeEvolver® protein engineering technology platform to develop new products for customers using NGS and PCR/qPCR for in vitro molecular diagnostic applications. We do not know if we can successfully compete in this new market. This new market is well established and consists of numerous large, well-funded entrenched market participants who have long and established track records and customer relationships. Our first proprietary enzyme for this market, which is designed to improve library preparation for NGS users, and any products that we may develop in the future for this market, may not succeed in displacing current products.   If we succeed in commercializing new products for this market, we may not generate significant revenues and cash flows from these activities. The failure to successfully deploy products on timely basis in this space may limit our growth and have a material adverse effect on our financial condition, operating results and business prospects.
Interim “top-line” and preliminary data from studies or trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publish interim “top-line” or preliminary data from preclinical studies or clinical trials. Interim data are subject to the risk that one or more of the outcomes may materially change as more data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Preliminary or “top-line” data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Additionally, interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects.
Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant by you or others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

26



We and any collaborators are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. To date, neither we nor our collaborators have submitted a BLA to FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidate. We and any collaborators must complete additional preclinical or nonclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans to the satisfaction of the regulatory authorities before we will be able to obtain these approvals. Our product candidates could fail to receive regulatory approval for many reasons, including the following:
the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our or our collaborators’ clinical trials;
we or our collaborators may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
we or our collaborators may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our or our collaborators’ interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of product candidates may not be sufficient to support the submission of a BLA to obtain regulatory approval in the United States or elsewhere;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we or our collaborators contract for clinical and commercial supplies;
the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with collaborators; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our or our collaborators’ clinical data insufficient for approval.
This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a REMS. Regulatory authorities may not approve the price we or our collaborators intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.
Clinical trials are difficult to design and implement, expensive, time-consuming and involve an uncertain outcome, and the inability to successfully conduct clinical trials and obtain regulatory approval for our product candidates would substantially harm our business.
Clinical testing is expensive and usually takes many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process, and product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. We do not know whether planned clinical trials will begin on time, need to be redesigned, recruit and enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed, suspended or terminated for a variety of reasons, including in connection with:
the inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical trials;
applicable regulatory authorities disagreeing as to the design or implementation of the clinical trials;
obtaining regulatory authorization to commence a trial;

27



reaching an agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
obtaining IRB approval at each site;
developing and validating the companion diagnostic to be used in a clinical trial, if applicable;
insufficient or inadequate supply or quality of product candidates or other materials necessary for use in clinical trials, or delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for clinical trials;
recruiting and retaining enough suitable patients to participate in a trial;
having enough patients complete a trial or return for post-treatment follow-up;
adding a sufficient number of clinical trial sites;
inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold;
clinical sites deviating from trial protocol or dropping out of a trial;
the inability to demonstrate the efficacy and benefits of a product candidate;
discovering that product candidates have unforeseen safety issues, undesirable side effects or other unexpected characteristics;
addressing patient safety concerns that arise during the course of a trial; receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from regulatory authorities to modify the design of a trial;
non-compliance with applicable regulatory requirements by us or third parties or changes in such regulations or administrative actions;
suspensions or terminations by IRBs of the institutions at which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities due to a number of factors, including those described above;
third parties being unable or unwilling to satisfy their contractual obligations to us; or
changes in our financial priorities, greater than anticipated costs of completing a trial or our inability to continue funding the trial.
Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. Additionally, we or our collaborators may experience unforeseen events during or resulting from clinical trials that could delay or prevent receipt of marketing approval for or commercialization of product candidates. For example, clinical trials of product candidates may produce negative, inconsistent or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs. Regulators may also revise the requirements for approving the product candidates, or such requirements may not be as we anticipate. If we or our collaborators are required to conduct additional clinical trials or other testing of product candidates beyond those that we or our collaborators currently contemplate, if we or our collaborators are unable to successfully complete clinical trials or other testing of such product candidates, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:
incur unplanned costs;
be delayed in obtaining or fail to obtain marketing approval for product candidates;
obtain marketing approval in some countries and not in others;
obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;
be subject to additional post-marketing testing requirements;
be subject to changes in the way the product is administered;
have regulatory authorities withdraw or suspend their approval of the product or impose restrictions on its distribution;
be sued; or

28



experience damage to our reputation.
If we or our collaborators experience delays in the commencement or completion of our clinical trials, or if we or our collaborators terminate a clinical trial prior to completion, we may experience increased costs, have difficulty raising capital and/or be required to slow down the development and approval process timelines. Furthermore, the product candidates that are the subject of such trials may never receive regulatory approval, and their commercial prospects and our ability to generate product revenues from them could be impaired or not realized at all.
We or our collaborators may experience delays or difficulties in enrolling patients in clinical trials, which could delay or prevent receipt of regulatory approvals.
We or our collaborators may not be able to initiate or continue clinical trials on a timely basis or at all for any product candidates we or our collaborators identify or develop if we or our collaborators are unable to locate and enroll a sufficient number of eligible patients to participate in the trials as required by applicable regulations or as needed to provide appropriate statistical power for a given trial. Additionally, some of our competitors may have ongoing clinical trials for product candidates that would treat the same indications as one or more of our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in our competitors’ clinical trials. Patient enrollment may also affected by many factors, including:
severity and difficulty of diagnosing of the disease under investigation;
size of the patient population and process for identifying subjects;
eligibility and exclusion criteria for the trial in question;
our or our collaborators’ ability to recruit clinical trial investigators with the appropriate competencies and experience;
design of the trial protocol;
availability and efficacy of approved medications or therapies, or other clinical trials, for the disease or condition under investigation;
perceived risks and benefits of the product candidate under trial or testing, or of the application of genome editing to human indications;
efforts to facilitate timely enrollment in clinical trials;
patient referral practices of physicians;
ability to obtain and maintain subject consent;
risk that enrolled subjects will drop out before completion of the trial;
ability to monitor patients adequately during and after treatment; and
proximity and availability of clinical trial sites for prospective patients.
We expect that some of our product candidates will focus on diseases with limited patient pools from which to draw for enrollment in clinical trials. The eligibility criteria of our clinical trials will further limit the pool of available trial participants. In addition to the factors identified above, patient enrollment in any clinical trials we or our collaborators may conduct may be adversely impacted by any negative outcomes our competitors may experience, including adverse side effects, clinical data showing inadequate efficacy or failures to obtain regulatory approval. Enrollment delays in clinical trials may result in increased development costs for any of our product candidates, which may cause the value of our company to decline and limit our ability to obtain additional financing. If we or our collaborators have difficulty enrolling a sufficient number of patients to conduct clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which may have an adverse effect on our results of operations and prospects.
Results of preclinical studies and early clinical trials of product candidates may not be predictive of results of later studies or trials. Our product candidates may not have favorable results in later clinical trials, if any, or receive regulatory approval.
Preclinical and clinical drug development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the preclinical study or clinical trial process. Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. The results from preclinical studies or early clinical trials of a product candidate may not be predictive of the results from later preclinical studies or clinical trials, and interim results of a clinical

29



trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials.
Many companies in the biopharmaceutical and biotechnology industries have suffered significant setbacks at later stages of development after achieving positive results in early stages of development, and we may face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in clinical trials, including previously unreported adverse events. Moreover, non-clinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain regulatory approval. Even if any product candidates progress to clinical trials, these product candidates may fail to show the safety and efficacy in clinical development required to obtain regulatory approval, despite the observation of positive results in animal studies. Our or our collaborators’ failure to replicate positive results from early research programs and preclinical or greenhouse studies may prevent us from further developing and commercializing those or other product candidates, which would limit our potential to generate revenues from them and harm our business and prospects.
For the foregoing reasons, we cannot be certain that any ongoing or future preclinical studies or clinical trials will be successful. Any safety or efficacy concerns observed in any one of our preclinical studies or clinical trials in a targeted area could limit the prospects for regulatory approval of product candidates in that and other areas, which could have a material adverse effect on our business and prospects.
If any of our product candidates do not work as intended or cause undesirable side effects, it could hinder or prevent receipt of regulatory approval or realization of commercial potential for them or our other product candidates and could substantially harm our business.
Our product candidates may be associated with serious adverse events, undesirable side effects or unexpected characteristics. Results of clinical trials could reveal severe or recurring side effects, toxicities or unexpected events. In addition to serious adverse events or side effects caused by product candidates we develop alone or with collaborators, the administration process or related procedures may also cause undesirable side effects. If any such events occur, clinical trials or commercial distribution of any product candidates or products we develop alone or with collaborators could be suspended or terminated, and our business and reputation could suffer substantial harm. Treatment-related side effects could affect patient recruitment and the ability of enrolled patients to complete the trial or result in potential liability claims. Regulatory authorities could order us or our collaborators to cease further development of, deny approval of or require us to cease selling any product candidates or products for any or all targeted indications. If we or our collaborators elect, or are required, to delay, suspend or terminate any clinical trial or commercialization efforts, the commercial prospects of such product candidates or products may be harmed, and our ability to generate product revenues from them or other product candidates that we develop may be delayed or eliminated.
Additionally, if we successfully develop a product candidate alone or with collaborators and it receives marketing approval, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Such identification could also have several additional significant negative consequences, such as:
regulatory authorities may suspend, withdraw or limit approvals of such product, or seek an injunction against its manufacture or distribution;
regulatory authorities may require additional warnings on the label, including “boxed” warnings, or issue safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about the product;
we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients;
we may be required to change the way a product is administered or conduct additional trials;
the product may become less competitive;
we or our collaborators may decide to remove the product from the marketplace;
we may be subject to fines, injunctions or the imposition of civil or criminal penalties;

30



we could be sued and be held liable for harm caused to patients; and
our reputation may suffer.
Any of these events could prevent us or our collaborators from achieving or maintaining market acceptance of any potential product.
Even if we obtain regulatory approval for any products that we develop alone or with collaborators, such products will remain subject to ongoing regulatory requirements, which may result in significant additional expense.
Even if products we develop alone or with collaborators receive regulatory approval, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, distribution, storage, advertising, promotion, sampling, record-keeping and submission of safety and other post-market information, among other things. Any regulatory approvals received for such products may also be subject to limitations on the approved indicated uses for which they may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing and surveillance studies. For example, the holder of an approved BLA in the United States is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. In the United States, the holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Similar provisions apply in the EU. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws. Similarly, in the EU any promotion of medicinal products is highly regulated and, depending on the specific jurisdiction involved, may require prior vetting by the competent national regulatory authority. In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the BLA or foreign marketing application.
If we, our collaborators or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured or disagrees with the promotion, marketing or labeling of that product, a regulatory agency may impose restrictions relative to that product, the manufacturing facility or us or our collaborators, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.
Moreover, if any of our product candidates are approved, our product labeling, advertising, promotion and distribution will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product’s approved labeling. If we or our collaborators fail to comply with applicable regulatory requirements following approval of any potential products we may develop, authorities may:
issue an untitled enforcement letter or a warning letter asserting a violation of the law;
seek an injunction, impose civil and criminal penalties, and impose monetary fines, restitution or disgorgement of profits or revenues;
suspend or withdraw regulatory approval;
suspend or terminate any ongoing clinical trials or implement requirements to conduct post-marketing studies or clinical trials;
refuse to approve a pending BLA or comparable foreign marketing application (or any supplements thereto) submitted by us or our collaborators;
restrict the labeling, marketing, distribution, use or manufacturing of products;
seize or detain products or otherwise require the withdrawal or recall of products from the market;
refuse to approve pending applications or supplements to approved applications that we or our collaborators submit;
refuse to permit the import or export of products; or
refuse to allow us or our collaborators to enter into government contracts.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our or our collaborators’ ability to commercialize products and our ability to generate revenues.

31



In addition, the FDA’s policies, and policies of foreign regulatory agencies, may change, and additional regulations may be enacted that could prevent, limit or delay regulatory approval of product candidates. For example, in December 2016, the 21st Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of biologics and spur innovation. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance and review and approval of marketing applications. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements, or if we or our collaborators are unable to maintain regulatory compliance, marketing approval that has been obtained may be lost.
Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products from being developed or commercialized in a timely manner, which could negatively impact our business.
The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.
Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business.  For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
Our product candidates for which we intend to seek approval as a biologic products may face competition sooner than anticipated.
The BCPIA enacted in the Patient Protection and Affordable Care Act, signed into law on March 23, 2010, created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor’s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when the FDA will fully adopt processes intended to implement BPCIA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.
We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.
We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development

32



programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects.
We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. As a result, we are and expect to remain dependent on third parties to conduct clinical trials of our product candidates. Specifically, we expect CROs, clinical investigators, and consultants to play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, we will not be able to control all aspects of their activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, clinical trial investigators and clinical trial sites. If we or any of our CROs or clinical trial sites fail to comply with applicable GCP requirements, the data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to stop and/or repeat clinical trials, which would delay the marketing approval process.
There is no guarantee that any such CROs, clinical trial investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, otherwise performs in a substandard manner, or terminates its engagement with us, the timelines for our development programs may be extended or delayed or our development activities may be suspended or terminated. If any of our clinical trial sites terminates for any reason, we may experience the loss of follow-up information on subjects enrolled in such clinical trials unless we are able to transfer those subjects to another qualified clinical trial site, which may be difficult or impossible. In addition, clinical trial investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA or comparable foreign regulatory authorities concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any marketing application we submit by the FDA or any comparable foreign regulatory authority. Any such delay or rejection could prevent us from commercializing our product candidates.
We contract with third parties for the manufacturing and supply of product candidates for use in preclinical testing and clinical trials and related services, which supply may become limited or interrupted or may not be of satisfactory quality and quantity.
We do not have any manufacturing facilities. We produce in our laboratory relatively small quantities of products for evaluation in our research programs. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates are approved. We currently have limited manufacturing arrangements and expect that each of our product candidates will only be covered by single source suppliers for the foreseeable future. This reliance increases the risk that we will not have sufficient quantities of our product candidates or products, if approved, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.
Furthermore, all entities involved in the preparation of therapeutics for clinical trials or commercial sale, including our existing contract manufacturers for our product candidates, are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in clinical trials must be manufactured in accordance with cGMP requirements. These regulations govern manufacturing processes and procedures, including record keeping, and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants, or to inadvertent changes in the properties or stability of our product candidates that may not be detectable in final product testing. We or our contract manufacturers must supply all necessary documentation in support of a BLA on a timely basis and must adhere to the FDA’s cGMP regulations enforced by the FDA through its facilities inspection program. Comparable foreign regulatory authorities may require compliance with similar requirements. The facilities and quality systems of our third-party contractor manufacturers must pass a pre-approval inspection for compliance with the applicable regulations as a condition of marketing approval of our product candidates. We do not control the manufacturing activities of, and are completely dependent on, our contract manufacturers for compliance with cGMP regulations.

33



In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.
Our or a third party’s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including:
an inability to initiate or continue clinical trials of our product candidates under development;
delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
loss of the cooperation of future collaborators;
subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;
requirements to cease development or to recall batches of our product candidates; and
in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates.
Our efforts to prosecute and protect our intellectual property may not be successful.
We will continue to file and prosecute patent applications and maintain trade secrets in an ongoing effort to protect our intellectual property. It is possible that our current patents, or patents which we may later acquire, may be successfully challenged or invalidated in whole or in part. It is also possible that we may not obtain issued patents from our pending patent applications or other inventions we seek to protect. We sometimes permit certain intellectual property to lapse or go abandoned under appropriate circumstances. Due to uncertainties inherent in prosecuting patent applications, sometimes patent applications are rejected and we subsequently abandon them. It is also possible that we may develop proprietary products or technologies in the future that are not patentable or that the patents of others will limit or altogether preclude our ability to conduct business. In addition, any patent issued to us may provide us with little or no competitive advantage, in which case we may abandon such patent or license it to another entity.
Our means of protecting our proprietary rights may not be adequate and our competitors may independently develop technology or products that are similar to ours or that compete with ours. Patent, trademark, and trade secret laws afford only limited protection for our technology platform and products. The laws of many countries do not protect our proprietary rights to as great an extent as do the laws of the United States. Despite our efforts to protect our proprietary rights, unauthorized parties have in the past attempted, and may in the future attempt, to operate under aspects of our intellectual property or products or to obtain and use information that we regard as proprietary. Third parties may also design around our proprietary rights, which may render our protected technology and products less valuable, if the design around is favorably received in the marketplace. In addition, if any of our products or technology is covered by third-party patents or other intellectual property rights, we could be subject to various legal actions. We cannot assure you that our technology platform and products do not infringe patents held by others or that they will not in the future.
Litigation may be necessary to enforce our intellectual property rights, to protect our trade secrets, to determine the validity and scope of the proprietary rights of others, or to defend against claims of infringement, invalidity, misappropriation, or other claims.

34



Any such litigation could result in substantial costs and diversion of our resources. Moreover, any settlement of or adverse judgment resulting from litigation relating to intellectual property could require us to obtain a license to continue to make, use or sell the products or technology that is the subject of the claim, or otherwise restrict or prohibit our use of the technology.
Our ability to compete may decline if we do not adequately protect our proprietary technologies or if we lose some of our intellectual property rights.
Our success depends in part on our ability to obtain patents and maintain adequate protection of our intellectual property for our technologies and products and potential products in the United States and other countries. We have adopted a strategy of seeking patent protection in the United States and in foreign countries with respect to certain of the technologies used in or relating to our products and processes. As such, as of December 31, 2018, we owned or controlled approximately 1,100 issued patents and pending patent applications in the United States and in various foreign jurisdictions. Our intellectual property rights, as of December 31, 2018, have terms that expire between 2019 and 2039. We also have license rights to a number of issued patents and pending patent applications in the United States and in various foreign jurisdictions. Our owned and licensed patents and patent applications include those directed to our enabling technologies and to the methods and products that support our business in the pharmaceuticals manufacturing and complex chemistry markets. We intend to continue to apply for patents relating to our technologies, methods and products as we deem appropriate.
Numerous patents in our portfolio involve complex legal and factual questions and, therefore, enforceability cannot be predicted with any certainty. Issued patents and patents issuing from pending applications may be challenged, invalidated, or circumvented. Moreover, the United States Leahy-Smith America Invents Act (“AIA”), enacted in September 2011, brought significant changes to the United States patent system, which include a change to a “first to file” system from a “first to invent” system and changes to the procedures for challenging issued patents and disputing patent applications during the examination process, among other things. While interference proceedings are possible for patent claims filed prior to March 16, 2013, many of our filings will be subject to the post- and pre-grant proceedings set forth in the AIA, including citation of prior art and written statements by third parties, third party pre-issuance submissions, ex parte reexamination, inter partes review, post-grant review, and derivation proceedings. We may need to utilize the processes provided by the AIA for supplemental examination or patent reissuance. These proceedings could result in substantial cost to us even if the outcome is favorable. Even if successful, any interference may result in loss of certain claims. Any litigation or proceedings could divert our management's time and efforts. Even unsuccessful claims filed by third parties could result in significant legal fees and other expenses, diversion of management time, and disruption in our business. Uncertainties resulting from initiation and continuation of any patent or related litigation could harm our ability to compete. We have not assessed the applicability of the AIA and new regulations on our patent portfolio. These changes could increase the costs and uncertainties surrounding the prosecution of our patent applications and the enforcement or defense of our patent rights.
Additional uncertainty may result from legal precedent handed down by the United States Federal Circuit Court and Supreme Court as they determine legal issues concerning the scope and construction of patent claims and inconsistent interpretation of patent laws by the lower courts. Accordingly, we cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies' patents. Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that: (i) we were the first to invent the inventions covered by each of our pending applications, (ii) we were the first to file patent applications for these inventions, or (iii) the proprietary technologies we develop will be patentable. In addition, unauthorized parties may attempt to copy or otherwise obtain and use our products or technology. Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technology, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States. Moreover, third parties could practice our inventions in territories where we do not have patent protection. Such third parties may then try to import products made using our inventions into the United States or other territories. If competitors are able to use our technology, our ability to compete effectively could be harmed. In addition, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies. If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could cause harm to our business.
Third parties may claim that we are infringing their intellectual property rights or other proprietary rights, which may subject us to costly and time consuming litigation and prevent us from developing or commercializing our products.
Our commercial success also depends in part on our ability to operate without infringing patents and proprietary rights of third parties, and without breaching any licenses or other agreements that we have entered into with regard to our technologies, products and business. We cannot ensure that patents have not been issued to third parties that could block our ability to obtain patents or to operate as we would like. There may be patents in some countries that, if valid, may block our ability to make, use or sell our products in those countries, or import our products into those countries, if we are unsuccessful in circumventing or

35



acquiring rights to these patents. There also may be claims in patent applications filed in some countries that, if granted and valid, may also block our ability to commercialize products or processes in these countries if we are unable to circumvent or license them.
The industries in which we operate and the biotechnology industry, in particular, are characterized by frequent and extensive litigation regarding patents and other intellectual property rights. Many biotechnology companies have employed intellectual property litigation as a way to gain a competitive advantage. Our involvement in litigation or other intellectual property proceedings inside and outside of the United States, to defend our intellectual property rights or as a result of alleged infringement of the rights of others, may divert our management’s time from focusing on business operations and could cause us to spend significant amounts of money. Any potential intellectual property litigation also could force us to do one or more of the following:
stop selling or using our products or technologies that use the subject intellectual property;
pay monetary damages or substantial royalties;
grant cross-licenses to third parties relating to our patents or proprietary rights;
obtain from the third party asserting its intellectual property rights a license to sell or use the relevant technology, which license may not be available on reasonable terms, or at all; or
redesign those products or processes that use any allegedly infringing technology, or relocate the operations relating to the allegedly infringing technology to another jurisdiction, which may result in significant cost or delay to us, could be technically infeasible or could prevent us from selling some of our products in the United States or other jurisdictions.
We are aware of some patents and patent applications relating to aspects of our technologies filed by, and issued to, third parties. We cannot assure you that if this third party intellectual property is asserted against us that we would ultimately prevail.
We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful.
Competitors may infringe our intellectual property rights or those of our licensors. To prevent infringement or unauthorized use, we have in the past filed, and may in the future be required to file, infringement claims, which can be expensive and time-consuming. See Item 3, “Legal Proceedings.” In addition, in a patent infringement proceeding, a court may decide that a patent we own or in-license is not valid, is unenforceable and/or is not infringed. In legal proceedings against a third party to enforce a patent directed at one of our technologies or products, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO, even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable, and prior art could render our patents or those of our licensors invalid. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product. Such a loss of patent protection would have a material adverse impact on our business.
Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our expenses and reduce the resources available for operations and research and development activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
We may not be able to enforce our intellectual property rights throughout the world.
The laws of some foreign countries where we do business do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual

36



property rights in certain foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property, particularly those relating to biotechnology and/or bioindustrial technologies. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. This could make it difficult for us to stop the infringement of our patents or misappropriation of our other intellectual property rights. Additionally, proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business.
If we lose key personnel, including key management personnel, or are unable to attract and retain additional personnel as needed in the future, it could disrupt the operation of our business, delay our product development programs, harm our research and development efforts, and/or impact our ability to pursue and build collaborations.
Our business involves complex, global operations across a variety of markets and requires a management team and employee workforce that is knowledgeable in the many areas in which we operate. The loss of any key members of our management team or the failure to attract or retain other key employees who possess the requisite expertise for the conduct of our business could prevent us from developing and commercializing our products for our target markets and entering into collaborations or licensing arrangements to execute on our business strategy.
In addition, the loss of any key scientific staff, or the failure to attract or retain other key scientific employees, could prevent us from developing and commercializing our products for our target markets and entering into collaborations or licensing arrangements to execute on our business strategy. We may not be able to attract or retain qualified employees in the future due to the intense competition for qualified personnel among biotechnology and other technology-based businesses or due to the availability of personnel with the qualifications or experience necessary for our business. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience staffing constraints that will adversely affect our ability to meet the demands of our collaborators and customers in a timely fashion or to support our internal research and development programs. Competition for experienced scientists and other technical personnel from numerous companies and academic and other research institutions may limit our ability to do so on acceptable terms. All of our employees are at-will employees, which mean that either the employee or we may terminate their employment at any time.
Our planned activities will require additional expertise in specific industries and areas applicable to the products and processes developed through our technology platform or acquired through strategic or other transactions, especially in the end markets that we seek to penetrate. These activities will require the addition of new personnel, and the development of additional expertise by existing personnel. The inability to attract personnel with appropriate skills or to develop the necessary expertise could impair our ability to grow our business.
If our protein catalysts, or the genes that code for our protein catalysts, are stolen, misappropriated or reverse engineered, others could use these biocatalysts or genes to produce competing products.
Third parties, including our contract manufacturers, customers and those involved in shipping our protein catalysts, often have custody or control of our protein catalysts. If our protein catalysts, or the genes that code for our protein catalysts, were stolen, misappropriated or reverse engineered, they could be used by other parties who may be able to reproduce these protein catalysts for their own commercial gain. If this were to occur, it may be difficult for us to challenge this type of use, especially in countries with limited intellectual property protection or in countries in which we do not have patents covering the misappropriated biocatalysts.
Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.
We rely in part on trade secret protection to protect our confidential and proprietary information and processes. However, trade secrets are difficult to protect. We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective. We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us. These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties. These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

37



We may need additional capital in the future in order to expand our business.
Our future capital requirements may be substantial, particularly as we continue to develop our business. Although we believe that, based on our current level of operations, our existing cash, cash equivalents and equity securities will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial success of our biocatalysis business, our spending to develop and commercialize new and existing products and the amount of collaboration funding we may receive to help cover the cost of such expenditures, the effect of any acquisitions of other businesses, technologies or facilities that we may make or develop in the future, our spending on new market opportunities, including opportunities in the fine chemicals markets, and the filing, prosecution, enforcement and defense of patent claims. If our capital resources are insufficient to meet our capital requirements, and we are unable to enter into or maintain collaborations with partners that are able or willing to fund our development efforts or commercialize any products that we develop or enable, we will have to raise additional funds to continue the development of our technology and products and complete the commercialization of products, if any, resulting from our technologies. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. We may seek to obtain such additional capital through equity offerings, debt financings, credit facilities and/or strategic collaborations. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. If we raise debt financing or enter into credit facilities, we may be subject to restrictive covenants that limit our ability to conduct our business. Strategic collaborations may also place restrictions on our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to control operating costs, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.
If we are unable to comply with the terms of our credit facility, our business and financial condition would be materially and adversely affected.
On June 30, 2017 we entered into a credit facility ("Credit Facility") financing arrangement secured by a lien on substantially all of our personal property other than our intellectual property. Although we have made no loans or draws under the Credit Facility as of December 31, 2018, the Credit Facility includes affirmative and negative covenants including, among others, covenants requiring us to achieve consolidated product revenues at minimum levels and restricting our ability to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens and sell assets. The Credit Facility also includes events of default including, among other things, our failure to pay any amounts due under the Credit Facility, a breach of covenants under the Credit Facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000 and a final judgment against us in an amount greater than $250,000. If an event of default occurs, it could cause our obligations to become immediately due and payable and our lender would be entitled to foreclose against the collateral securing the indebtedness, including our cash. If our indebtedness were to be accelerated, we may be unable to repay such debt and, therefore, such acceleration could materially and adversely affect our business and financial condition. For more information regarding our compliance with our financial covenants, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”
Debt service obligation may place us at a competitive disadvantage in our industry.
Draws under the Credit Facility would create debt service obligations for us. Although we have not drawn on the Credit Facility to date, any future draws under the Credit Facility and the related debt service requirements could adversely affect our ability to operate our business and may limit our ability to take advantage of potential business opportunities. For example, the Credit Facility presents the following risks, certain of which apply regardless of whether we draw on the Credit Facility:
we may be required to use a portion of our cash flow from operations to make debt service payments, thereby reducing the availability of our cash flow to fund working capital, capital expenditures, product development efforts, research and development, and other general corporate requirements;
our interest expense could increase if prevailing interest rates increase, because a portion of draws which could be made under the Credit Facility bear interest at floating rates;

38



the Credit Facility could reduce our flexibility to adjust to changing business conditions or obtain additional financing to fund working capital, capital expenditures, product development efforts, research and development, and other general corporate requirements; and
restrictive covenants in our Credit Facility, which apply regardless of whether we draw down under the facility, limit our ability to, among other things, transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens and sell assets.
Our revenues, financial condition and results of operations may also be adversely affected if one or more of our customers is delayed in paying, or becomes unable to pay, for our delivered products on a timely basis.
Certain of our customers may become subject to financial and other challenges that affect their cash flow. If these customers fail to pay us on a timely basis it may cause our financial results to fluctuate. Failure by such customers to pay us on timely basis, or at all, would adversely impact our financial condition.
If goodwill or other long-lived assets become impaired we may be required to record a significant charge to earnings.
Our total assets reflect goodwill of $3.2 million and other long-lived assets of $5.8 million as of December 31, 2018. Under accounting principles generally accepted in the United States (“GAAP”), we review goodwill for impairment on at least an annual basis and at any interim date whenever events or changes in circumstances indicate that the carrying value may not be recoverable. We review our long lived assets with finite lives for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable. Events or changes in circumstances (i.e., information that indicates an impairment might exist) could include: a significant decrease in the market price of our common stock; current period cash flow losses or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the assets; slower growth rates in our industry; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the assets; loss of significant customers or partners; or the current expectation that the assets will more likely than not be sold or disposed of significantly before the end of their estimated useful life. We tested goodwill for impairment as of December 31, 2018. Based on our analysis, we determined that the fair value of goodwill at the reporting unit level exceeded their carrying value and that no impairment was necessary as of December 31, 2018. Nevertheless, we may experience additional events or changes in circumstances in the future that we determine to be indicators of impairment and that may in turn require us to undertake impairment analysis in future periods. Depending on the circumstances and judgments made at such future time, the outcome of the analysis may require us to recognize impairment.
We may be required to record a significant charge to earnings in our financial statements during the period in which any impairment of our goodwill or other long-lived assets is determined, resulting in an adverse impact on our financial position and results of operations.
Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported results of operations.
Financial accounting standards may change or their interpretation may change. A change in accounting standards or practices can have a significant effect on our reported results and may even affect our reporting of transactions completed before the change becomes effective. Changes to existing rules or the re-examining of current practices may adversely affect our reported financial results or the way we conduct our business. In particular, in order to be able to comply with the requirements of the revenue recognition standard under Accounting Standards Update (ASU) 2014-09 Revenue from Contracts with Customers (Topic 606) and related amendments (“ASC 606”), we have updated and enhanced our internal accounting processes and our internal controls over financial reporting. This has required, and will continue to require, additional investments by us, and may require incremental resources that could increase our operating costs in future periods. Further, the timing of recognition for our product sales under certain license and supply agreements and research and development revenues, on or after January 1, 2018, have been changed as a result of ASC 606.
If we are unable to maintain effective internal control over financial reporting in the future, the accuracy and timeliness of our financial reporting may be adversely affected.
Section 404 of the Sarbanes-Oxley Act of 2002 requires companies to conduct a comprehensive evaluation of their disclosure controls and procedures over financial reporting. At the end of each fiscal year, we must perform an evaluation of our disclosure controls and procedures over financial reporting, include in our annual report the results of the evaluation, and have our external auditors publicly attest to such evaluation.

39



We have identified material weaknesses and other control deficiencies in the past, and while the material weaknesses have since been remediated, we cannot assure you that in the future additional material weaknesses or significant deficiencies will not exist or otherwise be discovered. If other deficiencies are discovered in the future, our ability to accurately report our financial position, results of operations or cash flows on timely basis could be impaired, which could result in late filings of our annual and quarterly reports under the Exchange Act, restatements of our consolidated financial statements, a decline in our stock price, suspension or delisting of our common stock by the Nasdaq Stock Market, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.
We are dependent on information technology systems, infrastructure and data, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.
Information technology helps us operate efficiently, interface with customers, maintain financial accuracy and efficiency, and accurately produce our financial statements. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology infrastructure, we could be subject to transaction errors, processing inefficiencies, the loss of customers, business disruptions, or the loss of or damage to intellectual property through security breach. If our data management systems do not effectively collect, store, process, and report relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human error, our ability to effectively plan, forecast, and execute our business plan and comply with applicable laws and regulations will be impaired, perhaps materially. Any such impairment could materially and adversely affect our financial condition, results of operations, cash flows, and the timeliness with which we report our internal and external operating results.
Our business may require us to use and store customer, employee, and business partner personally identifiable information (“PII”). This may include names, addresses, phone numbers, email addresses, contact preferences, tax identification numbers, and payment account information. We require user names and passwords in order to access our information technology systems. We also use encryption and authentication technologies to secure the transmission and storage of data. These security measures may be compromised as a result of security breaches by unauthorized persons, employee error, malfeasance, faulty password management, or other irregularity, and result in persons obtaining unauthorized access to our data or accounts. Third parties may attempt to fraudulently induce employees or customers into disclosing user names, passwords, or other sensitive information, which may in turn be used to access our information technology systems. For example, our employees have received “phishing” emails and phone calls attempting to induce them to divulge passwords and other sensitive information.
In addition, unauthorized persons may attempt to hack into our products or systems to obtain personal data relating to employees and other individuals, our confidential or proprietary information or confidential information we hold on behalf of third parties. If the unauthorized persons successfully hack into or interfere with our connected products or services, they may create issues with product functionality that could pose a risk of loss of data. We have programs in place to detect, contain, and respond to data security incidents, and we make ongoing improvements to our information-sharing products in order to minimize vulnerabilities, in accordance with industry and regulatory standards. However, because the techniques used to obtain unauthorized access to or sabotage systems change frequently and may be difficult to detect, we may not be able to anticipate and prevent these intrusions or mitigate them when and if they occur.
We also rely on external vendors to supply and/or support certain aspects of our information technology systems. The systems of these external vendors may contain defects in design or manufacture or other problems that could unexpectedly compromise information security of our own systems, and we are dependent on these third parties to deploy appropriate security programs to protect their systems.
While we devote significant resources to network security, data encryption, and other security measures to protect our systems and data, these security measures cannot provide absolute security. We may experience a breach of our systems and may be unable to protect sensitive data. The costs to us to eliminate or alleviate network security problems, bugs, viruses, worms, malicious software programs, and security vulnerabilities could be significant. Our efforts to address these problems may not be successful and could result in unexpected interruptions, delays, cessation of service, and harm to our business operations. Moreover, if a computer security breach affects our systems or results in the unauthorized release of PII, our reputation and brand could be materially damaged and use of our products and services could decrease. We would also be exposed to a risk of loss or litigation and potential liability, which could have a material adverse impact on our business, financial condition, results of operations, or cash flows.
Our business is subject to complex and evolving laws and regulations regarding privacy, data protection and other matters relating to information collection.

40



There are numerous state, federal and foreign laws, regulations, decisions, and directives regarding privacy and the collection, storage, transmission, use, processing, disclosure and protection of PII and other personal, customer, or other data, the scope of which is continually evolving and subject to differing interpretations. We may be subject to significant consequences, including penalties and fines, for any failure to comply with such laws, regulations and directives.
Furthermore, any failure, or perceived failure, by us to comply with or make effective modifications to our policies, or to comply with any federal, state or international privacy, data-retention or data-protection-related laws, regulations, orders or industry self-regulatory principles could result in proceedings or actions against us by governmental entities or others, a loss of customer confidence, damage to our brand and reputation and a loss of customers, any of which could have an adverse effect on our business. In addition, various federal, state and foreign legislative or regulatory bodies may enact new or additional laws and regulations concerning privacy, data-retention and data-protection issues, including laws or regulations mandating disclosure to domestic or international law enforcement bodies, which could adversely impact our business or our reputation with customers. For example, some countries have adopted laws mandating that some PII regarding customers in their country be maintained solely in their country. Having to maintain local data centers and redesign product, service and business operations to limit PII processing to within individual countries could increase our operating costs significantly.
Our product gross margins are variable and may decline from quarter to quarter.
Our product gross margins have varied significantly in the past and may continue to fluctuate from quarter to quarter and year to year in the future due to a variety of factors, including product mix, pricing pressure from our pharmaceutical customers and competition from other products or technologies. This variability may have a material adverse impact on our operating results and financial condition and cause our stock price to decline.
We face risks associated with our international business.
While we have a limited number of employees located outside of the United States, we are and will continue to be dependent upon contract manufacturers located outside of the United States. In addition, we have customers and partners located outside of the United States. Conducting business internationally exposes us to a variety of risks, including:
changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products, repatriate profits to the United States or operate our foreign-located facilities;
the imposition of tariffs;
the imposition of limitations on, or increase of, withholding and other taxes on remittances and other payments by foreign subsidiaries or joint ventures;
the imposition of limitations on genetically-engineered products or processes and the production or sale of those products or processes in foreign countries;
currency exchange rate fluctuations;
uncertainties relating to foreign laws, regulations and legal proceedings including tax, import/export, anti-corruption and exchange control laws;
the availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us;
increased demands on our limited resources created by our operations may constrain the capabilities of our administrative and operational resources and restrict our ability to attract, train, manage and retain qualified management, technicians, scientists and other personnel;
economic or political instability in foreign countries;
difficulties associated with staffing and managing foreign operations; and
the need to comply with a variety of United States and foreign laws applicable to the conduct of international business, including import and export control laws and anti-corruption laws.

41



Compliance with European Union chemical regulations could be costly and adversely affect our business and results of operations.
Some of our products are subject to the European Union regulatory regime known as The Registration, Evaluation and Authorization of Chemicals (“REACH”). REACH mandates that certain chemicals manufactured in, or imported into, the European Union be registered and evaluated for their potential effects on human health and the environment. Under REACH, we and our contract manufacturers located in the European Union are required to register certain of our products based on the quantity of such product imported into or manufactured in the European Union and on the product’s intended end-use. The registration, evaluation and authorization process under REACH can be costly and time consuming. Problems or delays in the registration, evaluation or authorization process under REACH could delay or prevent the manufacture of some of our products in, or the importation of some of our products into, the European Union, which could adversely affect our business and results of operations. In addition, if we or our contract manufacturers fail to comply with REACH, we may be subject to penalties or other enforcement actions, which could have a material adverse effect on our business and results of operations.
Competitors and potential competitors who have greater resources and experience than we do may develop products and technologies that make ours obsolete or may use their greater resources to gain market share at our expense.
The biocatalysis industry and each of our target markets are characterized by rapid technological change. Our future success will depend on our ability to maintain a competitive position with respect to technological advances. In addition, as we enter new markets, we will face new competition and will need to adapt to competitive factors that may be different from those we face today.
We are aware that other companies, including Royal DSM, N.V. (“DSM”), BASF, and Novozymes have alternative methods for obtaining and generating genetic diversity or use mutagenesis techniques to produce genetic diversity. Academic institutions such as the California Institute of Technology, the Max Planck Institute and the Austrian Centre of Industrial Biotechnology are also working in this field. Technological development by others may result in our products and technologies, as well as products developed by our customers using our biocatalysts, becoming obsolete.
Our primary competitors in the biocatalysis for pharmaceutical products are companies marketing either conventional, non-enzymatic processes or biocatalytic enzymes to manufacturers of pharmaceutical intermediates and APIs, and also existing in-house technologies (both biocatalysts and conventional catalysts) within our client and potential client companies. The principal methods of competition and competitive differentiation in this market are price, product quality and performance, including manufacturing yield, safety and environmental benefits, and speed of delivery of product. Pharmaceutical manufacturers that use biocatalytic processes can face increased competition from manufacturers that use more conventional processes and/or manufacturers that are based in regions (such as India and China) with lower regulatory, safety and environmental costs.
The market for the manufacture and supply of APIs and intermediates is large with many established companies. These companies include many of our large innovator and generic pharmaceutical customers, such as Merck, GSK, Pfizer, Bristol Myers, Squibb and Teva Pharmaceutical Industries Ltd., which have significant internal research and development efforts directed at developing processes to manufacture APIs and intermediates. The processes used by these companies include classical conventional organic chemistry reactions, chemo catalytic reactions, biocatalytic reactions or combinations thereof. Our biocatalytic based manufacturing processes must compete with these internally developed routes. Additionally, we also face competition from companies developing and marketing conventional catalysts such as Solvias Inc., BASF and Takasago International Corporation.
The market for supplying enzymes for use in pharmaceutical manufacturing is quite fragmented. There is competition from large industrial enzyme companies, such as Novozymes, as well as subsidiaries of larger CRO/CMOs, such as DSM, Cambrex Corporation and Almac Group Ltd. There is also competition in the customized and optimized enzyme area from several smaller companies, such as BRAIN AG, Arzeda, c-LEcta GmbH, Gingko Bioworks, Zymergen, and Evocatal GmbH.
We entered the fine chemicals market in 2013, by applying our protein engineering technology in the food market. We face similar forms of competition in this market as in the pharmaceutical markets with the exception that the risk of losing opportunities to larger competitors in fine chemicals is greater given the larger scale of opportunities available in the fine chemicals market compared to the pharmaceutical market. Our significant competitors in the fine chemicals markets include companies that have been in these marketplaces for many years, such as DuPont Industrial Biosciences (DuPont Genencor), DSM, Novozymes and A.B. Enzymes. These companies have greater resources in these markets than we do and have long-term supply arrangements already in place with customers. Our ability to compete in these markets may be limited by our relatively late entrance. We also face competition in both the fine chemicals and pharmaceutical markets from emerging companies offering whole cell metabolic pathway approaches to these markets.

42



There are numerous companies that participate in the biotherapeutics market generally and the PKU market specifically. Many of these companies are large, successful and well-capitalized. BioMarin Pharmaceutical Inc. (“BioMarin”) and Daiichi Sankyo Company market Kuvan® in the United States, Europe and Japan for the treatment of a certain type of PKU. In addition, BioMarin gained US FDA approval in 2018 and began commercial sales of PalynziqTM as an injectable enzyme substitution therapy for the potential treatment of PKU. Synlogic is developing SYNB1618 as a potential treatment for PKU, and in 2018, they completed a phase 1/2a clinical trial using SYNB1618. Takeda (who recently acquired Shire Plc), Genzyme / Sanofi S.A. and other companies market or are actively developing new enzyme therapeutics. There are numerous companies that are developing other forms of therapeutics, such as small molecules and gene therapies, which could compete with biotherapeutics.
Our ability to compete successfully in any of these markets will depend on our ability to develop proprietary products that reach the market in a timely manner and are technologically superior to and/or are less expensive than other products on the market. Many of our competitors have substantially greater production, financial, research and development, personnel and marketing resources than we do. They also started developing products earlier than we did, which may allow them to establish blocking intellectual property positions or bring products to market before we can. In addition, certain of our competitors may also benefit from local government subsidies and other incentives that are not available to us. As a result, our competitors may be able to develop competing and/or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we could. Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. We cannot be certain that any products we develop in the future will compare favorably to products offered by our competitors or that our existing or future products will compare favorably to any new products that are developed by our competitors. As more companies develop new intellectual property in our markets, the possibility of a competitor acquiring patent or other rights that may limit our products or potential products increases, which could lead to litigation.
Our limited resources relative to many of our competitors may cause us to fail to anticipate or respond adequately to new developments and other competitive pressures. This failure could reduce our competitiveness and market share, adversely affect our results of operations and financial position, and prevent us from obtaining or maintaining profitability.
We must rely on our suppliers, contract manufacturers and customers to deliver timely and accurate information in order to accurately report our financial results in the time frame and manner required by law.
We need to receive timely, accurate and complete information from a number of third parties in order to accurately report our financial results on a timely basis. We rely on suppliers and certain contract manufacturers to provide us with timely and accurate information regarding our inventories and manufacturing cost information, and we rely on current and former collaborators to provide us with product sales and cost saving information in connection with royalties owed to us. Any failure to receive timely information from one or more of these third parties could require that we estimate a greater portion of our revenues and other operating performance metrics for the period, which could cause our reported financial results to be incorrect. Moreover, if the information that we receive is not accurate, our financial statements may be materially incorrect and may require restatement, and we may not receive the full amount of revenues that we are entitled to under these arrangements. Although we typically have audit rights with these parties, performing such an audit could be harmful to our collaborative relationships, expensive and time consuming and may not be sufficient to reveal any discrepancies in a timeframe consistent with our reporting requirements.
Our results of operations may be adversely affected by the results of regulatory tax examinations.
We are subject to value added tax, customs tax, sales and use tax, withholding tax, payroll tax, income tax and other taxes in connection with the operation of our business. Regulators from the various jurisdictions in which we operate periodically perform audits, and we are regularly subject to, and are currently undergoing, audits and assessments by tax authorities in the United States and foreign jurisdictions for prior tax years. Although we believe our tax estimates are reasonable, and we intend to defend our positions if necessary, the final outcome of tax audits and related proceedings is inherently uncertain and could be materially different than that reflected in our historical income tax provisions and accruals. Moreover, we could be subject to assessments of substantial additional taxes and/or fines or penalties relating to ongoing or future audits. The adverse resolution of any audits or related proceedings could have an adverse effect on our financial position and results of operations.
Business interruptions could delay us in the process of developing our products and could disrupt our sales.
Our headquarters is located in the San Francisco Bay Area near known earthquake fault zones and is vulnerable to significant damage from earthquakes. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations, such as riot, civil disturbances, war, terrorist acts, flood, infections in our laboratory or production facilities or those of our contract manufacturers and other events beyond our control. We do not carry insurance for earthquakes and we may not

43



carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our cash flows and success as an overall business.
Ethical, legal and social concerns about genetically engineered products and processes could limit or prevent the use of our products, processes, and technologies and limit our revenues.
Some of our products and processes are genetically engineered or involve the use of genetically engineered products or genetic engineering technologies. If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, our products and processes may not be accepted. Any of the risks discussed below could result in increased expenses, delays, or other impediments to our programs or the public acceptance and commercialization of products and processes dependent on our technologies or inventions. Our ability to develop and commercialize one or more of our technologies, products, or processes could be limited by the following factors:
public attitudes about the safety and environmental hazards of, and ethical concerns over, genetic research and genetically engineered products and processes, which could influence public acceptance of our technologies, products and processes;
public attitudes regarding, and potential changes to laws governing ownership of genetic material, which could harm our intellectual property rights with respect to our genetic material and discourage collaborators from supporting, developing, or commercializing our products, processes and technologies; and
governmental reaction to negative publicity concerning genetically modified organisms, which could result in greater government regulation of genetic research and derivative products. The subject of genetically modified organisms has received negative publicity, which has aroused public debate. This adverse publicity could lead to greater regulation and trade restrictions on imports of genetically altered products. The protein catalysts that we develop have significantly enhanced characteristics compared to those found in naturally occurring enzymes or microbes. While we produce our biocatalysts only for use in a controlled industrial environment, the release of such biocatalysts into uncontrolled environments could have unintended consequences. Any adverse effect resulting from such a release could have a material adverse effect on our business and financial condition, and we may have exposure to liability for any resulting harm.
If we engage in any acquisitions, we will incur a variety of costs and may potentially face numerous risks that could adversely affect our business and operations.
We have made acquisitions in the past, and if appropriate opportunities become available, we expect to acquire additional businesses, assets, technologies, or products to enhance our business in the future. For example, in October 2010, we acquired substantially all of the patents and other intellectual property rights associated with Maxygen’s directed evolution technology.
In connection with any future acquisitions, we could:
issue additional equity securities, which would dilute our current stockholders;
incur substantial debt to fund the acquisitions;
use our cash to fund the acquisitions; or
assume significant liabilities including litigation risk.
Acquisitions involve numerous risks, including problems integrating the purchased operations, technologies or products, unanticipated costs and other liabilities, diversion of management’s attention from our core businesses, adverse effects on existing business relationships with current and/or prospective collaborators, customers and/or suppliers, risks associated with entering markets in which we have no or limited prior experience and potential loss of key employees. We do not have extensive experience in managing the integration process and we may not be able to successfully integrate any businesses, assets, products, technologies, or personnel that we might acquire in the future without a significant expenditure of operating, financial and management resources, if at all. The integration process could divert management’s time from focusing on operating our business, result in a decline in employee morale and cause retention issues to arise from changes in compensation, reporting relationships, future prospects or the direction of the business. Acquisitions may also require us to record goodwill and non-amortizable intangible assets that will be subject to impairment testing on a regular basis and potential periodic impairment charges, incur amortization expenses related to certain intangible assets, and incur large and immediate write offs and restructuring and other related expenses, all of which could harm our operating results and financial condition. In addition, we may acquire companies that have insufficient internal financial controls, which could impair our ability to integrate the acquired company and adversely impact our financial reporting. If we fail in our integration efforts with respect to any of our acquisitions and are unable to efficiently operate as a combined organization, our business and financial condition may be adversely affected.

44



We use hazardous materials in our business and we must comply with environmental laws and regulations. Any claims relating to improper handling, storage or disposal of these materials or noncompliance of applicable laws and regulations could be time consuming and costly and could adversely affect our business and results of operations.
Our research and development and commercial processes involve the use of hazardous materials, including chemical, radioactive, and biological materials. Our operations also produce hazardous waste. We cannot eliminate entirely the risk of accidental contamination or discharge and any resultant injury from these materials. Federal, state, local and foreign laws and regulations govern the use, manufacture, storage, handling and disposal of, and human exposure to, these materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials, and our liability may exceed our total assets. Although we believe that our activities comply in all material respects with environmental laws, there can be no assurance that violations of environmental, health and safety laws will not occur in the future as a result of human error, accident, equipment failure or other causes. Compliance with applicable environmental laws and regulations may be expensive, and the failure to comply with past, present, or future laws could result in the imposition of fines, third party property damage, product liability and personal injury claims, investigation and remediation costs, the suspension of production, or a cessation of operations, and our liability may exceed our total assets. Liability under environmental laws can be joint and several and without regard to comparative fault. Environmental laws could become more stringent over time imposing greater compliance costs and increasing risks and penalties associated with violations, which could impair our research, development or production efforts and harm our business. In addition, we may have to indemnify some of our customers or suppliers for losses related to our failure to comply with environmental laws, which could expose us to significant liabilities.
We may be sued for product liability.
The design, development, manufacture and sale of our products involve an inherent risk of product liability claims and the associated adverse publicity. For example, we may be named directly in product liability suits relating to drugs that are produced using our enzymes or that incorporate our intermediates and APIs. The biocatalysts, pharmaceutical intermediates and APIs that we produce or are produced for us by our manufacturing partners could be subject to quality control or contamination issues of which we are not aware. Claims could be brought by various parties, including customers who are purchasing products directly from us, other companies who purchase products from our customers or by the end users of the drugs. We could also be named as co-parties in product liability suits that are brought against our contract manufacturers who manufacture our enzymes, pharmaceutical intermediates and APIs. Insurance coverage is expensive and may be difficult to obtain, and may not be available in the future on acceptable terms, or at all. We cannot assure you that any contract manufacturer that we have used in the past or shall use in the future has or will have adequate insurance coverage to cover against potential claims. In addition, although we currently maintain product liability insurance for our products in amounts we believe to be commercially reasonable, if the coverage limits of these insurance policies are not adequate, a claim brought against us, whether covered by insurance or not, could have a material adverse effect on our business, results of operations, financial condition and cash flows. This insurance may not provide adequate coverage against potential losses, and if claims or losses exceed our liability insurance coverage, we may go out of business. Moreover, we have agreed to indemnify some of our customers for certain claims that may arise out of the use of our products, which could expose us to significant liabilities.
Uncertainties in the interpretation and application of the 2017 Tax Cuts and Jobs Act could materially affect our tax obligations and effective tax rate.
The 2017 Tax Cuts and Jobs Act (the “Tax Act”) was enacted on December 22, 2017, and significantly changed how the U.S. imposes income tax on multinational corporations. Changes include, but are not limited to, a corporate tax rate decrease from 35% to 21% effective for tax years beginning after December 31, 2017, the transition of U.S. international taxation from a worldwide tax system to a partially territorial system, and a one-time transition tax on the mandatory deemed repatriation of accumulated foreign earnings as of December 31, 2017. The U.S. Department of Treasury (“Treasury”) has broad authority to issue regulations and interpretative guidance that may significantly impact how we will apply the law and impact our results of operations in the period issued. The Tax Act requires complex computations not previously required under U.S. tax law. As of December 31, 2018, the application of accounting guidance for some of these items is still currently uncertain, as Treasury has yet to issue proposed or final regulations for many provisions of the Act. Further, compliance with the Tax Act and the accounting for such provisions require accumulation of information not previously required or regularly produced. As additional regulatory guidance is issued by the applicable taxing authorities, as accounting treatment is clarified, and as we perform additional analysis on the application of the law, our results may be different from our current amounts, which could materially affect our tax obligations and effective tax rate.

45



Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.
In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the “Code”), a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating loss carryforwards (“NOLs”), to offset future taxable income. If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Code. Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Code. Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. For these reasons, we may not be able to utilize a material portion of the NOLs reflected in our financial statements, even if we attain profitability.
Risks Related to Owning our Common Stock
We are subject to anti-takeover provisions in our certificate of incorporation and bylaws and under Delaware law that could delay or prevent an acquisition of our company, even if the acquisition would be beneficial to our stockholders.
Provisions in our amended and restated certificate of incorporation and our bylaws may delay or prevent an acquisition of us. Among other things, our amended and restated certificate of incorporation and bylaws provide for a board of directors which is divided into three classes, with staggered three-year terms and provide that all stockholder action must be effected at a duly called meeting of the stockholders and not by a consent in writing, and further provide that only our board of directors, the chairman of the board of directors, our chief executive officer or president may call a special meeting of the stockholders. In addition, our amended and restated certificate of incorporation allows our board of directors, without further action by our stockholders, to issue up to 5,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These provisions may also frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management team. Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law which prohibits, with some exceptions, stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Finally, our charter documents establish advanced notice requirements for nominations for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings. Although we believe these provisions together provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer to acquire our company may be considered beneficial by some stockholders.
Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.
Based on the number of shares outstanding as of December 31, 2018, our officers, directors and stockholders who hold at least 5% of our stock together beneficially own approximately 40% of our outstanding common stock. If these officers, directors, and principal stockholders or a group of our principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and control matters requiring stockholder approval, including the election of directors and approval of mergers or other business combination transactions. The interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders. For instance, officers, directors, and principal stockholders, acting together, could cause us to enter into transactions or agreements that we would not otherwise consider. Similarly, this concentration of ownership may have the effect of delaying or preventing a change in control of our company otherwise favored by our other stockholders. As of December 31, 2018, one stockholder beneficially owned approximately 12% of our common stock.
Our share price may be volatile which may cause the value of our common stock to decline and subject us to securities class action litigation.
The market price of shares of our common stock could be subject to wide fluctuations in response to many risk factors listed in this section, and others beyond our control, including:
actual or anticipated fluctuations in our financial condition and operating results;
the position of our cash, cash equivalents and equity securities;
actual or anticipated changes in our growth rate relative to our competitors;
actual or anticipated fluctuations in our competitors’ operating results or changes in their growth rate;
announcements of technological innovations by us, our collaborators or our competitors;

46



announcements by us, our collaborators or our competitors of significant acquisitions or dispositions, strategic partnerships, joint ventures or capital commitments;
additions or losses of one or more significant pharmaceutical products;
announcements or developments regarding pharmaceutical products manufactured using our protein catalysts and intermediates;
the entry into, modification or termination of collaborative arrangements;
additions or losses of customers;
additions or departures of key management or scientific personnel;
competition from existing products or new products that may emerge;
issuance of new or updated research reports by securities or industry analysts;
fluctuations in the valuation of companies perceived by investors to be comparable to us;
disputes or other developments related to proprietary rights, including patent litigation and our ability to obtain patent protection for our technologies;
contractual disputes or litigation with our partners, customers or suppliers;
announcement or expectation of additional financing efforts;
sales of our common stock by us, our insiders or our other stockholders;
share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
general market conditions in our industry; and
general economic and market conditions, including the recent financial crisis.
Furthermore, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business.
We may incur losses associated with currency fluctuations and may not be able to effectively hedge our exposure.
Our operating results and cash flows are subject to volatility due to fluctuations in foreign currency exchange rates. Our primary exposure to fluctuations in foreign currency exchange rates relates to cash denominated in currencies other than the U.S. dollar. The weakening of foreign currencies relative to the United States dollar adversely affects our foreign currency-denominated cash. In periods when the United States dollar declines in value as compared to the foreign currencies in which we incur expenses, our foreign-currency based cash decrease when translated into United States dollars. Conversely, the strengthening of foreign currencies relative to the United States dollar will generally be beneficial to our foreign currency-denominated cash when translated into United States dollars.
The effect of a 10% unfavorable change in exchange rates on foreign denominated receivables and cash as of December 31, 2018 would have had foreign exchange losses of approximately $0.1 million recognized as a component of other expense in our consolidated statement of operations.
We do not engage in foreign currency hedging transactions, and as a result, unfavorable movements in foreign currency exchange rates may have an adverse financial impact, which could materially adversely affect our financial condition or results of operations. See “Item 7A. Quantitative and Qualitative Disclosures About Market Risk” for additional discussion on the impact of foreign exchange risk.
If securities or industry analysts do not publish research or reports about our business, or publish negative reports about our business, our stock price and trading volume could decline.
The trading market for our common stock will be influenced by the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the analysts who cover us downgrade our stock or change their opinion of our stock in a negative manner, our stock price would likely decline. If one or

47



more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which could cause our stock price or trading volume to decline.
We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives.
As a public company, we incur significant legal, accounting and other expenses. In addition, the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as related rules implemented by the Securities and Exchange Commission and the Nasdaq Stock Market, impose various requirements on public companies that require our management and other personnel to devote a substantial amount of time to compliance initiatives.
In addition, the Sarbanes-Oxley Act requires, among other things, that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal control over financial reporting to allow management and our independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Our compliance with Section 404 requires that we incur substantial accounting expense and expend significant management time on compliance-related issues. Moreover, if we are not able to maintain compliance with the requirements of Section 404, our stock price could decline, and we could face sanctions, delisting or investigations by the Nasdaq Global Market, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity.
ITEM 1B. UNRESOLVED STAFF COMMENTS
Not applicable.
ITEM 2. PROPERTIES
Facilities
Our headquarters are located in Redwood City, California, where we lease approximately 107,200 square feet of office and laboratory space.
Our lease (“Lease”) with Metropolitan Life Insurance Company (“MetLife”) includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “Penobscot Space”), approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “Building 2 Space”), approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (“501 Chesapeake Space”), and approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”). Through December 31, 2018, there have been seven amendments to the Lease. Through November 30, 2019, we will continue to sublease approximately 26,500 square feet of the Saginaw Space to a subtenant and we will continue to sublease approximately 13,000 square feet of the Penobscot Space to a different subtenant.
In January 2019, we entered into an Eighth Amendment to the Lease ( the “Eighth Amendment”) with MetLife with respect to the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space to extend the term of the Lease for additional periods. Pursuant to the Eighth Amendment, the term of the lease of the Penobscot Space and the Building 2 Space has been extended through May 2027. The lease term for 501 Chesapeake Space has been extended to May 2029. We have two consecutive options to extend the term of the lease for the Penobscot Space, the Building 2 Space and 501 Chesapeake Space for an additional period of five years per option. Our lease on the Saginaw Space will expire on January 30, 2020.
We believe that the facilities that we currently lease in California are adequate for our needs for the immediate future and that, should it be needed, additional space can be leased to accommodate any future growth.

ITEM 3. LEGAL PROCEEDINGS
We are not currently a party to any material pending litigation or other material legal proceedings.
In February 2018, we and EnzymeWorks, Inc. (U.S.), Suzhou Hanmei Biotechnology Co. Ltd, d/b/a EnzymeWorks, Inc. (China) (collectively, "EnzymeWorks"), Junhua Tao, and Andrew Tao reached a settlement concerning the lawsuit filed by us in February 2016 against EnzymeWorks, Junhua Tao, and Andrew Tao in the United States District Court for the Northern District of California. The parties have entered into a settlement agreement, the terms of which are confidential. The parties have also

48



stipulated to a judgment of patent infringement of all asserted patents against EnzymeWorks, and a permanent injunction barring any future infringement. The remaining claims against EnzymeWorks, and all claims against Junhua Tao, and Andrew Tao including trade secret misappropriation, breach of contract and voidable transfer have been dismissed with prejudice. EnzymeWorks appealed the sanctions levied against them by Judge Orrick to the Federal Circuit and filed its opening brief on May 30, 2018.  On July 9, 2018, Codexis filed its response brief, and EnzymeWorks filed its reply on July 30, 2018. On February 8, 2019, the Federal Circuit panel of judges assigned to the case issued an opinion affirming the lower court’s ruling and remanding the case to the lower court on jurisdictional grounds to vacate the order to which the parties had earlier stipulated.

ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.

49



PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
Market Information
Our common stock is quoted on the Nasdaq Global Select Market (“Nasdaq”), under the symbol “CDXS.” The following table sets forth the high and low sales prices per share of the common stock as reported on Nasdaq. Such quotations represent inter dealer prices without retail markup, markdown or commission and may not necessarily represent actual transactions. 
Fiscal 2018
High
 
Low
First Quarter
$
13.60

 
$
7.95

Second Quarter
16.80

 
9.30

Third Quarter
19.60

 
12.85

Fourth Quarter
23.05

 
14.05

Fiscal 2017
High
 
Low
First Quarter
$
5.29

 
$
3.60

Second Quarter
5.45

 
3.95

Third Quarter
6.70

 
4.80

Fourth Quarter
8.55

 
5.70

As of February 22, 2019, there were approximately 132 stockholders of record. A substantially greater number of stockholders may be “street name” or beneficial holders, whose shares are held of record by banks, brokers and other financial institutions.
Stock Price Performance Graph
The following tabular information and graph compare our total common stock return with the total return for (i) the Nasdaq Composite Index and (ii) the Nasdaq Biotechnology Index for the period December 31, 2013 through December 31, 2018. The figures represented below assume an investment of $100 in our common stock at the closing price on December 31, 2013 and in the Nasdaq Composite Index and the Nasdaq Biotechnology Index on December 31, 2013 and the reinvestment of dividends into shares of common stock. The comparisons in the table and graph are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock. The tabular information and graph shall not be deemed “soliciting material” or to be “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act or the Exchange Act.
 
 
 
 
December 31,
$100 investment in stock or index
 
Ticker
 
2013
 
2014
 
2015
 
2016
 
2017
 
2018
Codexis, Inc.
 
CDXS
 
$
100.00

 
$
180.00

 
$
302.14

 
$
328.57

 
$
596.43

 
$
1,192.86

Nasdaq Composite Total Return
 
XCMP
 
$
100.00

 
$
114.75

 
$
122.74

 
$
133.62

 
$
173.22

 
$
168.30

Nasdaq Biotechnology (Total Return) Index
 
XNBI
 
$
100.00

 
$
136.28

 
$
152.32

 
$
119.80

 
$
145.71

 
$
132.80




50



chart-17ff03687634512f82f.jpg


51




ITEM 6. SELECTED FINANCIAL DATA
The following selected consolidated financial data should be read together with our consolidated financial statements and accompanying notes and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing elsewhere in this Annual Report on Form 10-K. The selected consolidated financial data in this section is not intended to replace our consolidated financial statements and the accompanying notes. Our historical results are not necessarily indicative of our future results.
We derived the consolidated statements of operations data for the fiscal years ended December 31, 2018, 2017, and 2016 and the consolidated balance sheets data as of December 31, 2018 and 2017 from our audited consolidated financial statements appearing elsewhere in this filing. The consolidated statements of operations data for the fiscal years ended December 31, 2015 and 2014 and the consolidated balance sheets data as of December 31, 2016, 2015 and 2014 have been derived from our audited consolidated financial statements not included in this filing. The data should be read in conjunction with the consolidated financial statements, related notes, and other financial information included herein.
SELECTED CONSOLIDATED FINANCIAL DATA
 
Year Ended December 31,
 
2018
 
2017
 
2016
 
2015
 
2014
 
(1) 
 
 
 
 
 
 
 
 
 
(In Thousands, Except Per Share Amounts)
Consolidated Statements of Operations Data:
 
 
 
 
 
 
 
 
 
Revenues:
 
 
 
 
 
 
 
 
 
Product revenue
$
25,590

 
$
26,685

 
$
15,321

 
$
11,376

 
$
13,064

Research and development revenue
35,004

 
23,339

 
33,516

 
30,428

 
22,243

Total revenues
60,594

 
50,024

 
48,837

 
41,804

 
35,307

Costs and operating expenses:
 
 
 
 
 
 
 
 
 
Cost of product revenue
12,620

 
14,327

 
9,753

 
6,586

 
9,726

Research and development
29,978

 
29,659

 
22,229

 
20,673

 
22,755

Selling, general and administrative
29,291

 
29,008

 
25,419

 
22,315

 
21,937

Total costs and operating expenses
71,889

 
72,994

 
57,401

 
49,574

 
54,418

Loss from operations
(11,295
)
 
(22,970
)
 
(8,564
)
 
(7,770
)
 
(19,111
)
Interest income
671

 
147

 
60

 
19

 
18

Other expenses, net
(291
)
 
(92
)
 
(94
)
 
(168
)
 
(234
)
Loss before income taxes
(10,915
)
 
(22,915
)
 
(8,598
)
 
(7,919
)
 
(19,327
)
Provision for (benefit from) income taxes
(37
)
 
81

 
(40
)
 
(338
)
 
(256
)
Net loss
$
(10,878
)
 
$
(22,996
)
 
$
(8,558
)
 
$
(7,581
)
 
$
(19,071
)
Net loss per share, basic and diluted
$
(0.21
)
 
$
(0.50
)
 
$
(0.21
)
 
$
(0.19
)
 
$
(0.50
)
Weighted average common shares used in computing net loss per share, basic and diluted
52,205

 
46,228

 
40,629

 
39,438

 
38,209

 
 
 
 
 
 
 
 
 
 
(1) Financial results for year ended December 31, 2018, as compared to the years ended December 31, 2017, 2016, 2015, and 2014 reflect the effects of adopting ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” and the related amendments (ASC 606), which provided a new basis of accounting for our revenue arrangements during fiscal year 2018. The adoption of ASC 606 limits the comparability of revenue and certain expenses, including revenues and costs and operating expenses, presented in the results of operations for the year ended December 31, 2018 when compared to the years ended December 31, 2017, 2016, 2015, and 2014. For additional information regarding the impact from adoption of this accounting standard, see Note 3, “Revenue Recognition” to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
 


52



 
December 31,
 
2018
 
2017
 
2016
 
2015
 
2014
Consolidated Balance Sheets Data:
(In Thousands)
Cash, cash equivalents and restricted cash
$
54,485

 
$
32,776

 
$
20,864

 
$
24,060

 
$
27,198

Working capital
50,085

 
20,087

 
14,860

 
17,998

 
19,272

Total assets
79,283

 
53,625

 
35,648

 
44,647

 
48,122

Total liabilities
22,977

 
29,078

 
16,549

 
21,768

 
21,811

Total stockholders’ equity
56,306

 
24,547

 
19,099

 
22,879

 
26,311


53



ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with our audited consolidated financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Exchange Act. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “estimate,” or “continue,” and similar expressions or variations. Such forward-looking statements are subject to risks, uncertainties and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section titled “Risk Factors,” set forth in Part I, Item 1A of this Annual Report on Form 10-K and elsewhere in this report. The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.
Business Overview
We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which we have been continuously improving over our sixteen year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.
We are a pioneer in the harnessing of computational technologies to drive biology advancements. Since our inception in 2002, we have made substantial investments in the development of our CodeEvolver® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.
Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design using our CodeEvolver® protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.
The successful embodiment of our CodeEvolver® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver® protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include several large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.
We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances and agricultural chemicals.
We have also begun using the CodeEvolver® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the

54



potential treatment of phenylketonuria ("PKU") in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement (the "Nestlé Agreement") with Nestec Ltd. ("Nestlé Health Science"), to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
In April 2018, we entered into a strategic agreement (the "Porton Agreement") with Porton Pharma Solutions, Ltd. ("Porton") to license key elements of our platform technology to Porton’s global custom intermediate and active pharmaceutical ingredients ("API") development and manufacturing business. This gives us access to a wide variety of small and medium-sized pharmaceutical customers.
We are also using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. Our first enzyme is a ligase which we began marketing to customers in 2018.
Business Segments
We manage our business as two business segments: Performance Enzymes and Novel Biotherapeutics. See Note 15, "Segment, Geographical and Other Revenue Information" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.

Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. In April 2018, we entered into the Porton Agreement related to our strategic collaboration with Porton to license key elements of our world-leading biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business.

Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.

55



We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.
For further description of our business segments, see Note 15, "Segment, Geographical and Other Revenue Information," in the Notes to Condensed Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Results of Operations Overview
On January 1, 2018, we adopted Accounting Standards Update, or ASU, 2014-09 “Revenue from Contracts with Customers (Topic 606)” and the related amendments (“ASC 606”). Under the modified retrospective method, we applied the new standard to contracts which were not completed as of January 1, 2018. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and continue to be reported in accordance with our historic accounting under ASU 2009-13 “Revenue Recognition”(Topic 605)”. The adoption of ASC 606 limits the comparability of revenue and certain expenses, including revenues and costs and operating expenses, presented in the results of operations for the year ended December 31, 2018 when compared to the years ended December 31, 2017 and 2016. For additional information regarding the adoption of this accounting standard, see Note 2, “Summary of Significant Accounting Policies”, to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Revenues were $60.6 million in 2018, a 21% increase from $50.0 million in 2017. Product revenue, which consists primarily of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits, was $25.6 million in 2018, a decrease of 4% compared with $26.7 million in 2017. The decrease in product revenue is primarily due to variability in our customers’ manufacturing schedules.
Research and development revenues, which include license, technology access and exclusivity fees, research service fees, milestone payments, royalties, and optimization and screening fees, totaled $35.0 million in 2018, an increase of 50%, compared with $23.3 million in 2017. The increase is primarily due to revenues from our collaborative arrangements with Nestlé Health Science for the development of CDX-6114 and development of novel enzymes for Nestlé Health Science under our Strategic Collaboration Agreement, research and development revenue from Tate & Lyle and Merck, and recognition of a license fee and technology transfer from Porton.
Our products’ profitability is affected by many factors including the margin of profit on products we sell. Our profit margins are affected by many factors including the costs of internal and third-party fixed and variable costs, including materials and supplies, labor, facilities and other overhead costs. Profit margin data is used as a management performance measure to provide additional information regarding our results of operations on a consolidated basis. Product gross margins increased to 51% in 2018, compared to 46% in 2017 due to improved sales mix.
Research and development expenses were $30.0 million in 2018, an increase of 1% from $29.7 million in 2017. The increase was primarily due to an increase in costs associated with higher headcount, higher allocable expenses, increases in lab supplies and stock compensation expense and were partially offset by a decrease in outside services which were mostly related to prior year development costs for project CDX-6114.
Selling, general and administrative expenses were $29.3 million in 2018, an increase of 1% compared to $29.0 million in 2017. The increase was primarily due to increases in costs associated with higher headcount, consulting and outside services, accounting fees, recruiting fees, and stock compensation expenses which were partially offset by a reduction in legal expenses related to 2017 activities and allocable expenses.
Net loss was $10.9 million, or a net loss of $0.21 per share, in 2018 compared to a net loss of $23.0 million, or a net loss of $0.50 per share, in 2017. The decreases in net loss and net loss per share are primarily attributable to a net increase in revenue and reductions in product costs. The net increase in revenue is primarily attributed to research and development revenue from Nestlé Health Science and Tate & Lyle partially offset by a decrease in product revenue. The reduction in product costs reflected the sale of higher gross margin products.
Cash and cash equivalents increased to $53.0 million as of December 31, 2018 compared to $31.2 million as of December 31, 2017. In addition, net cash used in operations was $14.1 million in 2018, as compared to net cash used in operations of $8.8 million in 2017. We believe that based on our current level of operations, our existing cash, cash equivalents, and equity securities will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months.
In June 2017, we entered into a loan and security agreement that allows us to borrow up to $10.0 million under a term loan, and up to $5.0 million under a revolving credit facility with 80% of certain eligible accounts receivable as a borrowing base (the "Credit Facility"). Obligations under the Credit Facility are secured by a lien on substantially all of our personal property other

56



than our intellectual property. In September 2018, we entered into a Fourth Amendment to the Credit Facility whereby the draw period on the term debt was extended to September 30, 2019. We may draw on the Term Debt at any time prior to September 30, 2019, subject to customary conditions for funding including, among others, that no event of default exists. As of December 31, 2018, no amounts were borrowed under the Credit Facility and we were in compliance with the covenants for the Credit Facility. See Note 13, "Commitments and Contingencies" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Below is an overview of our results of operations by business segments:
Performance Enzymes
Revenues increased by $4.7 million, or 11%, to $47.1 million in 2018, compared to 2017. The increase in revenues was due primarily to an increase in research and development revenue from Tate & Lyle and Novartis, and the recognition of a license fee and technology transfer from Porton. These increases were partially offset by a decrease in product revenue due to the variability in our customers’ manufacturing schedules.
Product gross margins were 51% in 2018, compared to 46% in the corresponding period in 2017. The increase in product gross margins was primarily due an increase in sales of higher margin products combined with a decrease in sales of lower margin products over the prior fiscal period.
Research and development expense increased $2.1 million, or 12%, to $18.9 million in 2018, compared to 2017, due primarily to an increase in costs associated with higher headcount, an increase in lab supplies and stock compensation expenses and an increase related to activities under the Tate and Lyle and Novartis collaboration agreements.
Selling, general and administrative expense increased by $0.2 million, or 2%, to $7.5 million in 2018, compared to the year of 2017, due primarily to an increase in costs associated with higher headcount.
Novel Biotherapeutics
Research and development revenue in 2018 was $13.5 million. Revenues in the Novel Biotherapeutics segment are derived entirely from research and development revenue relating to the development of our CDX-6114 product candidate in collaboration with Nestlé Health Science. In 2017, we signed a global development, option and license agreement with Nestlé Health Science and, thus, we had no revenues in the Novel Biotherapeutics segment prior to 2017.
Research and development expense decreased $1.9 million, or 16%, to $10.2 million in 2018, compared to 2017, due primarily to activities related to the development of our CDX-6114 in the prior year.
Selling, general and administrative expense was $0.8 million in 2018, compared to zero in 2017. This consisted of the allocated employee costs related to the development of our CDX-6114 product candidate and other product candidates in our Novel Biotherapeutics pipeline. De minimis selling, general and administrative expense incurred in 2017 were not allocated to the biotherapeutics segment.
Below is an overview of our collaborative arrangements:
GSK Platform Technology Transfer, Collaboration and License Agreement
In July 2014, we entered into a CodeEvolver® protein engineering platform technology transfer collaboration and license agreement (the "GSK CodeEvolver® Agreement") with GlaxoSmithKline ("GSK"). Pursuant to the terms of the agreement, we granted GSK a non-exclusive license to use the CodeEvolver® protein engineering platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products.
We received an upfront fee upon the execution of the agreement in July 2014 and milestone payments in each of the years from 2014 through April 2016. We completed the transfer of the CodeEvolver® protein engineering platform technology to GSK in April 2016 and all revenues relating to the technology transfer have been recognized as of April 2016. We have the potential to receive additional cumulative contingent payments that range from $5.75 million to $38.5 million per project based on GSK’s successful application of the licensed technology. We are also eligible to receive royalties based on net sales of GSK’s sales of licensed enzyme products that are currently not being recognized.

57



Merck Platform Technology Transfer and License Agreement
In August 2015, we entered into a CodeEvolver® platform technology transfer collaboration and license agreement (the "Merck CodeEvolver® Agreement") with Merck, Sharp & Dohme ("Merck") which allows Merck to use the CodeEvolver® protein engineering technology platform in the field of human and animal healthcare.
We received a $5.0 million up-front license fee upon execution of the Merck CodeEvolver® Agreement, and milestone payments in September 2015 and in September 2016, when we completed the transfer of the engineering platform technology. Additionally, we recognized research and development revenues of $4.1 million, $3.6 million, and $3.0 million in 2018, 2017 and 2016, respectively, for various research projects under our collaborative arrangement.
We have the potential to receive payments of up to a maximum of $15.0 million for each commercial API that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver® protein engineering technology platform. The API payments, which are currently not recognized as revenue, are based on quantity of API developed and manufactured by Merck and will be recognized as usage-based royalties. In February 2019, we have signed a new agreement with Merck to install certain CodeEvolver® protein engineering technology upgrades into Merck’s platform license installation and will maintain those upgrades for a multi-year term.
In October 2018, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we amended certain licensing provisions and one exhibit. In January 2019, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we will install certain CodeEvolver® protein engineering technology upgrades into Merck’s platform license installation and maintain those upgrades for a multi-year term.
Global Development, Option and License Agreement and Strategic Collaboration Agreement
In October 2017, we entered into the Nestlé Agreement with Nestlé Health Science and, solely for the purpose of the integration and the dispute resolution clauses of the Agreement, Nestlé Health Science S.A., to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU.
We received an upfront cash payment of $14.0 million upon the execution of the Nestlé Agreement and a $4.0 million milestone payment 60 days after dosing the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 for the potential treatment of PKU. The $4.0 million milestone payment that was triggered by the initiation of the trial was received in September 2018. The upfront payment and the variable consideration relating to the progress payment of $4.0 million are being recognized over time as the development work is being performed. Revenue is being recognized using a single measure of progress that depicts our performance in transferring control of the services, which is based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete all performance obligations under the agreement. We recognized development fees of $9.9 million in 2018 as research and development revenue and $7.2 million in 2017. We had deferred revenue under this agreement of $1.9 million at December 31, 2018 and $6.8 million at December 31, 2017.
In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
We are also eligible to receive payments from Nestlé Health Science under the Nestlé Agreement that include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
In addition to the Nestlé Agreement, we and Nestlé Health Science concurrently entered into a Strategic Collaboration Agreement (the “Strategic Collaboration Agreement”) pursuant to which we and Nestlé Health Science will collaborate to leverage the CodeEvolver® protein engineering technology platform to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. Under the Strategic Collaboration Agreement, we received an

58



upfront payment of $1.2 million in 2017 and an incremental $0.6 million payment in September 2018 for additional services. We recognized research and development fees of $3.6 million and $0.5 million in 2018 and 2017, respectively. As of December 31, 2018 and 2017, we had deferred revenue of $0.8 million and $1.1 million, respectively.
Strategic Collaboration Agreement
In April 2018, we entered into the Porton Agreement with Porton to license key elements of Codexis’ biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business. Under the Porton Agreement, we are eligible to receive annual collaboration fees and research and development revenues. We received an initial collaboration fee of $0.5 million within 30 days of the effective date of the agreement. As of December 31, 2018, we completed the technical transfer and we recognized revenue of $2.8 million in 2018 as research and development revenue. Revenue relating to the functional license provided to Porton was recognized at a point in time when control of the license transferred and technology transfer to the customer. We have the potential to receive performance payments based on products produced by Porton using our company’s technology under the license agreement.

Recent Accounting Pronouncements
For information on recent accounting pronouncements, see Note 2, “Summary of Significant Accounting Policies”, to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Financial results for the year ended December 31, 2018, as compared to the year ended December 31, 2017, reflect the effects of adopting ASU 2014-09, “Revenue from Contracts with Customers (Topic 606),” and the related amendments (“ASC 606”), which provided a new basis of accounting for our revenue arrangements during fiscal 2018.
The adoption of ASC 606 limits the comparability of revenue and certain expenses, including revenues and costs and operating expenses, presented in the results of operations for the year ended December 31, 2018 when compared to the year ended December 31, 2017. For additional information regarding the impact from adoption of this accounting standard, see Note 3, “Revenue Recognition” to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Results of Operations
The following table shows the amounts from our consolidated statements of operations for the periods presented (in thousands, except percentages):
 
Year Ended December 31,
 
% of Total Revenues
 
2018
 
2017
 
2016
 
2018
 
2017
 
2016
Revenues:
 
 
 
 
 
 
 
 
 
 
 
Product revenue
$
25,590

 
$
26,685

 
$
15,321

 
42
 %
 
53
 %
 
31
 %
Research and development revenue
35,004

 
23,339

 
33,516

 
58
 %
 
47
 %
 
69
 %
Total revenues
60,594

 
50,024

 
48,837

 
100
 %
 
100
 %
 
100
 %
Costs and operating expenses:
 
 
 
 
 
 
 
 
 
 
 
Cost of product revenue
12,620

 
14,327

 
9,753

 
21
 %
 
29
 %
 
20
 %
Research and development
29,978

 
29,659

 
22,229

 
50
 %
 
59
 %
 
46
 %
Selling, general and administrative
29,291

 
29,008

 
25,419

 
48
 %
 
58
 %
 
52
 %
Total costs and operating expenses
71,889

 
72,994

 
57,401

 
119
 %
 
146
 %
 
118
 %
Loss from operations
(11,295
)
 
(22,970
)
 
(8,564
)
 
(19
)%
 
(46
)%
 
(18
)%
Interest income
671

 
147

 
60

 
1
 %
 
 %
 
 %
Other expense, net
(291
)
 
(92
)
 
(94
)
 
 %
 
 %
 
 %
Loss before income taxes
(10,915
)
 
(22,915
)
 
(8,598
)
 
(18
)%
 
(46
)%
 
(18
)%
Provision for (benefit from) income taxes
(37
)
 
81

 
(40
)
 
 %
 
 %
 
 %
Net loss
$
(10,878
)
 
$
(22,996
)
 
$
(8,558
)
 
(18
)%
 
(46
)%
 
(18
)%

59



Revenues
Our revenues are comprised of product revenue and research and development revenue as follows:
Product revenue consist of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits.
Research and development revenue include license, technology access and exclusivity fees, research services fees, milestone payments, royalties, optimization and screening fees, and revenue sharing arrangement based upon sales of licensed products by our former revenue sharing partner, Exela PharmSci, Inc. (“Exela”) in 2017 and 2016.
Revenues is as follows (in thousands, except percentages):
 
 
 
 
 
 
 
Change
 
Year Ended December 31,
 
2018
 
2017
 
2018
 
2017
 
2016
 
$
 
%
 
$
 
%
Product revenue
$
25,590

 
$
26,685

 
$
15,321

 
$
(1,095
)
 
(4)%
 
$
11,364

 
74%
Research and development revenue
35,004

 
23,339

 
33,516

 
11,665

 
50%
 
(10,177
)
 
(30)%
Total revenues
$
60,594

 
$
50,024

 
$
48,837

 
$
10,570

 
21%
 
$
1,187

 
2%
Revenues typically fluctuate on a quarterly basis due to the variability in our customers' manufacturing schedules and the timing of our customers' clinical trials. In addition, we have limited internal capacity to manufacture enzymes. As a result, we are dependent upon the performance and capacity of third party manufacturers for the commercial scale manufacturing of the enzymes used in our pharmaceutical and fine chemicals business.
We accept purchase orders for deliveries covering periods from one day up to approximately one year from the date on which the order is placed. However, a majority of the purchase orders can be revised or cancelled by the customer without penalty. Considering these industry practices and our experience, we do not believe the total of customer purchase orders outstanding (backlog) provides meaningful information that can be relied on to predict actual sales for future periods.
2018 compared to 2017
Total revenues increased by $10.6 million in 2018 to $60.6 million, as compared to 2017. The increase was driven by growth in research and development revenue of $11.7 million or 50%, partially offset by a decrease of $1.1 million in product revenue.
Product revenue, which consist primarily of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits, were $25.6 million in 2018, a decrease of 4% compared with $26.7 million in 2017. The decrease was primarily due to variability in our customers’ manufacturing schedules.
Research and development revenue increased by $11.7 million in 2018 to $35.0 million, as compared to 2017, primarily due to revenues from our arrangements with Nestlé Health Science for the development of CDX-6114 and development of novel enzymes for Nestlé Health Science under our Strategic Collaboration Agreement, research and development revenue from Tate & Lyle, Merck and Novartis, and on the recognition of a functional license fee and technology transfer from Porton.
2017 compared to 2016
Total revenues increased by $1.2 million in 2017 to $50.0 million, as compared to 2016. The increase was driven by an increase in product revenue of $11.4 million or 74%, offset by a decrease of $10.2 million in research and development revenue.
Product revenue, which consist primarily of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits, were $26.7 million in 2017, an increase of 74% compared with $15.3 million in 2016. The increase was primarily due to higher customer demand in 2017 as compared to 2016, in particular higher sales of enzymes to the existing 2016 customer base.
Research and development revenue decreased by $10.2 million in 2017 to $23.3 million, as compared to 2016. The revenue decrease in 2017 was primarily due to the absence of $22.5 million of non-recurring revenues from the technology transfer of our proprietary CodeEvolver® protein engineering platform technology to Merck and GSK in 2016, which was comprised of a milestone payment of $8.0 million from Merck, a milestone payment of $7.5 million from GSK and $7.0 million in recognition of license fees under both agreements. The revenue decrease in 2017 was partially offset by revenues of $13.1 million for research services under our agreements with Nestlé Health Sciences, Tate & Lyle, Novartis, and revenue sharing arrangement revenues from Exela.

60



Cost and Operating Expenses (in thousands, except percentages):
 
 
 
 
 
 
 
Change
 
Year Ended December 31,
 
2018
 
2017
 
2018
 
2017
 
2016
 
$
 
%
 
$
 
%
Cost of product revenue
$
12,620

 
$
14,327

 
$
9,753

 
$
(1,707
)
 
(12)%
 
$
4,574

 
47%
Research and development
29,978

 
29,659

 
22,229

 
319

 
1%
 
7,430

 
33%
Selling, general and administrative
29,291

 
29,008

 
25,419

 
283

 
1%
 
3,589

 
14%
Total costs and operating expenses
$
71,889

 
$
72,994

 
$
57,401

 
$
(1,105
)
 
(2)%
 
$
15,593

 
27%
Cost of Product Revenue and Product Gross Margin
Our revenues from product revenue are derived entirely from our Performance Enzymes segment. Revenues from the Novel Biotherapeutics segment are from collaborative research and development activities and not from product revenue.
The following table shows the amounts of our product revenue, cost of product revenue, product gross profit and product gross margin from our consolidated statements of operations for the years ended (in thousands, except percentages):
 
Year Ended December 31,
 
Change
 
Year Ended December 31,
 
Change
 
2018
 
2017
 
$
 
%
 
2017
 
2016
 
$
 
%
Product revenue
$
25,590

 
$
26,685

 
$
(1,095
)
 
(4)%
 
$
26,685

 
$
15,321

 
$
11,364

 
74%
Cost of product revenue (1)
12,620

 
14,327

 
(1,707
)
 
(12)%
 
14,327

 
9,753

 
4,574

 
47%
Product gross profit
$
12,970

 
$
12,358

 
$
612

 
5%
 
$
12,358

 
$
5,568

 
$
6,790

 
122%
Product gross margin (%) (2)
51
%
 
46
%
 
 
 
 
 
46
%
 
36
%
 
 
 
 
(1) Cost of product revenue comprises both internal and third-party fixed and variable costs, including materials and supplies, labor, facilities and other overhead costs associated with our product revenue.
(2) Product gross margin is used as a performance measure to provide additional information regarding our results of operations on a consolidated basis.
2018 compared to 2017
Cost of product revenue decreased by $1.7 million in 2018 to $12.6 million, as compared to 2017. The decrease was primarily due to a reduction in costs associated with a reduction in product revenue. Product gross margin increased to 51% in 2018 as compared to 46% in 2017 due to the change in sales mix as we had an increase in sales of higher margin products in 2018 compared to 2017.
2017 compared to 2016
Cost of product revenue increased by $4.6 million in 2017 to $14.3 million, as compared to 2016. The increase was primarily due to higher product revenue from increased customer demand. Product gross margin increased to 46% in 2017 as compared to 36% in 2016 due to improved sales mix.
Research and Development Expenses 
Research and development expenses consist of costs incurred for internal projects as well as collaborative research and development activities. These costs primarily consist of (i) employee-related costs, which include salaries and other personnel-related expenses (including stock-based compensation), (ii) various allocable expenses, which include occupancy-related costs, supplies, depreciation of facilities and laboratory equipment, and (iii) external costs. Research and development expenses are expensed when incurred.
2018 compared to 2017
Research and development expenses were $30.0 million in 2018 compared to $29.7 million in 2017, an increase of $0.3 million or 1%. The increase was primarily due to $1.9 million in costs associated with higher headcount, $1.1 million in higher allocable expenses which include occupancy-related costs and supplies, and increases of $0.7 million in lab supplies, $0.6 million in stock compensation expenses, and $1.0 million increase in repairs and maintenance costs, outside consultants and travel costs. These increases were partially offset by a decrease of $4.9 million in outside services which were mostly related to prior year development costs for project CDX-6114.

61



2017 compared to 2016
Research and development expenses were $29.7 million in 2017 compared to $22.2 million in 2016, an increase of $7.4 million or 33%. The increase was primarily due to a $7.2 million increase in outside services, which were mostly related to the development project for CDX-6114, an increase of $1.5 million in costs associated with higher headcount relating to additional research and development projects, including the development of CDX-6114, and an increase of $0.7 million in lab supplies, which were partially offset by lower amortization of intangibles.
Selling, General and Administrative Expenses 
Selling, general and administrative expenses consist of employee-related costs, which include salaries and other personnel-related expenses (including stock-based compensation), hiring and training costs, consulting and outside services expenses (including audit and legal counsel related costs), marketing costs, building lease costs, and depreciation expenses.
2018 compared to 2017
Selling, general and administrative expenses were $29.3 million in 2018 compared to $29.0 million in 2017, an increase of $0.3 million or 1%. The increase was primarily due to increases of $1.2 million in salaries and personnel costs associated with higher headcount, $1.0 million in consulting and outside services, $0.4 million in recruiting fees, $0.3 million in accounting fees and $0.2 million in stock compensation expense which were partially offset by a decrease of $1.1 million in allocable expenses and $1.8 million in legal expenses related to 2017 activities.
2017 compared to 2016
Selling, general and administrative expenses were $29.0 million in 2017 compared to $25.4 million in 2016, an increase of $3.6 million or 14%. The increase was primarily due to an increase of $1.9 million in costs associated with higher headcount, including stock-based compensation costs, an increase of $1.2 million in legal expenses relating to intellectual property and higher consulting fees, partially offset by lower depreciation expense.
Other Income (Expense), net (in thousands, except percentages):
 
 
 
 
 
 
 
Change
 
Year Ended December 31,
 
2018
 
2017
 
2018
 
2017
 
2016
 
$
 
%
 
$
 
%
Interest income
$
671

 
$
147

 
$
60

 
$
524

 
356%
 
$
87

 
145%
Other expense, net
(291
)
 
(92
)
 
(94
)
 
199

 
216%
 
(2
)
 
(2)%
Total other income (expense), net
$
380

 
$
55

 
$
(34
)
 
$
325

 
591%
 
$
89

 
262%
Interest Income
Interest income increased by $0.5 million in 2018 compared to 2017, and increased by $87 thousand in 2017 compared to 2016. The changes were primarily due to higher interest rates on higher levels of cash, cash equivalents and short-term investment portfolio balances.
Other Expense
Other expense increased by $0.2 million in 2018 compared to 2017 primarily due to an unrealized loss of $83 thousand related to our investment in CO2 Solutions and expenses due to fluctuations in foreign currency. Other expense decreased by $2 thousand in 2017 compared to 2016, primarily due to fluctuations in foreign currency.
Provision for (benefit from) Income Taxes (in thousands, except percentages):
 
 
 
 
 
 
 
Change
 
Year Ended December 31,
 
2018
 
2017
 
2018
 
2017
 
2016
 
$
 
%
 
$
 
%
Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)
 
$
118

 
146%
 
$
(121
)
 
(303)%
The benefit from income taxes for 2018 is primarily related to a net loss from our foreign operations and a reduction in the deferred tax liability for accrued future withholding taxes on dividends. The provision for income taxes in 2017 is primarily

62



related to taxes on foreign earnings and an increase in the deferred tax liability for accrued future withholding taxes on dividends. The benefit from income taxes for 2016 is primarily related to a reduction in the deferred tax liability for accrued future withholding taxes on dividends. We continue to maintain a full valuation allowance against our net deferred tax assets as we believe that it is more likely than not that the majority of our deferred tax assets will not be realized.
Net Loss
Net loss for 2018 was $10.9 million, or a net loss per basic and diluted share of $0.21. This compares to a net loss of $23.0 million, or a net loss per basic and diluted share of $0.50 for 2017. The decreases in net loss is primarily attributable a net increase in revenue and reductions in product costs. The net increase in revenue is primarily attributed to research and development revenue from Nestlé Health Science and Tate & Lyle partially offset by a decrease in product revenue due to variability in our customers’ manufacturing schedules. The reduction in product costs reflected the sale of higher gross margins products partially offset by lower costs associated with the reduction in product revenue.
The increase in net loss for 2017 over a net loss of $8.6 million, or a net loss per basic and diluted share of $0.21, for 2016 is primarily related to a decrease in research and development revenues and an increase in research and development expenses which were partially offset by an increase in product revenue.
Results of Operations by Segment (in thousands, except percentages)
Revenues by segment
 
Year Ended December 31, 2018
 
Year Ended December 31, 2017
 
Change
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
 
 
 
 
 
 
 
 
 
 
 
 
$
 
%
 
$
 
%
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue
$
25,590

 
$

 
$
25,590

 
$
26,685

 
$

 
$
26,685

 
$
(1,095
)
 
(4)%
 
$

 
—%
Research and development revenue
21,483

 
13,521

 
35,004

 
15,648

 
7,691

 
23,339

 
5,835

 
37%
 
5,830

 
76%
Total revenues
$
47,073

 
$
13,521

 
$
60,594

 
$
42,333

 
$
7,691

 
$
50,024

 
$
4,740

 
11%
 
$
5,830

 
76%

Revenues from the Performance Enzymes segment increased by $4.7 million, or 11%, to $47.1 million in 2018, compared to $42.3 million in 2017 primarily due to an increase in research and development revenue from Tate & Lyle, Merck and Novartis, and on the recognition of a functional license fee from Porton. This increase was partially offset by a decrease in product revenue primarily due to variability in our customers’ manufacturing schedules.
Revenues from the Novel Biotherapeutics segment increased by $5.8 million, or 76%, to $13.5 million in 2018, compared to $7.7 million in 2017. Revenues from the Novel Biotherapeutics segment are derived primarily from research and development revenue relating to the development of our CDX-6114 product candidate in collaboration with Nestlé Health Science. Our dependence on revenues generated from Nestlé Health Science, if lost, would have a material adverse effect on the Novel Biotherapeutics segment.

63



Costs and operating expenses by segment
 
Year Ended December 31, 2018
 
Year Ended December 31, 2017
 
Change
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
 
 
 
 
 
 
 
 
 
 
 
 
$
 
%
 
$
 
%
Cost of product revenue
$
12,620

 
$

 
$
12,620

 
$
14,327

 
$

 
$
14,327

 
$
(1,707
)
 
(12)%
 
$

 
—%
Research and development(1)
18,924

 
10,185

 
29,109

 
16,847

 
12,107

 
28,954

 
2,077

 
12%
 
(1,922
)
 
(16)%
Selling, general and administrative(1)
7,538

 
771

 
8,309

 
7,371

 

 
7,371

 
167

 
2%
 
771

 
100%
Total segment costs and operating expenses
$
39,082

 
$
10,956

 
50,038

 
$
38,545

 
$
12,107

 
50,652

 
$
537

 
1%
 
$
(1,151
)
 
(10)%
Corporate costs
 
 
 
 
20,704

 
 
 
 
 
21,300

 
 
 
 
 
 
 
 
Depreciation
 
 
 
 
1,147

 
 
 
 
 
1,042

 
 
 
 
 
 
 
 
Total costs and operating expenses
 
 
 
 
$
71,889

 
 
 
 
 
$
72,994

 
 
 
 
 
 
 
 
(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation.

For a discussion of product cost of revenue, see “Results of Operations”.
Research and development expense in the Performance Enzymes segment increased by $2.1 million, or 12%, to $18.9 million in 2018, compared to $16.8 million in 2017. The increase was primarily due to $2.2 million in associated with increased headcount, $0.6 million in lab supplies costs and $0.5 million in stock compensation expenses. These increases were partially offset by a decrease of $1.2 million in allocable expenses, which include occupancy-related costs, supplies, and depreciation expense.
Selling, general and administrative expense in the Performance Enzymes segment increased by $0.2 million, or 2%, to $7.5 million in 2018, compared to $7.4 million in 2017. The increase was primarily due to $0.8 million in higher costs associated with increased headcount, partially offset by a decrease of $0.4 million in lower allocable expenses and $0.2 million in lower stock compensation expense.
Research and development expense in the Novel Biotherapeutics segment decreased by $1.9 million, or 16%, to $10.2 million in 2018, compared to $12.1 million in 2017. The decrease was primarily due to $4.9 million in lower costs associated with a reduction in the outside research and development services used in the development of the CDX-6114 product candidate. The decrease was partially offset by a $2.3 million increase in allocable expenses, a $0.6 million increase in costs associated with higher headcount and a $0.1 million increase in stock compensation expense.
Selling, general and administrative expense in the Novel Biotherapeutics segment was $0.8 million in 2018 and primarily consisted of $0.5 million in allocable costs and $0.2 million in costs associated with headcount. Selling, general and administrative expense in the Novel Biotherapeutics segment was zero in 2017. De minimis selling, general and administrative expense incurred in 2017 were not allocated to the biotherapeutics segment.
Income (loss) from operations by segment
 
Year Ended December 31, 2018
 
Year Ended December 31, 2017
 
Change
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
 
 
 
 
 
 
 
 
 
 
 
 
$
 
%
 
$
 
%
Income (loss) from operations
$
7,991

 
$
2,565

 
10,556

 
$
3,788

 
$
(4,416
)
 
(628
)
 
$
4,203

 
111%
 
$
6,981

 
158%

64




Income from operations in the Performance Enzymes segment increased $4.2 million, or 111%, to $8.0 million, in 2018, compared to $3.8 million in 2017. The increase in income from operations was primarily due to an increase in research and development revenue, a reduction in product costs associated with a decline in product revenue and a reduction in product costs associated with the sale of higher margin products. These were partially offset by a decrease in product revenues and an increase in research and development costs.
Income from operations in the Novel Biotherapeutics segment increased $7.0 million, or 158%, to $2.6 million in 2018 compared to in 2017. The increase in income from operation was primarily due to $5.8 million in revenue from the development of our CDX-6114 product candidate in collaboration with Nestlé Health Science, partially offset by lower costs associated with a reduction in the outside research and development services used in the CDX-6114 product candidate development.
Previously, we had only one business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets. See Note 15, "Segment, Geographical and Other Revenue Information" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for information about revenues by geographic area, long-lived assets by geographic area, and revenues by major customers.

Liquidity and Capital Resources
Liquidity is the measurement of our ability to meet working capital needs and to fund capital expenditures. We have historically funded our operations primarily through cash generated from operations, stock option exercises and public offerings of our common stock. We also have the ability to borrow up to $15.0 million under our Credit Facility. We actively manage our cash usage and investment of liquid cash to ensure the maintenance of sufficient funds to meet our working capital needs. The majority of our cash and cash equivalents are held in U.S. banks, and our foreign subsidiaries maintain a limited amount of cash in their local banks to cover their short-term operating expenses.
The following summarizes our cash and cash equivalents balance and working capital as of December 31, 2018, 2017 and 2016:
 
December 31,
(In Thousands)
2018
 
2017
 
2016
Cash and cash equivalents
$
53,039

 
$
31,219

 
$
19,240

Working capital
50,085

 
20,087

 
14,860

In addition to our existing cash and cash equivalents, we are eligible to earn milestone and other contingent payments for the achievement of defined collaboration objectives and certain royalty payments under our collaboration agreements. Our ability to earn these milestone and contingent payments and the timing of achieving these milestones is primarily dependent upon the outcome of our collaborators’ research and development activities and is uncertain at this time. In the third quarter of 2016, we completed the final phase in the transfer of CodeEvolver® technology to Merck under the Merck CodeEvolver® Agreement. Following the completion of the technology transfer to Merck, we are now eligible to receive payments of up to $15.0 million for each commercial API that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver® technology. In addition, depending upon GSK's successful application of the licensed technology, we have the potential to receive additional contingent payments that range from $5.75 million to $38.5 million per project.
We are actively collaborating with new and existing customers in the pharmaceutical and food industries. We believe that we can utilize our current products and services, and develop new products and services, to increase our revenues and gross margins in future periods.
We have historically experienced negative cash flows from operations as we continue to invest in key technology development projects and improvements to our CodeEvolver® protein engineering technology platform, and expand our business development and collaboration with new customers. Our cash flows from operations will continue to be affected principally by sales and gross margins from licensing our technology to major pharmaceutical companies, product sales and collaborative

65



research and development services provided to customers, as well as our headcount costs, primarily in research and development. Our primary source of cash flows from operating activities is cash receipts from licensing our technology to major pharmaceutical companies, and our customers for purchases of products and/or collaborative research and development services. Our largest uses of cash from operating activities are for employee-related expenditures, rent payments, inventory purchases to support our product sales and non-payroll research and development costs.
On December 9, 2016, we filed a registration statement on Form S-3 with the SEC, under which we may sell an aggregate of up to $80.0 million of common stock, preferred stock, debt securities, warrants, purchase contract and/or units. The SEC declared the registration statement effective on January 10, 2017. Subsequently, in April 2017, we completed an underwritten public offering of approximately 6.3 million shares of our common stock at an offering price of $4.00 per share. The net proceeds to us were approximately $23.8 million after deducting offering costs and the underwriting discounts and commissions. In April 2018, we completed an underwritten public offering of 4.3 million shares of our common stock at a public offering price of $9.25 per share resulting in net proceeds of approximately $37.3 million after deducting the underwriting discounts and commissions.
In June 2017, we entered into the Credit Facility, which consists of term debt for loans that allow us to borrow up to $10.0 million and a revolving credit facility that allows us to borrow up to $5.0 million with a certain eligible accounts receivable borrowing base of 80% of eligible accounts receivable. In September 2018, we entered into a Fourth Amendment to the Credit Facility whereby the draw period on the term debt was extended to September 30, 2019. We may draw on the term debt at any time prior to September 30, 2019, subject to customary conditions for funding including, among others, that no event of default exists. Draws on the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. We may draw on the revolving line of credit at any time prior to the maturity date. On October 1, 2022, any loans for Term Debt mature and the Revolving Line of Credit terminates. No amounts were drawn down under the credit facility as of December 31, 2018. At December 31, 2018, we were in compliance with the covenants for the Credit Facility. The Credit Facility requires us to maintain compliance with certain financial covenants including attainment of certain lender-approved projections or maintenance of certain minimum cash levels. Restrictive covenants in the Credit Facility restrict the payment of dividends or other distributions. For additional information about our contractual obligations, see Note 13 "Commitments and Contingencies" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
In October 2017, we entered into the Nestlé Agreement with Nestlé Health Science. Pursuant to the Nestlé Agreement, Nestlé Health Science paid us an upfront cash payment of $14.0 million. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 for the potential treatment of PKU. The initiation of the trial triggered a $4.0 million milestone payment from Nestlé Health Science which was paid in September 2018. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
As of December 31, 2018, we had cash and cash equivalents of $53.0 million and $15.0 million available to borrow under our Credit Facility. Our liquidity is dependent upon our cash and cash equivalents, cash flows provided by operating activities and the continued availability of borrowings under our Credit Facility. We may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial success of our business, the spending required to develop and commercialize new and existing products, the effect of any acquisitions of other businesses, technologies or facilities that we may make or develop in the future, our spending on new market opportunities, and the potential costs for the filing, prosecution, enforcement and defense of patent claims, if necessary.
We believe that, based on our current level of operations, our existing cash and cash equivalents will provide adequate funds for ongoing operations, planned capital expenditures and working capital requirements for at least the next 12 months.


66



However, we may need additional capital if our current plans and assumptions change. Our need for additional capital will depend on many factors, including the financial success of our business, the spending required to develop and commercialize new and existing products, the effect of any acquisitions of other businesses, technologies or facilities that we may make or develop in the future, our spending on new market opportunities, and the potential costs for the filing, prosecution, enforcement and defense of patent claims, if necessary. If our capital resources are insufficient to meet our capital requirements, and we are unable to enter into or maintain collaborations with partners that are able or willing to fund our development efforts or commercialize any products that we develop or enable, we will have to raise additional funds to continue the development of our technology and products and complete the commercialization of products, if any, resulting from our technologies. If future financings involve the issuance of equity securities, our existing stockholders would suffer dilution. If we raise debt financing or enter into credit facilities, we may be subject to restrictive covenants that limit our ability to conduct our business. We may not be able to raise sufficient additional funds on terms that are favorable to us, if at all. If we fail to raise sufficient funds and fail to generate sufficient revenues to achieve planned gross margins and to control operating costs, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited. If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, or grant licenses on terms that are not favorable to us. If adequate funds are not available, we will not be able to successfully execute our business plan or continue our business.
Cash Flows
The following is a summary of cash flows for the years ended December 31, 2018, 2017 and 2016:
 
Year Ended December 31,
(In Thousands)
2018
 
2017
 
2016
Net cash used in operating activities
$
(14,094
)
 
$
(8,755
)
 
$
(1,860
)
Net cash used in investing activities
(2,766
)
 
(983
)
 
(846
)
Net cash provided by (used in) financing activities
38,569

 
21,650

 
(490
)
Net increase (decrease) in cash, cash equivalents and restricted cash
$
21,709

 
$
11,912

 
$
(3,196
)
Cash Flows from Operating Activities
Cash used in operating activities was $14.1 million in 2018, which resulted from a net loss of $10.9 million adjusted for non-cash depreciation of $1.1 million and stock-based compensation of $7.9 million, as well as changes in operating assets and liabilities. The net change in operating assets and liabilities included decreases in deferred revenue of $10.6 million primarily related to the Nestlé Agreement, and a combined increase in accounts receivable and unbilled receivables of $1.4 million.
Cash used in operating activities was $8.8 million in 2017, which resulted from a net loss of $23.0 million adjusted for non-cash depreciation of $1.0 million and stock-based compensation of $7.1 million, as well as changes in operating assets and liabilities. The net change in operating assets and liabilities included increases in deferred revenue of $11.0 million primarily related to the Nestlé Agreement, an increase in accounts receivable and unbilled accounts receivables of $5.7 million, and an increase in other accrued liabilities of $1.4 million, offset by lower accounts payable of $0.8 million due to the timing of payment of invoices.
Cash used in operating activities was $1.9 million in 2016, which resulted from a net loss of $8.6 million adjusted for non-cash depreciation and amortization of $4.5 million and stock-based compensation of $5.7 million, as well as changes in operating assets and liabilities. The net change in operating assets and liabilities included decreases in deferred revenue of $6.4 million primarily related to revenue recognition on the achievement of milestones from collaborative arrangements with Merck and GSK, partially offset by a decrease in accounts receivable of $1.4 million, and increases in accrued compensation of $1.0 million primarily due to higher payroll costs and higher accounts payable of $0.9 million due to the timing of payment of invoices.
Cash Flows from Investing Activities
Cash used in investing activities was $2.8 million in 2018 primarily due to the purchase of property and equipment. We expect our capital spending including replacement and upgrades of lab equipment and information technology equipment will be higher in 2019 as compared to 2018.
Cash used in investing activities was $1.0 million in 2017, primarily due to the purchase of property and equipment.

67



Cash used investing activities was $0.8 million in 2016, primarily due to the purchase of property and equipment.
Cash Flows from Financing Activities
Cash provided by financing activities was $38.6 million in 2018, primarily due to net proceeds from our offering of common stock after deducting underwriting discounts and commission and related costs and proceeds from the exercises of employee stock options which were partially offset by the payment of taxes related to the net share settlement of equity awards.
Cash provided by financing activities was $21.7 million in 2017, primarily due to net proceeds from our offering of common stock after deducting underwriting discounts and commission and related costs and proceeds from the exercises of employee stock options which were partially offset by the payment of taxes related to the net share settlement of equity awards.
Cash used in financing activities was $0.5 million in 2016, which was the result of the payment of taxes related to the net share settlement of equity awards, partially offset by the proceeds from the exercises of employee stock options.
Contractual Obligations
The following table summarizes our significant contractual obligations at December 31, 2018 (in thousands): 
 
Payments due by period
 
Total
 
Less than 1 year
 
1 to 3 years
 
4 to 5 years
 
More than 5 years
Capital lease obligations
$
313

 
$
252

 
$
61

 
$

 
$

Operating leases obligations (1)
4,523

 
3,280

 
1,202

 
41

 

Total (2)
$
4,836

 
$
3,532

 
$
1,263

 
$
41

 
$

(1) 
Represents future minimum lease payments under non-cancellable operating leases in effect as of December 31, 2018 for our facilities in Redwood City, California. The minimum lease payments above do not include common area maintenance charges or real estate taxes. Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
(2) 
Excludes $0.7 million of uncertain tax liabilities for which we cannot make a reasonably reliable estimate of the period of cash settlement.

In February 2019, we entered into the eighth lease amendment ("Eighth Amendment") with MetLife for our buildings to extend the lease term to another 88 months except for building 101. The various terms for the remaining spaces under the Eighth Amendment have expiration dates that range from May 2027 to May 2029. See Note 16, “Subsequent Events” in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for additional information. Future minimum lease payments under the Eighth Amendment are as follows (in thousands): 
 
Payments due by period
 
Total
 
Less than 1 year
 
1 to 3 years
 
4 to 5 years
 
More than 5 years
Operating leases obligations
$
32,865

 
$

 
$
5,812

 
$
8,833

 
$
18,220


68



Other Commitments
We have other commitments related to supply and service arrangements entered into in the normal course of business. For additional information about other commitments, see Note 13 "Commitments and Contingencies" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K. Future minimum payments reflect amounts those obligations are expected to have on our liquidity and cash flows in future period and include obligations subject to risk of cancellation by us (in thousands):
Other Commitment Agreement Type
 
Agreement Date
 
Future Minimum Payment
Manufacture and supply agreement with expected future payment date of December, 2022
 
April 2016
 
$
1,458

Service agreement for stability study
 
July 2017
 
331

Service agreement for clinical trial
 
December 2017
 
1,258

Total other commitments
 

 
$
3,047

Credit Facility
In June 2017, we entered into a credit facility (“Credit Facility”) consisting of term loans (“Term Debt”) up to $10.0 million, and advances (“Advances”) under a revolving line of credit (“Revolving Line of Credit”) up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. At December 31, 2018, we have not drawn from the Credit Facility. We may draw on the Revolving Line of Credit at any time prior to the September 30, 2019 maturity date. On October 1, 2022, loans drawn under the Term Debt mature and the Revolving Line of Credit terminates. Loans made under the Term Debt bear interest through maturity at a variable rate based upon the LIBOR rate plus 3.6%. Advances made under the Revolving Line of Credit bear interest at a variable annual rate equal to the greater of (i) 1.00% above the prime rate and (ii) 5.00%.
Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictive financial covenants including meeting minimum product revenues levels and maintaining certain minimum cash levels with the lender. The Credit Facility’s financial covenants restrict the ability of the Company to transfer collateral, incur additional indebtedness, engage in mergers or acquisitions, pay dividends or make other distributions, make investments, create liens, sell assets, or sell certain assets held at foreign subsidiaries. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. At December 31, 2018, we were in compliance with the covenants for the Credit Facility.
For additional information about our credit facility, see Note 13 "Commitments and Contingencies" in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K.
Off-Balance Sheet Arrangements
As of December 31, 2018, we had no off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K as promulgated by the SEC.
Critical Accounting Policies and Estimates
Management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements. The consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States and include our accounts and the accounts of our wholly-owned subsidiaries. The preparation of our consolidated financial statements requires our management to make estimates, assumptions, and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the applicable periods. Management bases its estimates, assumptions and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances. Different assumptions and judgments would change the estimates used in the preparation of our consolidated financial statements, which, in turn, could change the results from those reported. Our management evaluates its estimates, assumptions and judgments on an ongoing basis.

69



The critical accounting policies requiring estimates, assumptions, and judgments that we believe have the most significant impact on our consolidated financial statements are described below.
Revenue Recognition
Policy from January 1, 2018
On January 1, 2018, we adopted the provisions of ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)” and the related amendments (“ASC 606”). The guidance provides a unified model to determine how revenue is recognized.
Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer.
In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.
The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.
We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition.
The following is a description of principal activities from which we generate revenue:
Product Revenue
Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex® Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer’s use.
Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire

70



additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.
Research and Development Revenues
We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.
The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.
Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to perform research and development services. If we determine that the customer cannot benefit from the license without our services, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct, we would recognize an allocable portion of the transaction price when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.
Our CodeEvolver® platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time.
We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We will recognize revenues for the functional license at a point in time when the control of the license transfers to the customer.
For agreements that include sales or usage-based royalty payments to us for which the license is the predominant item to which the royalty relates, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
We recognized revenues from a revenue sharing arrangement based upon sales of licensed products by our revenue sharing partner Exela PharmSci, Inc. (“Exela”) see Note 14 “Related Party Transactions” in the Notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K. We recognized revenues net of product and selling costs

71



upon notification from our revenue sharing partner of our portion of net profit based on the contractual percentage from the sale of licensed product. The revenue sharing arrangement was terminated in December 2017.
Policy before January 1, 2018
We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.
We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 605-25, “Multiple Element Arrangements.” For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.
Product Sales
Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.
Research and Development Revenues
Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (“FTE”) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee’s product sales or cost savings achieved by our customers.
We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.
We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.

72



A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.
We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer’s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.
We recognize revenue from royalties based on licensees’ sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.
Stock-Based Compensation
We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.
Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.
Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.
The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.
Impairment of Long-Lived Assets
We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair value based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of expected undiscounted cash flows.
No impairment charges for long-lived assets were recorded during the year ended December 31, 2018, 2017 and 2016.

73



Goodwill
Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level. Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill is allocated to the Performance Enzymes segment and 24% is allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill was assigned to the Performance Enzymes segment and $0.8 million was assigned to the Novel Biotherapeutics segment. There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
Income Taxes
We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.
We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of December 31, 2018, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as we believe that it is more likely than not that the majority of deferred tax assets will not be realized.
We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.
We account for uncertainty in income taxes as required by the provisions of ASC Topic 740, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.
The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (“NOL”) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited. We performed an analysis in 2018 and determined that there was not a limitation that would result in the expiration of carryforwards before they are utilized.
The adoption of ASC 606 primarily resulted in less cumulative revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.

74



We maintain a full valuation allowance against net deferred tax assets as we believe that it is more likely than not that the majority of deferred tax assets will not be realized.
Changes to Tax Law

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (“BEAT”), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (“GILTI”) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer’s compensation limitation.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed its accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now completed include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.

Because ASC 740-10-25-47 requires the effect of a change in tax laws or rates to be recognized as of the date of enactment, we remeasured our deferred tax assets and liabilities, and offsetting valuation allowance in 2017. There was no impact to tax expense as the remeasurement of net deferred tax assets was completely offset by a corresponding change in valuation allowance. The reduction to U.S. deferred tax assets and the offsetting valuation allowance was $34.1 million.

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. At December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.
The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.


ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity
We had unrestricted cash and cash equivalents totaling $53.0 million at December 31, 2018. These amounts were invested primarily in money market funds and are held for working capital purposes. We do not enter into investments for trading or speculative purposes. We believe we do not have material exposure to changes in fair value as a result of changes in interest rates. Declines in interest rates, however, will reduce future investment income. If overall interest rates fell by 10% in 2018, our results of operations and cash flows would not be materially affected.
Foreign Currency Risk
Our results of operations and cash flows are subject to fluctuations due to changes in foreign currency exchange rates. In periods when the United States dollar declines in value as compared to the foreign currencies in which we incur expenses, our foreign-currency based expenses increase when translated into United States dollars. Although substantially all of our sales are denominated in United States dollars, future fluctuations in the value of the United States dollar may affect the price

75



competitiveness of our products outside the United States. The effect of a 10% unfavorable change in exchange rates on foreign denominated receivables and cash as of December 31, 2018 would have had foreign exchange losses of approximately $0.1 million recognized as a component of other expense in our consolidated statement of operations. We did not engage in hedging transactions in 2018, 2017 and 2016.
Equity Price Risk
As described further in Note 6 to the Consolidated Financial Statements, we have an investment in common shares of CO2 Solutions Inc., a company based in Quebec, Canada (“CO2 Solutions”), whose shares are publicly traded in Canada on the TSX Venture Exchange. As of December 31, 2018, the fair value of our investment in CO2 Solutions’ common stock was $0.6 million.
This investment is exposed to fluctuations in both the market price of CO2 Solutions’ common shares and changes in the exchange rates between the United States dollar and the Canadian dollar. The effect of a 10% adverse change in the market price of CO2 Solutions’ common shares as of December 31, 2018 would have been a loss of approximately $0.1 million, recognized as a component of other expense in our consolidated statements of operations. The effect of a 10% unfavorable change in the exchange rates between the United States dollar and the Canadian dollar as of December 31, 2018 would have been a loss of approximately $0.1 million, recognized as a component of other expense in our consolidated statements of operations.

76



ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Codexis, Inc.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
 

77



Report of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Codexis, Inc.
Redwood City, California
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Codexis, Inc. (the “Company”) and subsidiaries as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2018, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company and subsidiaries at December 31, 2018 and 2017, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2018, in conformity with accounting principles generally accepted in the United States of America.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the Company's internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and our report dated March 1, 2019 expressed an unqualified opinion thereon.

Change in Accounting Principle
As discussed in Notes 2 and 3 to the consolidated financial statements, the Company has changed its accounting method for recognizing revenue from contracts with customers in fiscal year 2018 due to the adoption of Topic 606: Revenue from Contracts with Customers.
Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.
Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ BDO USA, LLP
We have served as the Company's auditor since 2013.
San Jose, California
March 1, 2019

78



Report of Independent Registered Public Accounting Firm
Shareholders and Board of Directors
Codexis, Inc.
Redwood City, California
Opinion on Internal Control over Financial Reporting
We have audited Codexis, Inc.’s (the “Company’s”) internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (the “COSO criteria”). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (“PCAOB”), the consolidated balance sheets of the Company and subsidiaries as of December 31, 2018 and 2017, the related consolidated statements of operations, comprehensive loss, stockholders’ equity, and cash flows for each of the three years in the period ended December 31, 2018 and the related notes, and our report dated March 1, 2019 expressed an unqualified opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying “Item 9A, Management’s Report on Internal Control over Financial Reporting”. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit of internal control over financial reporting in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ BDO USA, LLP
San Jose, California
March 1, 2019

79



Codexis, Inc.
Consolidated Balance Sheets
(In Thousands, Except Per Share Amounts)
 
 
December 31,
 
2018
 
2017
Assets
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
53,039

 
$
31,219

Accounts receivable, net of allowances of $34 at December 31, 2018 and 2017
11,551

 
11,447

Unbilled receivables, current
1,916

 
353

Inventories
589

 
1,036

Prepaid expenses and other current assets
1,068

 
984

Contract assets
35

 

Total current assets
68,198

 
45,039

Restricted cash
1,446

 
1,557

Equity securities
588

 
671

Property and equipment, net
4,759

 
2,815

Goodwill
3,241

 
3,241

Other non-current assets
1,051

 
302

Total assets
$
79,283

 
$
53,625

Liabilities and Stockholders’ Equity
 
 
 
Current liabilities:
 
 
 
Accounts payable
$
3,050

 
$
3,545

Accrued compensation
5,272

 
4,753

Other accrued liabilities
4,855

 
4,362

Deferred revenue
4,936

 
12,292

Total current liabilities
18,113

 
24,952

Deferred revenue, net of current portion
3,352

 
1,501

Lease incentive obligation, net of current portion
35

 
460

Capital lease obligation, net of current portion
61

 
302

Other long-term liabilities
1,416

 
1,863

Total liabilities
22,977

 
29,078

 
 
 
 
Commitments and contingencies (Note 13)

 

Stockholders’ equity:
 
 
 
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding

 

Common stock, $0.0001 par value per share; 100,000 shares authorized; 54,065 and 48,365 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively
5

 
5

Additional paid-in capital
386,775

 
340,079

Accumulated other comprehensive loss

 
(472
)
Accumulated deficit
(330,474
)
 
(315,065
)
Total stockholders’ equity
56,306

 
24,547

Total liabilities and stockholders’ equity
$
79,283

 
$
53,625


See Accompanying Notes to Consolidated Financial Statements

80



Codexis, Inc.
Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Revenues:
 
 
 
 
 
Product revenue
$
25,590

 
$
26,685

 
$
15,321

Research and development revenue
35,004

 
23,339

 
33,516

Total revenues
60,594

 
50,024

 
48,837

Costs and operating expenses:
 
 
 
 
 
Cost of product revenue
12,620

 
14,327

 
9,753

Research and development
29,978

 
29,659

 
22,229

Selling, general and administrative
29,291

 
29,008

 
25,419

Total costs and operating expenses
71,889

 
72,994

 
57,401

Loss from operations
(11,295
)
 
(22,970
)
 
(8,564
)
Interest income
671

 
147

 
60

Other expenses, net
(291
)
 
(92
)
 
(94
)
Loss before income taxes
(10,915
)
 
(22,915
)
 
(8,598
)
Provision for (benefit from) income taxes
(37
)
 
81

 
(40
)
Net loss
$
(10,878
)
 
$
(22,996
)
 
$
(8,558
)
 
 
 
 
 
 
Net loss per share, basic and diluted
$
(0.21
)
 
$
(0.50
)
 
$
(0.21
)
Weighted average common stock shares used in computing net loss per share, basic and diluted
52,205

 
46,228

 
40,629


See Accompanying Notes to Consolidated Financial Statements


81



Codexis, Inc.
Consolidated Statements of Comprehensive Loss
(In Thousands)
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Net loss
$
(10,878
)
 
$
(22,996
)
 
$
(8,558
)
Other comprehensive loss:
 
 
 
 
 
Unrealized loss on equity securities, net of tax (1)

 
(472
)
 
(405
)
Other comprehensive loss

 
(472
)
 
(405
)
Total comprehensive loss
$
(10,878
)
 
$
(23,468
)
 
$
(8,963
)


(1) In 2018, we adopted Accounting Standards Update No. 2016-01 (Subtopic 825-10) and recorded a cumulative-effect reclassification $0.5 million unrealized loss on equity securities from other accumulated comprehensive loss to the beginning accumulated deficit. See Note 2 “Summary of Significant Accounting Policies” in the Accompanying Notes to the Consolidated Financial Statements for more information.

See Accompanying Notes to Consolidated Financial Statements


82



Codexis, Inc.
Consolidated Statements of Stockholders’ Equity
(In Thousands)
 
 
 
Common Stock
 
Additional
Paid-in
Capital
 
Accumulated
Other
Comprehensive
Income (Loss)
 
Accumulated
Deficit
 
Total
Stockholders’
Equity 
 
 
Shares
 
Amount
 
December 31, 2015
 
40,343

 
$
4

 
$
305,981

 
$
405

 
$
(283,511
)
 
$
22,879

Exercise of stock options
 
398

 

 
1,034

 

 

 
1,034

Release of stock awards
 
911

 

 

 

 

 

Employee stock-based compensation
 

 

 
5,673

 

 

 
5,673

Taxes paid related to net share settlement of equity awards
 
(397
)
 

 
(1,524
)
 

 

 
(1,524
)
Total comprehensive loss
 

 

 

 
(405
)
 
(8,558
)
 
(8,963
)
December 31, 2016
 
41,255

 
4

 
311,164

 

 
(292,069
)
 
19,099

Exercise of stock options
 
86

 

 
266

 

 

 
266

Release of stock awards
 
1,096

 

 

 

 

 

Employee stock-based compensation
 

 

 
7,048

 

 

 
7,048

Non-employee stock-based compensation
 

 

 
43

 

 

 
43

Taxes paid related to net share settlement of equity awards
 
(397
)
 

 
(1,670
)
 

 

 
(1,670
)
Issuance of common stock, net of issuance costs
 
6,325

 
1

 
23,228

 

 

 
23,229

Total comprehensive loss
 

 

 

 
(472
)
 
(22,996
)
 
(23,468
)
December 31, 2017
 
48,365

 
5

 
340,079

 
(472
)
 
(315,065
)
 
24,547

Exercise of stock options
 
856

 

 
4,680

 

 

 
4,680

Release of stock awards
 
832

 

 

 

 

 

Employee stock-based compensation
 

 

 
7,865

 

 

 
7,865

Non-employee stock-based compensation
 

 

 
24

 

 

 
24

Taxes paid related to net share settlement of equity awards
 
(301
)
 

 
(3,190
)
 

 

 
(3,190
)
Issuance of common stock, net of issuance costs
 
4,313

 

 
37,317

 

 

 
37,317

Cumulative effect of change in accounting principles (1)
 

 

 

 
472

 
(4,531
)
 
(4,059
)
Net Loss
 

 

 

 

 
(10,878
)
 
$
(10,878
)
December 31, 2018
 
54,065

 
$
5

 
$
386,775

 
$

 
$
(330,474
)
 
$
56,306

 
 
 
 
 
 
 
 
 
 
 
 
 
 (1) Cumulative effect of change in accounting principles includes: Accounting Standards Update 2014-9 (Topic 606), of $4.1 million and Accounting Standards Update 2016-01 (Subtopic 825-10), of $0.5 million. See Note 2 “Summary of Significant Accounting Policies” in the Accompanying Notes to the Consolidated Financial Statements for more information.

 
See Accompanying Notes to Consolidated Financial Statements


83



Codexis, Inc.
Consolidated Statements of Cash Flows
(In Thousands)
 
Year Ended December 31,
 
2018

2017

2016
Operating activities:





Net loss
$
(10,878
)

$
(22,996
)

$
(8,558
)
Adjustments to reconcile net loss to net cash used in operating activities:





Amortization of intangible assets




2,812

Depreciation
1,147


1,042


1,734

Stock-based compensation
7,889


7,091


5,673

Loss (gain) on disposal of property and equipment
8


9


(42
)
Loss on investment securities
83





Gain from extinguishment of asset retirement obligation


(207
)


Changes in operating assets and liabilities:





Accounts receivable, net
960


(5,298
)

1,405

Inventories
447

 
(210
)
 
167

Prepaid expenses and other current assets
(37
)
 
157

 
7

Contract assets
(35
)
 

 

Unbilled receivables
(2,349
)
 
(353
)
 

Other non-current assets
228


(44
)

52

Accounts payable
(524
)

(801
)

942

Accrued compensation
519


439


983

Other accrued liabilities
(17
)

1,399


(593
)
Other long-term liabilities
(904
)


 

Deferred revenue
(10,631
)

11,017


(6,442
)
Net cash used in operating activities
(14,094
)

(8,755
)

(1,860
)
Investing activities:





Purchase of property and equipment
(2,768
)

(985
)

(888
)
Proceeds from disposal of property and equipment
2


2


42

Net cash used in investing activities
(2,766
)

(983
)

(846
)
Financing activities:





Proceeds from exercises of stock options
4,680


266


1,034

Proceeds from issuance of common stock in connection with public offering, net of underwriting discounts and commission
37,497

 
23,782



Costs incurred in connection with public offering
(180
)

(553
)


Principal payments on capital lease obligations
(238
)

(175
)


Taxes paid related to net share settlement of equity awards
(3,190
)

(1,670
)

(1,524
)
Net cash provided by (used in) financing activities
38,569


21,650


(490
)
Net increase (decrease) in cash, cash equivalents and restricted cash
21,709


11,912


(3,196
)
Cash, cash equivalents and restricted cash at the beginning of the year
32,776


20,864


24,060

Cash, cash equivalents and restricted cash at the end of the year
$
54,485


$
32,776


$
20,864







Supplemental disclosure of cash flow information:





Interest paid
$
84


$
141


$
14

Income taxes
$
5


$
32


$
5

Supplemental non-cash financing activities:








Equipment acquired under capital leases
$


$
862


$

Capital expenditures incurred but not yet paid
$
300


$
42


$
125


The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total of the same such amounts shown above (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Cash and cash equivalents
$
53,039

 
$
31,219

 
$
19,240

Restricted cash included in non-current assets
1,446

 
1,557

 
1,624

Total cash, cash equivalents and restricted cash at the end of the period
$
54,485

 
$
32,776

 
$
20,864



See Accompanying Notes to Consolidated Financial Statements

84



Codexis, Inc.
Notes to Consolidated Financial Statements
Note 1. Description of Business
In these notes to the consolidated financial statements, the “Company,” “we,” “us,’” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.
We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which have been continuously improved over our fifteen year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.
We are a pioneer in the harnessing of computational technologies to drive biology advancements. Over the last fifteen years, we have made substantial investments in the development of our CodeEvolver® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.
Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver® protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.
The successful embodiment of our CodeEvolver® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver® protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.
We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals.
We have also begun using the CodeEvolver® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement with Nestec, Ltd. (“Nestlé Health Science”) to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114.
In April 2018, we entered into a strategic agreement (the "Porton Agreement") with Porton Pharma Solutions, Ltd. ("Porton") to license key elements of our platform technology to Porton’s global custom intermediate and active pharmaceutical ingredients ("API") development and manufacturing business. This gives us access to a wide variety of small and medium-sized pharmaceutical customers.

85



We are also using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. Our first enzyme is a ligase which we began marketing to customers in 2018.
Below are brief descriptions of our business segments:
Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. In April 2018, we entered into the Porton Agreement related to our strategic collaboration with Porton to license key elements of our world-leading biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business.

Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” for additional details. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.

For additional discussion of our business segments, see Note 15, "Segment, Geographical and Other Revenue Information."


86



Note 2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Comprehensive income or loss
Comprehensive loss is equivalent to net loss in 2018 because after adopting Accounting Standards Update No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." (“Subtopic 825-10”), we do not have any other transactions recorded under comprehensive loss. Prior to our adoption of Subtopic 825-10, and for the year ended in December 31, 2017 and 2016, comprehensive loss included unrealized gains and unrealized losses from our equity investment in equity securities. See “Recently adopted accounting pronouncements below for additional information.
Certain prior year amounts have been reclassified to conform to 2018 presentation. These changes and reclassifications did not impact net loss or comprehensive loss.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of equity securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.
Segment Reporting

We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for our company. We do not allocate or evaluate assets by segment.
Previously, we had only one business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.
Foreign Currency Translation
The United States dollar is the functional currency for our operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in United States dollars at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-U.S. dollar transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s functional currency are included in other expense in the accompanying consolidated statements of operations.

87



Revenue Recognition
Policy from January 1, 2018
On January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606) and the related amendments (“ASC 606”). The guidance provides a unified model to determine how revenue is recognized.
Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer.
In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.
The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.
We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition.
The following is a description of principal activities from which we generate revenue:
Product Revenue
Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex® Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer’s use.
Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we

88



concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide under the contract. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.
Research and Development Revenues
We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.
The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.
Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to manufacture a product. If we determine that the customer cannot benefit from the license without our manufacturing capability, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct and has significant standalone functionality, we would recognize revenues from a functional license at a point in time when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.
Our CodeEvolver® platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time as our customer learns to use our technology.
We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We recognize revenues for the functional license at a point in time when the control of the license and technology transfers to the customer.
For agreements that include sales or usage-based royalty payments to us, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
Contract Assets
Contract assets include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. The contract assets are reclassified to receivables when the rights become unconditional.

89



Contract Liabilities
Contract liabilities are recorded as deferred revenues and include payments received in advance of performance under the contract. Contract liabilities are realized when the development services are provided to the customer or control of the products has been transferred to the customer. A portion of our contract liabilities relate to supply arrangements that contain material rights that are recognized using the alternative method, under which the aggregate amount invoiced to the customer for shipped products, including annual fees, is higher than the amount of revenue recognized based on the transaction price allocated to the shipped products.
Contract Costs
ASC 606 requires the recognition of an asset for the incremental costs of obtaining a contract with a customer if the entity expects to recover such costs. Incremental costs are costs that would not have been incurred if the contract had not been obtained. Examples of contract costs are commissions paid to sales personnel. We do not typically incur significant incremental costs because the compensation of our salespeople are not based on contracts closed but on a mixture of company goals, individual goals, and sales goals. If a commission paid is directly related to obtaining a specific contract, our policy is to capitalize and amortize such costs on a systematic basis, consistent with the pattern of transfer of the good or service to which the asset relates.
Contract costs are reported in other non-current assets.
Revenue Recognition Policy before January 1, 2018
We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.
We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 605-25, “Multiple Element Arrangements.” For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.
Product Sales
Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.
Research and Development Revenues

90



Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (“FTE”) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee’s product sales or cost savings achieved by our customers.
We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.
We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.
A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.
We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer’s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.
We recognize revenue from royalties based on licensees’ sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.
Cost of Product Revenue
Cost of product revenue comprises both internal and third party fixed and variable costs including materials and supplies, labor, facilities, and other overhead costs associated with our product sales. Shipping costs are included in our cost of product revenue. Such charges were not significant in any of the periods presented.
Fulfillment costs, such as shipping and handling, are recognized at a point in time and are included in cost of product sales.
Cost of Research and Development Services
Cost of research and development services related to FTE services under research and development agreements approximate the research funding over the term of the respective agreements and is included in research and development expense. Costs of services provided under license and platform technology transfer agreements are included in research and development expenses and are expensed in the periods in which such costs are incurred.
Research and Development Expenses
Research and development expenses consist of costs incurred for internal projects and partner-funded collaborative research and development activities, as well as license and platform technology transfer agreements, as mentioned above. These costs include our direct and research-related overhead expenses, which include salaries and other personnel-related expenses (including stock-based compensation), occupancy-related costs, supplies, and depreciation of facilities and laboratory

91



equipment, as well as external costs, and are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no alternative future use are expensed when incurred.
Advertising
Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of operations. Advertising costs were $0.5 million in 2018, $0.7 million in 2017 and $0.5 million in 2016.
Stock-Based Compensation
We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.
Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.
Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.
The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.
Cash and Cash Equivalents
We consider all highly liquid investments with maturity dates of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market funds. The majority of cash and cash equivalents is maintained with major financial institutions in the United States. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. Cash and cash equivalents totaled $53.0 million and comprised of cash of $21.8 million and money market funds of $31.2 million at December 31, 2018. Cash and cash equivalents totaled $31.2 million, comprised of cash of $24.4 million and money market funds of $6.8 million at December 31, 2017.
Restricted Cash
In 2016, we began the process of liquidating our Indian subsidiary. The local legal requirements for liquidation required us to maintain our subsidiary's cash balance in an account managed by a legal trustee to satisfy our financial obligations. This balance is recorded as non-current restricted cash on the consolidated balance sheets and totaled $0.7 million at December 31, 2018 and $0.8 million at December 31, 2017.
Pursuant to the terms of a lease agreement for our Redwood City, CA facilities, we obtained a letter of credit collateralized by cash deposit balances of $0.7 million as of December 31, 2018 and $0.8 million at December 31, 2017. These cash deposit balances are recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, “Commitments and Contingencies”. In January 2019, we entered into the Eighth Amendment to the Lease for our Redwood City, CA facilities and,

92



as a result, our letters of credit will be collateralized by a cash deposit balance of $1.1 million in 2019. See Note 16, “Subsequent Events” for additional information.
Equity Securities
We invest in equity securities that are carried at estimated fair value with changes in fair value recognized within earnings. Equity securities with remaining maturities of greater than one year or which we currently do not intend to sell are classified as long-term. See Note 6, “Cash Equivalents and Equity Securities.”
Unrealized holding gains and losses (the adjustment to fair value) and realized gains and losses are included in other income (expense) in the consolidated statement of operations subsequent to the adoption of ASU 2016-01 starting on January 1, 2018.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and we consider counterparty credit risk in our assessment of fair value. Carrying amounts of financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values as of the balance sheet dates because of their short maturities.
The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2: Inputs that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
See Note 7, “Fair Value Measurements” for additional details.
Concentrations of Credit Risk
Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, contract assets, equity securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India, and the Netherlands. Such deposits in those countries may be in excess of insured limits.
Accounts Receivable and Allowance for Doubtful Accounts
We currently sell primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable includes amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance for doubtful accounts.

The allowances for doubtful accounts reflect our best estimates of probable losses inherent in the accounts receivable and contract assets’ balances. We determine the allowances based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivables and contract assets are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received.

93



Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.
Unbilled receivable
Pursuant to ASC 606, the timing of revenue recognition may differ from the timing of invoicing to our customers. When we satisfy (or partially satisfy) a performance obligation, prior to being able to invoice the customer, we recognize an unbilled receivable when the right to consideration is unconditional. As of December 31, 2018, we recorded a total of unbilled receivables of $2.7 million included on our consolidated balance sheets.
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.
Concentrations of Supply Risk
We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the large scale manufacturing of our products to contract manufacturers with facilities in Austria and Italy.
Property and Equipment
Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:
 
Asset classification
Estimated useful life
 
Laboratory equipment
5 years
 
Computer equipment and software
3 to 5 years
 
Office equipment and furniture
5 years
 
Leasehold improvements
Lesser of useful life or lease term
Property and equipment classified as construction in process includes equipment that has been received but not yet placed in service. Normal repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets
Our tangible long-lived assets consist primarily of property and equipment.
In the first quarter of 2018, we determined that we operate in two segments. We have not identified property and equipment by segment since these assets are shared or commingled. We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of unexpected undiscounted cash flows.
As of December 31, 2018 and 2017, there were no events or changes in circumstances which indicated that the carrying amount of our Asset Group might not be recoverable. No impairment charges for long-lived assets were recorded during the years ended December 31, 2018, 2017 and 2016.
Goodwill
Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been

94



sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level. Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill is allocated to the Performance Enzymes segment and 24% is allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill was assigned to the Performance Enzymes segment and $0.8 million was assigned to the Novel Biotherapeutics segment. There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year.
The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology, we compared the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit’s carrying amount goodwill over the respective implied fair value is recognized as an impairment. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
Income Taxes
We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.
We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of December 31, 2018, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as we believe that it is more likely than not that the majority of deferred tax assets will not be realized.
We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.
We account for uncertainty in income taxes as required by the provisions of ASU 2009-06, Income Taxes (Topic 740) ”Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities”, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to

95



determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.
The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (“NOL”) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited.
The adoption of ASC 606 primarily resulted in less revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.
We recognized income tax benefit of $37 thousand, income tax provision of $81 thousand and income tax benefit of $40 thousand for the years ended December 31, 2018, 2017 and 2016, respectively. The income tax benefits were due to a net loss from our foreign operation and a reduction in the deferred tax liability for accrued future withholding taxes on dividends. We continue to maintain a full valuation allowance against our net deferred tax assets as we believe that it is more likely than not that the majority of our deferred tax assets will not be realized.
Changes to Tax Law

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (“BEAT”), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (“GILTI”) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer’s compensation limitation.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now complete include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.

Because ASC 740-10-25-47 requires the effect of a change in tax laws or rates to be recognized as of the date of enactment, we remeasured our deferred tax assets and liabilities, and offsetting valuation allowance in 2017. There was no impact to tax expense as the remeasurement of net deferred tax assets was completely offset by a corresponding change in valuation allowance. The reduction to U.S. deferred tax assets and the offsetting valuation allowance was $34.1 million.

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. At December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.
The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.


96



Recent Accounting Pronouncements
Recently adopted accounting pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)" , (“ASC 606”), amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for public companies effective for annual and interim reporting periods beginning after December 15, 2016. We have adopted the provisions of ASC 606 and the related amendments, effective January 1, 2018, using the modified retrospective transition method. We recognized the cumulative effect of applying the new revenue standard and recognized a $4.1 million increase to the opening balance of the accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented. See Note 3, "Revenue Recognition" for more details.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities" (“Subtopic 825-10”). This guidance principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of this new guidance, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. This new guidance primarily impacts our accounting for equity investments. In February 2018, the FASB issued ASU 2018-03, "Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, that clarifies the guidance in ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10)." Prior to the adoption of ASC 825, we recognized unrealized holding gains and losses from our equity investment in CO2 Solutions in other comprehensive loss. We adopted ASC 825 in the first quarter of 2018 using a modified retrospective approach by means of a cumulative-effect adjustment to accumulated deficit. Upon adoption of ASC 825, we reclassified $0.5 million of unrealized loss (net of $0.6 million tax) from other accumulated comprehensive loss to beginning accumulated deficit. Any changes in the fair value of our equity investments, except those accounted for under the equity method, will be recognized in earnings on a prospective basis.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" (“ASC 230”), which provides the FASB's guidance on certain cash flow statements items. ASC 230 is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. We adopted ASC 230 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, "Statement of Cash Flows (Topic 230) Restricted Cash a consensus of the FASB Emerging Issues Task Force” (“ASC 230”). The standard requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows. We adopted ASU 2016-18 in the first quarter of 2018 and the adoption had no material impact on our annual consolidated financial statements. The effect of the adoption of ASC 230 on our consolidated statements of cash flows was to include restricted cash balances in the beginning and end of period balances of cash and cash equivalents and restricted cash. The change in restricted cash was previously disclosed in operating and investing activities in the consolidated statements of cash flows.

In January 2017, the FASB issued ASU No. 2017-01 "Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASC 805”). The guidance requires the use of a framework to determine whether a set of assets and activities constitutes an acquired or a sold business. The guidance is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. The amendments should be applied prospectively as of the beginning of the period of adoption. We adopted ASC 805 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, "Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASC 718”). The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. The new standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. We adopted ASC 718 in the first quarter of 2018 and the adoption had no impact on our annual consolidated financial statements.


97



In March 2018, the FASB issued ASU 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118" (“ASC 740”) which amends Topic 740 by incorporating the SEC Staff Accounting Bulletin No. 118 (SAB 118) issued on December 22, 2017. SAB 118 provides guidance on accounting for the effects of the Tax Cuts and Jobs Act (Tax Reform) and allows a company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. See Income Taxes section above for additional information.
Recently issued accounting pronouncements not yet adopted
From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASC 842”), which replaces prior lease guidance (“ASC 840”). This guidance establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statement of Operations. The guidance also eliminates today’s real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Entities have the option to use certain practical expedients. Full retrospective application is prohibited. ASC 842 is effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU 2018-10, "Codification Improvements to ASC 842, Leases." These amendments affect narrow aspects of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under ASC 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under ASC 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. For entities that have not adopted ASC 842, the effective date and transition requirements will be the same as the effective date and transition requirements in ASC 842. The FASB also issued ASU 2018-11, "Leases (Topic 842): Targeted Improvements." These amendments provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). The amendments also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under ASC 606 and certain criteria are met. If the nonlease component or components associated with the lease component are the predominant component of the combined component, an entity is required to account for the combined component in accordance with ASC 606. Otherwise, the entity must account for the combined component as an operating lease in accordance with ASC 842. For entities that have not adopted ASC 842 before the issuance of ASU No. 2018-11, the effective date and transition requirements for the amendments related to separating components of a contract are the same as the effective date and transition requirements in ASU No. 2016-02. We plan to adopt ASC 842 on January 1, 2019 using a modified retrospective approach and effective date method per adoption of ASU 2018-11. We will recognize and measure all leases within the scope of the standard that exist as of January 1, 2017, beginning of the earliest period, as if the standard had always been applied, subject to the practical expedients and transition relief in “Practical Expedients” section. In the current period, we evaluated the practical expedients elections and on adoption, and may apply a practical expedient in which an entity need not reassess whether any expired or existing contracts are or contain leases; An entity need not reassess the lease classification for any expired or existing leases (for example, all existing leases that were classified as operating leases in accordance with ASC 840 will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 will be classified as finance leases); An entity need not reassess initial direct costs for any existing leases. We started the transition plan in the third quarter of 2018 and continued to perform the scoping work in the fourth quarter of 2018. We identified a total of 13 lease agreements that are subject to ASC 842 and seven of them meet the short-term lease exception. We completed the full analysis by January, 2019 and we evaluated the right-of-use (ROU) assets and lease liability using the incremental borrowing rate (IBR) at December 31, 2018 because the implicit rate is not readily determinable in the lease agreement. Upon adoption of ASC 842, all existing leases will be classified as either operating lease or finance lease. We expect to record a range from $20 million to $30 million of ROU assets and liabilities for operating leases and a range from $0.1 million to $0.8 million of ROU assets and liabilities for finance leases in

98



the balance sheet during the first quarter of 2019. This analysis was inclusive of the eighth amendment to the lease agreement disclosed in Note 16, “Subsequent Events.”
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model (known as the "current expected credit loss model") that is based on expected losses rather than incurred losses. ASU 2016-13 is effective for annual reporting periods ending after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements and related disclosures.
In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. This standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects and will be effective for us beginning January 1, 2019 and should be applied either in the period of adoption or retrospectively. Early adoption is permitted. We do not expect this standard to have any impact on our consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting," which expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In July 2018, the FASB issued ASU 2018-09, "Codification Improvements”, which represent changes to clarify, correct errors in, or make minor improvements to the Codification, eliminating inconsistencies and providing clarifications in current guidance. The amendments in this ASU include those made to: Subtopic 220-10, Income Statement-Reporting Comprehensive Income-Overall; Subtopic 470-50, Debt-Modifications and Extinguishments; Subtopic 480-10, Distinguishing Liabilities from Equity-Overall; Subtopic 718-740, Compensation-Stock Compensation-Income Taxes; Subtopic 805-740, Business Combinations-Income Taxes; Subtopic 815-10, Derivatives and Hedging-Overall; Subtopic 820-10, Fair Value Measurement-Overall; Subtopic 940-405, Financial Services-Brokers and Dealers-Liabilities; and Subtopic 962-325, Plan Accounting-Defined Contribution Pension Plans-Investments-Other. The transition and effective date guidance is based on the facts and circumstances of each amendment. Some of the amendments do not require transition guidance and will be effective upon issuance. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. We do not expect this standard to have any material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement." The primary focus of ASU 2018-13 is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. In general, the amendments in this standard are effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.


99



In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606." ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. In general, for public companies, the amendments in this standard are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.

In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments—Credit Losses." ASU 2018-19 clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. In general, the amendments in this standard are effective for public business entities that meet the definition of a SEC filer for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We do not expect this standard to have any material impact on our consolidated financial statements.


Note 3. Revenue Recognition
On January 1, 2018, we adopted ASC 606, applying the modified retrospective method to all contracts that were not completed as of that date. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606 while prior period results are not adjusted and continue to be reported under the accounting standards in effect for the prior period. We recorded an increase to opening accumulated deficit of $4.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact on revenue for the year ended December 31, 2018 was an increase of $5.0 million as a result of adopting ASC 606. The increase in revenues from the adoption of ASC 606 was primarily due to revenue from a product that was recognized over time as we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically for the customer’s use, and revenues from research and development contracts that were recognized when we had the right to invoice our customers for monthly services completed to date. Also, revenue from a distinct, functional license granted on January 1, 2018 contributed to the increase in revenue from the adoption of ASC 606.

We are entitled to certain future milestone payments under our collaborative arrangements. Such milestone payments represent variable consideration that was fully constrained as the realization of the variable consideration is highly uncertain.
Disaggregation of Revenue
The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, Latin America), EMEA (Europe, Middle East, Africa), and APAC (Australia, New Zealand, Southeast Asia, China).
We identified our biotherapeutics business as a standalone business segment in the beginning of 2018 and revenues related to the Novel Biotherapeutics segment were first generated in 2017. Therefore, segment information for fiscal year 2016 is not provided.


100



Segment information for fiscal year 2018 is as follows (in thousands):
 
Year Ended December 31, 2018
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
25,590

 
$

 
$
25,590

Research and development revenue
21,483

 
13,521

 
35,004

Total revenues
$
47,073

 
$
13,521

 
$
60,594

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,332

 
$
38

 
$
15,370

EMEA
8,878

 
13,483

 
22,361

APAC
22,863

 

 
22,863

Total revenues
$
47,073

 
$
13,521

 
$
60,594


Segment information for fiscal year 2017 is as follows (in thousands):
 
Year Ended December 31, 2017
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
26,685

 
$

 
$
26,685

Research and development revenue
15,648

 
7,691

 
23,339

Total revenues
$
42,333

 
$
7,691

 
$
50,024

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,575

 
$

 
$
15,575

EMEA
11,919

 
7,691

 
19,610

APAC
14,839

 

 
14,839

Total revenues
$
42,333

 
$
7,691

 
$
50,024


The following table shows the reconciliation of contract liabilities from what was disclosed in the Form 10-K for the year ended December 31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January 1, 2018 (in thousands):

 
Balance
Deferred Revenue, balance at December 31, 2017
$
13,793

Changes in estimated consideration

Unsatisfied performance obligations
$
5,173

Deferred Revenue, balance at January 1, 2018
$
18,966



101



Contract Balances
The following table presents changes in the contract assets, unbilled receivable, contract costs, and contract liabilities (in thousands):
 
January 1, 2018 balance
 
Additions
 
Deductions (1)
 
December 31, 2018
Contract Assets
$

 
8,934

 
(8,899
)
 
$
35

Unbilled receivables, current
$

 
2,908

 
(992
)
 
$
1,916

Unbilled receivables, non-current
$

 
786

 

 
$
786

Contract Costs
$
239

 

 
(197
)
 
$
42

Contract Liabilities: Deferred Revenue
$
18,966

 
6,446

 
(17,124
)
 
$
8,288

(1) The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.
We recognize accounts receivable when we have an unconditional right to recognize revenue and have issued an invoice to the customer. Our payment terms are generally between 30 and 90 days. We recognize unbilled receivables when we have an unconditional right to recognize revenue and have not issued an invoice to our customer. Unbilled receivables, current are transferred to accounts receivable on issuance of an invoice. Unbilled receivables, non-current are transferred to accounts receivable on issuance of an invoice; payment is expected from the customer thereon. Unbilled receivables are classified separately on the consolidated balance sheet as assets.
Contract assets represent our right to recognize revenue for custom products with no alternate use and under binding non-cancellable purchase orders and are largely related to our procurement of product. We recognize contract assets when we have a conditional right to recognize revenue. The delivery pattern of certain of products occurs in advance of the invoicing process, which generates contract assets. In addition, we recognize a contract asset related to milestones not eligible for royalty accounting when we assess it is probable of being achieved and there will be no significant reversal of cumulative revenues. Contract assets are classified separately on the consolidated balance sheet as an asset and transferred to accounts receivable when our rights to payment become unconditional.
Contract liabilities, or deferred revenue, represent our obligation to transfer a product or service to the customer, and for which we have received consideration from the customer. We recognize a contract liability when we receive advance customer payments under development agreements for research and development services, upfront license payments, and from upfront customer payments received under product supply agreements. Contract liabilities are classified as a liability on the consolidated balance sheet.
Contract costs relate to incremental costs of obtaining a contract with a customer. Contract costs are amortized along with the associated revenue over the term of the contract.
We had no asset impairment charges related to contract assets in the period.


102



During the year ended December 31, 2018, we recognized the following revenues (in thousands):
Revenue recognized in the period for:
Year Ended December 31, 2018
Amounts included in contract liabilities at the beginning of the period:
 
     Performance obligations satisfied
$
13,615

Changes in the period:
 
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods
374

Performance obligations satisfied from new activities in the period - contract revenue
46,605

Total revenue
$
60,594

Performance Obligations
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of December 31, 2018. We did not recognize any revenue from performance obligations satisfied in previous periods.

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):
 
2019
 
2020
 
2021
 
2022 and Thereafter
 
Total
Product Revenue
$
2,201

 
$
1,729

 
$
1,623

 
$

 
$
5,553

Research and development revenue
2,735

 

 

 

 
2,735

Total revenues
$
4,936

 
$
1,729

 
$
1,623

 
$

 
$
8,288


Practical Expedients, Elections, and Exemptions
We used a practical expedient available under ASC 606 which permits us to consider the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations.
We also used a practical expedient available under ASC 606 which permits us not to adjust the amount of consideration for the effects of a significant financing component if, at contract inception, the expected period between the transfer of promised goods or services and customer payment is one year or less.
We perform monthly services under our research and development agreements and we use a practical expedient available under ASC 606 permitting us to recognize revenue at the same time that we have the right to invoice our customer for monthly services completed to date.
We have elected to treat shipping and handling activities as fulfillment costs.
Additionally, we have elected to record revenue net of sales and other similar taxes.


103



Impact on Financial Statements
In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):
 
Year Ended December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Revenues:





Product revenue
$
25,590


$
(3,422
)

$
22,168

Research and development revenue
35,004


(1,609
)

33,395

Total revenues
60,594


(5,031
)

55,563

Costs and operating expenses:





Cost of product revenue
12,620


(285
)

12,335

Research and development
29,978


(196
)

29,782

Selling, general and administrative
29,291




29,291

Total costs and operating expenses
71,889


(481
)

71,408

Loss from operations
(11,295
)

(4,550
)

(15,845
)
Interest income
671




671

Other expenses
(291
)



(291
)
Loss before income taxes
(10,915
)

(4,550
)

(15,465
)
Provision for (benefit from) income taxes
(37
)



(37
)
Net loss
$
(10,878
)

$
(4,550
)

$
(15,428
)









Net loss per share, basic and diluted
$
(0.21
)

$
(0.09
)

$
(0.30
)
Weighted average common shares used in computing net loss per share, basic and diluted
52,205




52,205


 
December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Assets





Accounts receivable
$
11,551


$
(1,253
)

$
10,298

Unbilled receivables, current
1,916


(1,916
)


Contract assets
35


(35
)


Inventories
589


1


590

Unbilled receivables, non-current
786

 
(786
)
 

Other non-current assets
265


(42
)

223

Liabilities





Other accrued liabilities
4,855


(520
)

4,335

Deferred revenue - current
4,936


(1,574
)

3,362

Deferred revenue - non-current
3,352


(1,445
)

1,907

Stockholders' equity








Accumulated deficit
(330,474
)

(492
)

(330,966
)





104



Note 4. Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities. For all periods presented, diluted and basic net losses per share are identical since potential common shares are excluded from the calculation, as their effect was anti-dilutive.
Anti-Dilutive Securities
In periods of net loss, the weighted average number of shares outstanding related to potentially dilutive securities, prior to the application of the treasury stock method, are excluded from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect.
The following shares were not included in the computation of diluted net loss per share (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares issuable under Equity Incentive Plan
6,339

 
6,882

 
5,567

Shares issuable upon the conversion of warrants

 

 
73

Total anti-dilutive securities
6,339

 
6,882

 
5,640

Note 5. Collaborative Arrangements

Deferred revenue amounts discussed herein as of December 31, 2017 are derived from our Form 10-K for the year ended December 31, 2017. On January 1, 2018 we adopted Topic 606 and subsequently adjusted deferred revenue to give effect to the modified retrospective adoption of the revenue guidance. See Note 3, “Revenue Recognition” for additional information.

GSK Platform Technology Transfer, Collaboration and License Agreement
In July 2014, we entered into a CodeEvolver® protein engineering platform technology transfer collaboration and license agreement (the "GSK CodeEvolver® Agreement") with GlaxoSmithKline ("GSK"). Pursuant to the terms of the agreement, we granted GSK a non-exclusive license to use the CodeEvolver® protein engineering platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products.
We received an upfront fee upon the execution of the agreement in July 2014 and milestone payments in each of the years from 2014 through April 2016. We completed the transfer of the CodeEvolver® protein engineering platform technology to GSK in April 2016 and all revenues relating to the technology transfer have been recognized as of April 2016. We have the potential to receive additional cumulative contingent payments that range from $5.75 million to $38.5 million per project based on GSK’s successful application of the licensed technology. We are also eligible to receive royalties based on net sales of GSK’s sales of licensed enzyme products that are currently not being recognized.
Merck Platform Technology Transfer and License Agreement
In August 2015, we entered into a CodeEvolver® platform technology transfer collaboration and license agreement (the "Merck CodeEvolver® Agreement") with Merck, Sharp & Dohme ("Merck") which allows Merck to use the CodeEvolver® protein engineering technology platform in the field of human and animal healthcare.
We received a $5.0 million up-front license fee upon execution of the Merck CodeEvolver® Agreement, and milestone payments in September 2015 and in September 2016, when we completed the transfer of the engineering platform technology. We recognized research and development revenues of $4.1 million, $3.6 million, and $3.0 million in 2018, 2017 and 2016, respectively, for various research projects under our collaborative arrangement.
We have the potential to receive payments of up to a maximum of $15.0 million for each commercial active pharmaceutical ingredient ("API") that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver® protein engineering technology platform. The API payments, which are currently not recognized in revenue, are based on quantity of API developed and manufactured by Merck and will be recognized as usage-based royalties.

105



In October 2018, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we amended certain licensing provisions and one exhibit. In January 2019, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we will install certain CodeEvolver® protein engineering technology upgrades into Merck’s platform license installation and maintain those upgrades for a multi-year term.
Merck Sitagliptin Catalyst Supply Agreement
In February 2012, we entered into a five-year Sitagliptin Catalyst Supply Agreement (“Sitagliptin Catalyst Supply Agreement”) with Merck whereby Merck may obtain commercial scale enzyme for use in the manufacture of Januvia®, its product based on the active ingredient Sitagliptin. In December 2015, Merck exercised its option under the terms of the Sitagliptin Catalyst Supply Agreement to extend the agreement for an additional five years through February 2022.
Effective as of January 2016, we and Merck amended the Sitagliptin Catalyst Supply Agreement to prospectively provide for variable pricing based on the cumulative volume of sitagliptin catalyst purchased by Merck and to allow Merck to purchase a percentage of its requirements for sitagliptin catalyst from a specified third-party supplier. Merck received a distinct, functional license to manufacture a portion of its demand beginning January 1, 2018, which we recognized as research and development revenue. We recognized research and development revenues of $1.3 million, $1.3 million and $1.3 million in 2018, 2017 and 2016, respectively.
In June 2017, we completed a contractual milestone by qualifying the specified third-party enzyme supplier and recognized $0.3 million as research and development revenues.
We have determined that the variable pricing, which provides a discount based on the cumulative volume of sitagliptin catalyst purchased by Merck, provides Merck material rights and we are recognizing product revenues using the alternative method. Under the alternative approach, we estimate the total expected consideration and allocate it proportionately with the expected sales.
The Sitagliptin Catalyst Supply Agreement requires Merck to pay an annual fee for the rights to the sitagliptin technology each year for the term of the Sitagliptin Catalyst Supply Agreement. Amounts of annual license fees are based on contractually agreed prices and are on a declining scale over the term of the contract.
We had a deferred revenue balance from Merck of $3.6 million at December 31, 2018 and $1.5 million at December 31, 2017. Pursuant to the terms of the Sitagliptin Catalyst Supply Agreement, Merck may purchase supply from us for a fee based on contractually stated prices and we recognized $12.3 million, $9.0 million and $5.9 million in 2018, 2017 and 2016, respectively, in product revenue under this agreement.
Enzyme Supply Agreement
In November 2016, we entered into a supply agreement whereby our customer may purchase quantities of one of our proprietary enzymes for use in its commercial manufacture of a product. Pursuant to the supply agreement, we received an upfront payment of $0.8 million in December 2016, which we accordingly recorded as deferred revenues. Such upfront payment will be recognized over the period of the supply agreement as the customer purchases our proprietary enzyme. We additionally have determined that the volume discounts under the supply agreement provides the customer material rights and we are recognizing revenues using the alternative method. As of December 31, 2018 and 2017, we had deferred revenue from the supply agreement of $2.0 million and $0.7 million, respectively.
Research and Development Agreement
In March 2017, we entered into a multi-year research and development services agreement with Tate & Lyle Ingredients Americas LLC ("Tate & Lyle") to develop enzymes for use in the manufacture of Tate & Lyle’s zero-calorie TASTEVA® M Stevia sweetener. Under the agreement, we received an upfront payment of $3.0 million, which was originally recognized ratably over the maximum term of the services period of 21 months. Beginning January 1, 2018, we are recognizing revenue using a single measure of progress that depicts our performance in transferring the services. During the second quarter of 2018, Tate & Lyle opted to obtain additional development services that we completed by June 30, 2018 and we earned milestone payments upon completion of the services. We recognized $7.1 million and $3.2 million of revenue in 2018 and 2017, respectively, for research and development services under the research and development agreement. As of December 31, 2018 and 2017, we had deferred revenue from the development services agreement of zero and $3.1 million, respectively.

106



Global Development, Option and License Agreement and Strategic Collaboration Agreement
In October 2017, we entered into a Global Development, Option and License Agreement (the "Nestlé Agreement") with Nestec Ltd. ("Nestlé Health Science") and, solely for the purpose of the integration and the dispute resolution clauses of the Nestlé Agreement, Nestlé Health Science S.A., to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU.
We received an upfront cash payment of $14.0 million in 2017 upon the execution of the Nestlé Agreement and a $4.0 million milestone payment 60 days after dosing the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 for the potential treatment of PKU. The $4.0 million milestone payment that was triggered by the initiation of the trial was received in September 2018. The upfront payment and the variable consideration relating to the progress payment of $4.0 million are being recognized over time as the development work is being performed. Revenue is being recognized using a single measure of progress that depicts our performance in transferring control of the services, which is based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete all performance obligations under the agreement. We recognized development fees of $9.9 million in 2018 as research and development revenue and $7.2 million in 2017. We had deferred revenue related to the development fees attributed to the milestone payment and up-front fees of $1.9 million at December 31, 2018 and $6.8 million at December 31, 2017.
In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
In addition to the Nestlé Agreement, we and Nestlé Health Science concurrently entered into a Strategic Collaboration Agreement (the “Strategic Collaboration Agreement”) pursuant to which we and Nestlé Health Science will collaborate to leverage the CodeEvolver® protein engineering technology platform to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. Under the Strategic Collaboration Agreement, we received an upfront payment of $1.2 million in 2017 and an incremental $0.6 million payment in September 2018 for additional services. We recognized research and development fees of $3.6 million and $0.5 million in 2018 and 2017, respectively. As of December 31, 2018 and 2017, we had deferred revenue of $0.8 million and $1.1 million, respectively.
Strategic Collaboration Agreement
In April 2018, we entered into the Porton Agreement with Porton to license key elements of Codexis’ biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business. Under the Porton Agreement, we are eligible to receive annual collaboration fees and research and development revenues. We have the potential to receive performance payments based on products produced by Porton using our company technology under the license agreement. We received an initial collaboration fee of $0.5 million within 30 days of the effective date of the agreement. As of December 31, 2018, we completed the technical transfer and we recognized revenue of $2.8 million in 2018 as research and development revenue. Revenue relating to the functional license provided to Porton was recognized at a point in time when control of the license transferred to the customer.


107



Note 6. Cash Equivalents and Equity Securities
Cash equivalents and equity securities at December 31, 2018 and 2017 consisted of the following (in thousands): 
 
December 31, 2018
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
31,225

 
$

 
$

 
$
31,225

 
n/a
Common shares of CO2 Solutions (2)
563

 
25

 

 
588

 
n/a
Total
$
31,788

 
$
25

 
$

 
$
31,813

 
 
 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
6,778

 
$

 
$

 
$
6,778

 
n/a
Common shares of CO2 Solutions (2)
563

 
108

 

 
671

 
n/a
Total
$
7,341

 
$
108

 
$

 
$
7,449

 
 
(1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets.
(2) Common shares of CO2 Solutions are classified in equity securities on our consolidated balance sheets.
(3) As a result of adopting ASU 2016-01, in 2018 and thereafter gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recognized in other expense, in the consolidated statements of operations. Prior to 2018 gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recorded in accumulated other comprehensive loss on the balance sheet.
As of December 31, 2018, the total cash and cash equivalents balance of $53.0 million was comprised of money market funds of $31.2 million and cash of $21.8 million held with major financial institutions worldwide. As of December 31, 2017, the total cash and cash equivalents balance of $31.2 million was comprised of money market funds of $6.8 million and cash of $24.4 million held with major financial institutions worldwide.
In December 2009, we purchased 10,000,000 common shares of CO2 Solutions, a company based in Quebec, Canada, whose shares are publicly traded in Canada on TSX Venture Exchange. Our purchase represented approximately 16.6% of CO2 Solutions’ total common shares outstanding at the time of investment and was made in a private placement subject to a four-month statutory resale restriction. This restriction expired on April 15, 2010. Our investment in CO2 Solutions is recorded at its fair value. See Note 7, “Fair Value Measurements.” Through December 31, 2018, we concluded that we did not have the ability to exercise significant influence over CO2 Solutions’ operating and financial policies.
On January 1, 2018, we adopted ASU 2016-01. Upon adoption, we reclassified the $0.5 million net unrealized loss from accumulated other comprehensive loss to our opening accumulated deficit.
In 2018, we recognized an unrealized loss of $84 thousand related to our investment in CO2 Solutions in other expense, in the consolidated statements of operations.


108



Note 7. Fair Value Measurements
The following tables present the financial instruments that were measured at fair value on a recurring basis at December 31, 2018 and 2017 by level within the fair value hierarchy (in thousands): 
 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
31,225

 
$

 
$

 
$
31,225

Common shares of CO2 Solutions
588

 

 

 
588

Total
$
31,813

 
$

 
$

 
$
31,813

 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
6,778

 
$

 
$


$
6,778

Common shares of CO2 Solutions


671

 

 
671

Total
$
6,778

 
$
671

 
$

 
$
7,449

We determine the fair value of Level 1 and Level 2 assets using quoted prices in active markets for identical assets. We estimated the fair value of our investment in 10,000,000 common shares of CO2 Solutions using the market value of common shares as determined by trading on the TSX Venture Exchange, and we classified our investment in COSolutions within the fair value hierarchy as Level 1 and Level 2, at December 31, 2018 and December 31, 2017, respectively, using the quoted prices in an active market to determine their fair value.
A review of the fair value hierarchy classifications of our investments is conducted annually. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets. Reclassifications are reported as transfers in or transfers out of the applicable level at end of the calendar year in which the reclassifications occur. In the fourth quarter of 2018, we reclassified the $0.6 million fair value of the investment in the common shares of CO2 Solutions from Level 2 to Level 1 within the fair value hierarchy since we concluded that there was a sufficient level of transactional frequency and trading volume to indicate that the pricing information was representative of its fair value on an ongoing basis. (See also Note 6, “Cash Equivalents and Equity Securities” for additional information.)



109



Note 8. Balance Sheets Details
Accounts receivable
The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):
 
December 31,
 
2018
 
2017
 
2016
Allowance - beginning of period
$
(34
)
 
$
(421
)
 
$
(421
)
Write-offs and other (1)

 
387

 

Allowance - end of period
$
(34
)
 
$
(34
)
 
$
(421
)
(1) The change in allowance for doubtful accounts was mainly related to the write-off of receivables from a foreign customer.
Inventories
Inventories consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Raw materials
$
165

 
$
158

Work in process
47

 
53

Finished goods
377

 
825

Inventories
$
589

 
$
1,036

Property and Equipment, net
Property and equipment, net consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Laboratory equipment (1)
$
21,328

 
$
19,777

Leasehold improvements
10,359

 
10,327

Computer equipment and software
3,954

 
3,695

Office equipment and furniture
1,272

 
1,185

Construction in progress (2)
939

 
85

Property and equipment
37,852

 
35,069

Less: accumulated depreciation and amortization
(33,093
)
 
(32,254
)
Property and equipment, net
$
4,759

 
$
2,815

(1) Fully depreciated laboratory equipment with a cost of $0.3 million and $0.2 million were retired during 2018 and 2017, respectively.
(2) Construction in progress includes equipment received but not yet placed into service pending installation.
Goodwill
Goodwill had a carrying value of approximately of $3.2 million as of December 31, 2018 and 2017.

110



Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Accrued purchases
$
1,492

 
$
941

Accrued professional and outside service fees
2,020

 
2,393

Deferred rent
343

 
258

Lease incentive obligation
425

 
425

Other
575

 
345

Total
$
4,855

 
$
4,362


Note 9. Stock-based Compensation
Equity Incentive Plans
In March 2010, our board of directors (the "Board") and stockholders approved the 2010 Equity Incentive Award Plan (the "2010 Plan"), which became effective upon the completion of our initial public offering in April 2010. The number of shares of our common stock available for issuance under the 2010 Plan is equal to 1,100,000 shares plus any shares of common stock reserved for future grant or issuance under our 2002 Stock Plan (the “2002 Plan”) that remained unissued at the time of completion of the initial public offering. The 2010 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. All grants will reduce the 2010 Plan reserve by one share for every share granted. As of December 31, 2018, total shares remaining available for issuance under the 2010 Plan were approximately 7.9 million shares.
The 2010 Plan provides for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants.
Stock Options
The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of 10 years and vest over 4 years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier.
Restricted Stock Units (RSUs)
We also grant employees RSUs, which generally vest over either a three year period with one-third of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time.
Performance-contingent Restricted Stock Units (PSUs) and Performance Based Options (PBOs)
The compensation committee of the Board approved, solely in respect of non-executive employees, delegated to our Chief Executive Officer the authority to approve grants of PSUs. The compensation committee of the Board also approved grants of PBOs and PSUs to our executives. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number

111



of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs.
In the first quarter of 2018, we awarded PSUs ("2018 PSUs") and PBOs ("2018 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including core business revenue growth, cash balance, new licensing collaborations, new research and development service revenue arrangements, technology advancement and novel therapeutic enzymes advancement. As of December 31, 2018, we estimated that the 2018 PSUs and 2018 PBOs performance goals would be achieved at 118% of the target level, and recognized expenses accordingly.
In 2017, we awarded PSUs ("2017 PSUs") and PBOs ("2017 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including revenue growth, fundraising, service revenue, new platform license revenue, and strategic advancement of biotherapeutics pipeline. In the first quarter of 2018, we determined that the 2017 PSU and PBO performance goals had been achieved at 134.2% of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2017 PSUs and PBOs vested in the first quarter of 2018 and one-half of the shares underlying the 2017 PSUs and PBOs will vest in the first quarter of 2019, in each case subject to the recipient’s continued service on each vesting date.
In 2016, we awarded PSUs ("2016 PSUs") based upon the achievement of various weighted performance goals, including revenue growth, non-GAAP net income growth, new licensing collaborations, new research and development service revenue arrangements and novel therapeutic enzymes advancement. In the first quarter of 2017, we determined that the 2016 PSU performance goals had been achieved at 142.3% of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2016 PSUs vested in the first quarter of each of 2017 and 2018, in each case subject to the recipient’s continued service on each vesting date. No PBOs were awarded in 2016.
Stock-Based Compensation Expense:
Stock-based compensation expense is included in the consolidated statements of operations as follows (in thousands):
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Research and development
$
2,055

 
$
1,444

 
$
1,033

Selling, general and administrative
5,834

 
5,647

 
4,640

Total
$
7,889

 
$
7,091

 
$
5,673


The following table presents total stock-based compensation expense by security type included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Stock options
$
1,975

 
$
1,554

 
$
1,102

RSUs and RSAs
1,770

 
1,888

 
2,043

PSUs
1,511

 
1,792

 
2,528

PBOs
2,633

 
1,857

 

Total
$
7,889

 
$
7,091

 
$
5,673



112



Grant Award Activities:

Stock Option Awards

We estimated the fair value of stock options using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.6

 
5.4

 
5.3

Volatility
60.0
%
 
62.2
%
 
64.2
%
Risk-free interest rate
2.7
%
 
2.0
%
 
1.3
%
Expected dividend yield
0.0
%
 
0.0
%
 
0.0
%
In October 2017, we granted an option to purchase 11,100 shares of common stock to a non-employee as compensation for services valued at $48 thousand with the following assumptions used to estimate the fair value of non-employee stock options: (i) volatility rate at 60.6%, risk-free interest rate of 2.4% and (ii) no expected dividend yield. The option vested over a period of six months with one-sixth of total number of shares subject to the option vesting on each one month anniversary of the grant date. During the year ended December 31, 2018 and December 31, 2016, we did not grant any options to purchase shares of common stock to non-employees.
The following tables summarizes stock option activities:
 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
(In Thousands)
 
 
Outstanding at December 31, 2015
3,918

 
$
4.49

Granted
971

 
$
4.16

Exercised
(398
)
 
$
2.60

Forfeited/Expired
(601
)
 
$
5.76

Outstanding at December 31, 2016
3,890

 
$
4.40

Granted
856

 
$
4.57

Exercised
(86
)
 
$
3.10

Forfeited/Expired
(81
)
 
$
7.72

Outstanding at December 31, 2017
4,579

 
$
4.40

Granted
645

 
$
9.56

Exercised
(772
)
 
$
5.56

Forfeited/Expired
(340
)
 
$
6.66

Outstanding at December 31, 2018
4,112

 
$
4.81

 
 
 
 
Exercisable at December 31, 2018
2,876

 
$
3.83

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Outstanding at December 31, 2018
4,112

 
$
4.81

 
6.23
 
$
48,927

Exercisable at December 31, 2018
2,876

 
$
3.83

 
5.25
 
$
37,005

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
6.13
 
$
47,503


113





The weighted average grant date fair value per share of stock options granted in 2018, 2017 and 2016 were $5.34, $2.51 and $2.32, respectively. The total intrinsic value of options exercised in 2018, 2017 and 2016 were $7.6 million, $0.2 million and $0.6 million, respectively.
As of December 31, 2018, there was $3.5 million of unrecognized stock-based compensation cost related to non-vested options, which we expect to recognize over a weighted average period of 2.5 years.
Restricted Stock Awards (RSAs)
The following table summarizes RSA activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at December 31, 2015
480

 
$
3.29

Granted
185

 
$
4.21

Vested
(435
)
 
$
3.40

Non-vested balance at December 31, 2016
230

 
$
3.82

Granted
143

 
$
4.75

Vested
(214
)
 
$
3.81

Non-vested balance at December 31, 2017
159

 
$
4.68

Granted
47

 
$
14.35

Vested
(151
)
 
$
4.71

Non-vested balance at December 31, 2018
55

 
$
12.83

The weighted average grant date fair value per share of RSAs granted in 2018, 2017 and 2016 were $14.35, $4.75 and $4.21, respectively. The total fair value of RSAs vested in fiscal 2018, 2017 and 2016 were $2.1 million, $1.0 million and $1.8 million respectively.
As of December 31, 2018, there was $0.3 million of unrecognized stock-based compensation cost related to non-vested RSAs, which we expect to recognize over a weighted average period of 0.4 years.

114



Restricted Stock Units (RSUs)
The following table summarizes RSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
545

 
$
3.15

Granted
330

 
$
4.10

Vested
(243
)
 
$
3.11

Forfeited/Expired
(15
)
 
$
2.74

Non-vested balance at December 31, 2016
617

 
$
3.69

Granted
275

 
$
4.22

Vested
(302
)
 
$
3.40

Forfeited/Expired
(30
)
 
$
4.12

Non-vested balance at December 31, 2017
560

 
$
4.08

Granted
86

 
$
10.56

Vested
(290
)
 
$
4.09

Forfeited/Expired
(8
)
 
$
4.73

Non-vested balance at December 31, 2018
348

 
$
5.66

The weighted average grant date fair value per share of RSUs granted in 2018, 2017 and 2016 were $10.56, $4.22 and $4.10, respectively. The total fair value of RSUs vested in fiscal 2018, 2017 and 2016 were $2.9 million, $1.3 million and $1.0 million respectively.
As of December 31, 2018, there was $1.0 million of unrecognized stock-based compensation cost related to non-vested RSUs, which we expect to recognize over a weighted average period of 1.1 years.
Performance-Contingent Restricted Stock Units (PSUs)
The following table summarizes PSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
989

 
$
2.94

Granted
629

 
$
4.10

Vested
(482
)
 
$
2.89

Forfeited/Expired
(305
)
 
$
2.82

Non-vested balance at January 1, 2017
831

 
$
3.88

Granted
276

 
$
4.25

Vested
(651
)
 
$
3.84

Forfeited/Expired
(27
)
 
$
3.65

Non-vested balance at January 1, 2018
429

 
$
4.20

Granted
306

 
$
6.71

Vested
(495
)
 
$
4.16

Non-vested balance at December 31, 2018
240

 
$
7.48

The weighted average grant date fair value per share of PSUs granted in 2018, 2017 and 2016 were $6.71, $4.25 and $4.10, respectively. The total fair value of PSUs vested in fiscal 2018, 2017, and 2016 were $5.4 million, $2.7 million, and $1.8 million, respectively.

115



As of December 31, 2018, there was $0.6 million of unrecognized stock-based compensation cost related to non-vested PSUs, which we expect to recognize over a weighted average period of 0.5 years.
Performance Based Options (PBOs)

We estimated the fair value of PBO using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.63

 
5.33

 

Volatility
60.3
%
 
62.3
%
 

Risk-free interest rate
5.6
%
 
5.3
%
 

Expected dividend yield
0.0
%
 
0.0
%
 


The following table summarizes PBO activities in 2018:
 
Number of Shares
 
Weighted Average Grant Date Fair Value Per Share
 
(in thousands)
 
 
Outstanding at December 31, 2016

 
$

Granted
1,720

 
$
2.54

Outstanding at December 31, 2017
1,720

 
$
2.54

Granted
1,200

 
$
5.02

Exercised
(84
)
 
$
2.54

Forfeited
(1,254
)
 
$
3.73

Outstanding at December 31, 2018
1,582

 
$
3.47

 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Exercisable at December 31, 2018
493

 
$
4.60

 
5.60
 
$
5,968

Vested and expected to vest at December 31, 2018
1,582

 
$
6.24

 
5.44
 
$
16,553

The total fair value of exercised PBOs was $0.2 million for 2018, zero for 2017 and zero for 2016. As of December 31, 2018, there was $1.2 million of unrecognized stock-based compensation cost related to non-vested PBOs, which we expect to recognize over a weighted average period of 0.9 years.

Note 10. Capital Stock
Public Offering

In April 2018, we completed an underwritten public offering of 4,312,500 shares of our common stock, including the exercise in full by the underwriters of their option to purchase 562,500 of our shares, at a public offering price of $9.25 per share. After deducting the underwriting discounts and commissions and estimated offering expenses, net proceeds were approximately $37.3 million.

116



Note 11. 401(k) Plan
In January 2005, we implemented a 401(k) Plan covering certain employees. Currently, all of our United States based employees over the age of 18 are eligible to participate in the 401(k) Plan. Under the 401(k) Plan, eligible employees may elect to reduce their current compensation up to a certain annual limit and contribute these amounts to the 401(k) Plan. We may make matching or other contributions to the 401(k) Plan on behalf of eligible employees. We recorded employer matching contributions expense of $0.6 million, $0.6 million and $0.4 million in 2018, 2017, and 2016, respectively.
Note 12. Income Taxes
Our loss before provision for income taxes was as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
(10,653
)
 
$
(22,994
)
 
$
(8,174
)
Foreign
(262
)
 
79

 
(424
)
Loss before provision for income taxes
$
(10,915
)
 
$
(22,915
)
 
$
(8,598
)
The tax provision (benefit from) for the years ended December 31, 2018, 2017 and 2016 consists primarily of taxes attributable to foreign operations. The components of the provision for income taxes are as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current provision (benefit):
 
 
 
 
 
Federal
$

 
$

 
$

State
5

 
5

 
5

Foreign
(13
)
 
64

 
(14
)
Total current provision (benefit)
(8
)
 
69

 
(9
)
Deferred provision (benefit):
 
 
 
 
 
Federal

 

 

State

 

 

Foreign
(29
)
 
12

 
(31
)
Total deferred provision (benefit)
(29
)
 
12

 
(31
)
Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)

Reconciliation of the provision for income taxes calculated at the statutory rate to our provision for (benefit from) income taxes is as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Tax benefit at federal statutory rate
$
(2,292
)
 
$
(7,791
)
 
$
(2,924
)
State taxes
222

 
48

 
127

Research and development credits
(499
)
 
(399
)
 
(161
)
Foreign operations taxed at different rates
(17
)
 
(2
)
 
30

Stock-based compensation
(2,587
)
 
(216
)
 
327

Other nondeductible items
(3
)
 
326

 
405

Executive compensation
838

 
73

 
255

Change in valuation allowance
4,301

 
(26,058
)
 
1,901

Change in statutory tax rate

 
34,100

 

Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)

117



Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.
Significant components of our deferred tax assets and liabilities are as follows (in thousands): 
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
60,455

 
$
53,901

Credits
7,174

 
6,221

Deferred revenues
1,879

 
3,334

Stock-based compensation
2,967

 
2,872

Reserves and accruals
1,876

 
2,028

Depreciation
1,376

 
1,573

Intangible assets
2,557

 
3,172

Capital losses
576

 
576

Unrealized gain/loss
297

 
295

Other assets
83

 
78

Total deferred tax assets:
79,240

 
74,050

Deferred tax liabilities:
 
 
 
Other
(64
)
 
(115
)
Total deferred tax liabilities:
(64
)
 
(115
)
Valuation allowance
(79,222
)
 
(74,010
)
Net deferred tax liabilities
$
(46
)
 
$
(75
)
ASC Topic 740 requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a valuation allowance against our deferred tax assets. Accordingly, the net deferred tax assets in all our jurisdictions have been fully reserved by a valuation allowance. The change in valuation allowance differs from the amount included the rate reconciliation table due to the deferred tax impact of the adoption of ASC 606, which resulted in a $0.9 million adjustment to opening accumulated deficit before the offsetting change in valuation allowance. The net valuation allowance increased by $5.2 million during the year ended December 31, 2018; and decreased by $20.4 million during the year ended December 31, 2017; and increased by $1.9 million during the year ended December 31, 2016, respectively. At such time as it is determined that it is more likely than not that the deferred tax assets are realizable, the valuation allowance will be reduced.
The following table sets forth our federal, state and foreign NOL carryforwards and federal research and development tax credits as of December 31, 2018 (in thousands): 
 
December 31, 2018
 
Amount
 
Expiration
Years
Net operating losses, federal
$
254,208

 
2022-2038
Net operating losses, state
115,420

 
2018-2038
Tax credits, federal
7,430

 
2022-2038
Tax credits, state
9,121

 
Do not expire
Net operating losses, foreign
383

 
Various
Current U.S. federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax

118



credit carryforwards may be limited as a result of such ownership changes. We performed an analysis in 2018 and determined that there was not a limitation that would result in the expiration of carryforwards before they are utilized.
Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income. An exception is provided in ASC Topic 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year. In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets. In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale securities recorded as a component of other comprehensive income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets. For the year ended December 31, 2018, we did not record a tax expense in other comprehensive income related to available-for-sale securities.
In 2014, we determined that the undistributed earnings of our India subsidiary will be repatriated to the United States, and accordingly, we have provided a deferred tax liability totaling $0.1 million as of December 31, 2018, for local taxes that would be incurred upon repatriation. We have not provided for U.S. federal and state income taxes on all of the remaining non-U.S. subsidiaries’ undistributed earnings as of December 31, 2018 as the remaining foreign jurisdictions are in an accumulative loss position.
We apply the provisions of ASC Topic 740 to account for uncertainty in income taxes. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): 
 
Rollforward Table (at Gross): As of
 
December 31,
 
2018
 
2017
 
2016
Balance at beginning of year
$
9,422

 
$
8,566

 
$
8,152

Additions based on tax positions related to current year
1,087

 
880

 
459

Reductions to tax provision of prior years
(529
)
 
(24
)
 
(45
)
Balance at end of year
$
9,980

 
$
9,422

 
$
8,566

We recognize interest and penalties as a component of our income tax expense. Total interest and penalties recognized in the consolidated statement of operations was $37 thousand, $31 thousand and $35 thousand, respectively, in 2018, 2017 and 2016. Total penalties and interest recognized in the balance sheet was $0.4 million and $0.3 million, respectively, in 2018 and 2017. The total unrecognized tax benefits that, if recognized currently, would impact our company’s effective tax rate were $0.3 million and $0.4 million as of December 31, 2018 and 2017, respectively. We do not expect any material changes to our uncertain tax positions within the next 12 months. We are not subject to examination by United States federal or state tax authorities for years prior to 2002 and foreign tax authorities for years prior to 2012.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. The Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (GILTI) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer’s compensation limitation.


119



In December 2017, the SEC issued Staff Accounting Bulletin No. 118 ("SAB 118"), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now completed include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. On December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.

The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.


Note 13. Commitments and Contingencies
Operating Leases
Our headquarters are located in Redwood City, California, where we occupy approximately 107,200 square feet of office and laboratory space in four buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease (“Lease”) with MetLife includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “Penobscot Space”), approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “Building 2 Space”), approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”), and approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”).
We entered into the initial lease with MetLife for a portion of this space in 2004 and the lease has been amended multiple times since then to adjust space and amend the terms of the Lease, with the lease amendment ("Seventh Amendment") in October 2016 which, for one of our buildings, waived our existing asset retirement obligation, and extended the lease term to January 2022. The various terms for the spaces under the lease have expiration dates that range from January 2020 through January 2022. Beginning in February 2014, we have subleased certain office and laboratory space to different subtenants with separate options to extend the subleases. These subleases will expire in November 2019.
In February 2019, we entered into the eighth amendment to the Lease ("Eighth Amendment") with MetLife to extend the lease terms for the Penobscot Space, the Building 2 Space and the Chesapeake Space for another 88 months. The lease on the Saginaw Space will expire in January 2020. The lease terms for the Penobscot Space and Building 2 Space have an expiration date of May 2027. The lease term for the 501 Chesapeake Space has an expiration date of May 2029. Refer to Note 16, "Subsequent Events" for more details.
We incurred $3.6 million of capital improvement costs related to the facilities leased from MetLife through December 31, 2012. During 2011 and 2012, we requested and received $3.1 million of reimbursements from the landlord for the tenant improvement and HVAC allowances for the completed construction. The reimbursements were recorded once cash was received and are amortized on a straight line basis over the term of the lease as a reduction in rent expense. The remaining lease incentive obligations were $0.5 million and $0.9 million at December 31, 2018 and 2017, respectively, and are reflected as liabilities on the consolidated balance sheets. Rent expense for the Redwood City properties is recognized on a straight-line basis over the term of the lease.
We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.2 million as of December 31, 2018 and 2017, which are included in other liabilities on the consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in 2018 and 2017.

120



Pursuant to the terms of the 7th amended lease agreement, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $0.7 million as of December 31, 2018 and 2017, which is recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, “Commitments and Contingencies.” Pursuant to the terms of the Eighth Amendment, the amended letter of credit in the amount of $1.1 million is collateralized by deposit balances held by the bank in 2019.
Rent expense was $3.2 million, $3.2 million and $2.9 million in 2018, 2017 and 2016, respectively, partially offset by sublease income of $1.1 million, $1.4 million and $1.2 million, respectively.
Capital Leases
In December 2016, we entered into a three-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a capital lease of approximately $0.4 million. The lease became effective upon delivery of the equipment, which occurred in February 2017, and the term of the lease is three years from the effective date. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease.
In April 2017, we entered into a three-year financing lease agreement with a third party supplier for the purchase of information technology equipment for approximately $0.3 million. The effective date of the lease was May 19, 2017 and the term of the lease is three years. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease.
Leases
Future minimum payments under non-cancellable capital and operating leases at December 31, 2018 are as follows (in thousands): 
Years ending December 31,
Capital Leases
 
Operating Leases
2019
$
252

 
$
3,280

2020
61

 
712

2021

 
490

2022

 
41

2023

 

Total minimum lease payments (1)
313

 
$
4,523

Less: amount representing interest
(10
)
 
 
Present value of capital lease obligations
303

 
 
Less: current portion
(242
)
 
 
Long-term portion of capital leases
$
61

 
 
(1) 
Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
Other Commitments
We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.

121



The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Other Commitment Agreement Type
Agreement Date
 
Future Minimum Payment
Manufacture and supply agreement with expected future payment date of December, 2022
April 2016
 
$
1,458

Service agreement for stability study
July 2017
 
331

Service agreement for clinical trial
December 2017
 
1,258

Total other commitments

 
$
3,047

Credit Facility
Effective June 30, 2017, we entered into a credit facility (the “Credit Facility”) consisting of term loans (“Term Debt”) totaling up to $10.0 million, and advances (“Advances”) under a revolving line of credit (“Revolving Line of Credit”) totaling up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. At December 31, 2018, we have not drawn from the Credit Facility. In September 2018, we entered into a Fourth Amendment to the Credit Facility whereby the draw period on the term debt was extended to September 30, 2019. We may draw on the Term Debt at any time prior to September 30, 2019, subject to customary conditions for funding including, among others that no event of default exists. We may draw on the Revolving Line of Credit at any time prior to the maturity date. On October 1, 2022, any loans for Term Debt mature and the Revolving Line of Credit terminates. The Term Debt bears interest through maturity at a variable rate based on the London Interbank Offered Rate plus 3.60%. Advances under the Revolving Line of Credit bear interest at a variable annual rate equal to the greater of (i) 1.00% above the prime rate and (ii) 5.00%.
The Credit Facility allows for interest-only payments on the Term Debt through November 1, 2020. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Prepayments of Term Debt and early termination of the Revolving Line of Credit are subject to prepayment and final payment fees are as follows:
 
Term Debt
 
Revolving Line of Credit
Through and including the first anniversary of the funding date of the first Term Debt drawn
2.0%
 
 
After the first anniversary of the funding date of the first Term Debt drawn and before the maturity date
1.0%
 
 
On the earliest to occur of the maturity date, the acceleration of Term Debt drawn or prepayment of Term Debt drawn
5.5%
 
 
Through and including the first anniversary of the closing date
 
 
3.0%
After the first anniversary of the closing date through and including the second anniversary of the closing date
 
 
2.0%
After the second anniversary of the closing date through and including the third anniversary of the closing date
 
 
1.0%
Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictions which require us to comply with certain financial covenants including achieving consolidated product revenues levels at minimum levels as set forth in the Credit Facility through December 2018 and on and after January 2019, in each case unless we maintain certain minimum cash levels with the lender in an amount equal to or greater than six times the sum of the average six-month trailing operating cash flow net outlay plus the average monthly principal due and payable in the immediately succeeding three-month period. The Credit Facility places various restrictions on our company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens and selling assets and permitted assets to be held at foreign subsidiaries above specified caps, in each case subject to certain exceptions. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. At December 31, 2018, we were in compliance with the covenants for the Credit Facility.

122



As further discussed in Note 16, “Subsequent Events”, in February 2019, we entered into the eighth lease amendment of our business premises (the “Eighth Amendment”). Pursuant to the terms of the Eighth Amendment, we exercised an option to deliver a $1.1 million letter of credit to the lessor in lieu of a security deposit. In January 2019, we entered into the Fifth Amendment to the Credit Facility, which amended certain restrictive covenants with respect to letters of credit made in connection with the leasing of real property.
Legal Proceedings
We are not currently a party to any material pending litigation or other material legal proceedings.
In February 2018, we and EnzymeWorks, Inc. (U.S.), Suzhou Hanmei Biotechnology Co. Ltd, d/b/a EnzymeWorks, Inc. (China) (collectively, "EnzymeWorks"), Junhua Tao, and Andrew Tao reached a settlement concerning the lawsuit filed by us in February 2016 against EnzymeWorks, Junhua Tao, and Andrew Tao in the United States District Court for the Northern District of California. The parties have entered into a settlement agreement, the terms of which are confidential. The parties have also stipulated to a judgment of patent infringement of all asserted patents against EnzymeWorks, and a permanent injunction barring any future infringement. The remaining claims against EnzymeWorks, and all claims against Junhua Tao, and Andrew Tao including trade secret misappropriation, breach of contract and voidable transfer have been dismissed with prejudice. EnzymeWorks appealed the sanctions levied against them by Judge Orrick to the Federal Circuit and filed its opening brief on May 30, 2018. On July 9, 2018, Codexis filed its response brief, and EnzymeWorks filed its reply on July 30, 2018. On February 8, 2019, the Federal Circuit panel of judges assigned to the case issued an opinion affirming the lower court’s ruling and remanding the case to the lower court on jurisdictional grounds to vacate the order to which the parties had earlier stipulated.
Indemnifications
We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.
Note 14. Related Party Transactions
Exela PharmSci, Inc. (“Exela”)
We entered into a commercialization agreement with Exela in 2007. Under the license agreement, as amended, we and Exela cross-licensed certain technology relating to the manufacture of argatroban, an API, in exchange for rights to certain sublicensing fees or development payments and profit sharing. The revenue sharing arrangement was terminated in December 2017.
Thomas R. Baruch, one of our directors, serves on the board of directors of Exela, and is a retired general partner in Presidio Partners 2007, L.P., which owns over 10% of Exela’s outstanding capital stock. As such, Mr. Baruch has an indirect pecuniary interest in the shares of Exela held by Presidio Partners 2007, L.P.
We had no revenue from transactions with Exela in 2018. We recognized $2.6 million in 2017 and $2.2 million in 2016 as research and development revenue from transactions with Exela. We had no receivables at December 31, 2018 and $1.6 million of receivables due from Exela at December 31, 2017.
AstraZeneca PLC
Pam P. Cheng, a member of our board of directors, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sell biocatalyst products to AstraZeneca PLC, to Alfa Aesar, which is a purchasing agent of AstraZeneca PLC, and also to Asymchem Life Science Co, Ltd, which is a contract manufacturer for AstraZeneca PLC.
We recognized product revenue of $0.6 million in 2018, $0.1 million in 2017 and de minimis revenue in 2016 from transactions with AstraZeneca PLC. We recognized no revenue from transactions with Alfa Aesar in 2018 and 2017 and $0.4 million of product revenue in 2016. We recognized de minimis revenue from Asymchem Life Science Co, Ltd in 2018, $75 thousand in 2017, and de minimis revenue in 2016. At December 31, 2018, we had $0.2 million of receivables and at December 31, 2017,

123



we had $0.1 million of receivables due from AstraZeneca, PLC. At December 31, 2018, we had no receivables and at December 31, 2017, we had $0.1 million of receivables due from Asymchem Life Science Co, Ltd. At December 31, 2018 and 2017, we had no receivables due from Alfa Aesar.

Note 15. Segment, Geographical and Other Revenue Information
Segment Information

As discussed in Note 2, "Basis of Presentation and Summary of Significant Accounting Policies," beginning in 2018, we identified our biotherapeutics business as a standalone business segment. Our two reportable business segments as of January 1, 2018, consisted of Performance Enzymes and Novel Biotherapeutics.
We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments.
We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment.

Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications.

Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license for the global development and commercialization of CDX-6114 for the management of PKU. The exercise of the option triggers a $3 million milestone payment. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.

124



For the year ended December 31, 2018, primarily all revenues related to the Novel Biotherapeutics segment were generated from our collaboration with customer projects. There was no revenue related to the Novel Biotherapeutics segment in the year ended December 31, 2017. Novel Biotherapeutics had no operational activity in the year ended December 31, 2016.
Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation.
Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources.

125



The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


Year Ended December 31, 2018

Year Ended December 31, 2017


Performance Enzymes

Novel Biotherapeutics

Total

Performance Enzymes

Novel Biotherapeutics

Total
Revenues:












Product revenue

$
25,590


$


$
25,590


$
26,685


$


$
26,685

Research and development revenue

21,483


13,521


35,004


15,648


7,691


23,339

Total revenues

47,073


13,521


60,594


42,333


7,691


50,024

Costs and operating expenses:












Cost of product revenue

12,620




12,620


14,327




14,327

Research and development(1)

18,924


10,185


29,109


16,847


12,107


28,954

Selling, general and administrative

7,538


771


8,309


7,371




7,371

Total segment costs and operating expenses

39,082


10,956


50,038


38,545


12,107


50,652

Income (loss) from operations

$
7,991


$
2,565


$
10,556


$
3,788


$
(4,416
)

$
(628
)
Corporate costs (2)





(20,324
)





(21,245
)
Depreciation





(1,147
)





(1,042
)
Loss before income taxes





$
(10,915
)





$
(22,915
)
(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):
 
 
2018
 
2017
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Stock-based compensation
 
$
2,591

 
$
338

 
$
2,929

 
$
2,306

 
$
208

 
$
2,514

Significant Customers
Customers that each contributed 10% or more of our total revenues were as follows:
 
Percentage of Total Revenues
For The Years Ended December 31,
 
2018
 
2017
 
2016
Merck
29
%
 
28
%
 
47
%
Nestlé Health Science
22
%
 
15
%
 
*

Tate & Lyle
13
%
 
11
%
 
*

Novartis
*

 
14
%
 
*

GSK
*

 
*

 
22
%



Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:

126



 
Percentage of Accounts Receivables
As Of December 31,
 
2018
 
2017
Merck
37
%
 
31
%
Nestlé Health Science
17
%
 
*

Tate & Lyle
*

 
16
%
Novartis
11
%
 
15
%
Kyorin Pharmaceutical Co Ltd
16
%
 
*

Exela PharmaSci, Inc.
*

 
14
%
* Percentage was less than 10%
Geographic Information
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Revenues
 
 
 
 
 
Americas
$
15,370

 
$
15,575

 
$
23,126

EMEA
22,361

 
19,610

 
17,138

APAC
22,863

 
14,839

 
8,573

Total revenues
$
60,594

 
$
50,024

 
$
48,837


Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets
 
 
 
United States
$
4,759

 
$
2,815


 
 
 
December 31, 2018
 
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
 
 
 
 
 
 
 
Goodwill
 
 
$
2,463

 
$
778

 
$
3,241




127



Note 16. Subsequent Events
Operating Leases
In February 2019, we entered into the eighth lease amendment ("Eighth Amendment") with MetLife to extend the lease term for the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space for another 88 months. The various terms for these properties have expiration dates that range from May 2027 to May 2029. The terms include an optional renewal period of 5 years after the expiration date based on fair market rates for comparable transactions in the geographic area described in the Eighth Amendment. The Eighth Amendment requires us to install certain improvements to the buildings. On completion of the improvements to the building, the landlord will reimburse us up to a contractually specified amount and the landlord will become the owner of the improvements. Pursuant to the terms of the Eighth Amendment, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letters of credit are collateralized by deposit balances held by the bank in the amount of $1.1 million in 2019. These deposits will be recorded as restricted cash on the consolidated balance sheets. Total future minimum lease payments under the Eighth Amendment is $32.9 million.
FDA Approval and Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114
In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States.
In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sublicensable license to develop and commercialize certain products based on the our novel, orally delivered enzyme IND for the management of phenylketonuria. Nestlé Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. The exercise of the option triggered a $3 million milestone payment from Nestlé Health Science to Codexis. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019.


128



Selected Quarterly Financial Data (Unaudited)
The following table provides the selected quarterly financial data for 2018 and 2017:
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
 
Quarter Ended (1)
 
December 31, 2018 (3)
 
September 30,
2018
 
June 30,
2018
 
March 31,
2018
 
 
 
December 31, 2017 (3)
 
September 30,
2017
 
June 30,
2017
 
March 31,
2017
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenues:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Product revenue
$
7,299

 
$
8,405

 
$
3,723

 
$
6,163

 
 
 
$
7,551

 
$
6,948

 
$
6,600

 
$
5,586

Research and development revenue
8,769

 
8,541

 
9,815

 
7,879

 
 
 
14,171

 
3,036

 
3,747

 
2,385

Total revenues
$
16,068

 
$
16,946

 
$
13,538

 
$
14,042

 
 
 
$
21,722

 
$
9,984

 
$
10,347

 
$
7,971

Costs and operating expenses:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cost of product revenue
$
2,393

 
$
3,791

 
$
2,611

 
$
3,825

 
 
 
$
3,559

 
$
3,976

 
$
3,790

 
$
3,002

Research and development
7,513

 
7,917

 
7,370

 
7,178

 
 
 
9,417

 
8,055

 
6,348

 
5,839

Selling, general and administrative
6,806

 
7,344

 
7,395

 
7,746

 
 
 
7,867

 
7,989

 
6,546

 
6,606

Total costs and operating expenses
$
16,712

 
$
19,052

 
$
17,376

 
$
18,749

 
 
 
$
20,843

 
$
20,020

 
$
16,684

 
$
15,447

Income (loss) from operations
$
(644
)
 
$
(2,106
)
 
$
(3,838
)
 
$
(4,707
)
 
 
 
$
879

 
$
(10,036
)
 
$
(6,337
)
 
$
(7,476
)
Income (loss) before income taxes
$
(486
)
 
$
(1,987
)
 
$
(3,746
)
 
$
(4,696
)
 
 
 
$
919

 
$
(10,076
)
 
$
(6,322
)
 
$
(7,436
)
Net income (loss)
$
(461
)
 
$
(1,988
)
 
$
(3,735
)
 
$
(4,694
)
 
 
 
$
970

 
$
(10,226
)
 
$
(6,280
)
 
$
(7,460
)
Net income (loss) per share, basic
$
(0.01
)
 
$
(0.04
)
 
$
(0.07
)
 
$
(0.10
)
 
 
 
$
0.02

 
$
(0.21
)
 
$
(0.13
)
 
$
(0.18
)
Net income (loss) per share, diluted
$
(0.01
)
 
$
(0.04
)
 
$
(0.07
)
 
$
(0.10
)
 
 
 
$
0.02

 
$
(0.21
)
 
$
(0.13
)
 
$
(0.18
)
Weighted average common shares used in computing net income (loss) per share, basic (2)
53,973

 
53,597

 
52,787

 
48,385

 
 
 
48,187

 
48,147

 
47,232

 
41,250

Weighted average common shares used in computing net income (loss) per share, diluted(2)
53,973

 
53,597

 
52,787

 
48,385

 
 
 
50,599

 
48,147

 
47,232

 
41,250


 
(1) 
Amounts were computed independently for each quarter, and the sum of the quarters may not total the annual amounts due to rounding differences.
 
(2) 
The full year net loss per share of common stock, basic and diluted, may not equal the sum of the quarters due to weighting of outstanding shares.
 
(3) 
PSUs, PBOs, and cash bonus awards are granted to certain employees and executives and are subject to our performance in achieving pre-determined criteria approved by our board of directors. Based on the actual achievement of the annual goals, we updated the calculation of the annual expense in the fourth quarter which resulted in true-up adjustments of approximately $(0.5) million in 2018 and $0.1 million in 2017, primarily in selling, general and administrative expense.



129



ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES
None.
ITEM 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management, under the supervision of our Chief Executive Officer and Chief Financial Officer and with the participation of our disclosure committee, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2018. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of December 31, 2018 at the reasonable assurance level.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with United States generally accepted accounting principles.
Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2018 based on the guidelines established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on the results of our evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2018. We reviewed the results of management’s assessment with our Audit Committee.
Our internal control over financial reporting as of December 31, 2018 has been audited by BDO USA, LLP, an independent registered public accounting firm, as stated in their report which is included in Item 8 of this Annual Report.
Inherent Limitations on Effectiveness of Controls
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, even if determined effective and no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives to prevent or detect misstatements. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or 15d-15 of the Exchange Act, which occurred during the fourth fiscal quarter of the year ended December 31, 2018, which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Effective January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606) and the related amendments (“ASC 606”). In response, we have updated and enhanced our internal accounting processes and our internal controls over financial reporting to ensure that we maintain adequate internal controls over financial reporting. This has required, and will continue to require, additional investments by us. There were no other significant changes to our internal control over financial reporting.


130



ITEM 9B. OTHER INFORMATION
Not applicable.


PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this item concerning our directors, executive officers, compliance with Section 16 of the Exchange Act, our code of ethics and our Nominating and Corporate Governance Committee, and our Audit Committee is incorporated by reference from the information that will be set forth in the sections under the headings “Election of Directors,” “Other Matters—Section 16(a) Beneficial Ownership Reporting Compliance” and “Corporate Governance Matters” in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the Annual Meeting of Stockholders to be held in 2019 (the “2019 Proxy Statement”).
ITEM 11. EXECUTIVE COMPENSATION
The information required by this item concerning executive compensation is incorporated by reference from the information that will be set forth in the 2019 Proxy Statement under the headings “Executive Compensation,” and “Corporate Governance Matters.”
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
The information required by this item concerning securities authorized for issuance under equity compensation plans and security ownership of certain beneficial owners and management is incorporated by reference from the information that will be set forth in the 2019 Proxy Statement under the headings “Executive Compensation—Equity Compensation Plan Information” and “Information Concerning Voting and Solicitation—Security Ownership of Certain Beneficial Owners and Management.”
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS,
AND DIRECTOR INDEPENDENCE
The information required by this item concerning transactions with related persons and director independence is incorporated by reference from the information that will be set forth in the 2019 Proxy Statement under the headings “Certain Relationships and Related Transactions” and “Corporate Governance Matters.”
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this item is incorporated by reference from the information that will be set forth in the 2019 Proxy Statement under the heading “Ratification of Independent Registered Public Accounting Firm—Principal Accounting Fees and Services.”

131





PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
 
1.
Financial Statements: See “Index to Consolidated Financial Statements” in Part II, Item 8 of this Annual Report on Form 10-K
2.
Exhibits: The exhibits listed in the accompanying index to exhibits are filed or incorporated by reference as part of this Annual Report on Form 10-K.


ITEM 16. FORM 10-K SUMMARY
 
None.


132




EXHIBIT INDEX
Exhibit
No.
 
Description
 
 
3.1
 
 
 
3.2
 
 
 
 
3.3
 
 
 
 
4.1
 
Reference is made to Exhibits 3.1 through 3.3.
 
 
4.2
 
 
 
 
10.1A*
 
 
 
10.1B*
 
 
 
10.1C*
 
 
 
10.1D*
 
 
 
10.1E
 
 
 
10.1F
 
 
 
10.1G
 
 
 
 
10.1H
 
 
 
 
10.2+*
 
 
 
10.3+*
 
 
 
10.4*
 
 
 
10.5A+*
 
 

133



Exhibit
No.
 
Description
10.5B+
 

 
 
 
10.5C+
 
 
 
 
10.6
 
 
 
10.7A†
 
 
 
10.7B
 
 
 
10.8A+
 
 
 
10.8B+
 
 
 
10.9+
 
 
 
 
10.10A+
 
 
 
10.10B+
 
 
 
10.10C+
 
 
 
 
10.10D+
 
 
 
10.10E+
 
 
 
 
10.11A†

 
 
 
 
10.11B†
 
 
 
10.11C
 

134



Exhibit
No.
 
Description
 
 
 
10.11D
 
 
 
 
10.11E
 

 
 
 
10.12A†
 
 
 
 
10.12B†
 
 
 
 
10.12C†
 
 
 
 
10.13†
 
 
 
 
10.14†
 
 
 
 
10.14A†
 
 
 
 
10.15†
 
 
 
 
10.15A†
 
 
 
 
10.15B†
 
 
 
 
10.15C†
 
 
 
 
10.15D†
 
 
 
 
12.1
 
 
 
 
21.1
 
 
 
23.1
 
 
 
 
24.1
 
Power of Attorney (see signature page to this Annual Report on Form 10-K).
 
 

135



Exhibit
No.
 
Description
31.1
 
 
 
31.2
 
 
 
32.1**
 
 
 
101
 
The following materials from Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018, formatted in Extensible Business Reporting Language (XBRL) includes: (i) Consolidated Balance Sheets at December 31, 2018 and December 31, 2017, (ii) Consolidated Statements of Income for the years ended December 31, 2018, December 31, 2017 and December 31, 2016, (iii) Consolidated Statements of Comprehensive Loss for the years ended December 31, 2018, December 31, 2017 and December 31, 2016, (iv) Consolidated Statements of Cash Flows for the years ended December 31, 2018, December 31, 2017 and December 31, 2016, (v) Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2018, December 31, 2017 and December 31, 2016 and (vi) Notes to Consolidated Financial Statements.
+
Indicates a management contract or compensatory plan or arrangement.
Confidential treatment has been granted for certain information contained in this exhibit. Such information has been omitted and filed separately with the Securities and Exchange Commission.
*
Filed as exhibits to the registrant’s Registration Statement on Form S-1 (File No. 333-164044), effective April 21, 2010, and incorporated herein by reference.
**
Pursuant to Item 601(b)(32) of Regulation S-K this exhibit is furnished rather than filed with this report.

SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
 
CODEXIS, INC.
 
 
 
 
Date:
March 1, 2019
By:
/s/ John J. Nicols
 
 
 
President and Chief Executive Officer
 
 
 
(Principal Executive Officer)
POWER OF ATTORNEY
Each person whose individual signature appears below hereby authorizes and appoints John J. Nicols, Gordon T. B. Sangster, and Richard A. Sabalot, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.
 
SIGNATURE
 
TITLE
 
DATE
 
 
 
/s/ John J. Nicols
 
President, Chief Executive Officer and Director (Principal Executive Officer)
Date:
March 1, 2019
John J. Nicols
 
 
 
 
 
 
 
/s/ Gordon T. B. Sangster
 
Senior Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
Date:
March 1, 2019
Gordon T. B. Sangster
 
 
 
 
 
 
 
/s/ Bernard J. Kelley
 
Chairman of the Board of Directors
Date:
March 1, 2019
Bernard J. Kelley
 
 
 
 
 
 
 
 
 
/s/ Thomas R. Baruch
 
Chairman Emeritus, Director
Date:
March 1, 2019
Thomas R. Baruch
 
 
 
 
 
 
 
 
 
/s/ Pam P. Cheng
 
Director
Date:
March 1, 2019
Pam P. Cheng
 
 
 
 
 
 
 
/s/ Byron L. Dorgan
 
Director
Date:
March 1, 2019
Byron L. Dorgan
 
 
 
 
 
 
 
/s/ Kathleen S. Glaub
 
Director
Date:
March 1, 2019
Kathleen S. Glaub
 
 
 
 
 
 
 
 
 
/s/ David V. Smith
 
Director
Date:
March 1, 2019
David V. Smith
 
 
 
 
 
 
 
/s/ Dennis P. Wolf
 
Director
Date:
March 1, 2019
Dennis P. Wolf
 
 
 
 
 
 
 
/s/ Patrick Y. Yang
 
Director
Date:
March 1, 2019
Patrick Y. Yang
 
 
 
 

136
EX-10.12B 2 exhibit1012bnestle.htm EXHIBIT 10.12B AMENDMENT NO.1 NESTLE Exhibit


Confidential Treatment Requested by Codexis, Inc.

STRICTLY CONFIDENTIAL    EXECUTION VERSION



























AMENDMENT NO. 1 TO

GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT

between NESTEC LTD.
and CODEXIS, INC.



[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.



Confidential Treatment Requested by Codexis, Inc.

AMENDMENT NO. 1 TO GLOBAL DEVELOPMENT,
OPTION AND LICENSE AGREEMENT

This AMENDMENT TO GLOBAL DEVELOPMENT, OPTION AND LICENSE AGREEMENT (this “Amendment No. 1”) is made as of July 26, 2018 (the “Amendment No. 1 Effective Date”), by and between NESTEC LTD., a limited company organized and existing under the laws of Switzerland, having an office located at Avenue Nestlé 55, 1800 Vevey, Switzerland (“NHSc”), and CODEXIS, INC., a corporation incorporated and existing under the laws of the State of Delaware, having an office located at 200 Penobscot Drive, Redwood City, CA 94063, USA (“Codexis”). NHSc and Codexis are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

RECITALS

WHEREAS, NHSc and Codexis are parties to that certain Global Development, Option and License Agreement dated October 12, 2017 (“Agreement”); and

WHEREAS, NHSc and Codexis desire to amend the Agreement to include a new mechanistic study to be performed after the conclusion of the Phase Ia Clinical Trial;

NOW, THEREFORE in consideration of the foregoing and the mutual agreements set forth below, the Parties agree as follows:

ARTICLE 1 DEFINITIONS
Definitions. The terms in this Amendment No. 1 with initial letters capitalized, whether used in the singular or the plural, shall have the respective meanings either set forth below or in another part of this Agreement.

Mechanistic Study” means a clinical trial (which is not a Clinical Trial) to be conducted outside of the US and not under an IND and according to a study protocol to be agreed between the Parties.
 
ARTICLE 2
AMENDMENTS TO THE AGREEMENT

As of the Amendment No. 1 Effective Date, the Parties agree to amend the Agreement as follows:

1.    The Development Plan attached as Exhibit A to the Agreement is amended by the addition of the activities set out in the Mechanistic Study Development Plan attached as Exhibit A to this Amendment No. 1.

2.    Section 2.1.3 of the Agreement is amended to read in its entirety as follows:

2.1.3    Expiration of Option. The Option shall expire on the date that is forty (40) days after the Option Trigger Date if the Option Exercise has not occurred prior thereto or, if NHSc determines that a filing under the HSR Act is required in connection with the Option Exercise, if the Parties have


2
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




Confidential Treatment Requested by Codexis, Inc.

submitted all filings required therefor but have not cleared the review process within one hundred eighty (180) days after submission and such delay is not attributable to any material failure on the part of Codexis to provide such cooperation with such review process as NHSc, the FTC or DOJ may have reasonably requested (the “Option Expiration Date”). If the License Effective Date does not occur prior to the Option Expiration Date, the License Effective Date shall not occur and Codexis shall have no further obligation to NHSc with respect to the Compounds or Product, and all rights to the Compounds and Product shall revert to Codexis. In such case, [***] therein, [***].

3.    Section 4.1.1 is amended in its entirety to read as follows:

4.1.1    Prior to Option Exercise or Expiration. Subject to the terms and conditions of this Agreement, including Section 4.7, prior to the first to occur of the Option Expiration Date or the License Effective Date, Codexis will [***] to (i) file with the FDA an IND in respect of the study of the Initial Compound for the treatment of HPA in accordance with the Development Plan [***] without [***], or if the [***], Codexis [***] to [***] and [***], and/or that [***] subject to [***] in [***], (ii) initiate a Phase Ia Clinical Trial in respect of the Initial Compound for the treatment of HPA, which Phase Ia Clinical Trial shall be conducted in accordance with the Development Plan in [***] in [***], (iii) complete the Solid Dosage Form Development Study and achieve the Formulation Objectives, and (iv) following the completion of the Phase Ia Clinical Study, initiate the Mechanistic Study on the Initial Compound according to the Mechanistic Study Development Plan.

With respect to the Mechanistic Study, Codexis shall periodically update NHSc on the progress of the Mechanistic Study with respect to the Mechanistic Study Development Plan, but Codexis shall not be required to provide to NHSc any study report, test results, data or analysis of the Mechanistic Study until Option Exercise.

In the event that [***] that it would be [***] in respect of the [***] prior to [***], it shall so [***], whereupon [***] and [***] on which [***] to [***] prior to the [***], it being agreed that [***] shall not [***], or [***] to the [***] contemplated in this Agreement, in connection therewith.

4.    Section 4.1.2 is amended in its entirety to read as follows:

4.1.2    Following License Effective Date. Following the License Effective Date, NHSc, subject to the terms and conditions of this Agreement, will [***] to (a) Develop a Product containing the Initial Compound for the treatment of HPA and (b) seek and obtain approval of a BLA for such Product for the treatment of HPA in [***] and in [***] through [***]; provided, however, that NHSc shall not be obligated to commence any Phase II Clinical Trial in respect of the Initial Compound or any Product if the Formulation Objectives are not met. Subject to the foregoing, all Development decisions and actions after the License Effective Date, including the design of any and all Clinical Trials and the determination of protocols therefor and the endpoints thereof, shall be in NHSc’s or its Affiliates’ or sublicensees’ [***]. Following the License Effective Date, responsibility for the conduct of the Mechanistic Study on the Initial Compound shall transfer to NHSc and Codexis shall have no further obligations to conduct the Mechanistic Study on the Initial Compound. The Parties shall facilitate an orderly transfer of the conduct of the Mechanistic Study and Codexis will furnish to NHSc all documentation relating to the conduct of the Mechanistic Study on the Initial Compound. In addition, Codexis shall, [***], provide such reasonable assistance as NHSc may request in connection with transitioning its relationship with any Third Party with respect to the Mechanistic


3
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




Confidential Treatment Requested by Codexis, Inc.

Study of the Initial Compound to NHSc or its designee, including, to the extent requested by NHSc, by using [***] to assign any contracts with such Third Party relating [***] to the Mechanistic Study of the Initial Compound, so that NHSc can continue to conduct the Mechanistic Study on the Initial Compound [***].

5.    Section 5.6 is amended in its entirety to read as follows:

5.6    Transfer of Initial Compound. Within [***] following the License Effective Date, Codexis shall deliver to NHSc or its designee (EXW manufacturing or storage site (per INCOTERMS 2010)), and NHSc or its designee shall accept, all quantities of the Initial Compound in Codexis’ possession for use by NHSc or its designee in connection with its Development activities under this Agreement. Without limiting the foregoing, the Initial Compound delivered pursuant to this Section 5.6 shall include [***] which has, at all times prior to delivery to NHSc in accordance with the foregoing, been handled, stored and transported in accordance with industry standard practices, less any [***] which has been used by Codexis in conducting the Mechanistic Study on the Initial Compound.

6.    Section 7.3.1 is amended in its entirety to read as follows:

7.3.1    Development Milestone Payment and Other Payments Prior to Option Exercise. Subject to the terms and conditions of this Agreement, within [***] after Commencement of a Phase Ia Clinical Trial in respect of the Initial Compound for the treatment of HPA, NHSc shall make a one-time, non-refundable, non-creditable Milestone Payment to Codexis in the amount of four million U.S. dollars ($4,000,000). In addition to this Milestone Payment, and subject to the terms and conditions of this Agreement, after Commencement of the Mechanistic Study but not before [***], and subsequently every [***] thereafter, Codexis shall invoice NHSc [***] for and/or conduct of the Mechanistic Study on the Initial Compound plus [***], as determined in accordance with GAAP. NHSc shall pay each such invoice within [***] from the date of such invoice.

Except as expressly amended herein, all other terms and conditions of the Agreement remain unchanged.









IN WITNESS WHEREOF, the Parties have caused this Amendment No. 1 to be executed by their respective duly authorized officers.

CODEXIS, INC.



4
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




Confidential Treatment Requested by Codexis, Inc.

By: /s/ John J Nicols     (Signature)

Name: John J Nicols     Title: President & CEO    
Reviewed by Legal – RAS – 25 July 2018

NESTEC LTD.

By: /s/ Claudio Kuoni     (Signature)

Name: Claudio Kuoni     Title: Authorized Signatory    


Solely for purposes of Sections 13.1 and 14.11:

NESTLÉ HEALTH SCIENCE S. A.

By: /s/ Claudio Kuoni
(Signature)

Name: Claudio Kuoni     Title: General Counsel    






5
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.




Confidential Treatment Requested by Codexis, Inc.

EXHIBIT A

Mechanistic Study Development Plan

[***]



6
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

EX-10.12C 3 exhibit1012ccodexisctr-nes.htm EXHIBIT 10.12C LETTER AGREEMENT NESTLE 12.12.18 Exhibit
Confidential Treatment Requested by Codexis, Inc.
Page 1 of 3

12th December 2018
Nestec Ltd.
Avenue Nestlé 55
1800 Vevey
Switzerland
Attention: [***]
Re:
Section 7.3.2 of the Global Development Option and License Agreement (“GDOLA”) dated October 12, 2017, as amended, by and between Nestec Ltd. (“NHSc”) and Codexis, Inc. (“Codexis”)
Dear [***]
This letter will confirm our agreement with respect to the achievement and payment of the Solid Dosage Form Development Milestone of $[***] as described in Section 7.3.2 of the GDOLA and the conduct of a [***] study examining [***] and [***] of CDX-6114 [***].
As of the date of this letter and subject to the terms and conditions of the GDOLA, notwithstanding anything to the contrary in Section 7.3.2 or in Exhibits F and G of the GDOLA, NHSc hereby agrees that within [***] after the achievement of the Formulation Objectives, NHSc shall pay to Codexis [***]. Codexis will complete the following deliverables in relation to the Formulation Objectives:
(a)    Codexis delivers to NHSc [***].
(b)    Codexis delivers to NHSc [***].
(c)    Codexis delivers to NHSc [***].
(d)    Codexis delivers to NHSc [***].
(e)    Codexis delivers to NHSc [***].
(f)    Codexis delivers to NHSc [***].
Upon receipt of the final deliverable from (a) to (f), as defined above, NHSc shall have [***] business days in which to inform Codexis, in writing, of any material deficiencies in the deliverables. In such instance, the parties shall discuss in good faith with the intent to agree remediation to satisfy the Formulation Objectives. In the absence of such notification being received within [***] business days of receipt of the final deliverable, the Formulation Objectives shall be deemed met, and the Solid Dosage Form Development Milestone shall be deemed payable.
This letter will also confirm that Codexis and NHSc have agreed that, further to the Phase Ia Clinical Trial (Study # [***], completed in [***]), Codexis shall conduct, [***], a [***] study examining [***] in a [***] cohort volunteer study (Study # [***]), which received [***] on [***]. The [***] study will be conducted in [***] by [***], according to the protocol attached as Appendix 1 to this letter, and is expected to [***] on [***] with [***] on [***].
Codexis and NHSc recognize that the [***] study may not be completed prior to Option Expiration Date. Therefore, if NHSc exercises the Option through the Option Exercise, Codexis and NHSc agree that Codexis shall continue to conduct the [***] study after the Option Exercise at its sole cost and expense until its conclusion, which conclusion shall be defined as the provision of audited tables and listings from the study and a graphical summary of the [***].
If NHSc requests modifications to the [***] study that deviate from the protocol attached as Appendix 1, then any costs incurred in relation to such amendment (for example, but not limited to: [***]) beyond the original scope of study will be [***] and, in the event that NHSc has exercised its Option prior to conclusion of the original scope as defined in Appendix 1, [***].
By signature of this letter, by an authorized representative of NHSc, NHSc confirms its agreement to the terms contained herein. Thank you for your kind consideration and attention.
Sincerely,
CODEXIS, INC.
/s/ [***]
[***]
Executed by: /s/ [***]        Date: 12.12.2018    
Name & Title: [***]    
Cc:
[***]

APPENDIX 1
Protocol for Clinical Study [***]
(attached)

[***]

[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
EX-10.14A 4 exhibit1014amerck.htm EXHIBIT 10.14A Exhibit
Confidential Treatment Requested by Codexis, Inc.

AMENDMENT NO. 1 TO PLATFORM TECHNOLOGY
TRANSFER AND LICENSE AGREEMENT

AMENDMENT NO. 1 TO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT effective as of October 10, 2018 (the EFFECTIVE DATE) (this “Amendment”) by and between CODEXIS, INC., (the “Vendor”), a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, CA 94063 (“CODEXIS”) and MERCK SHARP AND DOHME CORP. (the “Company”), having a place of business at One Merck Drive, Whitehouse Station, NJ 08889-0100. (“MERCK”)

W I T N E S S E T H:

WHEREAS, the parties are party to that certain PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT dated as of August 3, 2015 (the “Agreement”); and

WHEREAS, the parties desire to amend the Agreement to modify the term of the Agreement as more fully set forth below;

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto hereby agree as follows:

1.
Additions and changes made to the contract in this Amendment.
1.01
Section 3.2.3 shall be amended to the following:
3.2.3    Manufacturing and Internal Research Purposes Licenses. Subject to the terms and conditions of this Agreement (including the limitations set forth in Section 3.4), Codexis hereby on behalf of itself and its Affiliates grants to Merck, during the Term, a non-transferable (except as provided in Section 14.8) right and license, with the right to grant sublicenses to Affiliates, contract manufacturing organizations (CMOs), contract research organizations (CROs), or other contract service organizations in accordance with and to the extent permitted under Section 3.3 under the Licensed IP in the Territory, solely to (a) make, have made, import and/or export Enzyme(s) for use in Therapeutic Product(s) and Merck Developed API(s) in the Territory and (b) make, have made, import and/or export Enzyme(s) for Internal Research Purposes in the Territory, which right and license shall be:
(a)           exclusive in the Merck Exclusive Field; and
(b)           non-exclusive in the Merck Non-Exclusive Field.
1.02
Exhibit 3.4.4 shall be amended to the following:
Exhibit 3.4.4
Third Party Enzyme Supplier(s)
[***]



1.
Miscellaneous
2.01
Effect of Amendment; Joinder. Except as expressly changed by this Amendment, the Agreement shall remain in full force and effect in accordance with its stated terms. The Agreement and the Schedules and Exhibits thereto, as amended by this Amendment and all preceding amendments, set forth the entire understanding of the parties with respect to the subject matter thereof. There are no agreements, restrictions, promises, warranties, covenants or undertakings other than those expressly set forth or referred to therein. The Agreement and the Schedules and Exhibits thereto, as amended by this Amendment, supersede all prior agreements and undertakings between the parties with respect to such subject matter.
2.02
Counterparts. This Amendment may be executed by the parties in separate counterparts, each of which when so executed and delivered is deemed an original. All such counterparts together constitute but one and the same instrument.
2.03
Definitions. All capitalized terms used but not defined in this Amendment shall have the respective definitions assigned to such terms in the Agreement.

IN WITNESS WHEREOF, the parties have caused this Amendment to be signed by their duly authorized representatives as of the date and year first written above.

Codexis Inc.
Merck Sharp & Dohme Corp.
 
 
 
 
By:___/s/ John J. Nicols_______________________
By:__/s/ Karen L. MacNaul_______________________
Name: John J. Nicols
Name: Karen L. MacNaul on behalf of Joseph P. Miletich, M.D., Ph.D., SVP, Discovery Research, MRL
Title: President and CEO
Title: Executive Director, Business Development & Licensing - MRL
Date: October 10, 2018
Date: Oct 08, 2018
 
 
 
 






-1-
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
EX-10.8B 5 exhibit108baldridge.htm EXHIBIT 10.8B Exhibit

SEPARATION AGREEMENT

This Separation Agreement (the “Agreement”) by and between Michael Aldridge (“Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (which shall in no event be prior to the Termination Date) with reference to the following facts:
 
A.    Executive’s employment with the Company and status as an officer and employee of the Company and each of its affiliates will end effective upon the Termination Date (as defined below).

B.    Executive and the Company want to end their relationship amicably and also to establish the obligations of the parties including, without limitation, all amounts due and owing to Executive.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:

1.Termination Date. Executive acknowledges and agrees that his status as an officer and employee of the Company will end effective as of August 17, 2018 (the “Termination Date”). Executive hereby agrees to execute such further document(s) as shall be determined by the Company as necessary or desirable to give effect to the termination of Executive’s status as an officer of the Company and each of its subsidiaries; provided that such documents shall not be inconsistent with any of the terms of this Agreement.
2.    Final Paycheck; Payment of Accrued Wages and Expenses.
(a)    Final Paycheck. As soon as administratively practicable on or after the Termination Date, the Company will pay Executive all accrued but unpaid base salary and all accrued and unused vacation earned through the Termination Date, subject to standard payroll deductions and withholdings. Executive is entitled to these payments regardless of whether Executive executes this Agreement.
(b)    Business Expenses. The Company shall reimburse Executive for all outstanding expenses incurred prior to the Termination Date which are consistent with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting and documenting such expenses. Executive is entitled to these reimbursement regardless of whether Executive executes this Agreement.
3.    Separation Benefits. Without admission of any liability, fact or claim, the Company hereby agrees, subject to the execution of this Agreement and Executive’s performance of his continuing obligations pursuant to this Agreement and that certain Employee Confidential Information and Inventions Assignment Agreement entered into between Executive and the Company effective as of October 16, 2016 (the “Confidentiality Agreement”), to provide Executive the severance benefits set forth below. Specifically, the Company and Executive agree as follows:
(a)    Cash Severance. On the first payroll date following the date this Agreement becomes effective and irrevocable, the Company shall pay to Executive $202,500, subject to continuing compliance by Executive with the terms hereof. Such payment shall be made in a single cash lump sum, subject to withholding taxes and authorized deductions.
(b)    Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive, Executive’s covered dependents and Executive’s spouse or domestic partner from the Termination Date through the earlier of (i) the six month anniversary of the Termination Date and (ii) the date Executive, Executive’s covered dependents, if any, and Executive’s spouse or domestic partner, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
(c)    Taxes. Executive understands and agrees that all payments under this Agreement will be subject to appropriate tax withholding and other deductions. To the extent any taxes may be payable by Executive for the benefits provided to him by this Agreement beyond those withheld by the Company, Executive agrees to pay them himself and to indemnify and hold the Company and the other entities released herein harmless for any tax claims or penalties, and associated attorneys’ fees and costs, resulting from any failure by him to make required payments.
(d)    SEC Reporting. Executive acknowledges that to the extent required by the Securities Exchange Act of 1934, as amended (the “Exchange Act”), he will have continuing obligations under Sections 16(a) and 16(b) of the Exchange Act to report any matching transactions in Company common stock for six months following the Termination Date. Executive hereby agrees not to undertake, directly or indirectly, any reportable transactions until the end of such six month period.
(e)    Sole Separation Benefit. Executive agrees that the benefits provided by this Section 3 are not required under the Company’s normal policies and procedures and are provided as a severance solely in connection with this Agreement. Executive acknowledges and agrees that the benefits referenced in this Section 3 constitute adequate and valuable consideration, in and of themselves, for the promises contained in this Agreement.
4.    Full Payment. Executive acknowledges that the payment and arrangements herein shall constitute full and complete satisfaction of any and all amounts properly due and owing to Executive as a result of his employment with the Company and the termination thereof. Executive further acknowledges that, other than the Confidentiality Agreement, this Agreement shall supersede each agreement entered into between Executive and the Company regarding Executive’s employment, including, without limitation, that certain offer letter agreement between Executive and the Company dated October 11, 2016 (the “Offer Letter”), that certain Change of Control Severance Agreement between Executive and the Company (the “Change of Control Severance Agreement”), and each such agreement shall be deemed terminated and of no further effect as of the Termination Date.
5.    Executive’s Release of the Company. Executive understands that by agreeing to the release provided by this Section 5, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its employees or other agents for any reason whatsoever based on anything that has occurred as of the date Executive signs this Agreement.
(a)    On behalf of Executive and Executive’s heirs, assigns, executors, administrators, trusts, spouse and estate, Executive hereby releases and forever discharges the “Releasees” hereunder, consisting of the Company, and each of its owners, affiliates, subsidiaries, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive’s hire, employment, remuneration or resignation by the Releasees, or any of them, Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, including any Claims arising under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §  2000, et seq.; Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621, et seq.; Civil Rights Act of 1866, and Civil Rights Act of 1991; 42 U.S.C. § 1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C.  § 2101 et seq.; the California Fair Employment and Housing Act, as amended, Cal. Lab. Code § 12940 et seq.; the California Equal Pay Law, as amended, Cal. Lab. Code §§ 1197.5(a),199.5; the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov’t Code §§12945.2, 19702.3; California Labor Code §§ 1101, 1102; the California WARN Act, California Labor Code §§ 1400 et. seq; California Labor Code §§ 1102.5(a),(b); claims for wages under the California Labor Code and any other federal, state or local laws of similar effect; the employment and civil rights laws of California; Claims for breach of contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees.
(b)    Notwithstanding the generality of the foregoing, Executive does not release the following claims:
(i)    Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
(ii)    Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;
(iii)    Claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA;
(iv)    Claims to any benefit entitlements vested as the date of Executive’s employment termination, pursuant to written terms of any Company employee benefit plan;
(v)    Claims for indemnification under any indemnification agreement, the Company’s Bylaws, California Labor Code Section 2802 or any other applicable law; and
(vi)    Executive’s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s right to secure any damages for alleged discriminatory treatment.
(c)    Acknowledgement. In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:
(i)    Executive should consult with an attorney before signing this Agreement;
(ii)    Executive has been given at least twenty-one (21) days to consider this Agreement;
(iii)    Executive has seven (7) days after signing this Agreement to revoke it. If Executive wishes to revoke this Agreement, Executive must deliver notice of Executive’s revocation in writing, no later than 5:00 p.m. on the 7th day following Executive’s execution of this Agreement to Eve Lai, 200 Penobscot Drive, Redwood City, California 94063, email: eve.lai@codexis.com. Executive understands that if he revokes this Agreement, it will be null and void in its entirety, and he will not be entitled to any payments or benefits provided in this Agreement, other than as provided in Section 2.
(d)    EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH, IF KNOWN BY HIM OR HER, MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.”
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
6.    Non-Disparagement, Transition, Transfer of Company Property and Limitations on Service. Executive further agrees that:
(a)    Non-Disparagement. Executive agrees that he shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners, stockholders, employees, products, services, technology or business, either publicly or privately. Nothing in this Section 6(a) shall have application to any evidence or testimony required by any court, arbitrator or government agency.
(b)    Transition. Each of the Company and Executive shall use their respective reasonable efforts to cooperate with each other in good faith to facilitate a smooth transition of Executive’s duties to other executive(s) of the Company.
(c)    Transfer of Company Property. Subject to Section 3(b) hereof, on or before the Termination Date, Executive shall turn over to the Company all files, memoranda, records, and other documents, and any other physical or personal property which are the property of the Company and which he had in his possession, custody or control at the time he signed this Agreement.
7.    Executive Representations. Executive warrants and represents that (a) he has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on his behalf, he will immediately cause it to be withdrawn and dismissed, (b) he has reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which he may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to him, except as provided in this Agreement, (c) he has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Agreement by Executive does not and will not conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, and (e) upon the execution and delivery of this Agreement by the Company and Executive, this Agreement will be a valid and binding obligation of Executive, enforceable in accordance with its terms.
8.    No Assignment by Executive. Executive warrants and represents that no portion of any of the matters released herein, and no portion of any recovery or settlement to which Executive might be entitled, has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Company or any other Releasee because of any actual assignment, subrogation or transfer by Executive, Executive agrees to indemnify and hold harmless the Company and all other Releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. In the event of Executive’s death, this Agreement shall inure to the benefit of Executive and Executive’s executors, administrators, heirs, distributees, devisees, and legatees. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only upon Executive’s death by will or operation of law.
9.    Non-Solicitation. Without limiting the Confidentiality Agreement, Executive hereby agrees that Executive shall not, at any time within the two (2) year period immediately following the Termination Date, directly or indirectly, either for himself or on behalf of any other person, recruit or otherwise solicit or induce any employee or consultant of the Company to terminate its employment or arrangement with the Company, or otherwise change its relationship with the Company. Notwithstanding the foregoing, nothing herein shall prevent Executive from directly or indirectly hiring any individual who submits a resume or otherwise applies for a position in response to a publicly posted job announcement or otherwise applies for employment with any person with whom Executive may be associated absent any violation of Executive’s obligations pursuant to the preceding sentence.
10.    Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions or those of any state other than California.
11.    Miscellaneous. This Agreement, together with the Confidentiality Agreement, comprises the entire agreement between the parties with regard to the subject matter hereof and supersedes, in their entirety, any other agreements between Executive and the Company with regard to the subject matter hereof, including, without limitation, the Offer Letter and Change of Control Severance Agreement. Executive acknowledges that there are no other agreements, written, oral or implied, and that he may not rely on any prior negotiations, discussions, representations or agreements. This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is intended to modify this Agreement. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.
12.    Company Assignment and Successors. The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns, personnel and legal representatives.
13.    Maintaining Confidential Information. Executive reaffirms his obligations under the Confidentiality Agreement. Executive acknowledges and agrees that the benefits provided in Section 3 above shall be subject to Executive’s continued compliance with Executive’s obligations under the Confidentiality Agreement. For the avoidance of doubt, nothing in the Confidentiality Agreement or this Agreement will be construed to prohibit Executive from filing a charge with, reporting possible violations to, or participating or cooperating with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making other disclosures that are protected under the whistleblower, anti-discrimination, or anti-retaliation provisions of federal, state or local law or regulation. Executive does not need the prior authorization of the Company to make any such reports or disclosures, and Executive is not required to notify the Company that he has made such reports or disclosures. Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in the Confidentiality Agreement or this Agreement: (i) Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.
14.    Executive’s Cooperation.  After the Termination Date, Executive shall cooperate with the Company and its affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive’s duties and responsibilities to the Company or its affiliates during his employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive’s possession during his employment); provided, however, that any such request by the Company shall not be unduly burdensome or interfere with Executive’s personal schedule or ability to engage in gainful employment. 
15.    Section 409A of the Code. This Agreement is intended, to the greatest extent permitted under law, to comply with the short-term deferral exemption and the separation pay exemption provided in Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and other interpretative guidance issued thereunder (“Section 409A”) such that no benefits or payments under this Agreement are subject to Section 409A. Notwithstanding anything herein to the contrary, the timing of any payments under this Agreement shall be made consistent with such exemption. Executive’s right to receive a series of installment payments under this Agreement, if any, shall be treated as a right to receive a series of separate payments. To the extent applicable, this Agreement shall be interpreted in accordance with Section 409A, including without limitation any such regulations or other guidance that may be issued after the Termination Date. Notwithstanding any provision of this Agreement to the contrary, in the event that the Company determines that any amounts payable hereunder may be subject to Section 409A, the Company may, to the extent permitted under Section 409A cooperate in good faith to adopt such amendments to this Agreement or adopt other appropriate policies and procedures, including amendments and policies with retroactive effect, that the Company determines are necessary or appropriate to avoid the imposition of taxes under Section 409A; provided, however, that this paragraph shall not create an obligation on the part of the Company to adopt any such amendment, policy or procedure or take any such other action, nor shall the Company have any liability for failing to do so. To the extent that any reimbursements payable pursuant to this Agreement are subject to the provisions of Section 409A, such reimbursements shall be paid to Executive no later than December 31 of the year following the year in which the expense was incurred, the amount of expenses reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year, and Executive’s right to reimbursement under this Agreement will not be subject to liquidation or exchange for another benefit.
(Signature page(s) follow)

IN WITNESS WHEREOF, the undersigned have caused this Separation Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.



DATED: _______________, 2018
/s/ Michael Aldridge _
Michael Aldridge


CODEXIS, INC.
DATED: _______________, 2018


By: /s/ John J Nicols_______________
Name: John J Nicols
Title: President & CEO
    



                    

1





US-DOCS\102586907.1
EX-12.1 6 exhibit121statementratioea.htm EXHIBIT 12.1 Exhibit





Exhibit 12.1

CODEXIS, INC.

STATEMENT OF COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(In Thousands)
 

 
 
 
Years Ended December 31,
 
 
 
2014
 
2015
 
2016
 
2017
 
2018
 
 
 
 
 
 
 
 
 
 
 
 
Fixed charges:
 
 
 
 
 
 
 
 
 
 
 
Interest Expense
 
 

 
14

 
141

 
84

 
Total Fixed Charges
 
 
 
 
 
14

 
141

 
84

 
 
 
 
 
 
 
 
 
 
 
 
Earnings (deficiency) available for fixed charges:
 
 
 
 
 
 
 
 
 
 
 
Pre-tax loss from continuing operations
 
(19,327)
 
(7,919)

 
(8,598)

 
(23,239
)
 
(10,878
)
 
add: Fixed Charges
 
 
 
 
 
14

 
141

 
84

 
Earnings (deficiency of earnings) available to cover fixed charges
 
(19,327)
 
(7,919)

 
(8,584)

 
(23,098
)
 
(10,794
)
Ratio of earnings to fixed charges (1)
 
 N/A
 
 N/A

 
 N/A

 
 N/A

 
N/A

 
 
 
(1)
Our earnings were inadequate to cover fixed charges for the years ended December 31, 2014 through December 31, 2018.






EX-21.1 7 exhibit211subsidiaries.htm EXHIBIT 21.1 Exhibit


Exhibit 21.1
Subsidiaries of Codexis, Inc.

Name of Subsidiary
 
State or Jurisdiction in which Incorporated or Organized
Codexis Mayflower Holdings LLC
 
Delaware



EX-23.1 8 exhibit231cdxs-20181231.htm EXHIBIT 23.1 Exhibit
Exhibit 23.1
 
Consent of Independent Registered Public Accounting Firm

We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-216587, 333-210022, 333-202596, 333-194524, 333-187711, 333-179903, 333-172166, and 333-167752) and the Registration Statement of Form S-3 (No. 333-215025) of Codexis, Inc. of our reports dated March 1, 2019, relating to the consolidated financial statements, and the effectiveness of Codexis, Inc.’s internal control over financial reporting, which appears in this Form 10-K.
    
/s/ BDO USA, LLP

San Jose, California
March 1, 2019




EX-31.1 9 exhibit311cdxs-20181231.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION
I, John J. Nicols, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Codexis, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
Date: March 1, 2019
 
 
/s/John J. Nicols
 
John J. Nicols
 
President and Chief Executive Officer




EX-31.2 10 exhibit312cdxs-20181231.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION
I, Gordon Sangster, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Codexis, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
 
Date: March 1, 2019
 
 
/s/Gordon Sangster
 
Gordon Sangster
 
Senior Vice President and Chief Financial Officer




EX-32.1 11 exhibit321cdxs-20181231.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Codexis, Inc. (the “Company”) on Form 10-K for the fiscal year ended December 31, 2018, as filed with the Securities and Exchange Commission (the “Report”), John J. Nicols, President and Chief Executive Officer of the Company and Gordon Sangster, Senior Vice President and Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date: March 1, 2019
 
/s/John J. Nicols
 
John J. Nicols
 
President and Chief Executive Officer
 
 
 
/s/Gordon Sangster
 
Gordon Sangster
 
Senior Vice President and Chief Financial Officer
 




EX-101.INS 12 cdxs-20181231.xml XBRL INSTANCE DOCUMENT 0001200375 2018-01-01 2018-12-31 0001200375 2018-06-30 0001200375 2019-02-22 0001200375 2018-12-31 0001200375 2017-12-31 0001200375 2017-01-01 2017-12-31 0001200375 2016-01-01 2016-12-31 0001200375 us-gaap:ServiceMember 2018-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember 2017-01-01 2017-12-31 0001200375 us-gaap:ServiceMember 2017-01-01 2017-12-31 0001200375 cdxs:ProductSalesMember 2018-01-01 2018-12-31 0001200375 us-gaap:ServiceMember 2016-01-01 2016-12-31 0001200375 cdxs:ProductSalesMember 2016-01-01 2016-12-31 0001200375 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 0001200375 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-12-31 0001200375 us-gaap:CommonStockMember 2017-12-31 0001200375 us-gaap:CommonStockMember 2017-01-01 2017-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2017-01-01 2017-12-31 0001200375 us-gaap:RetainedEarningsMember 2016-01-01 2016-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2015-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-12-31 0001200375 us-gaap:CommonStockMember 2016-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-01-01 2016-12-31 0001200375 us-gaap:RetainedEarningsMember 2017-01-01 2017-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2016-12-31 0001200375 us-gaap:CommonStockMember 2018-01-01 2018-12-31 0001200375 us-gaap:RetainedEarningsMember 2018-12-31 0001200375 2016-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001200375 2015-12-31 0001200375 us-gaap:CommonStockMember 2018-12-31 0001200375 us-gaap:RetainedEarningsMember 2016-12-31 0001200375 us-gaap:CommonStockMember 2016-01-01 2016-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001200375 us-gaap:CommonStockMember 2015-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2016-12-31 0001200375 us-gaap:RetainedEarningsMember 2018-01-01 2018-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001200375 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0001200375 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-01-01 2017-12-31 0001200375 us-gaap:RetainedEarningsMember 2017-12-31 0001200375 us-gaap:RetainedEarningsMember 2015-12-31 0001200375 us-gaap:AccountingStandardsUpdate201409Member 2018-12-31 0001200375 us-gaap:AccountingStandardsUpdate201601Member 2018-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:CDX6114Member us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2019-02-01 2019-02-28 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:CDX6114Member us-gaap:CollaborativeArrangementMember 2018-12-01 2018-12-31 0001200375 cdxs:DevelopmentandApprovalMember cdxs:NestecLtd.NestleHealthSciencesMember cdxs:CDX6114Member us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2019-02-01 2019-02-28 0001200375 cdxs:SalesBasedMilestoneMember cdxs:NestecLtd.NestleHealthSciencesMember cdxs:CDX6114Member us-gaap:SubsequentEventMember us-gaap:CollaborativeArrangementMember 2019-02-01 2019-02-28 0001200375 us-gaap:SubsequentEventMember 2019-01-01 0001200375 cdxs:EighthLeaseAmendmentMember us-gaap:SubsequentEventMember 2019-02-28 0001200375 cdxs:NovelBiotherapeuticsMember 2018-12-31 0001200375 cdxs:TrusteeDepositMember 2017-12-31 0001200375 us-gaap:LetterOfCreditMember us-gaap:DemandDepositsMember 2017-12-31 0001200375 cdxs:PerformanceEnzymesMember 2018-12-31 0001200375 us-gaap:AccountingStandardsUpdate201601Member 2018-01-01 2018-01-01 0001200375 cdxs:TrusteeDepositMember 2018-12-31 0001200375 us-gaap:LetterOfCreditMember us-gaap:DemandDepositsMember 2018-12-31 0001200375 us-gaap:EquipmentMember 2018-01-01 2018-12-31 0001200375 cdxs:OfficeEquipmentAndFurnitureMember 2018-01-01 2018-12-31 0001200375 srt:MinimumMember cdxs:ComputerEquipmentAndSoftwareMember 2018-01-01 2018-12-31 0001200375 srt:MaximumMember cdxs:ComputerEquipmentAndSoftwareMember 2018-01-01 2018-12-31 0001200375 cdxs:CoreSegmentMember 2018-01-01 2018-12-31 0001200375 cdxs:APACMember cdxs:CoreSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember cdxs:PerformanceEnzymesMember 2018-01-01 2018-12-31 0001200375 srt:AmericasMember cdxs:BiotherapeuticSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:EMEAMember cdxs:BiotherapeuticSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:EMEAMember 2018-01-01 2018-12-31 0001200375 cdxs:BiotherapeuticSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:EMEAMember cdxs:CoreSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember cdxs:NovelBiotherapeuticsMember 2018-01-01 2018-12-31 0001200375 srt:AmericasMember 2018-01-01 2018-12-31 0001200375 cdxs:APACMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember cdxs:NovelBiotherapeuticsMember 2018-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2018-01-01 2018-12-31 0001200375 cdxs:APACMember cdxs:BiotherapeuticSegmentMember 2018-01-01 2018-12-31 0001200375 srt:AmericasMember cdxs:CoreSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember cdxs:PerformanceEnzymesMember 2018-01-01 2018-12-31 0001200375 srt:MaximumMember 2018-01-01 2018-12-31 0001200375 srt:MinimumMember 2018-01-01 2018-12-31 0001200375 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2019-01-01 2018-12-31 0001200375 2022-01-01 2018-12-31 0001200375 2018-12-31 0001200375 2019-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2022-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember 2022-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2020-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2021-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember 2021-01-01 2018-12-31 0001200375 2020-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2018-12-31 0001200375 cdxs:ProductSalesMember 2018-12-31 0001200375 cdxs:ProductSalesMember 2020-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember 2019-01-01 2018-12-31 0001200375 2021-01-01 2018-12-31 0001200375 2018-01-02 2018-12-31 0001200375 2018-01-01 0001200375 cdxs:APACMember cdxs:CoreSegmentMember 2017-01-01 2017-12-31 0001200375 cdxs:APACMember 2017-01-01 2017-12-31 0001200375 cdxs:CoreSegmentMember 2017-01-01 2017-12-31 0001200375 srt:AmericasMember cdxs:CoreSegmentMember 2017-01-01 2017-12-31 0001200375 srt:AmericasMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember cdxs:NovelBiotherapeuticsMember 2017-01-01 2017-12-31 0001200375 cdxs:APACMember cdxs:BiotherapeuticSegmentMember 2017-01-01 2017-12-31 0001200375 srt:AmericasMember cdxs:BiotherapeuticSegmentMember 2017-01-01 2017-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember cdxs:PerformanceEnzymesMember 2017-01-01 2017-12-31 0001200375 us-gaap:EMEAMember cdxs:BiotherapeuticSegmentMember 2017-01-01 2017-12-31 0001200375 cdxs:BiotherapeuticSegmentMember 2017-01-01 2017-12-31 0001200375 us-gaap:EMEAMember cdxs:CoreSegmentMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember cdxs:PerformanceEnzymesMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember cdxs:NovelBiotherapeuticsMember 2017-01-01 2017-12-31 0001200375 us-gaap:EMEAMember 2017-01-01 2017-12-31 0001200375 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2017-12-31 0001200375 us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-01-01 0001200375 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-12-31 0001200375 us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-12-31 0001200375 us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001200375 cdxs:ProductSalesMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member 2018-01-01 2018-12-31 0001200375 cdxs:ResearchandDevelopmentRevenueMember us-gaap:CalculatedUnderRevenueGuidanceInEffectBeforeTopic606Member 2018-01-01 2018-12-31 0001200375 us-gaap:StockCompensationPlanMember 2017-01-01 2017-12-31 0001200375 us-gaap:StockCompensationPlanMember 2016-01-01 2016-12-31 0001200375 us-gaap:WarrantMember 2017-01-01 2017-12-31 0001200375 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001200375 us-gaap:StockCompensationPlanMember 2018-01-01 2018-12-31 0001200375 us-gaap:WarrantMember 2016-01-01 2016-12-31 0001200375 cdxs:SupplyAgreementMember us-gaap:LicenseAndServiceMember cdxs:MerckMember 2017-06-01 2017-06-30 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:StrategicCollaborationAgreementMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-12-31 0001200375 cdxs:ResearchandDevelopmentAgreementMember cdxs:FineChemicalCustomerMember 2017-03-01 2017-03-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:CollaborativeArrangementMember 2018-09-01 2018-09-30 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-12-31 0001200375 cdxs:TechnologyTransferCollaborationandLicenseAgreementMember cdxs:GSKMember srt:MinimumMember 2018-09-30 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:StrategicCollaborationAgreementMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-12-31 0001200375 cdxs:MerckMember cdxs:ResearchandDevelopmentRevenueMember us-gaap:CollaborativeArrangementMember 2017-01-01 2017-12-31 0001200375 cdxs:ResearchandDevelopmentAgreementMember cdxs:FineChemicalCustomerMember 2018-01-01 2018-12-31 0001200375 cdxs:SupplyAgreementMember cdxs:MerckMember 2018-12-31 0001200375 cdxs:PortonMember cdxs:PortonAgreementMember 2018-04-01 2018-04-30 0001200375 cdxs:ResearchandDevelopmentAgreementMember cdxs:FineChemicalCustomerMember 2018-12-31 0001200375 cdxs:TechnologyTransferCollaborationandLicenseAgreementMember cdxs:MerckMember 2015-08-01 2015-08-31 0001200375 cdxs:ResearchandDevelopmentAgreementMember cdxs:FineChemicalCustomerMember 2017-01-01 2017-12-31 0001200375 cdxs:MerckMember 2016-01-01 2016-12-31 0001200375 cdxs:MerckMember cdxs:ResearchandDevelopmentRevenueMember us-gaap:CollaborativeArrangementMember 2016-01-01 2016-12-31 0001200375 cdxs:SupplyAgreementMember cdxs:MerckMember 2012-02-01 2012-02-29 0001200375 cdxs:SupplyAgreementMember us-gaap:LicenseAndServiceMember cdxs:MerckMember 2018-01-01 2018-12-31 0001200375 cdxs:TechnologyTransferCollaborationandLicenseAgreementMember cdxs:GSKMember srt:MaximumMember 2018-09-30 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:TransferredOverTimeMember us-gaap:CollaborativeArrangementMember 2017-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:StrategicCollaborationAgreementMember us-gaap:CollaborativeArrangementMember 2018-09-01 2018-09-30 0001200375 cdxs:SupplyAgreementMember us-gaap:LicenseAndServiceMember cdxs:MerckMember 2016-01-01 2016-12-31 0001200375 cdxs:PortonMember cdxs:PortonAgreementMember 2018-01-01 2018-12-31 0001200375 cdxs:MerckMember us-gaap:CollaborativeArrangementMember 2015-08-01 2015-08-31 0001200375 cdxs:SupplyAgreementMember cdxs:MerckMember 2017-12-31 0001200375 cdxs:SupplyAgreementMember cdxs:CustomerMember 2017-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:CollaborativeArrangementMember 2017-10-01 2017-10-31 0001200375 cdxs:ResearchandDevelopmentAgreementMember cdxs:FineChemicalCustomerMember 2017-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:StrategicCollaborationAgreementMember us-gaap:CollaborativeArrangementMember 2017-12-31 0001200375 cdxs:MerckMember cdxs:ResearchandDevelopmentRevenueMember us-gaap:CollaborativeArrangementMember 2018-01-01 2018-12-31 0001200375 cdxs:MerckMember 2017-01-01 2017-12-31 0001200375 cdxs:MerckMember 2018-01-01 2018-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:StrategicCollaborationAgreementMember us-gaap:CollaborativeArrangementMember 2018-12-31 0001200375 cdxs:SupplyAgreementMember 2016-12-01 2016-12-31 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:GlobalDevelopmentOptionandLicenseAgreementMember us-gaap:TransferredOverTimeMember us-gaap:CollaborativeArrangementMember 2018-12-31 0001200375 cdxs:SupplyAgreementMember us-gaap:LicenseAndServiceMember cdxs:MerckMember 2017-01-01 2017-12-31 0001200375 cdxs:SupplyAgreementMember cdxs:CustomerMember 2018-12-31 0001200375 us-gaap:MoneyMarketFundsMember 2018-12-31 0001200375 2009-12-31 0001200375 cdxs:CommonSharesOfCoTwoSolutionMember 2018-01-01 2018-12-31 0001200375 2009-12-01 2009-12-31 0001200375 cdxs:CommonSharesOfCoTwoSolutionMember 2009-12-01 2009-12-31 0001200375 us-gaap:MoneyMarketFundsMember 2017-12-31 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001200375 us-gaap:FairValueInputsLevel1Member 2018-12-31 0001200375 us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001200375 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001200375 us-gaap:FairValueInputsLevel1Member us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2018-12-31 0001200375 us-gaap:FairValueInputsLevel3Member 2018-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2018-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2018-12-31 0001200375 us-gaap:FairValueInputsLevel3Member us-gaap:AvailableforsaleSecuritiesMember 2018-12-31 0001200375 us-gaap:FairValueInputsLevel2Member cdxs:CommonSharesOfCoTwoSolutionMember 2018-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2017-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member 2017-12-31 0001200375 us-gaap:FairValueInputsLevel1Member 2017-12-31 0001200375 us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0001200375 us-gaap:FairValueInputsLevel2Member 2017-12-31 0001200375 us-gaap:FairValueInputsLevel3Member us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0001200375 us-gaap:FairValueInputsLevel3Member 2017-12-31 0001200375 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2017-12-31 0001200375 us-gaap:FairValueInputsLevel2Member us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0001200375 us-gaap:FairValueInputsLevel1Member us-gaap:AvailableforsaleSecuritiesMember 2017-12-31 0001200375 us-gaap:EquipmentMember 2017-01-01 2017-12-31 0001200375 us-gaap:ComputerEquipmentMember 2017-12-31 0001200375 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001200375 us-gaap:EquipmentMember 2017-12-31 0001200375 us-gaap:EquipmentMember 2018-12-31 0001200375 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001200375 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001200375 us-gaap:ConstructionInProgressMember 2018-12-31 0001200375 us-gaap:ComputerEquipmentMember 2018-12-31 0001200375 us-gaap:FurnitureAndFixturesMember 2018-12-31 0001200375 us-gaap:ConstructionInProgressMember 2017-12-31 0001200375 us-gaap:PerformanceSharesMember 2016-01-01 2016-12-31 0001200375 us-gaap:PerformanceSharesMember 2018-01-01 2018-12-31 0001200375 us-gaap:PerformanceSharesMember 2017-01-01 2017-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2017-01-01 2017-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2016-01-01 2016-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2015-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2018-01-01 2018-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2017-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2018-12-31 0001200375 cdxs:PerformanceStockUnitsMember 2016-12-31 0001200375 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-12-31 0001200375 cdxs:RestrictedStockandRestrictedStockUnitsMember 2018-01-01 2018-12-31 0001200375 cdxs:RestrictedStockandRestrictedStockUnitsMember 2016-01-01 2016-12-31 0001200375 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001200375 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-12-31 0001200375 cdxs:RestrictedStockandRestrictedStockUnitsMember 2017-01-01 2017-12-31 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-12-31 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-12-31 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2016-01-01 2016-12-31 0001200375 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2017-01-01 2017-12-31 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001200375 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-12-31 0001200375 us-gaap:RestrictedStockMember 2017-12-31 0001200375 us-gaap:RestrictedStockMember 2016-12-31 0001200375 us-gaap:RestrictedStockMember 2018-12-31 0001200375 us-gaap:RestrictedStockMember 2015-12-31 0001200375 us-gaap:RestrictedStockMember 2017-01-01 2017-12-31 0001200375 us-gaap:RestrictedStockMember 2016-01-01 2016-12-31 0001200375 us-gaap:RestrictedStockMember 2018-01-01 2018-12-31 0001200375 us-gaap:PerformanceSharesMember 2018-12-31 0001200375 us-gaap:PerformanceSharesMember 2016-12-31 0001200375 us-gaap:PerformanceSharesMember 2017-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2015-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2017-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember 2016-12-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2010-03-01 2010-03-31 0001200375 us-gaap:EmployeeStockOptionMember 2017-10-01 2017-10-31 0001200375 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-09-30 0001200375 us-gaap:PerformanceSharesMember cdxs:A2016PSUPlanMember 2016-12-31 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2010-03-01 2010-03-31 0001200375 us-gaap:EmployeeStockOptionMember 2010-03-01 2010-03-31 0001200375 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2010-03-01 2010-03-31 0001200375 us-gaap:PerformanceSharesMember cdxs:A2018PSUandPBOPlanMember 2018-12-31 0001200375 cdxs:NonStatutoryStockOptionsMember 2010-03-01 2010-03-31 0001200375 cdxs:IncentiveStockOptionsMember 2010-03-01 2010-03-31 0001200375 cdxs:TwoThousandTenPlanMember 2010-03-31 0001200375 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2010-03-01 2010-03-31 0001200375 us-gaap:PerformanceSharesMember cdxs:A2017PSUandPBOPlanMember 2017-12-31 0001200375 us-gaap:PerformanceSharesMember cdxs:A2016PSUPlanMember 2016-01-01 2016-12-31 0001200375 cdxs:TwoThousandTenPlanMember 2010-03-01 2010-03-31 0001200375 us-gaap:PerformanceSharesMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-09-30 0001200375 2018-04-30 0001200375 2018-04-01 2018-04-30 0001200375 cdxs:UnderwrittenPublicOfferingMember 2018-04-01 2018-04-30 0001200375 us-gaap:OverAllotmentOptionMember 2018-04-01 2018-04-30 0001200375 us-gaap:InternalRevenueServiceIRSMember 2018-12-31 0001200375 us-gaap:StateAndLocalJurisdictionMember 2018-12-31 0001200375 us-gaap:ForeignCountryMember 2018-12-31 0001200375 country:IN 2018-12-31 0001200375 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-12-31 0001200375 cdxs:December2017Member us-gaap:SupplyCommitmentMember 2018-12-31 0001200375 cdxs:July2017Member us-gaap:SupplyCommitmentMember 2018-12-31 0001200375 us-gaap:SupplyCommitmentMember 2018-12-31 0001200375 cdxs:April2016Member us-gaap:SupplyCommitmentMember 2018-12-31 0001200375 cdxs:RepaymentPeriodFiveMember us-gaap:RevolvingCreditFacilityMember 2017-06-30 2017-06-30 0001200375 cdxs:RepaymentPeriodSixMember us-gaap:RevolvingCreditFacilityMember 2017-06-30 2017-06-30 0001200375 cdxs:RepaymentPeriodFourMember us-gaap:RevolvingCreditFacilityMember 2017-06-30 2017-06-30 0001200375 cdxs:RepaymentPeriodTwoMember cdxs:TermLoanMember 2017-06-30 2017-06-30 0001200375 cdxs:RepaymentPeriodThreeMember cdxs:TermLoanMember 2017-06-30 2017-06-30 0001200375 cdxs:RepaymentPeriodOneMember cdxs:TermLoanMember 2017-06-30 2017-06-30 0001200375 us-gaap:RevolvingCreditFacilityMember 2017-06-30 2017-06-30 0001200375 us-gaap:IndemnificationGuaranteeMember 2018-12-31 0001200375 cdxs:HeadquartersRedwoodCityMember 2018-12-31 0001200375 2017-04-30 0001200375 cdxs:Amendment7Member 2018-12-31 0001200375 cdxs:RedwoodCityCalifornia501ChesapeakeSpaceMember 2018-12-31 0001200375 cdxs:FifthAmendmentMember 2011-01-01 2012-12-31 0001200375 cdxs:TermLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2017-06-30 2017-06-30 0001200375 2016-12-01 2016-12-31 0001200375 2017-04-01 2017-04-30 0001200375 us-gaap:RevolvingCreditFacilityMember 2018-12-31 0001200375 cdxs:RedwoodCityCaliforniaSaginawSpaceMember 2018-12-31 0001200375 cdxs:RedwoodCityCaliforniaPenobscotSpaceMember 2018-12-31 0001200375 cdxs:FifthAmendmentMember 2012-01-01 2012-12-31 0001200375 us-gaap:RevolvingCreditFacilityMember 2017-06-30 0001200375 cdxs:TermLoanMember 2017-06-30 0001200375 cdxs:RedwoodCityCaliforniaBuilding2SpaceMember 2018-12-31 0001200375 cdxs:Amendment7Member 2017-12-31 0001200375 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2017-06-30 2017-06-30 0001200375 us-gaap:DemandDepositsMember 2017-12-31 0001200375 cdxs:HeadquartersRedwoodCityMember 2017-12-31 0001200375 us-gaap:RoyaltyMember cdxs:ExelaPharmSciIncMember 2016-01-01 2016-12-31 0001200375 us-gaap:RoyaltyMember cdxs:ExelaPharmSciIncMember 2017-01-01 2017-12-31 0001200375 cdxs:AlfaAesarMember 2018-12-31 0001200375 cdxs:AstraZenecaMember 2017-12-31 0001200375 cdxs:AlfaAesarMember 2016-12-31 0001200375 cdxs:AstraZenecaMember 2017-01-01 2017-12-31 0001200375 cdxs:AstraZenecaMember 2018-01-01 2018-12-31 0001200375 cdxs:AsymchemMember 2017-12-31 0001200375 cdxs:AsymchemMember 2017-01-01 2017-12-31 0001200375 us-gaap:RoyaltyMember cdxs:ExelaPharmSciIncMember 2018-01-01 2018-12-31 0001200375 cdxs:AstraZenecaMember 2018-12-31 0001200375 cdxs:AsymchemMember 2018-12-31 0001200375 cdxs:ExelaPharmSciIncMember 2018-12-31 0001200375 cdxs:ExelaPharmSciIncMember 2017-12-31 0001200375 cdxs:PresidioPartners2007L.P.Member cdxs:ExelaPharmSciIncMember 2018-12-31 0001200375 cdxs:AlfaAesarMember 2017-12-31 0001200375 cdxs:AstraZenecaMember 2016-01-01 2016-12-31 0001200375 cdxs:AsymchemMember 2018-01-01 2018-12-31 0001200375 cdxs:AsymchemMember 2016-01-01 2016-12-31 0001200375 us-gaap:OperatingSegmentsMember 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:PerformanceEnzymesMember 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:NovelBiotherapeuticsMember 2018-12-31 0001200375 cdxs:APACMember 2016-01-01 2016-12-31 0001200375 srt:AmericasMember 2016-01-01 2016-12-31 0001200375 us-gaap:EMEAMember 2016-01-01 2016-12-31 0001200375 cdxs:ExelaPharmSciIncMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:MerckMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:NovartisMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:KyorinPharmaceuticalCoLtdMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:NestleMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:NovartisMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:MerckMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:TateLyleMember us-gaap:AccountsReceivableMember us-gaap:CreditConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 country:US 2018-12-31 0001200375 country:US 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:NovelBiotherapeuticsMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:NovelBiotherapeuticsMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:PerformanceEnzymesMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:PerformanceEnzymesMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember 2017-01-01 2017-12-31 0001200375 us-gaap:CorporateNonSegmentMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ResearchandDevelopmentRevenueMember 2018-01-01 2018-12-31 0001200375 us-gaap:CorporateNonSegmentMember 2018-01-01 2018-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember 2017-01-01 2017-12-31 0001200375 us-gaap:OperatingSegmentsMember cdxs:ProductSalesMember 2018-01-01 2018-12-31 0001200375 cdxs:NestleMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:TateLyleMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:NestleMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:TateLyleMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:GSKMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001200375 cdxs:NovartisMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:MerckMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2017-01-01 2017-12-31 0001200375 cdxs:MerckMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2016-01-01 2016-12-31 0001200375 cdxs:MerckMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2018-01-01 2018-12-31 0001200375 cdxs:EighthLeaseAmendmentMember us-gaap:SubsequentEventMember 2019-03-01 0001200375 cdxs:NestecLtd.NestleHealthSciencesMember cdxs:CDX6114Member us-gaap:SubsequentEventMember 2019-01-01 2019-01-31 xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:USD cdxs:segment cdxs:multiplier utreg:sqft cdxs:installment 941000 1492000 31788000 P5Y 42000 239000 0 197000 8934000 2908000 992000 786000 0 17124000 6446000 46605000 6 0 255000 73000 838000 0.24 0.76 0 353000 2349000 0.10 107200 11200 37900 28200 29900 460000 35000 38500000 5750000 0.8 0.02 0.03 0.02 0.01 0.055 0.01 10000000 0.166 0.1 P60D P60D P60D 3000000 15000000 86000000 250000000 1000000000 P5Y 1000000 800000 3000000 14000000 500000 600000 P30D 4000000 3000000 4000000 P90D P30D 1.10 0.50 0.50 0 0 200000 1.423 1.342 1.18 2.54 2 0 1 P4M 34100000 P21M 786000 -786000 0 0 false --12-31 FY 2018 2018-12-31 10-K 0001200375 54158617 Yes false Large Accelerated Filer 731500000 CODEXIS INC false false No No 3545000 3050000 11447000 11551000 -1253000 10298000 400000 0 100000 100000 1600000 0 200000 0 0 4362000 4855000 -520000 4335000 2393000 2020000 32254000 33093000 -472000 0 340079000 386775000 -1524000 -1524000 -1670000 -1670000 -3190000 -3190000 43000 43000 24000 24000 5673000 5673000 7048000 7048000 7865000 7865000 500000 700000 500000 421000 421000 34000 34000 34000 34000 0 387000 0 2812000 0 0 5640000 5567000 73000 6882000 6882000 0 6339000 6339000 0 200000 200000 53625000 79283000 45039000 68198000 7449000 6778000 671000 0 31813000 31813000 0 0 108000 0 563000 0 671000 0 671000 588000 0 0 588000 108000 0 7341000 671000 125000 42000 300000 242000 302000 61000 313000 252000 0 0 0 61000 10000 303000 24400000 21800000 19240000 31219000 31200000 6778000 6778000 0 0 53000000 53039000 31225000 31225000 0 0 7449000 31813000 24060000 20864000 32776000 54485000 -3196000 11912000 21709000 0.000001 100000000 48365000 54605000 48365000 54605000 5000 5000 -8963000 -405000 -8558000 -23468000 -472000 -22996000 -10878000 0.22 0.47 0.14 0.31 0.28 0.15 0.15 0.14 0.16 0.11 0.16 0.37 0.29 0.17 0.22 0.11 0.13 0 0 35000 -35000 0 0 8899000 3100000 700000 1500000 6800000 13793000 8288000 0 2000000 3600000 1900000 18966000 13615000 374000 12292000 1100000 4936000 800000 -1574000 3362000 5173000 1501000 3352000 -1445000 1907000 500000 60594000 3600000 9753000 14327000 14327000 0 14327000 12620000 12620000 0 12620000 -285000 12335000 -4059000 -900000 472000 -4531000 500000 0 0 0 -14000 64000 -13000 -9000 69000 -8000 5000 5000 5000 0.036 0.01 0.05 1100000 0 0 0 -31000 12000 -29000 -31000 12000 -29000 115000 64000 258000 343000 0 0 0 576000 576000 3334000 1879000 3172000 2557000 74050000 79240000 295000 297000 53901000 60455000 78000 83000 1573000 1376000 6221000 7174000 2872000 2967000 2028000 1876000 74010000 79222000 75000 46000 115000 64000 100000 400000 600000 600000 1734000 1042000 -1042000 1147000 -1147000 -0.21 -0.50 -0.21 -0.09 -0.30 4753000 5272000 P6M P2Y6M P10M24D P4M24D P1Y1M 600000 1200000 300000 1000000 3500000 588000 563000 25000 0 800000 100000 42000 -9000 -8000 0 207000 0 3241000 3241000 3200000 3241000 778000 2463000 800000 2400000 0 0 0 0 0 0 900000 500000 -8174000 -22994000 -10653000 -424000 79000 -262000 -8598000 -22915000 -10915000 -4550000 -15465000 -40000 81000 -37000 0 -37000 1901000 -26058000 4301000 0 34100000 0 30000 -2000 -17000 -2924000 -7791000 -2292000 405000 326000 -3000 327000 -216000 -2587000 127000 48000 222000 161000 399000 499000 5000 32000 5000 942000 -801000 -524000 -1405000 5298000 -960000 0 0 35000 -6442000 11017000 -10631000 983000 439000 519000 -167000 210000 -447000 -593000 1399000 -17000 -52000 44000 -228000 0 0 -904000 -7000 -157000 37000 14000 141000 84000 825000 377000 1036000 589000 1000 590000 158000 165000 53000 47000 60000 147000 671000 0 671000 10000000 48000 2900000 3200000 3200000 425000 425000 P3Y P3Y P88M P5Y P88M 1100000 29078000 22977000 53625000 79283000 24952000 18113000 10000000.0 5000000.0 0 671000 588000 6800000 31200000 -490000 21650000 38569000 -846000 -983000 -2766000 -1860000 -8755000 -14094000 -8558000 -22996000 -10878000 -4550000 -15428000 -10878000 4100000 500000 0 862000 0 2815000 4759000 1 2 2 57401000 72994000 -21245000 50652000 12107000 38545000 71889000 -20324000 50038000 10956000 39082000 -481000 71408000 -8564000 -22970000 -628000 -4416000 3788000 -11295000 10556000 2565000 7991000 -4550000 -15845000 30000000 20000000 4523000 32900000 3280000 900000 0 41000 490000 712000 1200000 1400000 1100000 383000 254208000 115420000 345000 575000 265000 -42000 223000 302000 1051000 -405000 -472000 0 -405000 -472000 0 1863000 1416000 -94000 -92000 -291000 0 -291000 400000 300000 3600000 -3100000 0 553000 180000 1524000 1670000 3190000 888000 985000 2768000 0.0001 5000000 0 0 0 0 0 0 984000 1068000 0 23782000 37497000 5000000 42000 2000 2000 1034000 266000 4680000 200000 300000 35069000 3695000 85000 19777000 1185000 10327000 37852000 3954000 939000 21328000 1272000 10359000 2815000 4759000 P5Y P3Y P5Y P5Y 600000 0 175000 238000 3200000 7200000 1200000 7100000 9900000 2800000 22229000 29659000 28954000 12107000 16847000 29978000 29109000 10185000 18924000 -196000 29782000 1624000 1557000 1446000 800000 800000 700000 700000 700000 -315065000 -330474000 -492000 -330966000 300000 48837000 1300000 5900000 3000000 15321000 2200000 33516000 50024000 1300000 50024000 26685000 0 26685000 23339000 7691000 15648000 7691000 42333000 9000000 3600000 26685000 23339000 2600000 23339000 14839000 0 14839000 15575000 0 15575000 19610000 7691000 11919000 7691000 42333000 60594000 1300000 60594000 25590000 0 25590000 35004000 13521000 21483000 13521000 47073000 12300000 4100000 25590000 -3422000 22168000 35004000 -1609000 33395000 0 35004000 22863000 0 22863000 15370000 38000 15332000 22361000 13483000 8878000 -5031000 55563000 13521000 47073000 0 0 100000 75000 600000 0 2201000 1729000 1623000 0 5553000 2735000 0 0 0 2735000 4936000 1729000 1623000 0 8288000 P1Y P1Y P1Y P1Y P1Y P1Y P1Y P1Y P1Y 48837000 8573000 23126000 17138000 50024000 14839000 15575000 19610000 60594000 22863000 15370000 22361000 37300000 4312500 562500 9.25 25419000 29008000 7371000 0 7371000 29291000 8309000 771000 7538000 0 29291000 5673000 2528000 2043000 1102000 0 1033000 4640000 7091000 2514000 208000 2306000 1792000 1888000 1554000 1857000 1444000 5647000 7889000 2929000 338000 2591000 1511000 1770000 1975000 2633000 2055000 5834000 P4Y P3Y P4Y P6M 305000 15000 27000 30000 1254000 8000 2.82 2.74 3.65 4.12 3.73 4.73 629000 0 185000 330000 276000 1720000 143000 275000 306000 1200000 47000 86000 4.10 4.21 4.10 4.25 2.54 4.75 4.22 6.71 5.02 14.35 10.56 989000 480000 545000 831000 0 230000 617000 429000 1720000 159000 560000 240000 1582000 55000 348000 2.94 3.29 3.15 3.88 0.00 3.82 3.69 4.20 2.54 4.68 4.08 7.48 3.47 12.83 5.66 482000 435000 243000 651000 214000 302000 495000 151000 290000 2.89 3.40 3.11 3.84 3.81 3.40 4.16 4.71 4.09 0 0 0 0 0 0 0.024 0.013 0.000 0.020 0.053 0.027 0.056 0.606 0.642 0.000 0.622 0.623 0.600 0.603 84000 7897144 2876000 493000 3.83 4.60 600000 200000 7600000 601000 81000 340000 5.76 7.72 6.66 971000 856000 645000 2.32 2.51 5.34 48927000 3918000 3890000 4579000 4112000 4.49 4.40 4.40 4.81 47503000 16553000 3954000 1582000 4.69 6.24 2.60 3.10 5.56 4.16 4.57 9.56 11100 0 0 0.25 0.75 0.3333333333 0.25 0.1667 1800000 1800000 1000000 2700000 1000000 1300000 5400000 2100000 2900000 P10Y P5Y3M29D P5Y4M28D P5Y3M29D P5Y6M28D P5Y7M17D 37005000 5968000 P5Y3M P5Y7M7D P6Y2M23D P6Y1M17D P5Y5M8D 1 0.85 40343000 41255000 48365000 54065000 -397000 -397000 -301000 1458000 1258000 331000 3047000 6325000 4313000 911000 1096000 832000 398000 398000 86000 86000 772000 856000 23229000 23228000 1000 37317000 37317000 1034000 1034000 266000 266000 4680000 4680000 22879000 405000 305981000 4000 -283511000 19099000 0 311164000 4000 -292069000 24547000 -472000 340079000 5000 -315065000 56306000 0 386775000 5000 -330474000 7430000 9121000 353000 1916000 -1916000 0 0 2700000 0 0 -83000 -84000 8152000 8566000 9422000 9980000 45000 24000 529000 300000 400000 35000 31000 37000 459000 880000 1087000 400000 300000 1900000 -20400000 5200000 40629000 46228000 52205000 52205000 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Supply Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the large scale manufacturing of our products to contract manufacturers with facilities in Austria and Italy.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents and equity securities at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in days)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:8pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:5pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in days)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,341</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:9pt;">Money market funds are classified in cash and cash equivalents on our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:inherit;font-size:9pt;">Common shares of CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions are classified in equity securities on our consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:inherit;font-size:9pt;">As a result of adopting ASU 2016-01, in 2018 and thereafter gross unrealized gains and gross unrealized losses related to our investment in CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions were recognized in other expense, in the consolidated statements of operations. Prior to 2018 gross unrealized gains and gross unrealized losses related to our investment in CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions were recorded in accumulated other comprehensive loss on the balance sheet. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance - beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Write-offs and other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Allowance - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">The change in allowance for doubtful accounts was mainly related to the write-off of receivables from a foreign customer.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we began the process of liquidating our Indian subsidiary. The local legal requirements for liquidation required us to maintain our subsidiary's cash balance in an account managed by a legal trustee to satisfy our financial obligations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid investments with maturity dates of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market funds. The majority of cash and cash equivalents is maintained with major financial institutions in the United States. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Equivalents and Equity Securities</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash equivalents and equity securities at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in days)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:8pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:5pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td style="width:36%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Gains (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross Unrealized Losses (3)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Estimated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair&#160;Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Average</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Contractual</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Maturities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in days)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">563</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">n/a</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,341</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">108</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:9pt;">Money market funds are classified in cash and cash equivalents on our consolidated balance sheets.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:inherit;font-size:9pt;">Common shares of CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions are classified in equity securities on our consolidated balance sheets.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt"> </sup></font><font style="font-family:inherit;font-size:9pt;">As a result of adopting ASU 2016-01, in 2018 and thereafter gross unrealized gains and gross unrealized losses related to our investment in CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions were recognized in other expense, in the consolidated statements of operations. Prior to 2018 gross unrealized gains and gross unrealized losses related to our investment in CO</font><font style="font-family:inherit;font-size:9pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:6pt">2</sub></font><font style="font-family:inherit;font-size:9pt;"> Solutions were recorded in accumulated other comprehensive loss on the balance sheet. </font></div><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, the total cash and cash equivalents balance of </font><font style="font-family:inherit;font-size:10pt;">$53.0 million</font><font style="font-family:inherit;font-size:10pt;"> was comprised of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;"> and cash of </font><font style="font-family:inherit;font-size:10pt;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;"> held with major financial institutions worldwide. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total cash and cash equivalents balance of </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;"> was comprised of money market funds of </font><font style="font-family:inherit;font-size:10pt;">$6.8&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and cash of </font><font style="font-family:inherit;font-size:10pt;">$24.4 million</font><font style="font-family:inherit;font-size:10pt;"> held with major financial institutions worldwide.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2009, we purchased </font><font style="font-family:inherit;font-size:10pt;">10,000,000</font><font style="font-family:inherit;font-size:10pt;"> common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions, a company based in Quebec, Canada, whose shares are publicly traded in Canada on TSX Venture Exchange. Our purchase represented approximately </font><font style="font-family:inherit;font-size:10pt;">16.6%</font><font style="font-family:inherit;font-size:10pt;"> of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions&#8217; total common shares outstanding at the time of investment and was made in a private placement subject to a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;">-month statutory resale restriction. This restriction expired on April&#160;15, 2010. Our investment in CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions is recorded at its fair value. See Note 7, &#8220;Fair Value Measurements.&#8221; Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we concluded that we did not have the ability to exercise significant influence over CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions&#8217; operating and financial policies.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted ASU 2016-01. Upon adoption, we reclassified the </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> net unrealized loss from accumulated other comprehensive loss to our opening accumulated deficit.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2018, we recognized an unrealized loss of </font><font style="font-family:inherit;font-size:10pt;">$84 thousand</font><font style="font-family:inherit;font-size:10pt;"> related to our investment in CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions in other expense, in the consolidated statements of operations.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaborative Arrangements</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred revenue amounts discussed herein as of December 31, 2017 are derived from our Form&#160;10-K&#160;for the year ended December&#160;31, 2017. On January 1, 2018 we adopted Topic 606 and subsequently adjusted deferred revenue to give effect to the modified retrospective adoption of the revenue guidance. See Note 3, &#8220;Revenue Recognition&#8221; for additional information.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">GSK Platform Technology Transfer, Collaboration and License Agreement</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2014, we entered into a CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology transfer collaboration and license agreement (the "GSK CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Agreement") with GlaxoSmithKline ("GSK"). Pursuant to the terms of the agreement, we granted GSK a non-exclusive license to use the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received an upfront fee upon the execution of the agreement in July 2014 and milestone payments in each of the years from 2014 through April 2016. We completed the transfer of the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">protein engineering platform technology to GSK in April 2016 and all revenues relating to the technology transfer have been recognized as of April 2016. We have the potential to receive additional cumulative contingent payments that range from </font><font style="font-family:inherit;font-size:10pt;">$5.75 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$38.5 million</font><font style="font-family:inherit;font-size:10pt;"> per project based on GSK&#8217;s successful application of the licensed technology. We are also eligible to receive royalties based on net sales of GSK&#8217;s sales of licensed enzyme products that are currently not being recognized.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck Platform Technology Transfer and License Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2015, we entered into a CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform technology transfer collaboration and license agreement (the "Merck CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">Agreement") with Merck, Sharp &amp; Dohme ("Merck") which allows Merck to use the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">protein engineering technology platform in the field of human and animal healthcare.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received a </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> up-front license fee upon execution of the Merck CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Agreement, and milestone payments in September 2015 and in September 2016, when we completed the transfer of the engineering platform technology. We recognized research and development revenues of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, for various research projects under our collaborative arrangement.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have the potential to receive payments of up to a maximum of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> for each commercial active pharmaceutical ingredient ("API") that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform. The API payments, which are currently not recognized in revenue, are based on quantity of API developed and manufactured by Merck and will be recognized as usage-based royalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2018, we entered into an amendment to the Merck CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Agreement whereby we amended certain licensing provisions and one exhibit. In January 2019, we entered into an amendment to the Merck CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Agreement whereby we will install certain CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">protein engineering technology upgrades into Merck&#8217;s platform license installation and maintain those upgrades for a multi-year term. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Merck Sitagliptin Catalyst Supply Agreement</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2012, we entered into a </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">-year Sitagliptin Catalyst Supply Agreement (&#8220;Sitagliptin Catalyst Supply Agreement&#8221;) with Merck whereby Merck may obtain commercial scale enzyme for use in the manufacture of Januvia</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">, its product based on the active ingredient Sitagliptin. In December 2015, Merck exercised its option under the terms of the Sitagliptin Catalyst Supply Agreement to extend the agreement for an additional </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> years through February 2022. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective as of January 2016, we and Merck amended the Sitagliptin Catalyst Supply Agreement to prospectively provide for variable pricing based on the cumulative volume of sitagliptin catalyst purchased by Merck and to allow Merck to purchase a percentage of its requirements for sitagliptin catalyst from a specified third-party supplier. Merck received a distinct, functional license to manufacture a portion of its demand beginning January 1, 2018, which we recognized as research and development revenue. We recognized research and development revenues of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2017, we completed a contractual milestone by qualifying the specified third-party enzyme supplier and recognized&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#160;as research and development revenues.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have determined that the variable pricing, which provides a discount based on the cumulative volume of sitagliptin catalyst purchased by Merck, provides Merck material rights and we are recognizing product revenues using the alternative method. Under the alternative approach, we estimate the total expected consideration and allocate it proportionately with the expected sales.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Sitagliptin Catalyst Supply Agreement requires Merck to pay an annual fee for the rights to the sitagliptin technology each year for the term of the Sitagliptin Catalyst Supply Agreement. Amounts of annual license fees are based on contractually agreed prices and are on a declining scale over the term of the contract. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had a deferred revenue balance from Merck of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Pursuant to the terms of the Sitagliptin Catalyst Supply Agreement, Merck may purchase supply from us for a fee based on contractually stated prices and we recognized </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$5.9 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively, in product revenue under this agreement.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Enzyme Supply Agreement</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, we entered into a supply agreement whereby our customer may purchase quantities of one of our proprietary enzymes for use in its commercial manufacture of a product. Pursuant to the supply agreement, we received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in December 2016, which we accordingly recorded as deferred revenues.&#160;Such upfront payment will be recognized over the period of the supply agreement as the customer purchases our proprietary enzyme. We additionally have determined that the volume discounts under the supply agreement provides the customer material rights and we are recognizing revenues using the alternative method. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had deferred revenue from the supply agreement of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we entered into a multi-year research and development services agreement with Tate &amp; Lyle Ingredients Americas LLC ("Tate &amp; Lyle") to develop enzymes for use in the manufacture of Tate &amp; Lyle&#8217;s zero-calorie TASTEVA</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> M Stevia sweetener. Under the agreement, we received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, which was originally recognized ratably over the maximum term of the services period of </font><font style="font-family:inherit;font-size:10pt;">21 months</font><font style="font-family:inherit;font-size:10pt;">. Beginning January 1, 2018, we are recognizing revenue using a single measure of progress that depicts our performance in transferring the services. During the second quarter of 2018, Tate &amp; Lyle opted to obtain additional development services that we completed by June 30, 2018 and we earned milestone payments upon completion of the services. We recognized </font><font style="font-family:inherit;font-size:10pt;">$7.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, for research and development services under the research and development agreement. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had deferred revenue from the development services agreement of </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:16px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Global Development, Option and License Agreement and Strategic Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we entered into a Global Development, Option and License Agreement (the "Nestl&#233; Agreement") with Nestec Ltd. ("Nestl&#233; Health Science") and, solely for the purpose of the integration and the dispute resolution clauses of the Nestl&#233; Agreement, Nestl&#233; Health Science S.A., to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We received an upfront cash payment of </font><font style="font-family:inherit;font-size:10pt;">$14.0 million</font><font style="font-family:inherit;font-size:10pt;"> in 2017 upon the execution of the Nestl&#233; Agreement and a </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after dosing the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 for the potential treatment of PKU. The </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment that was triggered by the initiation of the trial was received in September 2018. The upfront payment and the variable consideration relating to the progress payment of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> are being recognized over time as the development work is being performed. Revenue is being recognized using a single measure of progress that depicts our performance in transferring control of the services, which is based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete all performance obligations under the agreement. We recognized development fees of </font><font style="font-family:inherit;font-size:10pt;">$9.9 million</font><font style="font-family:inherit;font-size:10pt;"> in 2018 as research and development revenue and </font><font style="font-family:inherit;font-size:10pt;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;"> in 2017. We had deferred revenue related to the development fees attributed to the milestone payment and up-front fees of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2018, Nestl&#233; Health Science became obligated to pay us an additional </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had completed its review of our investigational new drug application (&#8220;IND&#8221;) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestl&#233; Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestl&#233; Health Science is obligated to pay us </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after exercise of the option. Upon exercising its option, Nestl&#233; Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, &#8220;Subsequent Events&#8221; in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details. Other potential payments from Nestl&#233; Health Science to us under the Nestl&#233; Agreement include (i) development and approval milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$86.0 million</font><font style="font-family:inherit;font-size:10pt;">, (ii) sales-based milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, which aggregate amount is achievable if net sales exceed </font><font style="font-family:inherit;font-size:10pt;">$1.0 billion</font><font style="font-family:inherit;font-size:10pt;"> in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the Nestl&#233; Agreement, we and Nestl&#233; Health Science concurrently entered into a Strategic Collaboration Agreement (the &#8220;Strategic Collaboration Agreement&#8221;) pursuant to which we and Nestl&#233; Health Science will collaborate to leverage the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform to develop novel enzymes for Nestl&#233; Health Science&#8217;s established Consumer Care and Medical Nutrition business areas. Under the Strategic Collaboration Agreement, we received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> in 2017 and an incremental </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> payment in September 2018 for additional services. We recognized research and development fees of </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, we had deferred revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:174%;padding-top:12px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Strategic Collaboration Agreement</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we entered into the Porton Agreement with Porton to license key elements of Codexis&#8217; biocatalyst technology for use in Porton&#8217;s global custom intermediate and API development and manufacturing business. Under the Porton Agreement, we are eligible to receive annual collaboration fees and research and development revenues. We have the potential to receive performance payments based on products produced by Porton using our company technology under the license agreement. We received an initial collaboration fee of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">30 days</font><font style="font-family:inherit;font-size:10pt;"> of the effective date of the agreement. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we completed the technical transfer and we recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;"> in 2018 as research and development revenue. Revenue relating to the functional license provided to Porton was recognized at a point in time when control of the license transferred to the customer.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our headquarters are located in Redwood City, California, where we occupy approximately </font><font style="font-family:inherit;font-size:10pt;">107,200</font><font style="font-family:inherit;font-size:10pt;"> square feet of office and laboratory space in four buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease (&#8220;Lease&#8221;) with MetLife includes approximately </font><font style="font-family:inherit;font-size:10pt;">28,200</font><font style="font-family:inherit;font-size:10pt;"> square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the &#8220;Penobscot Space&#8221;), approximately </font><font style="font-family:inherit;font-size:10pt;">37,900</font><font style="font-family:inherit;font-size:10pt;"> square feet of space located at 400 Penobscot Drive, Redwood City, California (the &#8220;Building 2 Space&#8221;), approximately </font><font style="font-family:inherit;font-size:10pt;">11,200</font><font style="font-family:inherit;font-size:10pt;"> square feet of space located at 501 Chesapeake Drive, Redwood City, California (the &#8220;501 Chesapeake Space&#8221;), and approximately </font><font style="font-family:inherit;font-size:10pt;">29,900</font><font style="font-family:inherit;font-size:10pt;"> square feet of space located at 101 Saginaw Drive, Redwood City, California (the &#8220;Saginaw Space&#8221;).</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into the initial lease with MetLife for a portion of this space in 2004 and the lease has been amended multiple times since then to adjust space and amend the terms of the Lease, with the lease amendment ("Seventh Amendment") in October 2016 which, for one of our buildings, waived our existing asset retirement obligation, and extended the lease term to January 2022. The various terms for the spaces under the lease have expiration dates that range from January 2020 through January 2022. Beginning in February 2014, we have subleased certain office and laboratory space to different subtenants with separate options to extend the subleases. These subleases will expire in November 2019. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, we entered into the eighth amendment to the Lease ("Eighth Amendment") with MetLife to extend the lease terms for the Penobscot Space, the Building 2 Space and the Chesapeake Space for another </font><font style="font-family:inherit;font-size:10pt;">88 months</font><font style="font-family:inherit;font-size:10pt;">. The lease on the Saginaw Space will expire in January 2020. The lease terms for the Penobscot Space and Building 2 Space have an expiration date of May 2027. The lease term for the 501 Chesapeake Space has an expiration date of May 2029. Refer to Note 16,&#160;"Subsequent Events"&#160;for more details.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incurred </font><font style="font-family:inherit;font-size:10pt;">$3.6 million</font><font style="font-family:inherit;font-size:10pt;"> of capital improvement costs related to the facilities leased from MetLife through December 31, 2012. During 2011 and 2012, we requested and received </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;"> of reimbursements from the landlord for the tenant improvement and HVAC allowances for the completed construction. The reimbursements were recorded once cash was received and are amortized on a straight line basis over the term of the lease as a reduction in rent expense. The remaining lease incentive obligations were </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively, and are reflected as liabilities on the consolidated balance sheets. Rent expense for the Redwood City properties is recognized on a straight-line basis over the term of the lease.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, which are included in other liabilities on the consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of the 7th amended lease agreement, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, which is recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, &#8220;Commitments and Contingencies.&#8221; Pursuant to the terms of the Eighth Amendment, the amended letter of credit in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> is collateralized by deposit balances held by the bank in 2019. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Rent expense was </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> in 2018, 2017 and 2016, respectively, partially offset by sublease income of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Capital Leases</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, we entered into a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a capital lease of approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">. The lease became effective upon delivery of the equipment, which occurred in February 2017, and the term of the lease is </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> years from the effective date. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2017, we entered into a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">-year financing lease agreement with a third party supplier for the purchase of information technology equipment for approximately&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">. The effective date of the lease was May 19, 2017 and the term of the lease is&#160;</font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#160;years. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments under non-cancellable capital and operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,523</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of capital leases</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Minimum payments have not been reduced by future minimum sublease rentals of </font><font style="font-family:inherit;font-size:9pt;">$0.9 million</font><font style="font-family:inherit;font-size:9pt;"> to be received under non-cancellable subleases. </font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Commitments</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.</font></div><div style="line-height:120%;padding-bottom:21px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Commitment Agreement Type</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Agreement Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Future Minimum Payment</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacture and supply agreement with expected future payment date of December, 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreement for stability study</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreement for clinical trial</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other commitments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:174%;padding-top:16px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Credit Facility</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective June 30, 2017, we entered into a credit facility (the &#8220;Credit Facility&#8221;) consisting of term loans (&#8220;Term Debt&#8221;) totaling up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">, and advances (&#8220;Advances&#8221;) under a revolving line of credit (&#8220;Revolving Line of Credit&#8221;) totaling up to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> with an accounts receivable borrowing base of </font><font style="font-family:inherit;font-size:10pt;">80%</font><font style="font-family:inherit;font-size:10pt;"> of eligible accounts receivable. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we have not drawn from the Credit Facility. In September 2018, we entered into a Fourth Amendment to the Credit Facility whereby the draw period on the term debt was extended to September&#160;30, 2019. We may draw on the Term Debt at any time prior to September 30, 2019, subject to customary conditions for funding including, among others that no event of default exists. We may draw on the Revolving Line of Credit at any time prior to the maturity date. On October&#160;1, 2022, any loans for Term Debt mature and the Revolving Line of Credit terminates. The Term Debt bears interest through maturity at a variable rate based on the London Interbank Offered Rate plus </font><font style="font-family:inherit;font-size:10pt;">3.60%</font><font style="font-family:inherit;font-size:10pt;">. Advances under the Revolving Line of Credit bear interest at a variable annual rate equal to the greater of (i) </font><font style="font-family:inherit;font-size:10pt;">1.00%</font><font style="font-family:inherit;font-size:10pt;"> above the prime rate and (ii) </font><font style="font-family:inherit;font-size:10pt;">5.00%</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Credit Facility allows for </font><font style="font-family:inherit;font-size:10pt;">interest-only payments on the Term Debt through November&#160;1, 2020</font><font style="font-family:inherit;font-size:10pt;">. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Prepayments of Term Debt and early termination of the Revolving Line of Credit are subject to prepayment and final payment fees are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Term Debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revolving Line of Credit</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through and including the first anniversary of the funding date of the first Term Debt drawn</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the first anniversary of the funding date of the first Term Debt drawn and before the maturity date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the earliest to occur of the maturity date, the acceleration of Term Debt drawn or prepayment of Term Debt drawn</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through and including the first anniversary of the closing date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the first anniversary of the closing date through and including the second anniversary of the closing date</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the second anniversary of the closing date through and including the third anniversary of the closing date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictions which require us to comply with certain financial covenants including achieving consolidated product revenues levels at minimum levels as set forth in the Credit Facility through December 2018 and on and after January 2019, in each case unless we maintain certain minimum cash levels with the lender in an amount equal to or greater than </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> times the sum of the average six-month trailing operating cash flow net outlay plus the average monthly principal due and payable in the immediately succeeding three-month period. The Credit Facility places various restrictions on our company&#8217;s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens and selling assets and permitted assets to be held at foreign subsidiaries above specified caps, in each case subject to certain exceptions. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we were in compliance with the covenants for the Credit Facility.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As further discussed in Note 16, &#8220;Subsequent Events&#8221;, in </font><font style="font-family:inherit;font-size:10pt;">February 2019</font><font style="font-family:inherit;font-size:10pt;">, we entered into the eighth lease amendment of our business premises (the &#8220;Eighth Amendment&#8221;). Pursuant to the terms of the Eighth Amendment, we exercised an option to deliver a </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> letter of credit to the lessor in lieu of a security deposit. In January 2019, we entered into the Fifth Amendment to the Credit Facility, which amended certain restrictive covenants with respect to letters of credit made in connection with the leasing of real property.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are not currently a party to any material pending litigation or other material legal proceedings.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2018, we and EnzymeWorks, Inc. (U.S.), Suzhou Hanmei Biotechnology Co. Ltd, d/b/a EnzymeWorks, Inc. (China) (collectively, "EnzymeWorks"), Junhua Tao, and Andrew Tao reached a settlement concerning the lawsuit filed by us in February 2016 against EnzymeWorks, Junhua Tao, and Andrew Tao in the United States District Court for the Northern District of California. The parties have entered into a settlement agreement, the terms of which are confidential. The parties have also stipulated to a judgment of patent infringement of all asserted patents against EnzymeWorks, and a permanent injunction barring any future infringement. The remaining claims against EnzymeWorks, and all claims against Junhua Tao, and Andrew Tao including trade secret misappropriation, breach of contract and voidable transfer have been dismissed with prejudice. EnzymeWorks appealed the sanctions levied against them by Judge Orrick to the Federal Circuit and filed its opening brief on May 30, 2018. On July 9, 2018, Codexis filed its response brief, and EnzymeWorks filed its reply on July 30, 2018. On February 8, 2019, the Federal Circuit panel of judges assigned to the case issued an opinion affirming the lower court&#8217;s ruling and remanding the case to the lower court on jurisdictional grounds to vacate the order to which the parties had earlier stipulated.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnifications</font></div><div style="line-height:120%;padding-bottom:20px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> accruals for expenses related to indemnification issues for any periods presented.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive income or loss</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss is equivalent to net loss in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> because after adopting Accounting Standards Update&#160;No.&#160;2016-01,&#160;&quot;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">." (&#8220;Subtopic 825-10&#8221;), we do not have any other transactions recorded under comprehensive loss. Prior to our adoption of Subtopic 825-10, and for the year ended in </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, comprehensive loss included unrealized gains and unrealized losses from our equity investment in equity securities. See &#8220;Recently adopted accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</font><font style="font-family:inherit;font-size:10pt;"> below for additional information.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> presentation. These changes and reclassifications did not impact net loss or comprehensive loss.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, contract assets, equity securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India, and the Netherlands. Such deposits in those countries may be in excess of insured limits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the contract assets, unbilled receivable, contract costs, and contract liabilities (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2018 balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Liabilities: Deferred Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized the following revenues (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period for:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Performance obligations satisfied</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the period:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations satisfied from new activities in the period - contract revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the reconciliation of contract liabilities from what was disclosed in the Form&#160;10-K&#160;for the year ended December&#160;31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January&#160;1, 2018 (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Revenue, balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in estimated consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unsatisfied performance obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Revenue, balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment information for fiscal year 2018 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Major products and service:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,483</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Primary geographical markets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,878</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment information for fiscal year 2017 is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Major products and service:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Primary geographical markets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2010, our board of directors (the "Board") and stockholders approved the 2010 Equity Incentive Award Plan (the "2010 Plan"), which became effective upon the completion of our initial public offering in April 2010. The number of shares of our common stock available for issuance under the 2010 Plan is equal to </font><font style="font-family:inherit;font-size:10pt;">1,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares plus any shares of common stock reserved for future grant or issuance under our 2002 Stock Plan (the &#8220;2002 Plan&#8221;) that remained unissued at the time of completion of the initial public offering. The 2010 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. All grants will reduce the 2010 Plan reserve by </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> share for every share granted. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, total shares remaining available for issuance under the 2010 Plan were approximately </font><font style="font-family:inherit;font-size:10pt;">7.9 million</font><font style="font-family:inherit;font-size:10pt;"> shares.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2010 Plan provides for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The option exercise price for incentive stock options must be at least </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least </font><font style="font-family:inherit;font-size:10pt;">110%</font><font style="font-family:inherit;font-size:10pt;"> of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of </font><font style="font-family:inherit;font-size:10pt;">10 years</font><font style="font-family:inherit;font-size:10pt;"> and vest over </font><font style="font-family:inherit;font-size:10pt;">4 years</font><font style="font-family:inherit;font-size:10pt;"> from the date of grant, of which </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> vest at the end of one year, and </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also grant employees RSUs, which generally vest over either a </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> year period with one-third of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a </font><font style="font-family:inherit;font-size:10pt;">four</font><font style="font-family:inherit;font-size:10pt;"> year period with </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee&#8217;s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance-contingent Restricted Stock Units (PSUs) and Performance Based Options (PBOs)</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The compensation committee of the Board approved, solely in respect of non-executive employees, delegated to our Chief Executive Officer the authority to approve grants of PSUs. The compensation committee of the Board also approved grants of PBOs and PSUs to our executives. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> equal installments with </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> vesting upon achievement and the remaining </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> vesting on the first anniversary of achievement, in each case, subject to the recipient&#8217;s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares being eligible to vest in respect of the PSUs and PBOs. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we awarded PSUs ("2018 PSUs") and PBOs ("2018 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including core business revenue growth, cash balance, new licensing collaborations, new research and development service revenue arrangements, technology advancement and novel therapeutic enzymes advancement. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we estimated that the 2018 PSUs and 2018 PBOs performance goals would be achieved at </font><font style="font-family:inherit;font-size:10pt;">118%</font><font style="font-family:inherit;font-size:10pt;"> of the target level, and recognized expenses accordingly. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, we awarded PSUs ("2017 PSUs") and PBOs ("2017 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including revenue growth, fundraising, service revenue, new platform license revenue, and strategic advancement of biotherapeutics pipeline. In the first quarter of 2018, we determined that the 2017 PSU and PBO performance goals had been achieved at </font><font style="font-family:inherit;font-size:10pt;">134.2%</font><font style="font-family:inherit;font-size:10pt;"> of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2017 PSUs and PBOs vested in the first quarter of 2018 and one-half of the shares underlying the 2017 PSUs and PBOs will vest in the first quarter of 2019, in each case subject to the recipient&#8217;s continued service on each vesting date.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we awarded PSUs ("2016 PSUs") based upon the achievement of various weighted performance goals, including revenue growth, non-GAAP net income growth, new licensing collaborations, new research and development service revenue arrangements and novel therapeutic enzymes advancement. In the first quarter of 2017, we determined that the 2016 PSU performance goals had been achieved at </font><font style="font-family:inherit;font-size:10pt;">142.3%</font><font style="font-family:inherit;font-size:10pt;"> of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2016 PSUs vested in the first quarter of each of 2017 and 2018, in each case subject to the recipient&#8217;s continued service on each vesting date. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> PBOs were awarded in 2016.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation Expense:</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is included in the consolidated statements of operations as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,647</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents total stock-based compensation expense by security type included in the consolidated statements of operations (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs and RSAs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PSUs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PBOs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Grant Award Activities:</font></div><div style="line-height:120%;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Awards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated the fair value of stock options using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2017, we granted an option to purchase </font><font style="font-family:inherit;font-size:10pt;">11,100</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock to a non-employee as compensation for services valued at </font><font style="font-family:inherit;font-size:10pt;">$48 thousand</font><font style="font-family:inherit;font-size:10pt;"> with the following assumptions used to estimate the fair value of non-employee stock options: (i) volatility rate at </font><font style="font-family:inherit;font-size:10pt;">60.6%</font><font style="font-family:inherit;font-size:10pt;">, risk-free interest rate of </font><font style="font-family:inherit;font-size:10pt;">2.4%</font><font style="font-family:inherit;font-size:10pt;"> and (ii) no expected dividend yield. The option vested over a period of </font><font style="font-family:inherit;font-size:10pt;">six months</font><font style="font-family:inherit;font-size:10pt;"> with one-sixth of total number of shares subject to the option vesting on each one month anniversary of the grant date. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and December 31, 2016, we did not grant any options to purchase shares of common stock to non-employees.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarizes stock option activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(340</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Remaining<br clear="none"/>Contractual Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share of stock options granted in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$5.34</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.51</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.32</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total intrinsic value of options exercised in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$7.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.2&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6&#160;million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation cost related to non-vested options, which we expect to recognize over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">2.5 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Awards (RSAs)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes RSA activities:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share of RSAs granted in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$14.35</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.75</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.21</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of RSAs vested in fiscal </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation cost related to non-vested RSAs, which we expect to recognize over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">0.4 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Stock Units (RSUs)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes RSU activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share of RSUs granted in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$10.56</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.22</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.10</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of RSUs vested in fiscal </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> respectively.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation cost related to non-vested RSUs, which we expect to recognize over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">1.1 years</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance-Contingent Restricted Stock Units (PSUs)</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes PSU activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted average grant date fair value per share of PSUs granted in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$6.71</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$4.25</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$4.10</font><font style="font-family:inherit;font-size:10pt;">, respectively. The total fair value of PSUs vested in fiscal </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were </font><font style="font-family:inherit;font-size:10pt;">$5.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation cost related to non-vested PSUs, which we expect to recognize over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">0.5</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance Based Options (PBOs) </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimated the fair value of PBO using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes PBO activities in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Remaining<br clear="none"/>Contractual Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of exercised PBOs was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for 2018, </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for 2017 and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> for 2016. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, there was </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized stock-based compensation cost related to non-vested PBOs, which we expect to recognize over a weighted average period of </font><font style="font-family:inherit;font-size:10pt;">0.9 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities. For all periods presented, diluted and basic net losses per share are identical since potential common shares are excluded from the calculation, as their effect was anti-dilutive.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-Dilutive Securities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In periods of net loss, the weighted average number of shares outstanding related to potentially dilutive securities, prior to the application of the treasury stock method, are excluded from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following shares were not included in the computation of diluted net loss per share (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable under Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable upon the conversion of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total anti-dilutive securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the financial instruments that were measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> by level within the fair value hierarchy (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the financial instruments that were measured at fair value on a recurring basis at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> by level within the fair value hierarchy (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,225</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">588</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,813</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level&#160;3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;text-indent:30px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;">&#160;Solutions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,449</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We determine the fair value of Level 1 and Level 2 assets using quoted prices in active markets for identical assets.&#160;We estimated the fair value of our investment in </font><font style="font-family:inherit;font-size:10pt;">10,000,000</font><font style="font-family:inherit;font-size:10pt;"> common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions using the market value of common shares as determined by trading on the TSX Venture Exchange, and we classified our investment in CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2&#160;</sub></font><font style="font-family:inherit;font-size:10pt;">Solutions within the fair value hierarchy as Level 1 and Level 2, at December 31, 2018 and December 31, 2017, respectively, using the quoted prices in an active market to determine their fair value.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A review of the fair value hierarchy classifications of our investments is conducted annually. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets. Reclassifications are reported as transfers in or transfers out of the applicable level at end of the calendar year in which the reclassifications occur. In the fourth quarter of 2018, we reclassified the </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> fair value of the investment in the common shares of CO</font><font style="font-family:inherit;font-size:10pt;"><sub style="vertical-align:bottom;line-height:120%;font-size:7pt">2</sub></font><font style="font-family:inherit;font-size:10pt;"> Solutions from Level 2 to Level 1 within the fair value hierarchy since we concluded that there was a sufficient level of transactional frequency and trading volume to indicate that the pricing information was representative of its fair value on an ongoing basis. (See also Note 6, &#8220;Cash Equivalents and Equity Securities&#8221; for additional information.)</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and we consider counterparty credit risk in our assessment of fair value. Carrying amounts of financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values as of the balance sheet dates because of their short maturities.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Inputs that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;">Note 7, &#8220;Fair Value Measurements&#8221;</font><font style="font-family:inherit;font-size:10pt;"> for additional details.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States dollar is the functional currency for our operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in United States dollars at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-U.S. dollar transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#8217;s functional currency are included in other expense in the accompanying consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level.&#160;Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units.&#160;Using the relative fair value allocation methodology, we have determined that approximately </font><font style="font-family:inherit;font-size:10pt;">76%</font><font style="font-family:inherit;font-size:10pt;"> of goodwill is allocated to the Performance Enzymes segment and </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;"> is allocated to the Novel Biotherapeutics segment.&#160;As a result of the calculation, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the goodwill was assigned to the Performance Enzymes segment and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> was assigned to the Novel Biotherapeutics segment.&#160;There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology, we compared the allocated carrying amount of each reporting unit&#8217;s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit&#8217;s goodwill with the carrying amount of that goodwill. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit&#8217;s carrying amount goodwill over the respective implied fair value is recognized as an impairment. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we did </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> record impairment charges related to goodwill.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our tangible long-lived assets consist primarily of property and equipment. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we determined that we operate in two segments. We have not identified property and equipment by segment since these assets are shared or commingled. We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of unexpected undiscounted cash flows. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our loss before provision for income taxes was as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The tax provision (benefit from) for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> consists primarily of taxes attributable to foreign operations. The components of the provision for income taxes are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current provision (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred provision (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reconciliation of the provision for income taxes calculated at the statutory rate to our provision for (benefit from) income taxes is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax benefit at federal statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations taxed at different rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other nondeductible items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Executive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in statutory tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income taxes reflect the net tax effects of (a)&#160;temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b)&#160;operating losses and tax credit carryforwards.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of our deferred tax assets and liabilities are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain/loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,010</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC Topic 740 requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a valuation allowance against our deferred tax assets. Accordingly, the net deferred tax assets in all our jurisdictions have been fully reserved by a valuation allowance. The change in valuation allowance differs from the amount included the rate reconciliation table due to the deferred tax impact of the adoption of ASC 606, which resulted in a </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> adjustment to opening accumulated deficit before the offsetting change in valuation allowance. The net valuation allowance increased by </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">; and decreased by </font><font style="font-family:inherit;font-size:10pt;">$20.4 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">; and increased by </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. At such time as it is determined that it is more likely than not that the deferred tax assets are realizable, the valuation allowance will be reduced.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our federal, state and foreign NOL carryforwards and federal research and development tax credits as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">254,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022-2038</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, state</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018-2038</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits, federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022-2038</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits, state</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Do not expire</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current U.S. federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax credit carryforwards may be limited as a result of such ownership changes. We performed an analysis in 2018 and determined that there was not a limitation that would result in the expiration of carryforwards before they are utilized.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income. An exception is provided in ASC Topic 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year. In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets. In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale securities recorded as a component of other comprehensive income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets. For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we did not record a tax expense in other comprehensive income related to available-for-sale securities.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2014, we determined that the undistributed earnings of our India subsidiary will be repatriated to the United States, and accordingly, we have provided a deferred tax liability totaling </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, for local taxes that would be incurred upon repatriation. We have not provided for U.S. federal and state income taxes on all of the remaining non-U.S. subsidiaries&#8217; undistributed earnings as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> as the remaining foreign jurisdictions are in an accumulative loss position. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We apply the provisions of ASC Topic 740 to account for uncertainty in income taxes. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rollforward Table (at Gross): As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions based on tax positions related to current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Reductions to tax provision of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(529</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,980</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize interest and penalties as a component of our income tax expense. Total interest and penalties recognized in the consolidated statement of operations was </font><font style="font-family:inherit;font-size:10pt;">$37 thousand</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$31 thousand</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$35 thousand</font><font style="font-family:inherit;font-size:10pt;">, respectively, in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. Total penalties and interest recognized in the balance sheet was </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">. The total unrecognized tax benefits that, if recognized currently, would impact our company&#8217;s effective tax rate were </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. We do not expect any material changes to our uncertain tax positions within the next 12 months. We are not subject to examination by United States federal or state tax authorities for years prior to 2002 and foreign tax authorities for years prior to 2012.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. The Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (GILTI) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer&#8217;s compensation limitation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the SEC issued Staff Accounting Bulletin No. 118 ("SAB 118"), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now completed include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. On December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as&#160;we believe that it is more likely than not that the majority of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for uncertainty in income taxes as required by the provisions of ASU 2009-06, Income Taxes (Topic 740) </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities&#8221;</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (&#8220;NOL&#8221;) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section&#160;382.&#160;In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption of ASC 606 primarily resulted in less revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Securities</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest in equity securities that are carried at estimated fair value with changes in fair value recognized within earnings. Equity securities with remaining maturities of greater than one year or which we currently do not intend to sell are classified as long-term. See Note 6, &#8220;Cash Equivalents and Equity Securities.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized holding gains and losses (the adjustment to fair value) and realized gains and losses are included in other income (expense) in the consolidated statement of operations subsequent to the adoption of ASU 2016-01 starting on January 1, 2018.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the consolidated financial statements, the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8217;&#8221; and &#8220;our&#8221; refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which have been continuously improved over our fifteen year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a pioneer in the harnessing of computational technologies to drive biology advancements. Over the last fifteen years, we have made substantial investments in the development of our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants&#8217; performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The successful embodiment of our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We initially commercialized our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also begun using the CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement with Nestec, Ltd. (&#8220;Nestl&#233; Health Science&#8221;) to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestl&#233; Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we entered into a strategic agreement (the "Porton Agreement") with Porton Pharma Solutions, Ltd. ("Porton") to license key elements of our platform technology to Porton&#8217;s global custom intermediate and active pharmaceutical ingredients ("API") development and manufacturing business. This gives us access to a wide variety of small and medium-sized pharmaceutical customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> molecular diagnostic and genomic research applications. Our first enzyme is a ligase</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">which we began marketing to customers in 2018.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Below are brief descriptions of our business segments:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Performance Enzymes</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We initially commercialized our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> molecular diagnostic and molecular biology research applications. In April 2018, we entered into the Porton Agreement related to our strategic collaboration with Porton to license key elements of our world-leading biocatalyst technology for use in Porton&#8217;s global custom intermediate and API development and manufacturing business. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Novel Biotherapeutics</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer&#8217;s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of hyperphenylalaninemia (&#8220;HPA&#8221;) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestl&#233; Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestl&#233; Health Science became obligated to pay us an additional </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had completed its review of our investigational new drug application (&#8220;IND&#8221;) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestl&#233; Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestl&#233; Health Science is obligated to pay us </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after exercise of the option. Upon exercising its option, Nestl&#233; Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, &#8220;Subsequent Events&#8221; for additional details. Other potential payments from Nestl&#233; Health Science to us under the Nestl&#233; Agreement include (i) development and approval milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$86.0 million</font><font style="font-family:inherit;font-size:10pt;">, (ii) sales-based milestones of up to </font><font style="font-family:inherit;font-size:10pt;">$250.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, which aggregate amount is achievable if net sales exceed </font><font style="font-family:inherit;font-size:10pt;">$1.0 billion</font><font style="font-family:inherit;font-size:10pt;"> in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For additional discussion of our business segments, see Note 15, "Segment, Geographical and Other Revenue Information."</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently adopted accounting pronouncement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)" , </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 606&#8221;), amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for public companies effective for annual and interim reporting periods beginning after December 15, 2016. We have adopted the provisions of ASC 606 and the related amendments, effective January 1, 2018, using the modified retrospective transition method. We recognized the cumulative effect of applying the new revenue standard and recognized a </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> increase to the opening balance of the accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented.&#160;See Note 3, "Revenue Recognition" for more details. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU&#160;No.&#160;2016-01,&#160;&quot;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;Subtopic 825-10&#8221;). This guidance principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of this new guidance, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an&#160;available-for-sale&#160;classification and therefore no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. This new guidance primarily impacts our accounting for equity investments. In February 2018, the FASB issued ASU 2018-03, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, that clarifies the guidance in ASU No. 2016-01, Financial Instruments&#8212;Overall (Subtopic 825-10)</font><font style="font-family:inherit;font-size:10pt;">." Prior to the adoption of ASC 825, we recognized unrealized holding gains and losses from our equity investment in CO2 Solutions in other comprehensive loss. We adopted ASC 825 in the first quarter of 2018 using a modified retrospective approach by means of a cumulative-effect adjustment to accumulated deficit. Upon adoption of ASC 825, we reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> of unrealized loss (net of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> tax) from other accumulated comprehensive loss to beginning accumulated deficit. Any changes in the fair value of our equity investments, except those accounted for under the equity method, will be recognized in earnings on a prospective basis.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;ASC 230&#8221;), which provides the FASB's guidance on certain cash flow statements items.&#160;ASC 230 is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. We adopted ASC 230 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) Restricted Cash a consensus of the FASB Emerging Issues Task Force&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 230&#8221;). The standard requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows. We adopted ASU 2016-18 in the first quarter of 2018 and the adoption had no material impact on our annual consolidated financial statements. The effect of the adoption of ASC 230 on our consolidated statements of cash flows was to include restricted cash balances in the beginning and end of period balances of cash and cash equivalents and restricted cash. The change in restricted cash was previously disclosed in operating and investing activities in the consolidated statements of cash flows. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 805&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The guidance requires the use of a framework to determine whether a set of assets and activities constitutes an acquired or a sold business. The guidance is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. The amendments should be applied prospectively as of the beginning of the period of adoption. We adopted ASC 805 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 718&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. The new standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. We adopted ASC 718 in the first quarter of 2018 and the adoption had no impact on our annual consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU 2018-05, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;ASC 740&#8221;) which amends&#160;Topic 740&#160;by&#160;incorporating the SEC Staff Accounting Bulletin No. 118 (SAB 118) issued on December 22, 2017. SAB 118 provides guidance on accounting for the effects of the Tax Cuts and Jobs Act (Tax Reform) and allows a company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. See Income Taxes section above for additional information.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently issued accounting pronouncements not yet adopted</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)"</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 842&#8221;), which replaces prior lease guidance (&#8220;ASC 840&#8221;). This guidance establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statement of Operations. The guidance also eliminates today&#8217;s real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Entities have the option to use certain practical expedients. Full retrospective application is prohibited. ASC 842 is effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#160;Early adoption is permitted. In July 2018, the FASB issued ASU 2018-10, "</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Codification Improvements to ASC 842, Leases</font><font style="font-family:inherit;font-size:10pt;">." These amendments affect narrow aspects of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under ASC 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under ASC 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. For entities that have not adopted ASC 842, the effective date and transition requirements will be the same as the effective date and transition requirements in ASC 842. The FASB also issued ASU 2018-11,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> "Leases (Topic 842): Targeted Improvements."</font><font style="font-family:inherit;font-size:10pt;"> These amendments provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). The amendments also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under ASC 606 and certain criteria are met. If the nonlease component or components associated with the lease component are the predominant component of the combined component, an entity is required to account for the combined component in accordance with ASC 606. Otherwise, the entity must account for the combined component as an operating lease in accordance with ASC 842. For entities that have not adopted ASC 842 before the issuance of ASU No. 2018-11, the effective date and transition requirements for the amendments related to separating components of a contract are the same as the effective date and transition requirements in ASU No. 2016-02. We plan to adopt ASC 842 on January 1, 2019 using a modified retrospective approach and effective date method per adoption of ASU 2018-11. We will recognize and measure all leases within the scope of the standard that exist as of January 1, 2017, beginning of the earliest period, as if the standard had always been applied, subject to the practical expedients and transition relief in &#8220;Practical Expedients&#8221; section. In the current period, we evaluated the practical expedients elections and on adoption, and may apply a practical expedient in which an entity need not reassess whether any expired or existing contracts are or contain leases; An entity need not reassess the lease classification for any expired or existing leases (for example, all existing leases that were classified as operating leases in accordance with ASC 840 will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 will be classified as finance leases); An entity need not reassess initial direct costs for any existing leases. We started the transition plan in the third quarter of 2018 and continued to perform the scoping work in the fourth quarter of 2018. We identified a total of 13 lease agreements that are subject to ASC 842 and seven of them meet the short-term lease exception. We completed the full analysis by January, 2019 and we evaluated the right-of-use (ROU) assets and lease liability using the incremental borrowing rate (IBR) at December 31, 2018 because the implicit rate is not readily determinable in the lease agreement. Upon adoption of ASC 842, all existing leases will be classified as either operating lease or finance lease. We expect to record a range from </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> of ROU assets and liabilities for operating leases and a range from </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of ROU assets and liabilities for finance leases in the balance sheet during the first quarter of 2019. This analysis was inclusive of the eighth amendment to the lease agreement disclosed in Note 16, &#8220;Subsequent Events.&#8221;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style="font-family:inherit;font-size:10pt;">" which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model (known as the "current expected credit loss model") that is based on expected losses rather than incurred losses. ASU 2016-13 is effective for annual reporting periods ending after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment."</font><font style="font-family:inherit;font-size:10pt;"> The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;February&#160;2018,&#160;the&#160;FASB&#160;issued&#160;ASU&#160;No.&#160;2018-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&#8221;</font><font style="font-family:inherit;font-size:10pt;">. This standard allows a&#160;reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects and will be effective for us beginning January 1, 2019 and should be applied either in the period of adoption or retrospectively. Early adoption is permitted. We do not expect this standard to have any&#160;impact&#160;on&#160;our&#160;consolidated&#160;financial&#160;statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;">" which expands the scope of Topic 718, Compensation&#8212;Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Equity&#8212;Equity-Based Payments to Non-Employees</font><font style="font-family:inherit;font-size:10pt;">. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU 2018-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> "Codification Improvements&#8221;, </font><font style="font-family:inherit;font-size:10pt;">which represent changes to clarify, correct errors in, or make minor improvements to the Codification, eliminating inconsistencies and providing clarifications in current guidance. The amendments in this ASU include those made to: Subtopic 220-10, I</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ncome Statement-Reporting Comprehensive Income-Overall</font><font style="font-family:inherit;font-size:10pt;">; Subtopic 470-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-Modifications and Extinguishments;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 480-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity-Overall;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 718-740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation-Income Taxes; </font><font style="font-family:inherit;font-size:10pt;">Subtopic 805-740, B</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">usiness Combinations-Income Taxes</font><font style="font-family:inherit;font-size:10pt;">; Subtopic 815-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging-Overall; </font><font style="font-family:inherit;font-size:10pt;">Subtopic 820-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement-Overall;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 940-405,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Services-Brokers and Dealers-Liabilities</font><font style="font-family:inherit;font-size:10pt;">; and Subtopic 962-325, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plan Accounting-Defined Contribution Pension Plans-Investments-Other.</font><font style="font-family:inherit;font-size:10pt;"> The transition and effective date guidance is based on the facts and circumstances of each amendment. Some of the amendments do not require transition guidance and will be effective upon issuance. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. We do not expect this standard to have any material impact on our consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement."</font><font style="font-family:inherit;font-size:10pt;"> The primary focus of&#160;ASU&#160;2018-13&#160;is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. In general, the amendments in&#160;this standard&#160;are effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December&#160;15, 2019. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, "Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.</font><font style="font-family:inherit;font-size:10pt;">" ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. In general, for public companies, the amendments in this standard are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses."</font><font style="font-family:inherit;font-size:10pt;"> ASU 2018-19 clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. In general, the amendments in&#160;this standard&#160;are effective for public business entities that meet the definition of a SEC filer for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We do not expect this standard to have any material impact on our consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation and Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;) and the applicable rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive income or loss</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss is equivalent to net loss in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> because after adopting Accounting Standards Update&#160;No.&#160;2016-01,&#160;&quot;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">." (&#8220;Subtopic 825-10&#8221;), we do not have any other transactions recorded under comprehensive loss. Prior to our adoption of Subtopic 825-10, and for the year ended in </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, comprehensive loss included unrealized gains and unrealized losses from our equity investment in equity securities. See &#8220;Recently adopted accounting pronouncements</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;</font><font style="font-family:inherit;font-size:10pt;"> below for additional information.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior year amounts have been reclassified to conform to </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> presentation. These changes and reclassifications did not impact net loss or comprehensive loss.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of equity securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We report </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for our company. We do not allocate or evaluate assets by segment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously, we had only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Translation</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States dollar is the functional currency for our operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in United States dollars at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-U.S. dollar transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity&#8217;s functional currency are included in other expense in the accompanying consolidated statements of operations.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Policy from January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">and the related amendments (&#8220;ASC 606&#8221;). The guidance provides a unified model to determine how revenue is recognized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition. </font></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of principal activities from which we generate revenue:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Revenue</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer&#8217;s use. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide under the contract. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to manufacture a product. If we determine that the customer cannot benefit from the license without our manufacturing capability, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct and has significant standalone functionality, we would recognize revenues from a functional license at a point in time when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time as our customer learns to use our technology.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We recognize revenues for the functional license at a point in time when the control of the license and technology transfers to the customer.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For agreements that include sales or usage-based royalty payments to us, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. The contract assets are reclassified to receivables when the rights become unconditional. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Liabilities</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities are recorded as deferred revenues and include payments received in advance of performance under the contract. Contract liabilities are realized when the development services are provided to the customer or control of the products has been transferred to the customer. A portion of our contract liabilities relate to supply arrangements that contain material rights that are recognized using the alternative method, under which the aggregate amount invoiced to the customer for shipped products, including annual fees, is higher than the amount of revenue recognized based on the transaction price allocated to the shipped products.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Costs</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 requires the recognition of an asset for the incremental costs of obtaining a contract with a customer if the entity expects to recover such costs. Incremental costs are costs that would not have been incurred if the contract had not been obtained. Examples of contract costs are commissions paid to sales personnel. We do not typically incur significant incremental costs because the compensation of our salespeople are not based on contracts closed but on a mixture of company goals, individual goals, and sales goals. If a commission paid is directly related to obtaining a specific contract, our policy is to capitalize and amortize such costs on a systematic basis, consistent with the pattern of transfer of the good or service to which the asset relates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract costs are reported in other non-current assets.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition Policy before January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-25, &#8220;Multiple Element Arrangements.&#8221; For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (&#8220;FTE&#8221;) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee&#8217;s product sales or cost savings achieved by our customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer&#8217;s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from royalties based on licensees&#8217; sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Revenue</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue comprises both internal and third party fixed and variable costs including materials and supplies, labor, facilities, and other overhead costs associated with our product sales. Shipping costs are included in our cost of product revenue. Such charges were not significant in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fulfillment costs, such as shipping and handling, are recognized at a point in time and are included in cost of product sales.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Research and Development Services</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of research and development services related to FTE services under research and development agreements approximate the research funding over the term of the respective agreements and is included in research and development expense. Costs of services provided under license and platform technology transfer agreements are included in research and development expenses and are expensed in the periods in which such costs are incurred.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs incurred for internal projects and partner-funded collaborative research and development activities, as well as license and platform technology transfer agreements, as mentioned above. These costs include our direct and research-related overhead expenses, which include salaries and other personnel-related expenses (including stock-based compensation), occupancy-related costs, supplies, and depreciation of facilities and laboratory equipment, as well as external costs, and are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no alternative future use are expensed when incurred.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Advertising</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of operations. Advertising costs were </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consider all highly liquid investments with maturity dates of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market funds. The majority of cash and cash equivalents is maintained with major financial institutions in the United States. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. Cash and cash equivalents totaled </font><font style="font-family:inherit;font-size:10pt;">$53.0 million</font><font style="font-family:inherit;font-size:10pt;"> and comprised of cash of </font><font style="font-family:inherit;font-size:10pt;">$21.8 million</font><font style="font-family:inherit;font-size:10pt;"> and money market funds of </font><font style="font-family:inherit;font-size:10pt;">$31.2&#160;million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. Cash and cash equivalents totaled </font><font style="font-family:inherit;font-size:10pt;">$31.2 million</font><font style="font-family:inherit;font-size:10pt;">, comprised of cash of </font><font style="font-family:inherit;font-size:10pt;">$24.4&#160;million</font><font style="font-family:inherit;font-size:10pt;"> and money market funds of </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restricted Cash</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2016, we began the process of liquidating our Indian subsidiary. The local legal requirements for liquidation required us to maintain our subsidiary's cash balance in an account managed by a legal trustee to satisfy our financial obligations. This balance is recorded as non-current restricted cash on the consolidated balance sheets and totaled&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;at&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the terms of a lease agreement for our Redwood City, CA facilities, we obtained a letter of credit collateralized by cash deposit balances of&#160;</font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#160;as of&#160;</font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. These cash deposit balances are recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, &#8220;Commitments and Contingencies&#8221;. In January 2019, we entered into the Eighth Amendment to the Lease for our Redwood City, CA facilities and, as a result, our letters of credit will be collateralized by a cash deposit balance of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2019. See Note 16, &#8220;Subsequent Events&#8221; for additional information.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Securities</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We invest in equity securities that are carried at estimated fair value with changes in fair value recognized within earnings. Equity securities with remaining maturities of greater than one year or which we currently do not intend to sell are classified as long-term. See Note 6, &#8220;Cash Equivalents and Equity Securities.&#8221;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized holding gains and losses (the adjustment to fair value) and realized gains and losses are included in other income (expense) in the consolidated statement of operations subsequent to the adoption of ASU 2016-01 starting on January 1, 2018.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and we consider counterparty credit risk in our assessment of fair value. Carrying amounts of financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values as of the balance sheet dates because of their short maturities.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity&#8217;s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Inputs that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument&#8217;s anticipated life. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See </font><font style="font-family:inherit;font-size:10pt;">Note 7, &#8220;Fair Value Measurements&#8221;</font><font style="font-family:inherit;font-size:10pt;"> for additional details.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, contract assets, equity securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India, and the Netherlands. Such deposits in those countries may be in excess of insured limits.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently sell primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable includes amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance for doubtful accounts. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowances for doubtful accounts reflect our best estimates of probable losses inherent in the accounts receivable and contract assets&#8217; balances. We determine the allowances based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivables and contract assets are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.</font></div><div style="line-height:120%;padding-top:18px;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unbilled receivable</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to ASC 606, the timing of revenue recognition may differ from the timing of invoicing to our customers. When we satisfy (or partially satisfy) a performance obligation, prior to being able to invoice the customer, we recognize an unbilled receivable&#160;when the right to consideration is unconditional. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we recorded a total of unbilled receivables of </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> included on our consolidated balance sheets. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Supply Risk</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the large scale manufacturing of our products to contract manufacturers with facilities in Austria and Italy.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Estimated useful life</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lesser of useful life or lease term</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment classified as construction in process includes equipment that has been received but not yet placed in service. Normal repairs and maintenance costs are expensed as incurred.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our tangible long-lived assets consist primarily of property and equipment. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the first quarter of 2018, we determined that we operate in two segments. We have not identified property and equipment by segment since these assets are shared or commingled. We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of unexpected undiscounted cash flows. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, there were no events or changes in circumstances which indicated that the carrying amount of our Asset Group might not be recoverable. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> impairment charges for long-lived assets were recorded during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level.&#160;Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units.&#160;Using the relative fair value allocation methodology, we have determined that approximately </font><font style="font-family:inherit;font-size:10pt;">76%</font><font style="font-family:inherit;font-size:10pt;"> of goodwill is allocated to the Performance Enzymes segment and </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;"> is allocated to the Novel Biotherapeutics segment.&#160;As a result of the calculation, </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the goodwill was assigned to the Performance Enzymes segment and </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> was assigned to the Novel Biotherapeutics segment.&#160;There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology, we compared the allocated carrying amount of each reporting unit&#8217;s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit&#8217;s goodwill with the carrying amount of that goodwill. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit&#8217;s carrying amount goodwill over the respective implied fair value is recognized as an impairment. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, we did </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> record impairment charges related to goodwill.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as&#160;we believe that it is more likely than not that the majority of deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for uncertainty in income taxes as required by the provisions of ASU 2009-06, Income Taxes (Topic 740) </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8221;Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities&#8221;</font><font style="font-family:inherit;font-size:10pt;">, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (&#8220;NOL&#8221;) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section&#160;382.&#160;In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The adoption of ASC 606 primarily resulted in less revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$37 thousand</font><font style="font-family:inherit;font-size:10pt;">, income tax provision of </font><font style="font-family:inherit;font-size:10pt;">$81 thousand</font><font style="font-family:inherit;font-size:10pt;"> and income tax benefit of </font><font style="font-family:inherit;font-size:10pt;">$40 thousand</font><font style="font-family:inherit;font-size:10pt;"> for the years ended December 31, </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. The income tax benefits were due to a net loss from our foreign operation and a reduction in the deferred tax liability for accrued future withholding taxes on dividends. We continue to maintain a full valuation allowance against our net deferred tax assets as we believe that it is more likely than not that the majority of our deferred tax assets will not be realized.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes to Tax Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the &#8220;Tax Act&#8221;) was signed into law making significant changes to the Internal Revenue Code. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (&#8220;AMT&#8221;) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (&#8220;BEAT&#8221;), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (&#8220;GILTI&#8221;) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer&#8217;s compensation limitation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now complete include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because ASC 740-10-25-47 requires the effect of a change in tax laws or rates to be recognized as of the date of enactment, we remeasured our deferred tax assets and liabilities, and offsetting valuation allowance in 2017. There was no impact to tax expense as the remeasurement of net deferred tax assets was completely offset by a corresponding change in valuation allowance. The reduction to U.S. deferred tax assets and the offsetting valuation allowance was </font><font style="font-family:inherit;font-size:10pt;">$34.1 million</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary&#8217;s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. At December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently adopted accounting pronouncement</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued ASU 2014-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)" , </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 606&#8221;), amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for public companies effective for annual and interim reporting periods beginning after December 15, 2016. We have adopted the provisions of ASC 606 and the related amendments, effective January 1, 2018, using the modified retrospective transition method. We recognized the cumulative effect of applying the new revenue standard and recognized a </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> increase to the opening balance of the accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented.&#160;See Note 3, "Revenue Recognition" for more details. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued ASU&#160;No.&#160;2016-01,&#160;&quot;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;Subtopic 825-10&#8221;). This guidance principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of this new guidance, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an&#160;available-for-sale&#160;classification and therefore no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. This new guidance primarily impacts our accounting for equity investments. In February 2018, the FASB issued ASU 2018-03, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Technical Corrections and Improvements to Financial Instruments&#8212;Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, that clarifies the guidance in ASU No. 2016-01, Financial Instruments&#8212;Overall (Subtopic 825-10)</font><font style="font-family:inherit;font-size:10pt;">." Prior to the adoption of ASC 825, we recognized unrealized holding gains and losses from our equity investment in CO2 Solutions in other comprehensive loss. We adopted ASC 825 in the first quarter of 2018 using a modified retrospective approach by means of a cumulative-effect adjustment to accumulated deficit. Upon adoption of ASC 825, we reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> of unrealized loss (net of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> tax) from other accumulated comprehensive loss to beginning accumulated deficit. Any changes in the fair value of our equity investments, except those accounted for under the equity method, will be recognized in earnings on a prospective basis.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2016, the FASB issued ASU 2016-15, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;ASC 230&#8221;), which provides the FASB's guidance on certain cash flow statements items.&#160;ASC 230 is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. We adopted ASC 230 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2016, the FASB issued ASU No. 2016-18, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Statement of Cash Flows (Topic 230) Restricted Cash a consensus of the FASB Emerging Issues Task Force&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 230&#8221;). The standard requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows. We adopted ASU 2016-18 in the first quarter of 2018 and the adoption had no material impact on our annual consolidated financial statements. The effect of the adoption of ASC 230 on our consolidated statements of cash flows was to include restricted cash balances in the beginning and end of period balances of cash and cash equivalents and restricted cash. The change in restricted cash was previously disclosed in operating and investing activities in the consolidated statements of cash flows. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-01 "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Business Combinations (Topic 805): Clarifying the Definition of a Business&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 805&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The guidance requires the use of a framework to determine whether a set of assets and activities constitutes an acquired or a sold business. The guidance is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. The amendments should be applied prospectively as of the beginning of the period of adoption. We adopted ASC 805 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the FASB issued ASU No. 2017-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting&#8221; </font><font style="font-family:inherit;font-size:10pt;">(&#8220;ASC 718&#8221;)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. The new standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. We adopted ASC 718 in the first quarter of 2018 and the adoption had no impact on our annual consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2018, the FASB issued ASU 2018-05, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118</font><font style="font-family:inherit;font-size:10pt;">" (&#8220;ASC 740&#8221;) which amends&#160;Topic 740&#160;by&#160;incorporating the SEC Staff Accounting Bulletin No. 118 (SAB 118) issued on December 22, 2017. SAB 118 provides guidance on accounting for the effects of the Tax Cuts and Jobs Act (Tax Reform) and allows a company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. See Income Taxes section above for additional information.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently issued accounting pronouncements not yet adopted</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU 2016-02, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)"</font><font style="font-family:inherit;font-size:10pt;"> (&#8220;ASC 842&#8221;), which replaces prior lease guidance (&#8220;ASC 840&#8221;). This guidance establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statement of Operations. The guidance also eliminates today&#8217;s real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Entities have the option to use certain practical expedients. Full retrospective application is prohibited. ASC 842 is effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years.&#160;Early adoption is permitted. In July 2018, the FASB issued ASU 2018-10, "</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Codification Improvements to ASC 842, Leases</font><font style="font-family:inherit;font-size:10pt;">." These amendments affect narrow aspects of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under ASC 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under ASC 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. For entities that have not adopted ASC 842, the effective date and transition requirements will be the same as the effective date and transition requirements in ASC 842. The FASB also issued ASU 2018-11,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> "Leases (Topic 842): Targeted Improvements."</font><font style="font-family:inherit;font-size:10pt;"> These amendments provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). The amendments also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under ASC 606 and certain criteria are met. If the nonlease component or components associated with the lease component are the predominant component of the combined component, an entity is required to account for the combined component in accordance with ASC 606. Otherwise, the entity must account for the combined component as an operating lease in accordance with ASC 842. For entities that have not adopted ASC 842 before the issuance of ASU No. 2018-11, the effective date and transition requirements for the amendments related to separating components of a contract are the same as the effective date and transition requirements in ASU No. 2016-02. We plan to adopt ASC 842 on January 1, 2019 using a modified retrospective approach and effective date method per adoption of ASU 2018-11. We will recognize and measure all leases within the scope of the standard that exist as of January 1, 2017, beginning of the earliest period, as if the standard had always been applied, subject to the practical expedients and transition relief in &#8220;Practical Expedients&#8221; section. In the current period, we evaluated the practical expedients elections and on adoption, and may apply a practical expedient in which an entity need not reassess whether any expired or existing contracts are or contain leases; An entity need not reassess the lease classification for any expired or existing leases (for example, all existing leases that were classified as operating leases in accordance with ASC 840 will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 will be classified as finance leases); An entity need not reassess initial direct costs for any existing leases. We started the transition plan in the third quarter of 2018 and continued to perform the scoping work in the fourth quarter of 2018. We identified a total of 13 lease agreements that are subject to ASC 842 and seven of them meet the short-term lease exception. We completed the full analysis by January, 2019 and we evaluated the right-of-use (ROU) assets and lease liability using the incremental borrowing rate (IBR) at December 31, 2018 because the implicit rate is not readily determinable in the lease agreement. Upon adoption of ASC 842, all existing leases will be classified as either operating lease or finance lease. We expect to record a range from </font><font style="font-family:inherit;font-size:10pt;">$20 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$30 million</font><font style="font-family:inherit;font-size:10pt;"> of ROU assets and liabilities for operating leases and a range from </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> of ROU assets and liabilities for finance leases in the balance sheet during the first quarter of 2019. This analysis was inclusive of the eighth amendment to the lease agreement disclosed in Note 16, &#8220;Subsequent Events.&#8221;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU 2016-13, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,</font><font style="font-family:inherit;font-size:10pt;">" which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model (known as the "current expected credit loss model") that is based on expected losses rather than incurred losses. ASU 2016-13 is effective for annual reporting periods ending after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2017, the FASB issued ASU No. 2017-04, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment."</font><font style="font-family:inherit;font-size:10pt;"> The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In&#160;February&#160;2018,&#160;the&#160;FASB&#160;issued&#160;ASU&#160;No.&#160;2018-02,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8220;Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income&#8221;</font><font style="font-family:inherit;font-size:10pt;">. This standard allows a&#160;reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects and will be effective for us beginning January 1, 2019 and should be applied either in the period of adoption or retrospectively. Early adoption is permitted. We do not expect this standard to have any&#160;impact&#160;on&#160;our&#160;consolidated&#160;financial&#160;statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2018, the FASB issued ASU 2018-07, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting,</font><font style="font-family:inherit;font-size:10pt;">" which expands the scope of Topic 718, Compensation&#8212;Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Equity&#8212;Equity-Based Payments to Non-Employees</font><font style="font-family:inherit;font-size:10pt;">. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2018, the FASB issued ASU 2018-09,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> "Codification Improvements&#8221;, </font><font style="font-family:inherit;font-size:10pt;">which represent changes to clarify, correct errors in, or make minor improvements to the Codification, eliminating inconsistencies and providing clarifications in current guidance. The amendments in this ASU include those made to: Subtopic 220-10, I</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ncome Statement-Reporting Comprehensive Income-Overall</font><font style="font-family:inherit;font-size:10pt;">; Subtopic 470-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Debt-Modifications and Extinguishments;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 480-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity-Overall;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 718-740, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation-Stock Compensation-Income Taxes; </font><font style="font-family:inherit;font-size:10pt;">Subtopic 805-740, B</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">usiness Combinations-Income Taxes</font><font style="font-family:inherit;font-size:10pt;">; Subtopic 815-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging-Overall; </font><font style="font-family:inherit;font-size:10pt;">Subtopic 820-10, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement-Overall;</font><font style="font-family:inherit;font-size:10pt;"> Subtopic 940-405,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Financial Services-Brokers and Dealers-Liabilities</font><font style="font-family:inherit;font-size:10pt;">; and Subtopic 962-325, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Plan Accounting-Defined Contribution Pension Plans-Investments-Other.</font><font style="font-family:inherit;font-size:10pt;"> The transition and effective date guidance is based on the facts and circumstances of each amendment. Some of the amendments do not require transition guidance and will be effective upon issuance. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. We do not expect this standard to have any material impact on our consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In August 2018, the FASB issued ASU 2018-13, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement."</font><font style="font-family:inherit;font-size:10pt;"> The primary focus of&#160;ASU&#160;2018-13&#160;is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. In general, the amendments in&#160;this standard&#160;are effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December&#160;15, 2019. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-18</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, "Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606.</font><font style="font-family:inherit;font-size:10pt;">" ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. In general, for public companies, the amendments in this standard are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, the FASB issued ASU 2018-19, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">"Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses."</font><font style="font-family:inherit;font-size:10pt;"> ASU 2018-19 clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. In general, the amendments in&#160;this standard&#160;are effective for public business entities that meet the definition of a SEC filer for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We do not expect this standard to have any material impact on our consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">401(k) Plan</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2005, we implemented a 401(k) Plan covering certain employees. Currently, all of our United States based employees over the age of </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;"> are eligible to participate in the 401(k) Plan. Under the 401(k) Plan, eligible employees may elect to reduce their current compensation up to a certain annual limit and contribute these amounts to the 401(k) Plan. We may make matching or other contributions to the 401(k) Plan on behalf of eligible employees. We recorded employer matching contributions expense of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment classified as construction in process includes equipment that has been received but not yet placed in service. Normal repairs and maintenance costs are expensed as incurred.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3" rowspan="1"></td></tr><tr><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:45%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Asset classification</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Estimated useful life</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 to 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lesser of useful life or lease term</font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">Fully depreciated laboratory equipment with a cost of </font><font style="font-family:inherit;font-size:9pt;">$0.3 million</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">$0.2 million</font><font style="font-family:inherit;font-size:9pt;"> were retired during </font><font style="font-family:inherit;font-size:9pt;">2018</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">2017</font><font style="font-family:inherit;font-size:9pt;">, respectively.</font></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;"> Construction in progress includes equipment received but not yet placed into service pending installation.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable and Allowance for Doubtful Accounts</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently sell primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable includes amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance for doubtful accounts. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The allowances for doubtful accounts reflect our best estimates of probable losses inherent in the accounts receivable and contract assets&#8217; balances. We determine the allowances based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivables and contract assets are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Geographic revenues are identified by the location of the customer and consist of the following (in thousands):</font></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exela PharmSci, Inc. (&#8220;Exela&#8221;)</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We entered into a commercialization agreement with Exela in 2007. Under the license agreement, as amended, we and Exela cross-licensed certain technology relating to the manufacture of argatroban, an API, in exchange for rights to certain sublicensing fees or development payments and profit sharing. The revenue sharing arrangement was terminated in December 2017.</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thomas R. Baruch, one of our directors, serves on the board of directors of Exela, and is a retired general partner in Presidio Partners 2007, L.P., which owns over </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of Exela&#8217;s outstanding capital stock. As such, Mr. Baruch has an indirect pecuniary interest in the shares of Exela held by Presidio Partners 2007, L.P. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue from transactions with Exela in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">. We recognized </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> as research and development revenue from transactions with Exela. We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> receivables at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables due from Exela at December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">AstraZeneca PLC</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pam P. Cheng, a member of our board of directors, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sell biocatalyst products to AstraZeneca PLC, to Alfa Aesar, which is a purchasing agent of AstraZeneca PLC, and also to Asymchem Life Science Co, Ltd, which is a contract manufacturer for AstraZeneca PLC.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognized product revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and de minimis revenue in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> from transactions with AstraZeneca PLC. We recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue from transactions with Alfa Aesar in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> of product revenue in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. We recognized de minimis revenue from Asymchem Life Science Co, Ltd in 2018, </font><font style="font-family:inherit;font-size:10pt;">$75 thousand</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, and de minimis revenue in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables and at December 31, 2017, we had </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables due from AstraZeneca, PLC. At December 31, 2018, we had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> receivables and at December 31, 2017, we had </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of receivables due from Asymchem Life Science Co, Ltd. At December 31, 2018 and 2017, we had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> receivables due from Alfa Aesar.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Research and Development Services</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of research and development services related to FTE services under research and development agreements approximate the research funding over the term of the respective agreements and is included in research and development expense. Costs of services provided under license and platform technology transfer agreements are included in research and development expenses and are expensed in the periods in which such costs are incurred.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses consist of costs incurred for internal projects and partner-funded collaborative research and development activities, as well as license and platform technology transfer agreements, as mentioned above. These costs include our direct and research-related overhead expenses, which include salaries and other personnel-related expenses (including stock-based compensation), occupancy-related costs, supplies, and depreciation of facilities and laboratory equipment, as well as external costs, and are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no alternative future use are expensed when incurred.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Policy from January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">and the related amendments (&#8220;ASC 606&#8221;). The guidance provides a unified model to determine how revenue is recognized.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) we satisfy each performance obligation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition. </font></div><div style="line-height:174%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a description of principal activities from which we generate revenue:</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Revenue</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer&#8217;s use. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide under the contract. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to manufacture a product. If we determine that the customer cannot benefit from the license without our manufacturing capability, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct and has significant standalone functionality, we would recognize revenues from a functional license at a point in time when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time as our customer learns to use our technology.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We recognize revenues for the functional license at a point in time when the control of the license and technology transfers to the customer.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For agreements that include sales or usage-based royalty payments to us, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Assets </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. The contract assets are reclassified to receivables when the rights become unconditional. </font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Liabilities</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities are recorded as deferred revenues and include payments received in advance of performance under the contract. Contract liabilities are realized when the development services are provided to the customer or control of the products has been transferred to the customer. A portion of our contract liabilities relate to supply arrangements that contain material rights that are recognized using the alternative method, under which the aggregate amount invoiced to the customer for shipped products, including annual fees, is higher than the amount of revenue recognized based on the transaction price allocated to the shipped products.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Costs</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 606 requires the recognition of an asset for the incremental costs of obtaining a contract with a customer if the entity expects to recover such costs. Incremental costs are costs that would not have been incurred if the contract had not been obtained. Examples of contract costs are commissions paid to sales personnel. We do not typically incur significant incremental costs because the compensation of our salespeople are not based on contracts closed but on a mixture of company goals, individual goals, and sales goals. If a commission paid is directly related to obtaining a specific contract, our policy is to capitalize and amortize such costs on a systematic basis, consistent with the pattern of transfer of the good or service to which the asset relates.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract costs are reported in other non-current assets.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition Policy before January 1, 2018</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) Subtopic 605-25, &#8220;Multiple Element Arrangements.&#8221; For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Research and Development Revenues</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (&#8220;FTE&#8221;) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee&#8217;s product sales or cost savings achieved by our customers.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer&#8217;s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from royalties based on licensees&#8217; sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cost of Product Revenue</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue comprises both internal and third party fixed and variable costs including materials and supplies, labor, facilities, and other overhead costs associated with our product sales. Shipping costs are included in our cost of product revenue. Such charges were not significant in any of the periods presented.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fulfillment costs, such as shipping and handling, are recognized at a point in time and are included in cost of product sales.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Unbilled receivable</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to ASC 606, the timing of revenue recognition may differ from the timing of invoicing to our customers. When we satisfy (or partially satisfy) a performance obligation, prior to being able to invoice the customer, we recognize an unbilled receivable&#160;when the right to consideration is unconditional.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenue Recognition<br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 1, 2018, we adopted ASC 606, applying the modified retrospective method to all contracts that were not completed as of that date. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606 while prior period results are not adjusted and continue to be reported under the accounting standards in effect for the prior period. We recorded an increase to opening accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;"> as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact on revenue for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> was an increase of $</font><font style="font-family:inherit;font-size:10pt;">5.0 million</font><font style="font-family:inherit;font-size:10pt;"> as a result of adopting ASC 606. The increase in revenues from the adoption of ASC 606 was primarily due to revenue from a product that was recognized over time as we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically for the customer&#8217;s use, and revenues from research and development contracts that were recognized when we had the right to invoice our customers for monthly services completed to date. Also, revenue from a distinct, functional license granted on January 1, 2018 contributed to the increase in revenue from the adoption of ASC 606.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are entitled to certain future milestone payments under our collaborative arrangements. Such milestone payments represent variable consideration that was fully constrained as the realization of the variable consideration is highly uncertain.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, Latin America), EMEA (Europe, Middle East, Africa), and APAC (Australia, New Zealand, Southeast Asia, China).</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We identified our biotherapeutics business as a standalone business segment in the beginning of 2018 and revenues related to the Novel Biotherapeutics segment&#160;were first generated in 2017. Therefore, segment information for fiscal year 2016 is not provided.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment information for fiscal year 2018 is as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Major products and service:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,483</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Primary geographical markets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,878</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,483</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,361</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Segment information for fiscal year 2017 is as follows (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Major products and service:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Primary geographical markets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,919</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,610</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table shows the reconciliation of contract liabilities from what was disclosed in the Form&#160;10-K&#160;for the year ended December&#160;31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January&#160;1, 2018 (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:80%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Revenue, balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,793</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in estimated consideration</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unsatisfied performance obligations</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,173</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred Revenue, balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contract Balances</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents changes in the contract assets, unbilled receivable, contract costs, and contract liabilities (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">January 1, 2018 balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deductions</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,934</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,899</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,908</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, non-current</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">239</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(197</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract Liabilities: Deferred Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,288</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize accounts receivable when we have an unconditional right to recognize revenue and have issued an invoice to the customer. Our payment terms are generally between </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">90</font><font style="font-family:inherit;font-size:10pt;"> days. We recognize unbilled receivables when we have an unconditional right to recognize revenue and have not issued an invoice to our customer. Unbilled receivables, current are transferred to accounts receivable on issuance of an invoice. Unbilled receivables, non-current are transferred to accounts receivable on issuance of an invoice; payment is expected from the customer thereon. Unbilled receivables are classified separately on the consolidated balance sheet as assets. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets represent our right to recognize revenue for custom products with no alternate use and under binding non-cancellable purchase orders and are largely related to our procurement of product. We recognize contract assets when we have a conditional right to recognize revenue. The delivery pattern of certain of products occurs in advance of the invoicing process, which generates contract assets. In addition, we recognize a contract asset related to milestones not eligible for royalty accounting when we assess it is probable of being achieved and there will be no significant reversal of cumulative revenues. Contract assets are classified separately on the consolidated balance sheet as an asset and transferred to accounts receivable when our rights to payment become unconditional.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract liabilities, or deferred revenue, represent our obligation to transfer a product or service to the customer, and for which we have received consideration from the customer. We recognize a contract liability when we receive advance customer payments under development agreements for research and development services, upfront license payments, and from upfront customer payments received under product supply agreements. Contract liabilities are classified as a liability on the consolidated balance sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract costs relate to incremental costs of obtaining a contract with a customer. Contract costs are amortized along with the associated revenue over the term of the contract. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> asset impairment charges related to contract assets in the period.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, we recognized the following revenues (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Revenue recognized in the period for:</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts included in contract liabilities at the beginning of the period:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Performance obligations satisfied</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,615</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the period:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">374</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Performance obligations satisfied from new activities in the period - contract revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,605</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance Obligations</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">. We did not recognize any revenue from performance obligations satisfied in previous periods.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2022 and Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,288</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Practical Expedients, Elections, and Exemptions</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We used a practical expedient available under ASC 606 which permits us to consider the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also used a practical expedient available under ASC 606 which permits us not to adjust the amount of consideration for the effects of a significant financing component if, at contract inception, the expected period between the transfer of promised goods or services and customer payment is one year or less.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We perform monthly services under our research and development agreements and we use a practical expedient available under ASC 606 permitting us to recognize revenue at the same time that we have the right to invoice our customer for monthly services completed to date. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have elected to treat shipping and handling activities as fulfillment costs.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, we have elected to record revenue net of sales and other similar taxes.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Impact on Financial Statements</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balances without adoption of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,609</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,031</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares used in computing net loss per share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balances without adoption of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,253</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue - current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue - non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20" rowspan="1"></td></tr><tr><td style="width:31%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2021</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2022 and Thereafter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,553</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,735</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,936</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,729</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,623</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,288</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued purchases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional and outside service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease incentive obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-left:4px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following shares were not included in the computation of diluted net loss per share (in thousands):</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable under Equity Incentive Plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,567</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares issuable upon the conversion of warrants</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total anti-dilutive securities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,882</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,640</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The components of the provision for income taxes are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current provision (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred provision (benefit):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred provision (benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Significant components of our deferred tax assets and liabilities are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,879</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,334</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,967</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,872</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reserves and accruals</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,028</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,573</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,557</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,172</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Capital losses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">576</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain/loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">297</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">295</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax assets:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79,240</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total deferred tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(79,222</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(74,010</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred tax liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(75</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reconciliation of the provision for income taxes calculated at the statutory rate to our provision for (benefit from) income taxes is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax benefit at federal statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,292</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,791</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">222</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credits</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(499</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(399</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(161</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign operations taxed at different rates</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,587</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(216</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">327</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other nondeductible items</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">405</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Executive compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">838</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,301</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(26,058</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,901</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in statutory tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,100</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">81</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is included in the consolidated statements of operations as follows (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,444</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,033</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,834</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,647</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,640</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents total stock-based compensation expense by security type included in the consolidated statements of operations (in thousands):</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,554</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RSUs and RSAs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,770</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,888</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,043</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PSUs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,511</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">PBOs</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,633</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,857</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,889</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,091</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,673</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments under non-cancellable capital and operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,523</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of capital leases</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Minimum payments have not been reduced by future minimum sublease rentals of </font><font style="font-family:inherit;font-size:9pt;">$0.9 million</font><font style="font-family:inherit;font-size:9pt;"> to be received under non-cancellable subleases. </font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum payments under non-cancellable capital and operating leases at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:65%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years ending December 31,</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">712</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">490</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total minimum lease payments </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,523</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: amount representing interest</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Present value of capital lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">303</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(242</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term portion of capital leases</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup>&#160;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:9pt;">Minimum payments have not been reduced by future minimum sublease rentals of </font><font style="font-family:inherit;font-size:9pt;">$0.9 million</font><font style="font-family:inherit;font-size:9pt;"> to be received under non-cancellable subleases. </font></div></td></tr></table></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">uture minimum lease payments under the Eighth Amendment is </font><font style="font-family:inherit;font-size:10pt;">$32.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our loss before provision for income taxes was as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,994</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(262</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">79</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(424</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:9px;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepayments of Term Debt and early termination of the Revolving Line of Credit are subject to prepayment and final payment fees are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Term Debt</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Revolving Line of Credit</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through and including the first anniversary of the funding date of the first Term Debt drawn</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the first anniversary of the funding date of the first Term Debt drawn and before the maturity date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On the earliest to occur of the maturity date, the acceleration of Term Debt drawn or prepayment of Term Debt drawn</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.5%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through and including the first anniversary of the closing date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the first anniversary of the closing date through and including the second anniversary of the closing date</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the second anniversary of the closing date through and including the third anniversary of the closing date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.0%</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balances without adoption of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,422</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,168</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,609</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,395</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,031</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55,563</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,335</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,978</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(196</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,889</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(481</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">71,408</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,295</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,845</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">671</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(291</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provision for (benefit from) income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,878</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,550</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15,428</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average common shares used in computing net loss per share, basic and diluted</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As reported</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Balances without adoption of </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">ASC 606</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,551</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,253</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,916</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(35</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">589</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">590</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unbilled receivables, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">786</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(786</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other non-current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">223</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,335</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue - current</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,936</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,574</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,362</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue - non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,907</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330,474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(330,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,483</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment costs and operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,082</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,038</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,545</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,416</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate costs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation </font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:9pt;">Research and development expenses and Selling, general and administrative expenses exclude depreciation.</font></div><div style="line-height:120%;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></font><font style="font-family:inherit;font-size:9pt;">Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes RSA activities:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">480</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.21</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(435</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.75</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.68</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.35</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarizes stock option activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,918</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.49</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">971</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(398</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(601</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">856</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.57</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(86</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(81</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.72</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,579</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">645</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.56</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(340</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.66</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.83</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Remaining<br clear="none"/>Contractual Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,112</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.81</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,927</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,876</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.83</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.25</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,503</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year&#160;Ended&#160;December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes RSU activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">545</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">330</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(243</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(15</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.74</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">617</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">275</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.56</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(290</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.09</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">348</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Rollforward Table (at Gross): As of</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at beginning of year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,422</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,152</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions based on tax positions related to current year</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">880</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">459</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Reductions to tax provision of prior years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(529</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(45</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at end of year</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,980</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,422</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers that each contributed 10% or more of our total revenues were as follows:</font></div><div style="line-height:120%;padding-top:6px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage&#160;of&#160;Total&#160;Revenues</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For&#160;The&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nestl&#233; Health Science</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tate &amp; Lyle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Novartis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GSK</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage of Accounts Receivables </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nestl&#233; Health Science</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tate &amp; Lyle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Novartis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kyorin Pharmaceutical Co Ltd</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exela PharmaSci, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">* Percentage was less than 10%</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Segment, Geographical and Other Revenue Information<br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information </font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As discussed in Note 2, "Basis of Presentation and Summary of Significant Accounting Policies," beginning in 2018, we identified our biotherapeutics business as a standalone business segment. Our </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> reportable business segments as of January 1, 2018, consisted of Performance Enzymes and Novel Biotherapeutics. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments. </font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Performance Enzymes</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We initially commercialized our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:10pt;"> molecular diagnostic and molecular biology research applications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Novel Biotherapeutics</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer&#8217;s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestl&#233; Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU.&#160;In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestl&#233; Health Science became obligated to pay us an additional </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> within </font><font style="font-family:inherit;font-size:10pt;">60 days</font><font style="font-family:inherit;font-size:10pt;"> after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had completed its review of our investigational new drug application (&#8220;IND&#8221;) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestl&#233; Health Science exercised its option to obtain an exclusive license for the global development and commercialization of CDX-6114 for the management of PKU. The exercise of the option triggers a </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment. Upon exercising its option, Nestl&#233; Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, &#8220;Subsequent Events&#8221; in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;">, primarily all revenues related to the Novel Biotherapeutics segment were generated from our collaboration with customer projects.&#160;There was no revenue related to the Novel Biotherapeutics segment in the year ended December 31, 2017. Novel Biotherapeutics had no operational activity in the year ended December 31, 2016.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):</font></div><div style="line-height:120%;padding-top:12px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Revenues:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product revenue</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,590</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,685</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development revenue</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,483</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,004</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,648</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,339</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,073</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,521</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,333</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Costs and operating expenses:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cost of product revenue</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,620</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,924</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,538</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">771</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,309</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,371</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total segment costs and operating expenses</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,082</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,956</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,038</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,545</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,652</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,565</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,556</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,788</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,416</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(628</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate costs</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(2)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation </font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,147</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,042</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss before income taxes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,915</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1) </sup></font><font style="font-family:inherit;font-size:9pt;">Research and development expenses and Selling, general and administrative expenses exclude depreciation.</font></div><div style="line-height:120%;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2) </sup></font><font style="font-family:inherit;font-size:9pt;">Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td style="width:22%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,591</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,929</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,306</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">208</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,514</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Significant Customers</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers that each contributed 10% or more of our total revenues were as follows:</font></div><div style="line-height:120%;padding-top:6px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage&#160;of&#160;Total&#160;Revenues</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">For&#160;The&#160;Years&#160;Ended&#160;December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nestl&#233; Health Science</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tate &amp; Lyle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Novartis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">GSK</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:</font></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Percentage of Accounts Receivables </font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">As Of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Merck</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Nestl&#233; Health Science</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tate &amp; Lyle</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Novartis</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kyorin Pharmaceutical Co Ltd</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exela PharmaSci, Inc.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;">* Percentage was less than 10%</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Geographic Information</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Geographic revenues are identified by the location of the customer and consist of the following (in thousands):</font></div><div style="line-height:120%;padding-top:18px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:56%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Americas</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,370</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,575</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,126</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EMEA</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">APAC</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,863</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,839</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,573</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60,594</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,024</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,837</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):</font></div><div style="line-height:120%;padding-top:4px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-lived assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:61%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Performance Enzymes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Novel Biotherapeutics</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,463</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">778</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,241</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We report </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for our company. We do not allocate or evaluate assets by segment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously, we had only </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes PBO activities in </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Grant Date Fair Value Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,720</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.02</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,254</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.73</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,582</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.47</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:47%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Exercise Price Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted<br clear="none"/>Average<br clear="none"/>Remaining<br clear="none"/>Contractual Term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Aggregate Intrinsic<br clear="none"/>Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable at December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest at December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,582</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.24</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.44</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,553</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes PSU activities:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:71%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number <br clear="none"/>of <br clear="none"/>Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average<br clear="none"/>Grant Date<br clear="none"/>Fair Value<br clear="none"/>Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">(In Thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.94</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">629</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.10</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.89</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(305</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">831</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited/Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(27</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at January 1, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">429</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.20</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">306</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.71</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(495</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-vested balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">240</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Capital Stock</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Public Offering</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2018, we completed an underwritten public offering of&#160;</font><font style="font-family:inherit;font-size:10pt;">4,312,500</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of our common stock, including the exercise in full by the underwriters of their option to purchase&#160;</font><font style="font-family:inherit;font-size:10pt;">562,500</font><font style="font-family:inherit;font-size:10pt;"> of&#160;our shares, at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$9.25</font><font style="font-family:inherit;font-size:10pt;"> per share. After deducting the underwriting discounts and commissions and estimated offering expenses, net proceeds were approximately </font><font style="font-family:inherit;font-size:10pt;">$37.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Subsequent Events</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">February 2019</font><font style="font-family:inherit;font-size:10pt;">, we entered into the eighth lease amendment ("Eighth Amendment") with MetLife to extend the lease term for the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space for another </font><font style="font-family:inherit;font-size:10pt;">88 months</font><font style="font-family:inherit;font-size:10pt;">. The various terms for these properties have expiration dates that range from </font><font style="font-family:inherit;font-size:10pt;">May 2027</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">May 2029</font><font style="font-family:inherit;font-size:10pt;">. The terms include an optional renewal period of </font><font style="font-family:inherit;font-size:10pt;">5</font><font style="font-family:inherit;font-size:10pt;"> years after the expiration date based on fair market rates for comparable transactions in the geographic area described in the Eighth Amendment. The Eighth Amendment requires us to install certain improvements to the buildings. On completion of the improvements to the building, the landlord will reimburse us up to a contractually specified amount and the landlord will become the owner of the improvements. Pursuant to the terms of the Eighth Amendment, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letters of credit are collateralized by deposit balances held by the bank in the amount of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> in 2019. These deposits will be recorded as restricted cash on the consolidated balance sheets. Total future minimum lease payments under the Eighth Amendment is </font><font style="font-family:inherit;font-size:10pt;">$32.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:16px;text-align:left;padding-left:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Approval and Nestl&#233; Health Science Exercises Option for Exclusive Global License to CDX-6114 </font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2019, we received notice from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) that it had completed its review of our investigational new drug application (&#8220;IND&#8221;) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States.</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2019, Nestl&#233; Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sublicensable license to develop and commercialize certain products based on the our novel, orally delivered enzyme IND for the management of phenylketonuria. Nestl&#233; Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. The exercise of the option triggered a </font><font style="font-family:inherit;font-size:10pt;">$3 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment from Nestl&#233; Health Science to Codexis. Upon exercising its option, Nestl&#233; Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table sets forth our federal, state and foreign NOL carryforwards and federal research and development tax credits as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Years</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, federal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">254,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022-2038</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, state</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,420</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018-2038</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits, federal</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022-2038</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Tax credits, state</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,121</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Do not expire</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net operating losses, foreign</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Various</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheets Details</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts receivable</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Allowance - beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Write-offs and other </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;background-color:transparent; font-size:7pt">(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">387</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Allowance - end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(421</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">The change in allowance for doubtful accounts was mainly related to the write-off of receivables from a foreign customer.</font></div><div style="line-height:120%;padding-top:16px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following (in thousands):&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raw materials </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Work in process</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finished goods </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#cceeff;">Inventories</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">589</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,036</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment, net</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory equipment </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,328</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,777</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,327</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,954</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,695</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Office equipment and furniture</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,272</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,185</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">939</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,852</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,069</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,093</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32,254</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,759</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;">Fully depreciated laboratory equipment with a cost of </font><font style="font-family:inherit;font-size:9pt;">$0.3 million</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">$0.2 million</font><font style="font-family:inherit;font-size:9pt;"> were retired during </font><font style="font-family:inherit;font-size:9pt;">2018</font><font style="font-family:inherit;font-size:9pt;"> and </font><font style="font-family:inherit;font-size:9pt;">2017</font><font style="font-family:inherit;font-size:9pt;">, respectively.</font></div><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:9pt;"> Construction in progress includes equipment received but not yet placed into service pending installation.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Goodwill had a carrying value of approximately of </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Accrued Liabilities</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities consisted of the following (in thousands):</font><font style="font-family:inherit;font-size:9pt;">&#160;</font></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued purchases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,492</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">941</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued professional and outside service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,020</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,393</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease incentive obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">425</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">575</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">345</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,362</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:21px;padding-top:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:66%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other Commitment Agreement Type</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Agreement Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Future Minimum Payment</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacture and supply agreement with expected future payment date of December, 2022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,458</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreement for stability study</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">July 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Service agreement for clinical trial</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December 2017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total other commitments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,047</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;text-align:left;padding-left:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of equity securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.</font></div></div> In 2018, we adopted Accounting Standards Update No. 2016-01 (Subtopic 825-10) and recorded a cumulative-effect reclassification $0.5 million unrealized loss on equity securities from other accumulated comprehensive loss to the beginning accumulated deficit. See Note 2 “Summary of Significant Accounting Policies” in the Accompanying Notes to the Consolidated Financial Statements for more information. EX-101.SCH 13 cdxs-20181231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2113100 - Disclosure - 401(k) Plan link:presentationLink link:calculationLink link:definitionLink 2413401 - Disclosure - 401(k) Plan (Details) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Balance Sheets Details link:presentationLink link:calculationLink link:definitionLink 2408407 - Disclosure - Balance Sheets Details - Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Balance Sheets Details - Allowance for Doubtful Accounts Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 2408406 - Disclosure - Balance Sheets Details - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2408404 - Disclosure - Balance Sheets Details - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Balance Sheets Details - Schedule of Inventory Components (Details) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Balance Sheets Details (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2401403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2401404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Plant, Property, and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2301302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Capital Stock link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Capital Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Cash Equivalents and Equity Securities link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Cash Equivalents and Equity Securities - Components of Cash Equivalents and Equity Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Cash Equivalents and Equity Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Cash Equivalents and Equity Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - Collaborative Arrangements (Details) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2415405 - Disclosure - Commitments and Contingencies - Credit Facility (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2415404 - Disclosure - Commitments and Contingencies - Other Commitments (Details) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1003001 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 1004001 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Description of Business Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Fair Value Measurements - Financial Assets measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Income Taxes - Components of Loss Before Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414407 - Disclosure - Income Taxes - NOL Carryforwards and Federal Research and Development Tax Credits (Details) link:presentationLink link:calculationLink link:definitionLink 2414408 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Income Taxes - Tax Rate Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2416401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Revenue Recognition - Contracts with Customer (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402407 - Disclosure - Revenue Recognition - Impact to Financial Statements (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Revenue Recognition - Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Revenue Recognition - Reconciliation of Contract Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Segment, Geographical and Other Revenue Information link:presentationLink link:calculationLink link:definitionLink 2417404 - Disclosure - Segment, Geographical and Other Revenue Information - Concentration Risk (Details) link:presentationLink link:calculationLink link:definitionLink 2417406 - Disclosure - Segment, Geographical and Other Revenue Information - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Segment, Geographical and Other Revenue Information - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2417405 - Disclosure - Segment, Geographical and Other Revenue Information - Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Segment, Geographical and Other Revenue Information - Segment Reporting (Details) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Segment, Geographical and Other Revenue Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Stock-based Compensation link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Stock-based Compensation - Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 2411406 - Disclosure - Stock-based Compensation - Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Stock-based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Stock-based Compensation - Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Stock-based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Subsequent Events (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 14 cdxs-20181231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 15 cdxs-20181231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 16 cdxs-20181231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] RSAs Restricted Stock [Member] RSUs Restricted Stock Units (RSUs) [Member] PSUs Performance Stock Units [Member] Performance Stock Units [Member] PBOs Performance Shares [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Non-vested, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised Vested (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Forfeited/expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Non-vested, end of period (shares) Weighted-average Grant Date Fair Value per Share Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Non-vested, beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Granted, weighted average grant date fair value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Exercised, weighted average grant date fair value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised, Weighted Average Grant Date Fair Value Vested, weighted average grant date fair value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Forfeited/Expired, weighted average exercise price per share (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Non-vested, end of period (usd per share) Exercisable and Expected to Vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract] Options exercisable (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Options vested and expected to vest (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Options exercisable (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Options vested and expected to vest (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Weighted average remaining contractual terms, exercisable options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Weighted average remaining contractual terms, vested and expected to vest options Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Aggregate intrinsic value, exercisable options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Aggregate intrinsic value, options vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Statement of Financial Position [Abstract] Accounts receivable, allowances Allowance for Doubtful Accounts Receivable, Current Preferred stock, par value (usd per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares issued (shares) Preferred Stock, Shares Issued Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (usd per share) Common Stock, Par or Stated Value Per Share Common stock, shares authorized (shares) Common Stock, Shares Authorized Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Balance Sheet Related Disclosures [Abstract] Accrued purchases Accrued Purchase, Received Not Yet Billed Accrued Purchase, Received Not Yet Billed Accrued professional and outside service fees Accrued Professional Fees Deferred rent Deferred Rent Credit, Current Lease incentive obligation Lease Incentive, Payable, Current Other Other Accrued Liabilities Total Accrued Liabilities, Current Revenue from Contract with Customer [Abstract] Revenue, Initial Application Period Cumulative Effect Transition [Table] Revenue, Initial Application Period Cumulative Effect Transition [Table] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Product Sales Product Sales [Member] Product Sales [Member] Research and Development Revenues Research and Development Revenue [Member] Research and Development Revenue [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Revenue, Initial Application Period Cumulative Effect Transition [Line Items] Performance obligation Revenue, Remaining Performance Obligation, Amount Expected timing of satisfaction, period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Income Tax Disclosure [Abstract] Income Tax Rate Reconciliation Effective Income Tax Rate Reconciliation, Amount [Abstract] Tax benefit at federal statutory rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount State taxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Research and development credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Foreign operations taxed at different rates Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Stock-based compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount Other nondeductible items Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Executive Compensation Change in valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Change in statutory tax rate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount Provision for (benefit from) income taxes Income Tax Expense (Benefit) Components of Deferred Tax Assets and Liabilities [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Deferred tax assets: Deferred Tax Assets, Gross [Abstract] Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Credits Deferred Tax Assets, Tax Credit Carryforwards Deferred revenues Deferred Tax Assets, Deferred Income Stock-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost Reserves and accruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Depreciation Deferred Tax Assets, Property, Plant and Equipment Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Capital losses Deferred Tax Assets, Capital Loss Carryforwards Unrealized gain/loss Deferred Tax Assets, Investments Other assets Deferred Tax Assets, Other Total deferred tax assets: Deferred Tax Assets, Gross Deferred tax liabilities: Deferred Tax Liabilities, Gross [Abstract] Other Deferred Tax Liabilities, Other Total deferred tax liabilities: Deferred Tax Liabilities, Gross Valuation allowance Deferred Tax Assets, Valuation Allowance Net deferred tax liabilities Deferred Tax Liabilities, Net Income Taxes [Table] Valuation Allowance [Table] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated Deficit Retained Earnings [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] India INDIA Income Taxes [Line Items] Valuation Allowance [Line Items] Cumulative effect of change in accounting principles Cumulative Effect of New Accounting Principle in Period of Adoption Increase (decrease) in deferred tax asset valuation allowance Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Deferred tax liability from undistributed foreign earnings Deferred Tax Liabilities, Undistributed Foreign Earnings Interest and penalties recognize in income tax expense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense Interest and penalties recognized on the balance sheet Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Fair Value Disclosures [Abstract] Investment [Table] Investment [Table] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Common shares of CO2 Solutions Common Shares of Co Two Solution [Member] Common shares of co two solution. Available-for-sale Securities [Member] Available-for-sale Securities [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Investment [Line Items] Investment [Line Items] Fair value of common shares (in shares) Investment Owned, Balance, Shares Available-for-sale Securities Available-for-sale Securities Accounting Policies [Abstract] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment, Type [Domain] Property, Plant and Equipment, Type [Domain] Laboratory equipment Equipment [Member] Computer equipment and software Computer Equipment and Software [Member] Computer Equipment and Software [Member] Office equipment and furniture Office Equipment and Furniture [Member] Office Equipment and Furniture [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Estimated useful life (years) Property, Plant and Equipment, Useful Life Loss Contingency [Abstract] Schedule of future minimum payments under non-cancellable operating leases Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] Schedule of future minimum lease payments for capital leases Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block] Schedule of supply commitment Supply Commitment [Table Text Block] Schedule of credit facility prepayment terms Schedule of Line of Credit Facilities [Table Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Description of Business Nature of Operations [Text Block] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Performance Enzymes Core Segment [Member] Core Segment [Member] Novel Biotherapeutics Biotherapeutic Segment [Member] Biotherapeutic Segment [Member] Americas Americas [Member] EMEA EMEA [Member] APAC APAC [Member] Regions of Australia, New Zealand, Southeast Asia and China Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Total revenues Revenue from Contract with Customer, Excluding Assessed Tax United States Income (Loss) from Continuing Operations before Income Taxes, Domestic Foreign Income (Loss) from Continuing Operations before Income Taxes, Foreign Loss before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Research and Development [Abstract] Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Statement of Comprehensive Income [Abstract] Statement [Table] Statement [Table] Accounting Standards Update 2016-01 Accounting Standards Update 2016-01 [Member] Statement [Line Items] Statement [Line Items] Cumulative effect of change in accounting principles Fair Value Measurements Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Statement of Stockholders' Equity [Abstract] Cumulative effect of change on equity or net assets New Accounting Pronouncement or Change in Accounting Principle, Cumulative Effect of Change on Equity or Net Assets Segment Reporting [Abstract] Concentration Risk [Table] Concentration Risk [Table] Customer [Axis] Customer [Axis] Customer [Domain] Customer [Domain] Merck Merck [Member] Merck [Member] Nestle Health Science Nestle [Member] Nestle [Member] Tate & Lyle Tate & Lyle [Member] Tate & Lyle [Member] Novartis Novartis [Member] Novartis [Member] GSK GSK [Member] GSK [Member] Kyorin Pharmaceutical Co Ltd Kyorin Pharmaceutical Co Ltd [Member] Kyorin Pharmaceutical Co Ltd [Member] Exela PharmSci, Inc Exela PharmSci, Inc [Member] Exela PharmSci, Inc Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Sales Sales [Member] Accounts Receivable Accounts Receivable [Member] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Credit Concentration Risk Credit Concentration Risk [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Concentration risk, percentage Concentration Risk, Percentage Earnings Per Share [Abstract] Net Loss per Share Earnings Per Share [Text Block] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Axis] Initial Application Period Cumulative Effect Transition [Domain] Initial Application Period Cumulative Effect Transition [Domain] Difference between Revenue Guidance in Effect before and after Topic 606 Difference between Revenue Guidance in Effect before and after Topic 606 [Member] Payment terms Revenue from Contract with Customer, Payment Terms Revenue from Contract with Customer, Payment Terms Impairment charges related to contract assets Contract with Customer, Asset, Credit Loss Expense Segment Reporting Information, Operating Income (Loss) [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] United States UNITED STATES Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Schedule of revenues by geographical area Revenues [Abstract] Revenues Revenues Long-lived assets Long-Lived Assets Number of Shares Subject to Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding, beginning of period (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited/Expired (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period Outstanding, end of period (shares) Weighted-average Exercise Price of Outstanding Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding, beginning of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (usd per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited/Expired (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Outstanding, end of period (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted average remaining contractual terms Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Beginning balance (shares) Shares, Outstanding Beginning balance Stockholders' Equity Attributable to Parent Exercise of stock options (shares) Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Release of stock awards (shares) Stock Issued During Period, Shares, Other Employee stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Non-employee stock-based compensation Adjustments to Additional Paid in Capital, Share-based Compensation, Other Long-term Incentive Plans, Requisite Service Period Recognition Taxes paid related to net share settlement of equity awards (shares) Shares Paid for Tax Withholding for Share Based Compensation Taxes paid related to net share settlement of equity awards Adjustment to Additional Paid in Capital, Income Tax Effect from Share-based Compensation, Net Issuance of common stock, net of issuance costs (shares) Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Net loss Net Income (Loss) Attributable to Parent Ending balance (shares) Ending balance Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Income Tax Expense (Benefit), Continuing Operations [Abstract] Current provision (benefit): Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Current Federal Tax Expense (Benefit) State Current State and Local Tax Expense (Benefit) Foreign Current Foreign Tax Expense (Benefit) Total current provision (benefit) Current Income Tax Expense (Benefit) Deferred provision (benefit): Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense (Benefit) State Deferred State and Local Income Tax Expense (Benefit) Foreign Deferred Foreign Income Tax Expense (Benefit) Total deferred provision (benefit) Deferred Income Tax Expense (Benefit) Goodwill Goodwill Income Taxes Income Tax Disclosure [Text Block] Capital Leases Capital Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract] 2019 Capital Leases, Future Minimum Payments Due, Next Twelve Months 2020 Capital Leases, Future Minimum Payments Due in Two Years 2021 Capital Leases, Future Minimum Payments Due in Three Years 2022 Capital Leases, Future Minimum Payments Due in Four Years 2023 Capital Leases, Future Minimum Payments Due in Five Years Total minimum lease payments Capital Leases, Future Minimum Payments Due Less: amount representing interest Capital Leases, Future Minimum Payments, Interest Included in Payments Present value of capital lease obligations Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments Less: current portion Capital Lease Obligations, Current Long-term portion of capital leases Capital Lease Obligations, Noncurrent Operating leases Operating Leases, Future Minimum Payments Receivable [Abstract] 2019 Operating Leases, Future Minimum Payments Due, Next Twelve Months 2020 Operating Leases, Future Minimum Payments, Due in Two Years 2021 Operating Leases, Future Minimum Payments, Due in Three Years 2022 Operating Leases, Future Minimum Payments, Due in Four Years 2023 Operating Leases, Future Minimum Payments, Due in Five Years Total minimum lease payments Operating Leases, Future Minimum Payments Due Total future minimum sublease rentals to be received under noncancellable subleases Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals Schedule of loss before income taxes, domestic and foreign Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Components of provision for income taxes Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Reconciliation of provision for income taxes calculated at the statutory rate to provision for income taxes Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Significant components of our deferred tax assets and liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Summary of federal, state and foreign NOL carryforwards and federal research and development tax credits Summary of Operating Loss Carryforwards [Table Text Block] Reconciliation of the beginning and ending amount of unrecognized tax benefits Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block] Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Operating Segments Operating Segments [Member] Performance Enzymes Performance Enzymes [Member] Performance Enzymes [Member] Novel Biotherapeutics Novel Biotherapeutics [Member] Novel Biotherapeutics [Member] Equity [Abstract] Capital Stock Stockholders' Equity Note Disclosure [Text Block] Allowance for doubtful accounts Allowance for Credit Losses on Financing Receivables [Table Text Block] Schedule of inventory components Schedule of Inventory, Current [Table Text Block] Property and equipment, net Property, Plant and Equipment [Table Text Block] Schedule of accrued liabilities Schedule of Accrued Liabilities [Table Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Project [Axis] Project [Axis] Project [Domain] Project [Domain] CDX-6114 CDX-6114 [Member] CDX-6114 [Member] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Nestec Ltd. (Nestle Health Sciences) Nestec Ltd. (Nestle Health Sciences) [Member] Nestec Ltd. (Nestle Health Sciences) [Member] Type of Arrangement and Non-arrangement Transactions [Axis] Type of Arrangement and Non-arrangement Transactions [Axis] Arrangements and Non-arrangement Transactions [Domain] Arrangements and Non-arrangement Transactions [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Agreement Type [Axis] Agreement Type [Axis] Agreement Type [Axis] Agreement Type [Domain] Agreement Type [Domain] [Domain] for Agreement Type [Axis] Development and Approval Development and Approval [Member] Development and Approval [Member] Sales-based Milestone Sales-Based Milestone [Member] Sales-Based Milestone [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Milestone payment amount Revenue Recognition, Milestone Payment Amount Revenue Recognition, Milestone Payment Amount Duration to pay after milestone achievement Revenue Recognition, Duration to Pay After Milestone Achievement Revenue Recognition, Duration to Pay After Milestone Achievement Amount from exercising alternative option Revenue Recognition, Event of Counterparty Exercising Alternative Option Revenue Recognition, Event of Counterparty Exercising Alternative Option Duration to pay after license effective date Revenue Recognition, Duration to Pay After License Effective Date Revenue Recognition, Duration to Pay After License Effective Date Maximum milestone receivable Revenue Recognition, Milestone Method, Additional Milestones, Maximum Milestone Receivable Revenue Recognition, Milestone Method, Additional Milestones, Maximum Milestone Receivable Threshold to achieve aggregate milestone amount Revenue Recognition, Milestone Method, Net Sales Threshold to Achieve Aggregate Milestone Amount Revenue Recognition, Milestone Method, Net Sales Threshold to Achieve Aggregate Milestone Amount Shares not included in computation of diluted net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Other comprehensive loss: Other Comprehensive Income (Loss), Net of Tax [Abstract] Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Other comprehensive loss Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total comprehensive loss Income Statement [Abstract] Research and Development Revenues Service [Member] Revenues: Costs and operating expenses: Operating Costs and Expenses [Abstract] Cost of product revenue Cost of Goods and Services Sold Research and development Research and Development Expense Selling, general and administrative Selling, General and Administrative Expense Total costs and operating expenses Operating Expenses Loss from operations Operating Income (Loss) Interest income Investment Income, Interest Other expenses, net Other Nonoperating Income (Expense) Provision for (benefit from) income taxes Net loss Net loss per share, basic and diluted (usd per share) Earnings Per Share, Basic and Diluted Weighted average common stock shares used in computing net loss per share, basic and diluted (shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Schedule of estimated ranges of useful lives of property and equipment Summary of financial instruments measured at fair value on a recurring basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Debt Securities, Available-for-sale [Abstract] Schedule of Available-for-sale Securities [Table] Schedule of Available-for-sale Securities [Table] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Money market funds Money Market Funds [Member] Equity Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Equity securities, adjusted cost basis Equity Securities, FV-NI, Cost Equity securities, gross unrealized gains Equity Securities, FV-NI, Unrealized Gain Equity securities, gross unrealized losses Equity Securities, FV-NI, Unrealized Loss Equity securities, estimated fair value Equity Securities, FV-NI Equity securities, adjusted cost Cash, Cash Equivalents, And Short-term Investments, Amortized Cost Cash, Cash Equivalents, And Short-term Investments, Amortized Cost Equity securities, adjusted cost Available-for-sale Equity Securities, Amortized Cost Basis Equity securities, gross unrealized gains Available-for-sale Equity Securities, Accumulated Gross Unrealized Gain, before Tax Equity securities, gross unrealized losses Available-for-sale Equity Securities, Accumulated Gross Unrealized Loss, before Tax Equity securities, estimated fair value Available-for-sale Securities, Equity Securities Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Gross unrealized gains Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax Gross unrealized losses Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax Estimated Fair Value Cash, Cash Equivalents, and Short-term Investments Investment Type [Axis] Investment Type [Axis] Investments [Domain] Investments [Domain] Common shares of CO2 Solutions Money market funds Money Market Funds, at Carrying Value Cash Cash Number of CO2 Solutions common shares we invested in (shares) Number of Common Shares Fair Value Number of common shares fair value. Initial ownership percentage at the time of investment Percentage of Outstanding Shares Owned at Time of Investment Percentage of Outstanding Shares Owned at Time of Investment Statutory resale restriction expiry period Statutory Resale Restriction Expiry Period Statutory resale restriction expiry period. Gross unrealized gains Unrealized loss on investments Unrealized Gain (Loss) on Investments Cash Equivalents and Equity Securities Cash, Cash Equivalents, and Marketable Securities [Text Block] Retirement Benefits [Abstract] Employer matching contribution amount Defined Benefit Plan, Plan Assets, Contributions by Employer Segment, Geographical and Other Revenue Information Segment Reporting Disclosure [Text Block] Schedule of stock-based compensation expense Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Assumptions used to estimate the fair value of option grants Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of share-based compensation, stock options, activity Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule of share-based compensation, RSA activity Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block] Schedule of share-based compensation, RSU activity Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Share-based compensation, performance shares sward outstanding activity Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block] Schedule of assumptions used Schedule of Assumptions Used [Table Text Block] Related Party Transaction, Due from (to) Related Party [Abstract] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Ownership [Axis] Ownership [Axis] Ownership [Domain] Ownership [Domain] Exela Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Alfa Aesar Alfa Aesar [Member] Alfa Aesar [Member] AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Asymchem Asymchem [Member] Asymchem [Member] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Presidio Partners 2007, L.P. Presidio Partners 2007, L.P. [Member] Presidio Partners 2007, L.P. [Member] Investment, Name [Axis] Investment, Name [Axis] Investment, Name [Domain] Investment, Name [Domain] Revenue sharing arrangement Royalty [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Investment, ownership percentage Investment, Ownership Percentage Investment, Ownership Percentage Accounts receivable, related parties Accounts Receivable, Related Parties Revenue from related parties Revenue from Related Parties Operating Loss and Tax Credit Carryforwards Operating Loss and Tax Credit Carryforwards [Table] Operating Loss and Tax Credit Carryforwards [Table] Income Tax Authority [Axis] Income Tax Authority [Axis] Income Tax Authority [Domain] Income Tax Authority [Domain] Federal Internal Revenue Service (IRS) [Member] State State and Local Jurisdiction [Member] Foreign Tax Authority [Member] Foreign Tax Authority [Member] Net Operating Losses and Tax Credit Carryforwards Operating Loss and Tax Credit Carryforwards [Line Items] [Line Items] for Operating Loss and Tax Credit Carryforwards [Table] Net operating losses, amount Operating Loss Carryforwards Tax credits, amount Tax Credit Carryforward, Amount 401(k) Plan Pension and Other Postretirement Benefits Disclosure [Text Block] Basis of Presentation and Principles of Consolidation Basis of Accounting, Policy [Policy Text Block] Comprehensive income or loss Comprehensive Income, Policy [Policy Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Foreign Currency Translation Foreign Currency Transactions and Translations Policy [Policy Text Block] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Cost of Research and Development Services and Research and Development Expense Research and Development Expense, Policy [Policy Text Block] Advertising Advertising Costs, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Equity Securities Marketable Securities, Policy [Policy Text Block] Fair Value Measurements Fair Value of Financial Instruments, Policy [Policy Text Block] Concentrations of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Accounts Receivable and Allowance for Doubtful Accounts Receivables, Policy [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Concentrations of Supply Risk Concentration Risk, Supply Risk [Policy Text Block] Concentration Risk, Supply Risk [Policy Text Block] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Supply Commitment [Axis] Supply Commitment [Axis] Supply Commitment Arrangement [Domain] Supply Commitment Arrangement [Domain] Supply Commitment Supply Commitment [Member] Agreement Date [Axis] Agreement Date [Axis] Agreement Date [Axis] Agreement Date [Domain] Agreement Date [Domain] [Domain] for Agreement Date [Axis] April 2016 April 2016 [Member] April 2016 [Member] July 2017 July 2017 [Member] July 2017 [Member] December 2017 December 2017 [Member] December 2017 [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Future Minimum Payment Supply Commitment, Remaining Minimum Amount Committed Long-term Purchase Commitment [Table] Long-term Purchase Commitment [Table] Name of Property [Axis] Name of Property [Axis] Name of Property [Domain] Name of Property [Domain] Redwood City, California, Penobscot Space Redwood City, California, Penobscot Space [Member] Redwood City, California, Penobscot Space [Member] Redwood City, California, Building 2 Space Redwood City, California, Building 2 Space [Member] Redwood City, California, Building 2 Space [Member] Redwood City, California, 501 Chesapeake Space Redwood City, California, 501 Chesapeake Space [Member] Redwood City, California, 501 Chesapeake Space [Member] Redwood City, California, Saginaw Space Redwood City, California, Saginaw Space [Member] Redwood City, California, Saginaw Space [Member] Headquarters Redwood City Headquarters Redwood City [Member] Headquarters, Redwood city. Lease Arrangement, Type [Axis] Lease Arrangement, Type [Axis] Lease Arrangement, Type [Domain] Lease Arrangement, Type [Domain] Eighth Lease Amendment Eighth Lease Amendment [Member] Eighth Lease Amendment [Member] Fifth Amendment Fifth Amendment [Member] Fifth amendment. Amendment 7 Amendment 7 [Member] Amendment 7 [Member] Restricted Cash and Cash Equivalents [Axis] Restricted Cash and Cash Equivalents [Axis] Demand Deposits [Member] Demand Deposits [Member] Credit Facility [Axis] Credit Facility [Axis] Credit Facility [Domain] Credit Facility [Domain] Term Debt Term Loan [Member] Term Loan [Member] Revolving Line of Credit Revolving Credit Facility [Member] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] London Interbank Offered Rate (LIBOR) London Interbank Offered Rate (LIBOR) [Member] Prime Rate [Member] Prime Rate [Member] Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Indemnification agreement Indemnification Agreement [Member] Long-term Purchase Commitment [Line Items] Long-term Purchase Commitment [Line Items] Lease area space occupancy Lease Area Space Occupancy Lease area space occupancy. Renewal term Lessee, Operating Lease, Renewal Term Payments for capital improvements Payments for Capital Improvements Payments for (proceeds from) tenant allowance Payments for (Proceeds from) Tenant Allowance Incentive from lessor Incentive from Lessor Asset retirement obligations Asset Retirement Obligation Restricted cash and investments, noncurrent Restricted Cash and Investments, Noncurrent Letters of credit Letters of Credit Outstanding, Amount Rent expense Operating Leases, Rent Expense Sublease rentals Operating Leases, Rent Expense, Sublease Rentals Term of contract Lessee, Finance Lease, Lease Not yet Commenced, Term of Contract Current borrowing capacity Line of Credit Facility, Current Borrowing Capacity Accounts receivable borrowing base percentage Line of Credit Facility, Accounts Receivable Borrowing Base Percentage Line of Credit Facility, Accounts Receivable Borrowing Base Percentage Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Interest rate, stated percentage Debt Instrument, Interest Rate, Stated Percentage Minimum cash multiplier Debt Instrument, Minimum Cash Multiplier of Average Six-Month Trailing Operating Cash Flow Net Outlay Plus the Average Monthly Principal Due and Payable in the Immediately Succeeding Three-Months Debt Instrument, Minimum Cash Multiplier of Average Six-Month Trailing Operating Cash Flow Net Outlay Plus the Average Monthly Principal Due and Payable in the Immediately Succeeding Three-Months Accruals for expenses related to indemnification issues Loss Contingency, Accrual, Current Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Total Assets, Fair Value Disclosure Schedule of cash equivalents and marketable securities Investment [Table Text Block] Related Party Transactions Related Party Transactions Disclosure [Text Block] Restrictions on Cash and Cash Equivalents [Table] Restrictions on Cash and Cash Equivalents [Table] Letter of Credit Letter of Credit [Member] Trustee Deposit Trustee Deposit [Member] Trustee Deposit [Member] Restricted Cash and Cash Equivalents Items [Line Items] Restricted Cash and Cash Equivalents Items [Line Items] Number of reportable segments Number of Reportable Segments Number of operating segments Number of Operating Segments Advertising expense Advertising Expense Unbilled receivables, not billable Unbilled Receivables, Not Billable Impairment of long-lived assets held-for-use Impairment of Long-Lived Assets Held-for-use Goodwill, allocation percent Goodwill, Allocation Percent Goodwill, Allocation Percent Goodwill impairment Goodwill, Impairment Loss Provisional income tax expense valuation Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Asset, Provisional Income Tax Expense Reclassification from AOCI, current period, tax Reclassification from AOCI, Current Period, Tax Operating lease, right-of-use asset Operating Lease, Right-of-Use Asset Operating lease, liability Operating Lease, Liability Finance lease, right-of-use asset Finance Lease, Right-of-Use Asset Finance lease, liability Finance Lease, Liability Balances without adoption of Topic 606 Calculated under Revenue Guidance in Effect before Topic 606 [Member] Movement in Deferred Revenue [Roll Forward] Movement in Deferred Revenue [Roll Forward] Beginning balance Contract with Customer, Liability Changes in estimated consideration Deferred Revenue, Increase (Decrease) In Estimate Deferred Revenue, Increase (Decrease) In Estimate Unsatisfied performance obligations Contract with Customer, Liability, Increase (Decrease) for Contract Acquired in Business Combination Ending balance Document and Entity Information [Abstract] Document and entity information. Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Common Stock, Shares Outstanding (shares) Entity Common Stock, Shares Outstanding Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Entity Public Float Entity Public Float Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Shares issuable under Equity Incentive Plan Stock Compensation Plan [Member] Shares issuable upon the conversion of warrants Warrant [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Total anti-dilutive securities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Statement of Cash Flows [Abstract] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Amortization of intangible assets Amortization of Intangible Assets Depreciation Depreciation Stock-based compensation Share-based Compensation Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Loss on investment securities Gain from extinguishment of asset retirement obligation Gain (Loss) on Extinguishment of Debt Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable, net Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Contract assets Increase (Decrease) in Contract with Customer, Asset Unbilled receivables Increase (Decrease) in Contract with Customer, Asset, Unbilled Increase (Decrease) in Contract with Customer, Asset, Unbilled Other non-current assets Increase (Decrease) in Other Noncurrent Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued compensation Increase (Decrease) in Employee Related Liabilities Other accrued liabilities Increase (Decrease) in Other Accrued Liabilities Other long-term liabilities Increase (Decrease) in Other Noncurrent Liabilities Deferred revenue Increase (Decrease) in Contract with Customer, Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Proceeds from disposal of property and equipment Proceeds from Sale of Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercises of stock options Proceeds from Stock Options Exercised Proceeds from issuance of common stock in connection with public offering, net of underwriting discounts and commission Proceeds from Issuance Initial Public Offering Costs incurred in connection with public offering Payments of Stock Issuance Costs Principal payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Taxes paid related to net share settlement of equity awards Payments Related to Tax Withholding for Share-based Compensation Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Net increase (decrease) in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at the beginning of the year Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at the end of the year Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Income taxes Income Taxes Paid, Net Supplemental non-cash financing activities: Noncash Investing and Financing Items [Abstract] Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash or Part Noncash Acquisition, Fixed Assets Acquired Capital expenditures incurred but not yet paid Capital Expenditures Incurred but Not yet Paid Restricted cash included in non-current assets Restricted Cash and Cash Equivalents Total cash, cash equivalents and restricted cash at the end of the period Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Accounts receivable, net of allowances of $34 at December 31, 2018 and 2017 Accounts Receivable, Net, Current Unbilled receivables, current Unbilled Receivables, Current Inventories Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Contract assets Contract with Customer, Asset, Net Total current assets Assets, Current Restricted cash Equity securities Marketable Securities, Noncurrent Property and equipment, net Property, Plant and Equipment, Net Goodwill Other non-current assets Other Assets, Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued compensation Employee-related Liabilities, Current Other accrued liabilities Deferred revenue Contract with Customer, Liability, Current Total current liabilities Liabilities, Current Deferred revenue, net of current portion Contract with Customer, Liability, Noncurrent Lease incentive obligation, net of current portion Lease Incentive Obligation, Noncurrent Lease Incentive Obligation, Noncurrent Capital lease obligation, net of current portion Other long-term liabilities Other Liabilities, Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 13) Commitments and Contingencies Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding Preferred Stock, Value, Issued Common stock, $0.0001 par value per share; 100,000 shares authorized; 54,065 and 48,365 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Total liabilities and stockholders’ equity Liabilities and Equity Stock options Employee Stock Option [Member] Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Sale of Stock [Axis] Sale of Stock [Axis] Sale of Stock [Domain] Sale of Stock [Domain] Underwritten Public Offering Underwritten Public Offering [Member] Underwritten Public Offering [Member] Over-Allotment Option Over-Allotment Option [Member] Class of Stock [Line Items] Class of Stock [Line Items] Issuance of common stock, net of issuance costs (shares) Sale of Stock, Number of Shares Issued in Transaction Price per share issued (usd per share) Sale of Stock, Price Per Share Proceeds from public offering Sale of Stock, Consideration Received on Transaction Stockholders' Equity Note [Abstract] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Income Statement Location [Axis] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] Income Statement Location [Domain] Research and development Research and Development Expense [Member] Selling, general and administrative Selling, General and Administrative Expenses [Member] RSUs and RSAs Restricted Stock and Restricted Stock Units [Member] Restricted Stock and Restricted Stock Units [Member] Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Schedule of stock-based compensation expense Employee Service Share-based Compensation, Aggregate Disclosures [Abstract] Corporate, Non-Segment Corporate, Non-Segment [Member] Depreciation Loss before income taxes Share-based compensation Balance Sheets Details Supplemental Balance Sheet Disclosures [Text Block] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward] Balance at beginning of year Unrecognized Tax Benefits Additions based on tax positions related to current year Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions Reductions to tax provision of prior years Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions Balance at end of year Disaggregation of revenue Disaggregation of Revenue [Table Text Block] Contract with customer Contract with Customer, Asset and Liability [Table Text Block] Performance obligation, expected timing of satisfaction Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Impact of adoption on financial statements Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block] Schedule of Inventory Components Inventory, Net [Abstract] Raw materials Inventory, Raw Materials, Gross Work in process Inventory, Work in Process, Gross Finished goods Inventory, Finished Goods, Gross Inventories GSK Platform Customer Customer [Member] Customer [Member] Fine Chemical Customer Fine Chemical Customer [Member] Fine Chemical Customer [Member] Porton Porton [Member] Porton [Member] Technology Transfer and License Agreement Technology Transfer, Collaboration and License Agreement [Member] Technology Transfer, Collaboration and License Agreement [Member] Supply Agreement Supply Agreement [Member] Supply Agreement [Member] Research and Development Agreement Research and Development Agreement [Member] Research and Development Agreement [Member] License and Service License and Service [Member] Collaboration Partner [Domain] Global Development, Option and License Agreement Global Development, Option and License Agreement [Member] Global Development, Option and License Agreement [Member] Strategic Collaboration Agreement Strategic Collaboration Agreement [Member] Strategic Collaboration Agreement [Member] Porton Agreement Porton Agreement [Member] Porton Agreement [Member] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Axis] Timing of Transfer of Good or Service [Domain] Timing of Transfer of Good or Service [Domain] Transferred over Time Transferred over Time [Member] Contingent receivables License Revenue, Contingent Receivables License Revenue, Contingent Receivables Proceeds from license fees received Proceeds from License Fees Received Sales revenue, goods Term of milestone agreement Revenue Recognition, Milestone Method, Term of Milestone Agreement Revenue Recognition, Milestone Method, Term of Milestone Agreement Term of agreement extension Collaborative Research and Development Agreement, Optional Extension Period Collaborative Research and Development Agreement, Optional Extension Period Contract with customer, liability Upfront milestone payment Revenue Recognition, Milestone Revenue Revenue Recognition, Milestone Revenue Term of collaborative research and development agreement Term of Collaborative Research and Development Agreement Term of collaborative research and development agreement. Research and development revenues Research and Development Arrangement, Contract to Perform for Others, Compensation Earned Progress payment eligible after commencement of Phase 1a clinical trial Revenue Recognition, Progress Payment, Amount Revenue Recognition, Progress Payment, Amount Deferred revenue - current Liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Number of days for payment Revenue Recognition, Milestone Revenue, Number of Days for Payment Revenue Recognition, Milestone Revenue, Number of Days for Payment Revenue Recognition Revenue from Contract with Customer [Text Block] Subsequent Event [Table] Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Lease, term of contract Lessee, Operating Lease, Term of Contract Total minimum lease payments Progress payment eligible after exercise Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] 2010 Plan Two Thousand Ten Plan [Member] 2010 plan. 2018 PSU and PBO Plan 2018 PSU and PBO Plan [Member] 2018 PSU and PBO Plan [Member] 2017 PSU and PBO Plan 2017 PSU and PBO Plan [Member] 2017 PSU and PBO Plan [Member] 2016 PSU Plan 2016 PSU Plan [Member] 2016 PSU Plan [Member] Incentive Stock Options Incentive Stock Options [Member] Incentive Stock Options [Member] Non-Statutory Stock Options Non-Statutory Stock Options [Member] Non-Statutory Stock Options [Member] Vesting [Axis] Vesting [Axis] Vesting [Domain] Vesting [Domain] Tranche One Share-based Compensation Award, Tranche One [Member] Tranche Two Share-based Compensation Award, Tranche Two [Member] Shares initially available for future issuance (shares) Deferred Compensation Arrangement with Individual, Shares Authorized for Issuance Reduction of share reserve for each share granted (shares) Share-based Compensation Arrangement by Share-based Payment Award, Reduction of Share Reserve For Each Share Granted, Share Share-based Compensation Arrangement by Share-based Payment Award, Reduction of Share Reserve For Each Share Granted, Share Total shares remaining available for issuance (shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Option price as a percent of common stock Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent Percent of voting interests Percent of Voting Interests Threshold to trigger higher exercise price Percent of Voting Interests Threshold to trigger higher exercise price Purchase price of common stock when voting percent is above minimum threshold Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Above Minimum Threshold, Percent Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock Above Minimum Threshold, Percent Expiration period Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period Vesting period of units granted Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Award vesting rights percentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Number of installments Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments Share-based Compensation Arrangement by Share-based Payment Award, Number of Installments Future vesting rights, percentage Share-based Compensation Arrangement By Share-based Payment Award, Future Vesting Rights, Percentage Share-based Compensation Arrangement By Share-based Payment Award, Future Vesting Rights, Percentage Threshold level multiplier Share-based Compensation Arrangement by Share-based Payment Award, Performance Awards, Threshold Level, Number of Shares, Multiplier Share-based Compensation Arrangement by Share-based Payment Award, Performance Awards, Threshold Level, Number of Shares, Multiplier Estimated performance goal achievement rate Share-based Compensation Arrangement by Share-based Payment Award, Estimated Performance Goal Achievement Rate Share-based Compensation Arrangement by Share-based Payment Award, Estimated Performance Goal Achievement Rate Nonemployee services transaction, quantity of securities issued (shares) Share-based Goods and Nonemployee Services Transaction, Quantity of Securities Issued Nonemployee services transaction, value of securities issued Issuance of Stock and Warrants for Services or Claims Weighted average grant date fair value (usd per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Aggregate intrinsic value of options exercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value Unrecognized compensation cost, options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options Weighted-average remaining amortization period (years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Weighted average grant date fair value (usd per share) Equity instruments other than options, aggregate intrinsic value, vested Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Unrecognized compensation cost, awards other than options Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options Exercises in period, intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises in Period, Intrinsic Value Contract Assets Change in Contract with Customer, Asset [Roll Forward] Change in Contract with Customer, Asset [Roll Forward] Beginning balance Additions Contract with Customer, Asset, New Contract Additions Contract with Customer, Asset, New Contract Additions Deductions Contract with Customer, Asset, Reclassified to Receivable Ending balance Unbilled receivables, current Unbilled Receivables, Current [Roll Forward] Unbilled Receivables, Current [Roll Forward] Beginning balance Additions Contract with Customer, Asset, Unbilled Receivables, Current, Additions Contract with Customer, Asset, Unbilled Receivables, Current, Additions Deductions Contract with Customer, Asset, Unbilled Receivables, Current, Deductions Contract with Customer, Asset, Unbilled Receivables, Current, Deductions Ending balance Unbilled receivables, non-current Unbilled Receivables, Long-term [Roll Forward] Unbilled Receivables, Long-term [Roll Forward] Beginning balance Unbilled Receivables, Noncurrent Unbilled Receivables, Noncurrent Additions Contract with Customer, Asset, Unbilled Receivables, Long-term, Additions Contract with Customer, Asset, Unbilled Receivables, Long-term, Additions Deductions Contract with Customer, Asset, Unbilled Receivables, Long-term, Deductions Contract with Customer, Asset, Unbilled Receivables, Long-term, Deductions Ending balance Contract Costs Change in Contract with Customer, Contract Costs [Roll Forward] Change in Contract with Customer, Contract Costs [Roll Forward] Beginning balance Contract With Customer, Contract Costs Contract With Customer, Contract Costs Additions Contract With Customer, Contract Costs, Additions Contract With Customer, Contract Costs, Additions Deductions Contract With Customer, Contract Costs, Deductions Contract With Customer, Contract Costs, Deductions Ending balance Contract Liabilities: Deferred Revenue Change in Contract with Customer, Liability [Roll Forward] Change in Contract with Customer, Liability [Roll Forward] Additions Contract with Customer, Liability, Increase from Cash Receipts Contract with Customer, Liability, Increase from Cash Receipts Deductions Contract with Customer, Liability, Deductions Contract with Customer, Liability, Deductions Change in Contract with Customer, Liability [Abstract] Change in Contract with Customer, Liability [Abstract] Performance obligations satisfied Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Performance obligations satisfied from new activities in the period - contract revenue Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition Contract with Customer, Liability, New Activities, Performance Obligation Satisfied, Revenue Recognition Total revenue Allowance for Doubtful Accounts Receivable [Roll Forward] Allowance for Doubtful Accounts Receivable [Roll Forward] Allowance - beginning of period Allowance for Doubtful Accounts Receivable Write-offs and other Allowance for Doubtful Accounts Receivable, Write-offs Allowance - end of period Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedules of Concentration of Risk Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Schedule of Revenues by Geographical Area Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Schedule of Long-lived Assets by Geographical Area Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block] Schedule of Goodwill Schedule of Intangible Assets and Goodwill [Table Text Block] Initial Application Period, Cumulative Effect Transition [Table] New Accounting Pronouncements or Change in Accounting Principle [Table] Adjustments Income Statement [Abstract] Weighted average common stock shares used in computing net loss per share, basic and diluted (shares) Accounts receivable Unbilled receivables, non-current Other non-current assets Other Assets, Miscellaneous, Noncurrent Liabilities Liabilities [Abstract] Deferred revenue - non-current Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Credit Facility, Repayment Period [Axis] Credit Facility, Repayment Period [Axis] Credit Facility, Repayment Period [Axis] Credit Facility, Repayment Period [Domain] Credit Facility, Repayment Period [Domain] [Domain] for Credit Facility, Repayment Period [Axis] Repayment Period 1 Repayment Period One [Member] Repayment Period One [Member] Repayment Period 2 Repayment Period Two [Member] Repayment Period Two [Member] Repayment Period 3 Repayment Period Three [Member] Repayment Period Three [Member] Repayment Period 4 Repayment Period Four [Member] Repayment Period Four [Member] Repayment Period 5 Repayment Period Five [Member] Repayment Period Five [Member] Repayment Period 6 Repayment Period Six [Member] Repayment Period Six [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Prepayment fee percentage Line of Credit Facility, Prepayment Fee Percentage Line of Credit Facility, Prepayment Fee Percentage Leasehold improvements Leasehold Improvements [Member] Computer equipment and software Computer Equipment [Member] Office equipment and furniture Furniture and Fixtures [Member] Construction in progress Construction in Progress [Member] Property, Plant and Equipment, Net, by Type [Abstract] Property, Plant and Equipment, Net, by Type [Abstract] Property and equipment Property, Plant and Equipment, Gross Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property and equipment, net Equipment retired during period Property, Plant and Equipment, Disposals Stock-based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] EX-101.PRE 17 cdxs-20181231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 18 chart-17ff03687634512f82f.jpg begin 644 chart-17ff03687634512f82f.jpg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end XML 19 R1.htm IDEA: XBRL DOCUMENT v3.10.0.1
Document and Entity Information - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Feb. 22, 2019
Jun. 30, 2018
Document and Entity Information [Abstract]      
Entity Registrant Name CODEXIS INC    
Entity Central Index Key 0001200375    
Document Type 10-K    
Document Period End Date Dec. 31, 2018    
Amendment Flag false    
Document Fiscal Year Focus 2018    
Document Fiscal Period Focus FY    
Current Fiscal Year End Date --12-31    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Common Stock, Shares Outstanding (shares)   54,158,617  
Entity Well-known Seasoned Issuer No    
Entity Public Float     $ 731.5
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
XML 20 R2.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Current assets:    
Cash and cash equivalents $ 53,039 $ 31,219
Accounts receivable, net of allowances of $34 at December 31, 2018 and 2017 11,551 11,447
Unbilled receivables, current 1,916 353
Inventories 589 1,036
Prepaid expenses and other current assets 1,068 984
Contract assets 35 0
Total current assets 68,198 45,039
Restricted cash 1,446 1,557
Equity securities 588 671
Property and equipment, net 4,759 2,815
Goodwill 3,241 3,241
Other non-current assets 1,051 302
Total assets 79,283 53,625
Current liabilities:    
Accounts payable 3,050 3,545
Accrued compensation 5,272 4,753
Other accrued liabilities 4,855 4,362
Deferred revenue 4,936 12,292
Total current liabilities 18,113 24,952
Deferred revenue, net of current portion 3,352 1,501
Lease incentive obligation, net of current portion 35 460
Capital lease obligation, net of current portion 61 302
Other long-term liabilities 1,416 1,863
Total liabilities 22,977 29,078
Commitments and contingencies (Note 13)
Stockholders’ equity:    
Preferred stock, $0.0001 par value per share; 5,000 shares authorized, none issued and outstanding 0 0
Common stock, $0.0001 par value per share; 100,000 shares authorized; 54,065 and 48,365 shares issued and outstanding at December 31, 2018 and December 31, 2017, respectively 5 5
Additional paid-in capital 386,775 340,079
Accumulated other comprehensive loss 0 (472)
Accumulated deficit (330,474) (315,065)
Total stockholders’ equity 56,306 24,547
Total liabilities and stockholders’ equity $ 79,283 $ 53,625
XML 21 R3.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Statement of Financial Position [Abstract]    
Accounts receivable, allowances $ 34 $ 34
Preferred stock, par value (usd per share) $ 0.0001  
Preferred stock, shares authorized (shares) 5,000,000  
Preferred stock, shares issued (shares) 0 0
Preferred stock, shares outstanding (shares) 0 0
Common stock, par value (usd per share) $ 0.000001  
Common stock, shares authorized (shares) 100,000,000  
Common stock, shares issued (shares) 54,605,000 48,365,000
Common stock, shares outstanding (shares) 54,605,000 48,365,000
XML 22 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenues:      
Total revenues $ 60,594 $ 50,024 $ 48,837
Costs and operating expenses:      
Cost of product revenue 12,620 14,327 9,753
Research and development 29,978 29,659 22,229
Selling, general and administrative 29,291 29,008 25,419
Total costs and operating expenses 71,889 72,994 57,401
Loss from operations (11,295) (22,970) (8,564)
Interest income 671 147 60
Other expenses, net (291) (92) (94)
Loss before income taxes (10,915) (22,915) (8,598)
Provision for (benefit from) income taxes (37) 81 (40)
Net loss $ (10,878) $ (22,996) $ (8,558)
Net loss per share, basic and diluted (usd per share) $ (0.21) $ (0.50) $ (0.21)
Weighted average common stock shares used in computing net loss per share, basic and diluted (shares) 52,205 46,228 40,629
Product Sales      
Revenues:      
Total revenues $ 25,590 $ 26,685 $ 15,321
Research and Development Revenues      
Revenues:      
Total revenues $ 35,004 $ 23,339 $ 33,516
XML 23 R5.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Other comprehensive loss:      
Net loss $ (10,878) $ (22,996) $ (8,558)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [1] 0 (472) (405)
Other comprehensive loss 0 (472) (405)
Total comprehensive loss $ (10,878) $ (23,468) $ (8,963)
[1] In 2018, we adopted Accounting Standards Update No. 2016-01 (Subtopic 825-10) and recorded a cumulative-effect reclassification $0.5 million unrealized loss on equity securities from other accumulated comprehensive loss to the beginning accumulated deficit. See Note 2 “Summary of Significant Accounting Policies” in the Accompanying Notes to the Consolidated Financial Statements for more information.
XML 24 R6.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2018
Jan. 01, 2018
Cumulative effect of change in accounting principles $ (4,059)  
Accounting Standards Update 2016-01    
Cumulative effect of change in accounting principles   $ 500
XML 25 R7.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Beginning balance (shares) at Dec. 31, 2015   40,343      
Beginning balance at Dec. 31, 2015 $ 22,879 $ 4 $ 305,981 $ 405 $ (283,511)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (shares) 398 398      
Exercise of stock options $ 1,034   1,034    
Release of stock awards (shares)   911      
Employee stock-based compensation 5,673   5,673    
Taxes paid related to net share settlement of equity awards (shares)   (397)      
Taxes paid related to net share settlement of equity awards (1,524)   (1,524)    
Total comprehensive loss (8,963)     (405) (8,558)
Net loss (8,558)        
Ending balance (shares) at Dec. 31, 2016   41,255      
Ending balance at Dec. 31, 2016 $ 19,099 $ 4 311,164 0 (292,069)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (shares) 86 86      
Exercise of stock options $ 266   266    
Release of stock awards (shares)   1,096      
Employee stock-based compensation 7,048   7,048    
Non-employee stock-based compensation 43   43    
Taxes paid related to net share settlement of equity awards (shares)   (397)      
Taxes paid related to net share settlement of equity awards (1,670)   (1,670)    
Issuance of common stock, net of issuance costs (shares)   6,325      
Issuance of common stock, net of issuance costs 23,229 $ 1 23,228    
Total comprehensive loss (23,468)     (472) (22,996)
Net loss (22,996)        
Ending balance (shares) at Dec. 31, 2017   48,365      
Ending balance at Dec. 31, 2017 $ 24,547 $ 5 340,079 (472) (315,065)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (shares) 772 856      
Exercise of stock options $ 4,680   4,680    
Release of stock awards (shares)   832      
Employee stock-based compensation 7,865   7,865    
Non-employee stock-based compensation 24   24    
Taxes paid related to net share settlement of equity awards (shares)   (301)      
Taxes paid related to net share settlement of equity awards (3,190)   (3,190)    
Issuance of common stock, net of issuance costs (shares)   4,313      
Issuance of common stock, net of issuance costs 37,317   37,317    
Total comprehensive loss (10,878)        
Net loss (10,878)       (10,878)
Ending balance (shares) at Dec. 31, 2018   54,065      
Ending balance at Dec. 31, 2018 56,306 $ 5 $ 386,775 0 (330,474)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Cumulative effect of change in accounting principles $ (4,059)     $ 472 $ (4,531)
XML 26 R8.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Stockholders' Equity (Parenthetical)
$ in Millions
Dec. 31, 2018
USD ($)
Accounting Standards Update 2016-01  
Cumulative effect of change on equity or net assets $ 0.5
Accounting Standards Update 2014-09  
Cumulative effect of change on equity or net assets $ 4.1
XML 27 R9.htm IDEA: XBRL DOCUMENT v3.10.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Operating activities:      
Net loss $ (10,878) $ (22,996) $ (8,558)
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization of intangible assets 0 0 2,812
Depreciation 1,147 1,042 1,734
Stock-based compensation 7,889 7,091 5,673
Loss (gain) on disposal of property and equipment 8 9 (42)
Loss on investment securities 83 0 0
Gain from extinguishment of asset retirement obligation 0 (207) 0
Changes in operating assets and liabilities:      
Accounts receivable, net 960 (5,298) 1,405
Inventories 447 (210) 167
Prepaid expenses and other current assets (37) 157 7
Contract assets (35) 0 0
Unbilled receivables (2,349) (353) 0
Other non-current assets 228 (44) 52
Accounts payable (524) (801) 942
Accrued compensation 519 439 983
Other accrued liabilities (17) 1,399 (593)
Other long-term liabilities (904) 0 0
Deferred revenue (10,631) 11,017 (6,442)
Net cash used in operating activities (14,094) (8,755) (1,860)
Investing activities:      
Purchase of property and equipment (2,768) (985) (888)
Proceeds from disposal of property and equipment 2 2 42
Net cash used in investing activities (2,766) (983) (846)
Financing activities:      
Proceeds from exercises of stock options 4,680 266 1,034
Proceeds from issuance of common stock in connection with public offering, net of underwriting discounts and commission 37,497 23,782 0
Costs incurred in connection with public offering (180) (553) 0
Principal payments on capital lease obligations (238) (175) 0
Taxes paid related to net share settlement of equity awards (3,190) (1,670) (1,524)
Net cash provided by (used in) financing activities 38,569 21,650 (490)
Net increase (decrease) in cash, cash equivalents and restricted cash 21,709 11,912 (3,196)
Cash, cash equivalents and restricted cash at the beginning of the year 32,776 20,864 24,060
Cash, cash equivalents and restricted cash at the end of the year 54,485 32,776 20,864
Supplemental disclosure of cash flow information:      
Interest paid 84 141 14
Income taxes 5 32 5
Supplemental non-cash financing activities:      
Noncash or Part Noncash Acquisition, Fixed Assets Acquired 0 862 0
Capital expenditures incurred but not yet paid 300 42 125
Total cash, cash equivalents and restricted cash at the end of the period $ 32,776 $ 20,864 $ 24,060
XML 28 R10.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Comprehensive income or loss
Comprehensive loss is equivalent to net loss in 2018 because after adopting Accounting Standards Update No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." (“Subtopic 825-10”), we do not have any other transactions recorded under comprehensive loss. Prior to our adoption of Subtopic 825-10, and for the year ended in December 31, 2017 and 2016, comprehensive loss included unrealized gains and unrealized losses from our equity investment in equity securities. See “Recently adopted accounting pronouncements below for additional information.
Certain prior year amounts have been reclassified to conform to 2018 presentation. These changes and reclassifications did not impact net loss or comprehensive loss.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of equity securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.
Segment Reporting

We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for our company. We do not allocate or evaluate assets by segment.
Previously, we had only one business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.
Foreign Currency Translation
The United States dollar is the functional currency for our operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in United States dollars at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-U.S. dollar transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s functional currency are included in other expense in the accompanying consolidated statements of operations.
Revenue Recognition
Policy from January 1, 2018
On January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606) and the related amendments (“ASC 606”). The guidance provides a unified model to determine how revenue is recognized.
Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer.
In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.
The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.
We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition.
The following is a description of principal activities from which we generate revenue:
Product Revenue
Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex® Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer’s use.
Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide under the contract. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.
Research and Development Revenues
We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.
The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.
Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to manufacture a product. If we determine that the customer cannot benefit from the license without our manufacturing capability, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct and has significant standalone functionality, we would recognize revenues from a functional license at a point in time when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.
Our CodeEvolver® platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time as our customer learns to use our technology.
We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We recognize revenues for the functional license at a point in time when the control of the license and technology transfers to the customer.
For agreements that include sales or usage-based royalty payments to us, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
Contract Assets
Contract assets include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. The contract assets are reclassified to receivables when the rights become unconditional.
Contract Liabilities
Contract liabilities are recorded as deferred revenues and include payments received in advance of performance under the contract. Contract liabilities are realized when the development services are provided to the customer or control of the products has been transferred to the customer. A portion of our contract liabilities relate to supply arrangements that contain material rights that are recognized using the alternative method, under which the aggregate amount invoiced to the customer for shipped products, including annual fees, is higher than the amount of revenue recognized based on the transaction price allocated to the shipped products.
Contract Costs
ASC 606 requires the recognition of an asset for the incremental costs of obtaining a contract with a customer if the entity expects to recover such costs. Incremental costs are costs that would not have been incurred if the contract had not been obtained. Examples of contract costs are commissions paid to sales personnel. We do not typically incur significant incremental costs because the compensation of our salespeople are not based on contracts closed but on a mixture of company goals, individual goals, and sales goals. If a commission paid is directly related to obtaining a specific contract, our policy is to capitalize and amortize such costs on a systematic basis, consistent with the pattern of transfer of the good or service to which the asset relates.
Contract costs are reported in other non-current assets.
Revenue Recognition Policy before January 1, 2018
We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.
We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 605-25, “Multiple Element Arrangements.” For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.
Product Sales
Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.
Research and Development Revenues
Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (“FTE”) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee’s product sales or cost savings achieved by our customers.
We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.
We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.
A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.
We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer’s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.
We recognize revenue from royalties based on licensees’ sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.
Cost of Product Revenue
Cost of product revenue comprises both internal and third party fixed and variable costs including materials and supplies, labor, facilities, and other overhead costs associated with our product sales. Shipping costs are included in our cost of product revenue. Such charges were not significant in any of the periods presented.
Fulfillment costs, such as shipping and handling, are recognized at a point in time and are included in cost of product sales.
Cost of Research and Development Services
Cost of research and development services related to FTE services under research and development agreements approximate the research funding over the term of the respective agreements and is included in research and development expense. Costs of services provided under license and platform technology transfer agreements are included in research and development expenses and are expensed in the periods in which such costs are incurred.
Research and Development Expenses
Research and development expenses consist of costs incurred for internal projects and partner-funded collaborative research and development activities, as well as license and platform technology transfer agreements, as mentioned above. These costs include our direct and research-related overhead expenses, which include salaries and other personnel-related expenses (including stock-based compensation), occupancy-related costs, supplies, and depreciation of facilities and laboratory equipment, as well as external costs, and are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no alternative future use are expensed when incurred.
Advertising
Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of operations. Advertising costs were $0.5 million in 2018, $0.7 million in 2017 and $0.5 million in 2016.
Stock-Based Compensation
We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.
Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.
Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.
The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.
Cash and Cash Equivalents
We consider all highly liquid investments with maturity dates of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market funds. The majority of cash and cash equivalents is maintained with major financial institutions in the United States. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits. Cash and cash equivalents totaled $53.0 million and comprised of cash of $21.8 million and money market funds of $31.2 million at December 31, 2018. Cash and cash equivalents totaled $31.2 million, comprised of cash of $24.4 million and money market funds of $6.8 million at December 31, 2017.
Restricted Cash
In 2016, we began the process of liquidating our Indian subsidiary. The local legal requirements for liquidation required us to maintain our subsidiary's cash balance in an account managed by a legal trustee to satisfy our financial obligations. This balance is recorded as non-current restricted cash on the consolidated balance sheets and totaled $0.7 million at December 31, 2018 and $0.8 million at December 31, 2017.
Pursuant to the terms of a lease agreement for our Redwood City, CA facilities, we obtained a letter of credit collateralized by cash deposit balances of $0.7 million as of December 31, 2018 and $0.8 million at December 31, 2017. These cash deposit balances are recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, “Commitments and Contingencies”. In January 2019, we entered into the Eighth Amendment to the Lease for our Redwood City, CA facilities and, as a result, our letters of credit will be collateralized by a cash deposit balance of $1.1 million in 2019. See Note 16, “Subsequent Events” for additional information.
Equity Securities
We invest in equity securities that are carried at estimated fair value with changes in fair value recognized within earnings. Equity securities with remaining maturities of greater than one year or which we currently do not intend to sell are classified as long-term. See Note 6, “Cash Equivalents and Equity Securities.”
Unrealized holding gains and losses (the adjustment to fair value) and realized gains and losses are included in other income (expense) in the consolidated statement of operations subsequent to the adoption of ASU 2016-01 starting on January 1, 2018.
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and we consider counterparty credit risk in our assessment of fair value. Carrying amounts of financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values as of the balance sheet dates because of their short maturities.
The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2: Inputs that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
See Note 7, “Fair Value Measurements” for additional details.
Concentrations of Credit Risk
Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, contract assets, equity securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India, and the Netherlands. Such deposits in those countries may be in excess of insured limits.
Accounts Receivable and Allowance for Doubtful Accounts
We currently sell primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable includes amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance for doubtful accounts.

The allowances for doubtful accounts reflect our best estimates of probable losses inherent in the accounts receivable and contract assets’ balances. We determine the allowances based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivables and contract assets are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.
Unbilled receivable
Pursuant to ASC 606, the timing of revenue recognition may differ from the timing of invoicing to our customers. When we satisfy (or partially satisfy) a performance obligation, prior to being able to invoice the customer, we recognize an unbilled receivable when the right to consideration is unconditional. As of December 31, 2018, we recorded a total of unbilled receivables of $2.7 million included on our consolidated balance sheets.
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.
Concentrations of Supply Risk
We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the large scale manufacturing of our products to contract manufacturers with facilities in Austria and Italy.
Property and Equipment
Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:
 
Asset classification
Estimated useful life
 
Laboratory equipment
5 years
 
Computer equipment and software
3 to 5 years
 
Office equipment and furniture
5 years
 
Leasehold improvements
Lesser of useful life or lease term

Property and equipment classified as construction in process includes equipment that has been received but not yet placed in service. Normal repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets
Our tangible long-lived assets consist primarily of property and equipment.
In the first quarter of 2018, we determined that we operate in two segments. We have not identified property and equipment by segment since these assets are shared or commingled. We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of unexpected undiscounted cash flows.
As of December 31, 2018 and 2017, there were no events or changes in circumstances which indicated that the carrying amount of our Asset Group might not be recoverable. No impairment charges for long-lived assets were recorded during the years ended December 31, 2018, 2017 and 2016.
Goodwill
Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level. Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill is allocated to the Performance Enzymes segment and 24% is allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill was assigned to the Performance Enzymes segment and $0.8 million was assigned to the Novel Biotherapeutics segment. There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year.
The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology, we compared the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit’s carrying amount goodwill over the respective implied fair value is recognized as an impairment. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
Income Taxes
We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.
We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of December 31, 2018, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as we believe that it is more likely than not that the majority of deferred tax assets will not be realized.
We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.
We account for uncertainty in income taxes as required by the provisions of ASU 2009-06, Income Taxes (Topic 740) ”Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities”, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.
The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (“NOL”) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited.
The adoption of ASC 606 primarily resulted in less revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.
We recognized income tax benefit of $37 thousand, income tax provision of $81 thousand and income tax benefit of $40 thousand for the years ended December 31, 2018, 2017 and 2016, respectively. The income tax benefits were due to a net loss from our foreign operation and a reduction in the deferred tax liability for accrued future withholding taxes on dividends. We continue to maintain a full valuation allowance against our net deferred tax assets as we believe that it is more likely than not that the majority of our deferred tax assets will not be realized.
Changes to Tax Law

On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was signed into law making significant changes to the Internal Revenue Code. The Tax Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (“AMT”) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (“BEAT”), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (“GILTI”) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer’s compensation limitation.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now complete include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.

Because ASC 740-10-25-47 requires the effect of a change in tax laws or rates to be recognized as of the date of enactment, we remeasured our deferred tax assets and liabilities, and offsetting valuation allowance in 2017. There was no impact to tax expense as the remeasurement of net deferred tax assets was completely offset by a corresponding change in valuation allowance. The reduction to U.S. deferred tax assets and the offsetting valuation allowance was $34.1 million.

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. At December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.
The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.

Recent Accounting Pronouncements
Recently adopted accounting pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)" , (“ASC 606”), amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for public companies effective for annual and interim reporting periods beginning after December 15, 2016. We have adopted the provisions of ASC 606 and the related amendments, effective January 1, 2018, using the modified retrospective transition method. We recognized the cumulative effect of applying the new revenue standard and recognized a $4.1 million increase to the opening balance of the accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented. See Note 3, "Revenue Recognition" for more details.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities" (“Subtopic 825-10”). This guidance principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of this new guidance, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. This new guidance primarily impacts our accounting for equity investments. In February 2018, the FASB issued ASU 2018-03, "Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, that clarifies the guidance in ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10)." Prior to the adoption of ASC 825, we recognized unrealized holding gains and losses from our equity investment in CO2 Solutions in other comprehensive loss. We adopted ASC 825 in the first quarter of 2018 using a modified retrospective approach by means of a cumulative-effect adjustment to accumulated deficit. Upon adoption of ASC 825, we reclassified $0.5 million of unrealized loss (net of $0.6 million tax) from other accumulated comprehensive loss to beginning accumulated deficit. Any changes in the fair value of our equity investments, except those accounted for under the equity method, will be recognized in earnings on a prospective basis.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" (“ASC 230”), which provides the FASB's guidance on certain cash flow statements items. ASC 230 is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. We adopted ASC 230 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, "Statement of Cash Flows (Topic 230) Restricted Cash a consensus of the FASB Emerging Issues Task Force” (“ASC 230”). The standard requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows. We adopted ASU 2016-18 in the first quarter of 2018 and the adoption had no material impact on our annual consolidated financial statements. The effect of the adoption of ASC 230 on our consolidated statements of cash flows was to include restricted cash balances in the beginning and end of period balances of cash and cash equivalents and restricted cash. The change in restricted cash was previously disclosed in operating and investing activities in the consolidated statements of cash flows.

In January 2017, the FASB issued ASU No. 2017-01 "Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASC 805”). The guidance requires the use of a framework to determine whether a set of assets and activities constitutes an acquired or a sold business. The guidance is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. The amendments should be applied prospectively as of the beginning of the period of adoption. We adopted ASC 805 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, "Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASC 718”). The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. The new standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. We adopted ASC 718 in the first quarter of 2018 and the adoption had no impact on our annual consolidated financial statements.

In March 2018, the FASB issued ASU 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118" (“ASC 740”) which amends Topic 740 by incorporating the SEC Staff Accounting Bulletin No. 118 (SAB 118) issued on December 22, 2017. SAB 118 provides guidance on accounting for the effects of the Tax Cuts and Jobs Act (Tax Reform) and allows a company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. See Income Taxes section above for additional information.
Recently issued accounting pronouncements not yet adopted
From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASC 842”), which replaces prior lease guidance (“ASC 840”). This guidance establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statement of Operations. The guidance also eliminates today’s real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Entities have the option to use certain practical expedients. Full retrospective application is prohibited. ASC 842 is effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU 2018-10, "Codification Improvements to ASC 842, Leases." These amendments affect narrow aspects of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under ASC 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under ASC 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. For entities that have not adopted ASC 842, the effective date and transition requirements will be the same as the effective date and transition requirements in ASC 842. The FASB also issued ASU 2018-11, "Leases (Topic 842): Targeted Improvements." These amendments provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). The amendments also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under ASC 606 and certain criteria are met. If the nonlease component or components associated with the lease component are the predominant component of the combined component, an entity is required to account for the combined component in accordance with ASC 606. Otherwise, the entity must account for the combined component as an operating lease in accordance with ASC 842. For entities that have not adopted ASC 842 before the issuance of ASU No. 2018-11, the effective date and transition requirements for the amendments related to separating components of a contract are the same as the effective date and transition requirements in ASU No. 2016-02. We plan to adopt ASC 842 on January 1, 2019 using a modified retrospective approach and effective date method per adoption of ASU 2018-11. We will recognize and measure all leases within the scope of the standard that exist as of January 1, 2017, beginning of the earliest period, as if the standard had always been applied, subject to the practical expedients and transition relief in “Practical Expedients” section. In the current period, we evaluated the practical expedients elections and on adoption, and may apply a practical expedient in which an entity need not reassess whether any expired or existing contracts are or contain leases; An entity need not reassess the lease classification for any expired or existing leases (for example, all existing leases that were classified as operating leases in accordance with ASC 840 will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 will be classified as finance leases); An entity need not reassess initial direct costs for any existing leases. We started the transition plan in the third quarter of 2018 and continued to perform the scoping work in the fourth quarter of 2018. We identified a total of 13 lease agreements that are subject to ASC 842 and seven of them meet the short-term lease exception. We completed the full analysis by January, 2019 and we evaluated the right-of-use (ROU) assets and lease liability using the incremental borrowing rate (IBR) at December 31, 2018 because the implicit rate is not readily determinable in the lease agreement. Upon adoption of ASC 842, all existing leases will be classified as either operating lease or finance lease. We expect to record a range from $20 million to $30 million of ROU assets and liabilities for operating leases and a range from $0.1 million to $0.8 million of ROU assets and liabilities for finance leases in the balance sheet during the first quarter of 2019. This analysis was inclusive of the eighth amendment to the lease agreement disclosed in Note 16, “Subsequent Events.”
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model (known as the "current expected credit loss model") that is based on expected losses rather than incurred losses. ASU 2016-13 is effective for annual reporting periods ending after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements and related disclosures.
In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. This standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects and will be effective for us beginning January 1, 2019 and should be applied either in the period of adoption or retrospectively. Early adoption is permitted. We do not expect this standard to have any impact on our consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting," which expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In July 2018, the FASB issued ASU 2018-09, "Codification Improvements”, which represent changes to clarify, correct errors in, or make minor improvements to the Codification, eliminating inconsistencies and providing clarifications in current guidance. The amendments in this ASU include those made to: Subtopic 220-10, Income Statement-Reporting Comprehensive Income-Overall; Subtopic 470-50, Debt-Modifications and Extinguishments; Subtopic 480-10, Distinguishing Liabilities from Equity-Overall; Subtopic 718-740, Compensation-Stock Compensation-Income Taxes; Subtopic 805-740, Business Combinations-Income Taxes; Subtopic 815-10, Derivatives and Hedging-Overall; Subtopic 820-10, Fair Value Measurement-Overall; Subtopic 940-405, Financial Services-Brokers and Dealers-Liabilities; and Subtopic 962-325, Plan Accounting-Defined Contribution Pension Plans-Investments-Other. The transition and effective date guidance is based on the facts and circumstances of each amendment. Some of the amendments do not require transition guidance and will be effective upon issuance. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. We do not expect this standard to have any material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement." The primary focus of ASU 2018-13 is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. In general, the amendments in this standard are effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606." ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. In general, for public companies, the amendments in this standard are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.

In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments—Credit Losses." ASU 2018-19 clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. In general, the amendments in this standard are effective for public business entities that meet the definition of a SEC filer for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We do not expect this standard to have any material impact on our consolidated financial statements.
XML 29 R11.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business
12 Months Ended
Dec. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Description of Business
Description of Business
In these notes to the consolidated financial statements, the “Company,” “we,” “us,’” and “our” refers to Codexis, Inc. and its subsidiaries on a consolidated basis.
We discover, develop and sell proteins that deliver value to our clients in a growing set of industries. We view proteins as a vast untapped source of value-creating materials, and we are using our proven technologies, which have been continuously improved over our fifteen year history, to commercialize an increasing number of novel proteins, both as proprietary Codexis products and in partnership with our customers.
We are a pioneer in the harnessing of computational technologies to drive biology advancements. Over the last fifteen years, we have made substantial investments in the development of our CodeEvolver® protein engineering technology platform, the primary source of our competitive advantage. Our technology platform is powered by proprietary, artificial intelligence-based, computational algorithms that rapidly mine our large and continuously growing library of protein variants’ performance attributes. These computational outputs enable increasingly reliable predictions for next generation protein variants to be engineered, enabling delivery of targeted performance enhancements in a time-efficient manner. In addition to its computational prowess, our CodeEvolver® protein engineering technology platform integrates additional modular competencies, including robotic high-throughput screening and genomic sequencing, organic chemistry and process development which are all coordinated to create our novel protein innovations.
Our approach to developing commercially viable biocatalytic manufacturing processes begins by conceptually designing the most cost-effective and practical process for a targeted product. We then develop optimized protein catalysts to enable that process design, using our CodeEvolver® protein engineering platform technology. Engineered protein catalyst candidates - many thousands for each protein engineering project - are then rapidly screened and validated in high throughput screening under relevant manufacturing operating conditions. This approach results in an optimized protein catalyst enabling cost-efficient processes that typically are relatively simple to run in conventional manufacturing equipment. This also allows for the efficient technical transfer of our process to our manufacturing partners.
The successful embodiment of our CodeEvolver® protein engineering technology platform in commercial manufacturing processes requires well-integrated expertise in a number of technical disciplines. In addition to those directly involved in practicing our CodeEvolver® protein engineering platform technology, such as molecular biology, enzymology, microbiology, cellular engineering, metabolic engineering, bioinformatics, biochemistry and high throughput analytical chemistry, our process development projects also involve integrated expertise in organic chemistry, chemical process development, chemical engineering, fermentation process development and fermentation engineering. Our integrated, multi-disciplinary approach to biocatalyst and process development is a critical success factor for our company.
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, which remains our primary business focus. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development.
We have also used the technology to develop protein catalysts for use in the fine chemicals market. The fine chemicals market consists of several large market verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals.
We have also begun using the CodeEvolver® protein engineering technology platform to develop early stage, novel biotherapeutic product candidates, both for our customers and for our own business, most notably our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we entered into a Global Development, Option and License Agreement with Nestec, Ltd. (“Nestlé Health Science”) to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license to develop and commercialize CDX-6114.
In April 2018, we entered into a strategic agreement (the "Porton Agreement") with Porton Pharma Solutions, Ltd. ("Porton") to license key elements of our platform technology to Porton’s global custom intermediate and active pharmaceutical ingredients ("API") development and manufacturing business. This gives us access to a wide variety of small and medium-sized pharmaceutical customers.
We are also using our technology to develop enzymes for customers using next generation sequencing ("NGS") and polymerase chain reaction ("PCR/qPCR") for in vitro molecular diagnostic and genomic research applications. Our first enzyme is a ligase which we began marketing to customers in 2018.
Below are brief descriptions of our business segments:
Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications. In April 2018, we entered into the Porton Agreement related to our strategic collaboration with Porton to license key elements of our world-leading biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business.

Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of hyperphenylalaninemia (“HPA”) (also referred to as PKU) in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” for additional details. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.

For additional discussion of our business segments, see Note 15, "Segment, Geographical and Other Revenue Information."
XML 30 R12.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition
12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Revenue Recognition
Revenue Recognition
On January 1, 2018, we adopted ASC 606, applying the modified retrospective method to all contracts that were not completed as of that date. Results for reporting periods beginning after January 1, 2018 are presented under ASC 606 while prior period results are not adjusted and continue to be reported under the accounting standards in effect for the prior period. We recorded an increase to opening accumulated deficit of $4.1 million as of January 1, 2018 due to the cumulative impact of adopting ASC 606. The impact on revenue for the year ended December 31, 2018 was an increase of $5.0 million as a result of adopting ASC 606. The increase in revenues from the adoption of ASC 606 was primarily due to revenue from a product that was recognized over time as we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically for the customer’s use, and revenues from research and development contracts that were recognized when we had the right to invoice our customers for monthly services completed to date. Also, revenue from a distinct, functional license granted on January 1, 2018 contributed to the increase in revenue from the adoption of ASC 606.

We are entitled to certain future milestone payments under our collaborative arrangements. Such milestone payments represent variable consideration that was fully constrained as the realization of the variable consideration is highly uncertain.
Disaggregation of Revenue
The following table provides information about disaggregated revenue from contracts with customers into the nature of the products and services, and geographic regions, and includes a reconciliation of the disaggregated revenue with reportable segments. The geographic regions that are tracked are the Americas (United States, Canada, Latin America), EMEA (Europe, Middle East, Africa), and APAC (Australia, New Zealand, Southeast Asia, China).
We identified our biotherapeutics business as a standalone business segment in the beginning of 2018 and revenues related to the Novel Biotherapeutics segment were first generated in 2017. Therefore, segment information for fiscal year 2016 is not provided.

Segment information for fiscal year 2018 is as follows (in thousands):
 
Year Ended December 31, 2018
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
25,590

 
$

 
$
25,590

Research and development revenue
21,483

 
13,521

 
35,004

Total revenues
$
47,073

 
$
13,521

 
$
60,594

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,332

 
$
38

 
$
15,370

EMEA
8,878

 
13,483

 
22,361

APAC
22,863

 

 
22,863

Total revenues
$
47,073

 
$
13,521

 
$
60,594


Segment information for fiscal year 2017 is as follows (in thousands):
 
Year Ended December 31, 2017
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
26,685

 
$

 
$
26,685

Research and development revenue
15,648

 
7,691

 
23,339

Total revenues
$
42,333

 
$
7,691

 
$
50,024

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,575

 
$

 
$
15,575

EMEA
11,919

 
7,691

 
19,610

APAC
14,839

 

 
14,839

Total revenues
$
42,333

 
$
7,691

 
$
50,024



The following table shows the reconciliation of contract liabilities from what was disclosed in the Form 10-K for the year ended December 31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January 1, 2018 (in thousands):

 
Balance
Deferred Revenue, balance at December 31, 2017
$
13,793

Changes in estimated consideration

Unsatisfied performance obligations
$
5,173

Deferred Revenue, balance at January 1, 2018
$
18,966



Contract Balances
The following table presents changes in the contract assets, unbilled receivable, contract costs, and contract liabilities (in thousands):
 
January 1, 2018 balance
 
Additions
 
Deductions (1)
 
December 31, 2018
Contract Assets
$

 
8,934

 
(8,899
)
 
$
35

Unbilled receivables, current
$

 
2,908

 
(992
)
 
$
1,916

Unbilled receivables, non-current
$

 
786

 

 
$
786

Contract Costs
$
239

 

 
(197
)
 
$
42

Contract Liabilities: Deferred Revenue
$
18,966

 
6,446

 
(17,124
)
 
$
8,288

(1) The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.
We recognize accounts receivable when we have an unconditional right to recognize revenue and have issued an invoice to the customer. Our payment terms are generally between 30 and 90 days. We recognize unbilled receivables when we have an unconditional right to recognize revenue and have not issued an invoice to our customer. Unbilled receivables, current are transferred to accounts receivable on issuance of an invoice. Unbilled receivables, non-current are transferred to accounts receivable on issuance of an invoice; payment is expected from the customer thereon. Unbilled receivables are classified separately on the consolidated balance sheet as assets.
Contract assets represent our right to recognize revenue for custom products with no alternate use and under binding non-cancellable purchase orders and are largely related to our procurement of product. We recognize contract assets when we have a conditional right to recognize revenue. The delivery pattern of certain of products occurs in advance of the invoicing process, which generates contract assets. In addition, we recognize a contract asset related to milestones not eligible for royalty accounting when we assess it is probable of being achieved and there will be no significant reversal of cumulative revenues. Contract assets are classified separately on the consolidated balance sheet as an asset and transferred to accounts receivable when our rights to payment become unconditional.
Contract liabilities, or deferred revenue, represent our obligation to transfer a product or service to the customer, and for which we have received consideration from the customer. We recognize a contract liability when we receive advance customer payments under development agreements for research and development services, upfront license payments, and from upfront customer payments received under product supply agreements. Contract liabilities are classified as a liability on the consolidated balance sheet.
Contract costs relate to incremental costs of obtaining a contract with a customer. Contract costs are amortized along with the associated revenue over the term of the contract.
We had no asset impairment charges related to contract assets in the period.

During the year ended December 31, 2018, we recognized the following revenues (in thousands):
Revenue recognized in the period for:
Year Ended December 31, 2018
Amounts included in contract liabilities at the beginning of the period:
 
     Performance obligations satisfied
$
13,615

Changes in the period:
 
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods
374

Performance obligations satisfied from new activities in the period - contract revenue
46,605

Total revenue
$
60,594


Performance Obligations
The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of December 31, 2018. We did not recognize any revenue from performance obligations satisfied in previous periods.

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):
 
2019
 
2020
 
2021
 
2022 and Thereafter
 
Total
Product Revenue
$
2,201

 
$
1,729

 
$
1,623

 
$

 
$
5,553

Research and development revenue
2,735

 

 

 

 
2,735

Total revenues
$
4,936

 
$
1,729

 
$
1,623

 
$

 
$
8,288



Practical Expedients, Elections, and Exemptions
We used a practical expedient available under ASC 606 which permits us to consider the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented when identifying satisfied and unsatisfied performance obligations, transaction price, and allocating the transaction price to the satisfied and unsatisfied performance obligations.
We also used a practical expedient available under ASC 606 which permits us not to adjust the amount of consideration for the effects of a significant financing component if, at contract inception, the expected period between the transfer of promised goods or services and customer payment is one year or less.
We perform monthly services under our research and development agreements and we use a practical expedient available under ASC 606 permitting us to recognize revenue at the same time that we have the right to invoice our customer for monthly services completed to date.
We have elected to treat shipping and handling activities as fulfillment costs.
Additionally, we have elected to record revenue net of sales and other similar taxes.

Impact on Financial Statements
In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):
 
Year Ended December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Revenues:





Product revenue
$
25,590


$
(3,422
)

$
22,168

Research and development revenue
35,004


(1,609
)

33,395

Total revenues
60,594


(5,031
)

55,563

Costs and operating expenses:





Cost of product revenue
12,620


(285
)

12,335

Research and development
29,978


(196
)

29,782

Selling, general and administrative
29,291




29,291

Total costs and operating expenses
71,889


(481
)

71,408

Loss from operations
(11,295
)

(4,550
)

(15,845
)
Interest income
671




671

Other expenses
(291
)



(291
)
Loss before income taxes
(10,915
)

(4,550
)

(15,465
)
Provision for (benefit from) income taxes
(37
)



(37
)
Net loss
$
(10,878
)

$
(4,550
)

$
(15,428
)









Net loss per share, basic and diluted
$
(0.21
)

$
(0.09
)

$
(0.30
)
Weighted average common shares used in computing net loss per share, basic and diluted
52,205




52,205


 
December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Assets





Accounts receivable
$
11,551


$
(1,253
)

$
10,298

Unbilled receivables, current
1,916


(1,916
)


Contract assets
35


(35
)


Inventories
589


1


590

Unbilled receivables, non-current
786

 
(786
)
 

Other non-current assets
265


(42
)

223

Liabilities





Other accrued liabilities
4,855


(520
)

4,335

Deferred revenue - current
4,936


(1,574
)

3,362

Deferred revenue - non-current
3,352


(1,445
)

1,907

Stockholders' equity








Accumulated deficit
(330,474
)

(492
)

(330,966
)
XML 31 R13.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Net Loss per Share
Net Loss per Share
Basic net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture. Diluted net loss per share is computed by dividing net loss by the weighted-average number of shares of common stock outstanding, less RSAs subject to forfeiture, plus all additional common shares that would have been outstanding, assuming dilutive potential common shares had been issued for other dilutive securities. For all periods presented, diluted and basic net losses per share are identical since potential common shares are excluded from the calculation, as their effect was anti-dilutive.
Anti-Dilutive Securities
In periods of net loss, the weighted average number of shares outstanding related to potentially dilutive securities, prior to the application of the treasury stock method, are excluded from the computation of diluted net loss per common share because including such shares would have an anti-dilutive effect.
The following shares were not included in the computation of diluted net loss per share (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares issuable under Equity Incentive Plan
6,339

 
6,882

 
5,567

Shares issuable upon the conversion of warrants

 

 
73

Total anti-dilutive securities
6,339

 
6,882

 
5,640

XML 32 R14.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements
12 Months Ended
Dec. 31, 2018
Research and Development [Abstract]  
Collaborative Arrangements
Collaborative Arrangements

Deferred revenue amounts discussed herein as of December 31, 2017 are derived from our Form 10-K for the year ended December 31, 2017. On January 1, 2018 we adopted Topic 606 and subsequently adjusted deferred revenue to give effect to the modified retrospective adoption of the revenue guidance. See Note 3, “Revenue Recognition” for additional information.

GSK Platform Technology Transfer, Collaboration and License Agreement
In July 2014, we entered into a CodeEvolver® protein engineering platform technology transfer collaboration and license agreement (the "GSK CodeEvolver® Agreement") with GlaxoSmithKline ("GSK"). Pursuant to the terms of the agreement, we granted GSK a non-exclusive license to use the CodeEvolver® protein engineering platform technology to develop novel enzymes for use in the manufacture of GSK's pharmaceutical and health care products.
We received an upfront fee upon the execution of the agreement in July 2014 and milestone payments in each of the years from 2014 through April 2016. We completed the transfer of the CodeEvolver® protein engineering platform technology to GSK in April 2016 and all revenues relating to the technology transfer have been recognized as of April 2016. We have the potential to receive additional cumulative contingent payments that range from $5.75 million to $38.5 million per project based on GSK’s successful application of the licensed technology. We are also eligible to receive royalties based on net sales of GSK’s sales of licensed enzyme products that are currently not being recognized.
Merck Platform Technology Transfer and License Agreement
In August 2015, we entered into a CodeEvolver® platform technology transfer collaboration and license agreement (the "Merck CodeEvolver® Agreement") with Merck, Sharp & Dohme ("Merck") which allows Merck to use the CodeEvolver® protein engineering technology platform in the field of human and animal healthcare.
We received a $5.0 million up-front license fee upon execution of the Merck CodeEvolver® Agreement, and milestone payments in September 2015 and in September 2016, when we completed the transfer of the engineering platform technology. We recognized research and development revenues of $4.1 million, $3.6 million, and $3.0 million in 2018, 2017 and 2016, respectively, for various research projects under our collaborative arrangement.
We have the potential to receive payments of up to a maximum of $15.0 million for each commercial active pharmaceutical ingredient ("API") that is manufactured by Merck using one or more novel enzymes developed by Merck using the CodeEvolver® protein engineering technology platform. The API payments, which are currently not recognized in revenue, are based on quantity of API developed and manufactured by Merck and will be recognized as usage-based royalties.
In October 2018, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we amended certain licensing provisions and one exhibit. In January 2019, we entered into an amendment to the Merck CodeEvolver® Agreement whereby we will install certain CodeEvolver® protein engineering technology upgrades into Merck’s platform license installation and maintain those upgrades for a multi-year term.
Merck Sitagliptin Catalyst Supply Agreement
In February 2012, we entered into a five-year Sitagliptin Catalyst Supply Agreement (“Sitagliptin Catalyst Supply Agreement”) with Merck whereby Merck may obtain commercial scale enzyme for use in the manufacture of Januvia®, its product based on the active ingredient Sitagliptin. In December 2015, Merck exercised its option under the terms of the Sitagliptin Catalyst Supply Agreement to extend the agreement for an additional five years through February 2022.
Effective as of January 2016, we and Merck amended the Sitagliptin Catalyst Supply Agreement to prospectively provide for variable pricing based on the cumulative volume of sitagliptin catalyst purchased by Merck and to allow Merck to purchase a percentage of its requirements for sitagliptin catalyst from a specified third-party supplier. Merck received a distinct, functional license to manufacture a portion of its demand beginning January 1, 2018, which we recognized as research and development revenue. We recognized research and development revenues of $1.3 million, $1.3 million and $1.3 million in 2018, 2017 and 2016, respectively.
In June 2017, we completed a contractual milestone by qualifying the specified third-party enzyme supplier and recognized $0.3 million as research and development revenues.
We have determined that the variable pricing, which provides a discount based on the cumulative volume of sitagliptin catalyst purchased by Merck, provides Merck material rights and we are recognizing product revenues using the alternative method. Under the alternative approach, we estimate the total expected consideration and allocate it proportionately with the expected sales.
The Sitagliptin Catalyst Supply Agreement requires Merck to pay an annual fee for the rights to the sitagliptin technology each year for the term of the Sitagliptin Catalyst Supply Agreement. Amounts of annual license fees are based on contractually agreed prices and are on a declining scale over the term of the contract.
We had a deferred revenue balance from Merck of $3.6 million at December 31, 2018 and $1.5 million at December 31, 2017. Pursuant to the terms of the Sitagliptin Catalyst Supply Agreement, Merck may purchase supply from us for a fee based on contractually stated prices and we recognized $12.3 million, $9.0 million and $5.9 million in 2018, 2017 and 2016, respectively, in product revenue under this agreement.
Enzyme Supply Agreement
In November 2016, we entered into a supply agreement whereby our customer may purchase quantities of one of our proprietary enzymes for use in its commercial manufacture of a product. Pursuant to the supply agreement, we received an upfront payment of $0.8 million in December 2016, which we accordingly recorded as deferred revenues. Such upfront payment will be recognized over the period of the supply agreement as the customer purchases our proprietary enzyme. We additionally have determined that the volume discounts under the supply agreement provides the customer material rights and we are recognizing revenues using the alternative method. As of December 31, 2018 and 2017, we had deferred revenue from the supply agreement of $2.0 million and $0.7 million, respectively.
Research and Development Agreement
In March 2017, we entered into a multi-year research and development services agreement with Tate & Lyle Ingredients Americas LLC ("Tate & Lyle") to develop enzymes for use in the manufacture of Tate & Lyle’s zero-calorie TASTEVA® M Stevia sweetener. Under the agreement, we received an upfront payment of $3.0 million, which was originally recognized ratably over the maximum term of the services period of 21 months. Beginning January 1, 2018, we are recognizing revenue using a single measure of progress that depicts our performance in transferring the services. During the second quarter of 2018, Tate & Lyle opted to obtain additional development services that we completed by June 30, 2018 and we earned milestone payments upon completion of the services. We recognized $7.1 million and $3.2 million of revenue in 2018 and 2017, respectively, for research and development services under the research and development agreement. As of December 31, 2018 and 2017, we had deferred revenue from the development services agreement of zero and $3.1 million, respectively.
Global Development, Option and License Agreement and Strategic Collaboration Agreement
In October 2017, we entered into a Global Development, Option and License Agreement (the "Nestlé Agreement") with Nestec Ltd. ("Nestlé Health Science") and, solely for the purpose of the integration and the dispute resolution clauses of the Nestlé Agreement, Nestlé Health Science S.A., to advance CDX-6114, our enzyme biotherapeutic product candidate for the potential treatment of PKU.
We received an upfront cash payment of $14.0 million in 2017 upon the execution of the Nestlé Agreement and a $4.0 million milestone payment 60 days after dosing the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114 for the potential treatment of PKU. The $4.0 million milestone payment that was triggered by the initiation of the trial was received in September 2018. The upfront payment and the variable consideration relating to the progress payment of $4.0 million are being recognized over time as the development work is being performed. Revenue is being recognized using a single measure of progress that depicts our performance in transferring control of the services, which is based on the ratio of level of effort incurred to date compared to the total estimated level of effort required to complete all performance obligations under the agreement. We recognized development fees of $9.9 million in 2018 as research and development revenue and $7.2 million in 2017. We had deferred revenue related to the development fees attributed to the milestone payment and up-front fees of $1.9 million at December 31, 2018 and $6.8 million at December 31, 2017.
In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sub-licensable license for the global development and commercialization of CDX-6114 for the management of PKU. As a result of the option exercise, Nestlé Health Science is obligated to pay us $3.0 million within 60 days after exercise of the option. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details. Other potential payments from Nestlé Health Science to us under the Nestlé Agreement include (i) development and approval milestones of up to $86.0 million, (ii) sales-based milestones of up to $250.0 million in the aggregate, which aggregate amount is achievable if net sales exceed $1.0 billion in a single year, and (iii) tiered royalties, at percentages ranging from the middle single digits to low double-digits, of net sales of Product.
In addition to the Nestlé Agreement, we and Nestlé Health Science concurrently entered into a Strategic Collaboration Agreement (the “Strategic Collaboration Agreement”) pursuant to which we and Nestlé Health Science will collaborate to leverage the CodeEvolver® protein engineering technology platform to develop novel enzymes for Nestlé Health Science’s established Consumer Care and Medical Nutrition business areas. Under the Strategic Collaboration Agreement, we received an upfront payment of $1.2 million in 2017 and an incremental $0.6 million payment in September 2018 for additional services. We recognized research and development fees of $3.6 million and $0.5 million in 2018 and 2017, respectively. As of December 31, 2018 and 2017, we had deferred revenue of $0.8 million and $1.1 million, respectively.
Strategic Collaboration Agreement
In April 2018, we entered into the Porton Agreement with Porton to license key elements of Codexis’ biocatalyst technology for use in Porton’s global custom intermediate and API development and manufacturing business. Under the Porton Agreement, we are eligible to receive annual collaboration fees and research and development revenues. We have the potential to receive performance payments based on products produced by Porton using our company technology under the license agreement. We received an initial collaboration fee of $0.5 million within 30 days of the effective date of the agreement. As of December 31, 2018, we completed the technical transfer and we recognized revenue of $2.8 million in 2018 as research and development revenue. Revenue relating to the functional license provided to Porton was recognized at a point in time when control of the license transferred to the customer.
XML 33 R15.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Equity Securities
12 Months Ended
Dec. 31, 2018
Debt Securities, Available-for-sale [Abstract]  
Cash Equivalents and Equity Securities
Cash Equivalents and Equity Securities
Cash equivalents and equity securities at December 31, 2018 and 2017 consisted of the following (in thousands): 
 
December 31, 2018
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
31,225

 
$

 
$

 
$
31,225

 
n/a
Common shares of CO2 Solutions (2)
563

 
25

 

 
588

 
n/a
Total
$
31,788

 
$
25

 
$

 
$
31,813

 
 

 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
6,778

 
$

 
$

 
$
6,778

 
n/a
Common shares of CO2 Solutions (2)
563

 
108

 

 
671

 
n/a
Total
$
7,341

 
$
108

 
$

 
$
7,449

 
 

(1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets.
(2) Common shares of CO2 Solutions are classified in equity securities on our consolidated balance sheets.
(3) As a result of adopting ASU 2016-01, in 2018 and thereafter gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recognized in other expense, in the consolidated statements of operations. Prior to 2018 gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recorded in accumulated other comprehensive loss on the balance sheet.
As of December 31, 2018, the total cash and cash equivalents balance of $53.0 million was comprised of money market funds of $31.2 million and cash of $21.8 million held with major financial institutions worldwide. As of December 31, 2017, the total cash and cash equivalents balance of $31.2 million was comprised of money market funds of $6.8 million and cash of $24.4 million held with major financial institutions worldwide.
In December 2009, we purchased 10,000,000 common shares of CO2 Solutions, a company based in Quebec, Canada, whose shares are publicly traded in Canada on TSX Venture Exchange. Our purchase represented approximately 16.6% of CO2 Solutions’ total common shares outstanding at the time of investment and was made in a private placement subject to a four-month statutory resale restriction. This restriction expired on April 15, 2010. Our investment in CO2 Solutions is recorded at its fair value. See Note 7, “Fair Value Measurements.” Through December 31, 2018, we concluded that we did not have the ability to exercise significant influence over CO2 Solutions’ operating and financial policies.
On January 1, 2018, we adopted ASU 2016-01. Upon adoption, we reclassified the $0.5 million net unrealized loss from accumulated other comprehensive loss to our opening accumulated deficit.
In 2018, we recognized an unrealized loss of $84 thousand related to our investment in CO2 Solutions in other expense, in the consolidated statements of operations.
XML 34 R16.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements
The following tables present the financial instruments that were measured at fair value on a recurring basis at December 31, 2018 and 2017 by level within the fair value hierarchy (in thousands): 
 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
31,225

 
$

 
$

 
$
31,225

Common shares of CO2 Solutions
588

 

 

 
588

Total
$
31,813

 
$

 
$

 
$
31,813

 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
6,778

 
$

 
$


$
6,778

Common shares of CO2 Solutions


671

 

 
671

Total
$
6,778

 
$
671

 
$

 
$
7,449


We determine the fair value of Level 1 and Level 2 assets using quoted prices in active markets for identical assets. We estimated the fair value of our investment in 10,000,000 common shares of CO2 Solutions using the market value of common shares as determined by trading on the TSX Venture Exchange, and we classified our investment in COSolutions within the fair value hierarchy as Level 1 and Level 2, at December 31, 2018 and December 31, 2017, respectively, using the quoted prices in an active market to determine their fair value.
A review of the fair value hierarchy classifications of our investments is conducted annually. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets. Reclassifications are reported as transfers in or transfers out of the applicable level at end of the calendar year in which the reclassifications occur. In the fourth quarter of 2018, we reclassified the $0.6 million fair value of the investment in the common shares of CO2 Solutions from Level 2 to Level 1 within the fair value hierarchy since we concluded that there was a sufficient level of transactional frequency and trading volume to indicate that the pricing information was representative of its fair value on an ongoing basis. (See also Note 6, “Cash Equivalents and Equity Securities” for additional information.)
XML 35 R17.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details
12 Months Ended
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]  
Balance Sheets Details
Balance Sheets Details
Accounts receivable
The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):
 
December 31,
 
2018
 
2017
 
2016
Allowance - beginning of period
$
(34
)
 
$
(421
)
 
$
(421
)
Write-offs and other (1)

 
387

 

Allowance - end of period
$
(34
)
 
$
(34
)
 
$
(421
)

(1) The change in allowance for doubtful accounts was mainly related to the write-off of receivables from a foreign customer.
Inventories
Inventories consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Raw materials
$
165

 
$
158

Work in process
47

 
53

Finished goods
377

 
825

Inventories
$
589

 
$
1,036


Property and Equipment, net
Property and equipment, net consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Laboratory equipment (1)
$
21,328

 
$
19,777

Leasehold improvements
10,359

 
10,327

Computer equipment and software
3,954

 
3,695

Office equipment and furniture
1,272

 
1,185

Construction in progress (2)
939

 
85

Property and equipment
37,852

 
35,069

Less: accumulated depreciation and amortization
(33,093
)
 
(32,254
)
Property and equipment, net
$
4,759

 
$
2,815

(1) Fully depreciated laboratory equipment with a cost of $0.3 million and $0.2 million were retired during 2018 and 2017, respectively.
(2) Construction in progress includes equipment received but not yet placed into service pending installation.
Goodwill
Goodwill had a carrying value of approximately of $3.2 million as of December 31, 2018 and 2017.
Other Accrued Liabilities
Other accrued liabilities consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Accrued purchases
$
1,492

 
$
941

Accrued professional and outside service fees
2,020

 
2,393

Deferred rent
343

 
258

Lease incentive obligation
425

 
425

Other
575

 
345

Total
$
4,855

 
$
4,362

XML 36 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation
12 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-based Compensation
Stock-based Compensation
Equity Incentive Plans
In March 2010, our board of directors (the "Board") and stockholders approved the 2010 Equity Incentive Award Plan (the "2010 Plan"), which became effective upon the completion of our initial public offering in April 2010. The number of shares of our common stock available for issuance under the 2010 Plan is equal to 1,100,000 shares plus any shares of common stock reserved for future grant or issuance under our 2002 Stock Plan (the “2002 Plan”) that remained unissued at the time of completion of the initial public offering. The 2010 Plan also provides for automatic annual increases in the number of shares reserved for future issuance. All grants will reduce the 2010 Plan reserve by one share for every share granted. As of December 31, 2018, total shares remaining available for issuance under the 2010 Plan were approximately 7.9 million shares.
The 2010 Plan provides for the grant of incentive stock options, non-statutory stock options, RSUs, RSAs, PSUs, PBOs, stock appreciation rights, and stock purchase rights to our employees, non-employee directors and consultants.
Stock Options
The option exercise price for incentive stock options must be at least 100% of the fair value of our common stock on the date of grant and the option exercise price for non-statutory stock options is 85% of the fair value of our common stock on the date of grant, as determined by the Board. If, at the time of a grant, the optionee directly or by attribution owns stock possessing more than 10% of the total combined voting power of all of our outstanding capital stock, the exercise price for these options must be at least 110% of the fair value of the underlying common stock. Stock options granted to employees generally have a maximum term of 10 years and vest over 4 years from the date of grant, of which 25% vest at the end of one year, and 75% vest monthly over the remaining three years. We may grant options with different vesting terms from time to time. Unless an employee's termination of service is due to disability or death, upon termination of service, any unexercised vested options will be forfeited at the end of three months or the expiration of the option, whichever is earlier.
Restricted Stock Units (RSUs)
We also grant employees RSUs, which generally vest over either a three year period with one-third of the shares subject to the RSUs vesting on each yearly anniversary of the vesting commencement date or over a four year period with 25% of the shares subject to the RSU vesting on each yearly anniversary of the vesting commencement date, in each case contingent upon such employee’s continued service on such vesting date. RSUs are generally subject to forfeiture if employment terminates prior to the release of vesting restrictions. We may grant RSUs with different vesting terms from time to time.
Performance-contingent Restricted Stock Units (PSUs) and Performance Based Options (PBOs)
The compensation committee of the Board approved, solely in respect of non-executive employees, delegated to our Chief Executive Officer the authority to approve grants of PSUs. The compensation committee of the Board also approved grants of PBOs and PSUs to our executives. The PSUs and PBOs vest based upon both the successful achievement of certain corporate operating milestones in specified timelines and continued employment through the applicable vesting date. When the performance goals are deemed to be probable of achievement for these types of awards, recognition of stock-based compensation expense commences. Once the number of shares eligible to vest is determined, those shares vest in two equal installments with 50% vesting upon achievement and the remaining 50% vesting on the first anniversary of achievement, in each case, subject to the recipient’s continued service through the applicable vesting date. If the performance goals are achieved at the threshold level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to half the number of PSUs granted and one-quarter the number of shares underlying the PBOs granted. If the performance goals are achieved at the target level, the number of shares eligible to vest in respect of the PSUs and PBOs would be equal to the number of PSUs granted and half of the shares underlying the PBOs granted. If the performance goals are achieved at the superior level, the number of shares eligible to vest in respect of the PSUs would be equal to two times the number of PSUs granted and equal to the number of PBOs granted. The number of shares issuable upon achievement of the performance goals at the levels between the threshold and target levels for the PSUs and PBOs or between the target level and superior levels for the PSUs would be determined using linear interpolation. Achievement below the threshold level would result in no shares being eligible to vest in respect of the PSUs and PBOs.
In the first quarter of 2018, we awarded PSUs ("2018 PSUs") and PBOs ("2018 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including core business revenue growth, cash balance, new licensing collaborations, new research and development service revenue arrangements, technology advancement and novel therapeutic enzymes advancement. As of December 31, 2018, we estimated that the 2018 PSUs and 2018 PBOs performance goals would be achieved at 118% of the target level, and recognized expenses accordingly.
In 2017, we awarded PSUs ("2017 PSUs") and PBOs ("2017 PBOs"), each of which commence vesting based upon the achievement of various weighted performance goals, including revenue growth, fundraising, service revenue, new platform license revenue, and strategic advancement of biotherapeutics pipeline. In the first quarter of 2018, we determined that the 2017 PSU and PBO performance goals had been achieved at 134.2% of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2017 PSUs and PBOs vested in the first quarter of 2018 and one-half of the shares underlying the 2017 PSUs and PBOs will vest in the first quarter of 2019, in each case subject to the recipient’s continued service on each vesting date.
In 2016, we awarded PSUs ("2016 PSUs") based upon the achievement of various weighted performance goals, including revenue growth, non-GAAP net income growth, new licensing collaborations, new research and development service revenue arrangements and novel therapeutic enzymes advancement. In the first quarter of 2017, we determined that the 2016 PSU performance goals had been achieved at 142.3% of the target level, and recognized expenses accordingly. Accordingly, one-half of the shares underlying the 2016 PSUs vested in the first quarter of each of 2017 and 2018, in each case subject to the recipient’s continued service on each vesting date. No PBOs were awarded in 2016.
Stock-Based Compensation Expense:
Stock-based compensation expense is included in the consolidated statements of operations as follows (in thousands):
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Research and development
$
2,055

 
$
1,444

 
$
1,033

Selling, general and administrative
5,834

 
5,647

 
4,640

Total
$
7,889

 
$
7,091

 
$
5,673



The following table presents total stock-based compensation expense by security type included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Stock options
$
1,975

 
$
1,554

 
$
1,102

RSUs and RSAs
1,770

 
1,888

 
2,043

PSUs
1,511

 
1,792

 
2,528

PBOs
2,633

 
1,857

 

Total
$
7,889

 
$
7,091

 
$
5,673



Grant Award Activities:

Stock Option Awards

We estimated the fair value of stock options using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.6

 
5.4

 
5.3

Volatility
60.0
%
 
62.2
%
 
64.2
%
Risk-free interest rate
2.7
%
 
2.0
%
 
1.3
%
Expected dividend yield
0.0
%
 
0.0
%
 
0.0
%
In October 2017, we granted an option to purchase 11,100 shares of common stock to a non-employee as compensation for services valued at $48 thousand with the following assumptions used to estimate the fair value of non-employee stock options: (i) volatility rate at 60.6%, risk-free interest rate of 2.4% and (ii) no expected dividend yield. The option vested over a period of six months with one-sixth of total number of shares subject to the option vesting on each one month anniversary of the grant date. During the year ended December 31, 2018 and December 31, 2016, we did not grant any options to purchase shares of common stock to non-employees.
The following tables summarizes stock option activities:
 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
(In Thousands)
 
 
Outstanding at December 31, 2015
3,918

 
$
4.49

Granted
971

 
$
4.16

Exercised
(398
)
 
$
2.60

Forfeited/Expired
(601
)
 
$
5.76

Outstanding at December 31, 2016
3,890

 
$
4.40

Granted
856

 
$
4.57

Exercised
(86
)
 
$
3.10

Forfeited/Expired
(81
)
 
$
7.72

Outstanding at December 31, 2017
4,579

 
$
4.40

Granted
645

 
$
9.56

Exercised
(772
)
 
$
5.56

Forfeited/Expired
(340
)
 
$
6.66

Outstanding at December 31, 2018
4,112

 
$
4.81

 
 
 
 
Exercisable at December 31, 2018
2,876

 
$
3.83

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Outstanding at December 31, 2018
4,112

 
$
4.81

 
6.23
 
$
48,927

Exercisable at December 31, 2018
2,876

 
$
3.83

 
5.25
 
$
37,005

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
6.13
 
$
47,503




The weighted average grant date fair value per share of stock options granted in 2018, 2017 and 2016 were $5.34, $2.51 and $2.32, respectively. The total intrinsic value of options exercised in 2018, 2017 and 2016 were $7.6 million, $0.2 million and $0.6 million, respectively.
As of December 31, 2018, there was $3.5 million of unrecognized stock-based compensation cost related to non-vested options, which we expect to recognize over a weighted average period of 2.5 years.
Restricted Stock Awards (RSAs)
The following table summarizes RSA activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at December 31, 2015
480

 
$
3.29

Granted
185

 
$
4.21

Vested
(435
)
 
$
3.40

Non-vested balance at December 31, 2016
230

 
$
3.82

Granted
143

 
$
4.75

Vested
(214
)
 
$
3.81

Non-vested balance at December 31, 2017
159

 
$
4.68

Granted
47

 
$
14.35

Vested
(151
)
 
$
4.71

Non-vested balance at December 31, 2018
55

 
$
12.83


The weighted average grant date fair value per share of RSAs granted in 2018, 2017 and 2016 were $14.35, $4.75 and $4.21, respectively. The total fair value of RSAs vested in fiscal 2018, 2017 and 2016 were $2.1 million, $1.0 million and $1.8 million respectively.
As of December 31, 2018, there was $0.3 million of unrecognized stock-based compensation cost related to non-vested RSAs, which we expect to recognize over a weighted average period of 0.4 years.
Restricted Stock Units (RSUs)
The following table summarizes RSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
545

 
$
3.15

Granted
330

 
$
4.10

Vested
(243
)
 
$
3.11

Forfeited/Expired
(15
)
 
$
2.74

Non-vested balance at December 31, 2016
617

 
$
3.69

Granted
275

 
$
4.22

Vested
(302
)
 
$
3.40

Forfeited/Expired
(30
)
 
$
4.12

Non-vested balance at December 31, 2017
560

 
$
4.08

Granted
86

 
$
10.56

Vested
(290
)
 
$
4.09

Forfeited/Expired
(8
)
 
$
4.73

Non-vested balance at December 31, 2018
348

 
$
5.66


The weighted average grant date fair value per share of RSUs granted in 2018, 2017 and 2016 were $10.56, $4.22 and $4.10, respectively. The total fair value of RSUs vested in fiscal 2018, 2017 and 2016 were $2.9 million, $1.3 million and $1.0 million respectively.
As of December 31, 2018, there was $1.0 million of unrecognized stock-based compensation cost related to non-vested RSUs, which we expect to recognize over a weighted average period of 1.1 years.
Performance-Contingent Restricted Stock Units (PSUs)
The following table summarizes PSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
989

 
$
2.94

Granted
629

 
$
4.10

Vested
(482
)
 
$
2.89

Forfeited/Expired
(305
)
 
$
2.82

Non-vested balance at January 1, 2017
831

 
$
3.88

Granted
276

 
$
4.25

Vested
(651
)
 
$
3.84

Forfeited/Expired
(27
)
 
$
3.65

Non-vested balance at January 1, 2018
429

 
$
4.20

Granted
306

 
$
6.71

Vested
(495
)
 
$
4.16

Non-vested balance at December 31, 2018
240

 
$
7.48


The weighted average grant date fair value per share of PSUs granted in 2018, 2017 and 2016 were $6.71, $4.25 and $4.10, respectively. The total fair value of PSUs vested in fiscal 2018, 2017, and 2016 were $5.4 million, $2.7 million, and $1.8 million, respectively.
As of December 31, 2018, there was $0.6 million of unrecognized stock-based compensation cost related to non-vested PSUs, which we expect to recognize over a weighted average period of 0.5 years.
Performance Based Options (PBOs)

We estimated the fair value of PBO using the Black-Scholes-Merton option-pricing model based on the date of grant. The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.63

 
5.33

 

Volatility
60.3
%
 
62.3
%
 

Risk-free interest rate
5.6
%
 
5.3
%
 

Expected dividend yield
0.0
%
 
0.0
%
 



The following table summarizes PBO activities in 2018:
 
Number of Shares
 
Weighted Average Grant Date Fair Value Per Share
 
(in thousands)
 
 
Outstanding at December 31, 2016

 
$

Granted
1,720

 
$
2.54

Outstanding at December 31, 2017
1,720

 
$
2.54

Granted
1,200

 
$
5.02

Exercised
(84
)
 
$
2.54

Forfeited
(1,254
)
 
$
3.73

Outstanding at December 31, 2018
1,582

 
$
3.47


 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Exercisable at December 31, 2018
493

 
$
4.60

 
5.60
 
$
5,968

Vested and expected to vest at December 31, 2018
1,582

 
$
6.24

 
5.44
 
$
16,553


The total fair value of exercised PBOs was $0.2 million for 2018, zero for 2017 and zero for 2016. As of December 31, 2018, there was $1.2 million of unrecognized stock-based compensation cost related to non-vested PBOs, which we expect to recognize over a weighted average period of 0.9 years.
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock
12 Months Ended
Dec. 31, 2018
Equity [Abstract]  
Capital Stock
Capital Stock
Public Offering

In April 2018, we completed an underwritten public offering of 4,312,500 shares of our common stock, including the exercise in full by the underwriters of their option to purchase 562,500 of our shares, at a public offering price of $9.25 per share. After deducting the underwriting discounts and commissions and estimated offering expenses, net proceeds were approximately $37.3 million.
XML 38 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
401(k) Plan
12 Months Ended
Dec. 31, 2018
Retirement Benefits [Abstract]  
401(k) Plan
401(k) Plan
In January 2005, we implemented a 401(k) Plan covering certain employees. Currently, all of our United States based employees over the age of 18 are eligible to participate in the 401(k) Plan. Under the 401(k) Plan, eligible employees may elect to reduce their current compensation up to a certain annual limit and contribute these amounts to the 401(k) Plan. We may make matching or other contributions to the 401(k) Plan on behalf of eligible employees. We recorded employer matching contributions expense of $0.6 million, $0.6 million and $0.4 million in 2018, 2017, and 2016, respectively.
XML 39 R21.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Income Taxes
Income Taxes
Our loss before provision for income taxes was as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
(10,653
)
 
$
(22,994
)
 
$
(8,174
)
Foreign
(262
)
 
79

 
(424
)
Loss before provision for income taxes
$
(10,915
)
 
$
(22,915
)
 
$
(8,598
)

The tax provision (benefit from) for the years ended December 31, 2018, 2017 and 2016 consists primarily of taxes attributable to foreign operations. The components of the provision for income taxes are as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current provision (benefit):
 
 
 
 
 
Federal
$

 
$

 
$

State
5

 
5

 
5

Foreign
(13
)
 
64

 
(14
)
Total current provision (benefit)
(8
)
 
69

 
(9
)
Deferred provision (benefit):
 
 
 
 
 
Federal

 

 

State

 

 

Foreign
(29
)
 
12

 
(31
)
Total deferred provision (benefit)
(29
)
 
12

 
(31
)
Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)


Reconciliation of the provision for income taxes calculated at the statutory rate to our provision for (benefit from) income taxes is as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Tax benefit at federal statutory rate
$
(2,292
)
 
$
(7,791
)
 
$
(2,924
)
State taxes
222

 
48

 
127

Research and development credits
(499
)
 
(399
)
 
(161
)
Foreign operations taxed at different rates
(17
)
 
(2
)
 
30

Stock-based compensation
(2,587
)
 
(216
)
 
327

Other nondeductible items
(3
)
 
326

 
405

Executive compensation
838

 
73

 
255

Change in valuation allowance
4,301

 
(26,058
)
 
1,901

Change in statutory tax rate

 
34,100

 

Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)

Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.
Significant components of our deferred tax assets and liabilities are as follows (in thousands): 
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
60,455

 
$
53,901

Credits
7,174

 
6,221

Deferred revenues
1,879

 
3,334

Stock-based compensation
2,967

 
2,872

Reserves and accruals
1,876

 
2,028

Depreciation
1,376

 
1,573

Intangible assets
2,557

 
3,172

Capital losses
576

 
576

Unrealized gain/loss
297

 
295

Other assets
83

 
78

Total deferred tax assets:
79,240

 
74,050

Deferred tax liabilities:
 
 
 
Other
(64
)
 
(115
)
Total deferred tax liabilities:
(64
)
 
(115
)
Valuation allowance
(79,222
)
 
(74,010
)
Net deferred tax liabilities
$
(46
)
 
$
(75
)

ASC Topic 740 requires that the tax benefit of NOLs, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is “more likely than not.” Realization of the future tax benefits is dependent on our ability to generate sufficient taxable income within the carryforward period. Because of our history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not more likely than not to be realized and, accordingly, has provided a valuation allowance against our deferred tax assets. Accordingly, the net deferred tax assets in all our jurisdictions have been fully reserved by a valuation allowance. The change in valuation allowance differs from the amount included the rate reconciliation table due to the deferred tax impact of the adoption of ASC 606, which resulted in a $0.9 million adjustment to opening accumulated deficit before the offsetting change in valuation allowance. The net valuation allowance increased by $5.2 million during the year ended December 31, 2018; and decreased by $20.4 million during the year ended December 31, 2017; and increased by $1.9 million during the year ended December 31, 2016, respectively. At such time as it is determined that it is more likely than not that the deferred tax assets are realizable, the valuation allowance will be reduced.
The following table sets forth our federal, state and foreign NOL carryforwards and federal research and development tax credits as of December 31, 2018 (in thousands): 
 
December 31, 2018
 
Amount
 
Expiration
Years
Net operating losses, federal
$
254,208

 
2022-2038
Net operating losses, state
115,420

 
2018-2038
Tax credits, federal
7,430

 
2022-2038
Tax credits, state
9,121

 
Do not expire
Net operating losses, foreign
383

 
Various

Current U.S. federal and California tax laws include substantial restrictions on the utilization of NOLs and tax credit carryforwards in the event of an ownership change of a corporation. Accordingly, the Company's ability to utilize NOLs and tax credit carryforwards may be limited as a result of such ownership changes. We performed an analysis in 2018 and determined that there was not a limitation that would result in the expiration of carryforwards before they are utilized.
Income tax expense or benefit from continuing operations is generally determined without regard to other categories of earnings, such as discontinued operations and other comprehensive income. An exception is provided in ASC Topic 740 when there is aggregate income from categories other than continuing operations and a loss from continuing operations in the current year. In this case, the tax benefit allocated to continuing operations is the amount by which the loss from continuing operations reduces the tax expenses recorded with respect to the other categories of earnings, even when a valuation allowance has been established against the deferred tax assets. In instances where a valuation allowance is established against current year losses, income from other sources, including gain from available-for-sale securities recorded as a component of other comprehensive income, is considered when determining whether sufficient future taxable income exists to realize the deferred tax assets. For the year ended December 31, 2018, we did not record a tax expense in other comprehensive income related to available-for-sale securities.
In 2014, we determined that the undistributed earnings of our India subsidiary will be repatriated to the United States, and accordingly, we have provided a deferred tax liability totaling $0.1 million as of December 31, 2018, for local taxes that would be incurred upon repatriation. We have not provided for U.S. federal and state income taxes on all of the remaining non-U.S. subsidiaries’ undistributed earnings as of December 31, 2018 as the remaining foreign jurisdictions are in an accumulative loss position.
We apply the provisions of ASC Topic 740 to account for uncertainty in income taxes. A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): 
 
Rollforward Table (at Gross): As of
 
December 31,
 
2018
 
2017
 
2016
Balance at beginning of year
$
9,422

 
$
8,566

 
$
8,152

Additions based on tax positions related to current year
1,087

 
880

 
459

Reductions to tax provision of prior years
(529
)
 
(24
)
 
(45
)
Balance at end of year
$
9,980

 
$
9,422

 
$
8,566


We recognize interest and penalties as a component of our income tax expense. Total interest and penalties recognized in the consolidated statement of operations was $37 thousand, $31 thousand and $35 thousand, respectively, in 2018, 2017 and 2016. Total penalties and interest recognized in the balance sheet was $0.4 million and $0.3 million, respectively, in 2018 and 2017. The total unrecognized tax benefits that, if recognized currently, would impact our company’s effective tax rate were $0.3 million and $0.4 million as of December 31, 2018 and 2017, respectively. We do not expect any material changes to our uncertain tax positions within the next 12 months. We are not subject to examination by United States federal or state tax authorities for years prior to 2002 and foreign tax authorities for years prior to 2012.
On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “Act”) was signed into law making significant changes to the Internal Revenue Code. The Act made broad and complex changes to the U.S. tax code, including, but not limited to, (i) reducing the U.S. federal statutory tax rate from 35% to 21%; (ii) requiring companies to pay a one-time transition tax on certain un-repatriated earnings of foreign subsidiaries; (iii) generally eliminating U.S federal income taxes on dividends from foreign subsidiaries; (iv) requiring a current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations; (v) eliminating the corporate alternative minimum tax (AMT) and changing how existing AMT credits can be realized; (vi) creating the base erosion anti-abuse tax (BEAT), a new minimum tax; (vii) creating a tax on global intangible low-taxed income (GILTI) of foreign subsidiaries; (viii) creating a new limitation on deductible interest expense; (ix) changing rules related to uses and limitations of net operating loss carryforwards created in tax years beginning after December 31, 2017; and (x) modifying the officer’s compensation limitation.

In December 2017, the SEC issued Staff Accounting Bulletin No. 118 ("SAB 118"), which provided a measurement period of up to one year from the enactment date of the Tax Act for companies to complete the accounting for the Tax Act and its related impacts. In 2018, we completed our accounting for the Tax Act. The income tax effects of the Tax Act for which the accounting is now completed include: the impact of the transition tax, the revaluation of deferred tax assets and liabilities to reflect the 21% corporate tax rate, and the impact to the aforementioned items on state income taxes. We have completed our accounting for the income tax effects under the Tax Act that are relevant to us and required to be recorded and disclosed pursuant to FASB ASC 740, Income Taxes. Accordingly, any and all provisional amounts previously recorded in accordance with SEC Staff Accounting Bulletin No. 118 have been adjusted to reflect their final amounts.

Beginning in 2018, the GILTI provisions in the Tax Act require us to include, in our U.S. income tax return, foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. Per guidance issued by the FASB, companies can either account for deferred taxes related to GILTI or treat tax arising from GILTI as a period cost. Both are acceptable methods subject to an accounting policy election. On December 31, 2018, we finalized our policy and have elected to use the period cost method for GILTI. In 2018, we did not incur any GILTI inclusion as our foreign subsidiaries generated losses.

The BEAT provisions in the Tax Act eliminate the deduction of certain base-erosion payments made to related foreign corporations, and impose a minimum base erosion anti-abuse tax if greater than regular tax. In 2018, our company was not subject to BEAT as it did not meet the requirements to be subject to BEAT.
XML 40 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2018
Loss Contingency [Abstract]  
Commitments and Contingencies
Commitments and Contingencies
Operating Leases
Our headquarters are located in Redwood City, California, where we occupy approximately 107,200 square feet of office and laboratory space in four buildings within the same business park of Metropolitan Life Insurance Company ("MetLife"). Our lease (“Lease”) with MetLife includes approximately 28,200 square feet of space located at 200 and 220 Penobscot Drive, Redwood City, California (the “Penobscot Space”), approximately 37,900 square feet of space located at 400 Penobscot Drive, Redwood City, California (the “Building 2 Space”), approximately 11,200 square feet of space located at 501 Chesapeake Drive, Redwood City, California (the “501 Chesapeake Space”), and approximately 29,900 square feet of space located at 101 Saginaw Drive, Redwood City, California (the “Saginaw Space”).
We entered into the initial lease with MetLife for a portion of this space in 2004 and the lease has been amended multiple times since then to adjust space and amend the terms of the Lease, with the lease amendment ("Seventh Amendment") in October 2016 which, for one of our buildings, waived our existing asset retirement obligation, and extended the lease term to January 2022. The various terms for the spaces under the lease have expiration dates that range from January 2020 through January 2022. Beginning in February 2014, we have subleased certain office and laboratory space to different subtenants with separate options to extend the subleases. These subleases will expire in November 2019.
In February 2019, we entered into the eighth amendment to the Lease ("Eighth Amendment") with MetLife to extend the lease terms for the Penobscot Space, the Building 2 Space and the Chesapeake Space for another 88 months. The lease on the Saginaw Space will expire in January 2020. The lease terms for the Penobscot Space and Building 2 Space have an expiration date of May 2027. The lease term for the 501 Chesapeake Space has an expiration date of May 2029. Refer to Note 16, "Subsequent Events" for more details.
We incurred $3.6 million of capital improvement costs related to the facilities leased from MetLife through December 31, 2012. During 2011 and 2012, we requested and received $3.1 million of reimbursements from the landlord for the tenant improvement and HVAC allowances for the completed construction. The reimbursements were recorded once cash was received and are amortized on a straight line basis over the term of the lease as a reduction in rent expense. The remaining lease incentive obligations were $0.5 million and $0.9 million at December 31, 2018 and 2017, respectively, and are reflected as liabilities on the consolidated balance sheets. Rent expense for the Redwood City properties is recognized on a straight-line basis over the term of the lease.
We are required to restore certain areas of the Redwood City facilities that we are renting to their original form. We are expensing the asset retirement obligation over the terms of the respective leases. We review the estimated obligation each reporting period and make adjustments if our estimates change. We recorded asset retirement obligations of $0.2 million as of December 31, 2018 and 2017, which are included in other liabilities on the consolidated balance sheets. Accretion expense related to our asset retirement obligations was nominal in 2018 and 2017.
Pursuant to the terms of the 7th amended lease agreement, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letter of credit is collateralized by deposit balances held by the bank in the amount of $0.7 million as of December 31, 2018 and 2017, which is recorded as non-current restricted cash on the consolidated balance sheets. See Note 13, “Commitments and Contingencies.” Pursuant to the terms of the Eighth Amendment, the amended letter of credit in the amount of $1.1 million is collateralized by deposit balances held by the bank in 2019.
Rent expense was $3.2 million, $3.2 million and $2.9 million in 2018, 2017 and 2016, respectively, partially offset by sublease income of $1.1 million, $1.4 million and $1.2 million, respectively.
Capital Leases
In December 2016, we entered into a three-year financing lease agreement with a third party supplier for the purchase of laboratory equipment that was partially financed through a capital lease of approximately $0.4 million. The lease became effective upon delivery of the equipment, which occurred in February 2017, and the term of the lease is three years from the effective date. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease.
In April 2017, we entered into a three-year financing lease agreement with a third party supplier for the purchase of information technology equipment for approximately $0.3 million. The effective date of the lease was May 19, 2017 and the term of the lease is three years. This financing agreement was accounted for as a capital lease due to the bargain purchase option at the end of the lease.
Leases
Future minimum payments under non-cancellable capital and operating leases at December 31, 2018 are as follows (in thousands): 
Years ending December 31,
Capital Leases
 
Operating Leases
2019
$
252

 
$
3,280

2020
61

 
712

2021

 
490

2022

 
41

2023

 

Total minimum lease payments (1)
313

 
$
4,523

Less: amount representing interest
(10
)
 
 
Present value of capital lease obligations
303

 
 
Less: current portion
(242
)
 
 
Long-term portion of capital leases
$
61

 
 

(1) 
Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
Other Commitments
We enter into supply and service arrangements in the normal course of business. Supply arrangements are primarily for fixed-price manufacture and supply. Service agreements are primarily for the development of manufacturing processes and certain studies. Commitments under service agreements are subject to cancellation at our discretion which may require payment of certain cancellation fees. The timing of completion of service arrangements is subject to variability in estimates of the time required to complete the work.
The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Other Commitment Agreement Type
Agreement Date
 
Future Minimum Payment
Manufacture and supply agreement with expected future payment date of December, 2022
April 2016
 
$
1,458

Service agreement for stability study
July 2017
 
331

Service agreement for clinical trial
December 2017
 
1,258

Total other commitments

 
$
3,047


Credit Facility
Effective June 30, 2017, we entered into a credit facility (the “Credit Facility”) consisting of term loans (“Term Debt”) totaling up to $10.0 million, and advances (“Advances”) under a revolving line of credit (“Revolving Line of Credit”) totaling up to $5.0 million with an accounts receivable borrowing base of 80% of eligible accounts receivable. At December 31, 2018, we have not drawn from the Credit Facility. In September 2018, we entered into a Fourth Amendment to the Credit Facility whereby the draw period on the term debt was extended to September 30, 2019. We may draw on the Term Debt at any time prior to September 30, 2019, subject to customary conditions for funding including, among others that no event of default exists. We may draw on the Revolving Line of Credit at any time prior to the maturity date. On October 1, 2022, any loans for Term Debt mature and the Revolving Line of Credit terminates. The Term Debt bears interest through maturity at a variable rate based on the London Interbank Offered Rate plus 3.60%. Advances under the Revolving Line of Credit bear interest at a variable annual rate equal to the greater of (i) 1.00% above the prime rate and (ii) 5.00%.
The Credit Facility allows for interest-only payments on the Term Debt through November 1, 2020. Monthly payments of principal and interest on the Term Debt are required following the applicable amortization date. We may elect to prepay in full the Term Debt and Advances under the Revolving Line of Credit at any time. Prepayments of Term Debt and early termination of the Revolving Line of Credit are subject to prepayment and final payment fees are as follows:
 
Term Debt
 
Revolving Line of Credit
Through and including the first anniversary of the funding date of the first Term Debt drawn
2.0%
 
 
After the first anniversary of the funding date of the first Term Debt drawn and before the maturity date
1.0%
 
 
On the earliest to occur of the maturity date, the acceleration of Term Debt drawn or prepayment of Term Debt drawn
5.5%
 
 
Through and including the first anniversary of the closing date
 
 
3.0%
After the first anniversary of the closing date through and including the second anniversary of the closing date
 
 
2.0%
After the second anniversary of the closing date through and including the third anniversary of the closing date
 
 
1.0%

Our obligations under the Credit Facility are secured by a lien on substantially all of our personal property other than our intellectual property. The Credit Facility includes a number of customary covenants and restrictions which require us to comply with certain financial covenants including achieving consolidated product revenues levels at minimum levels as set forth in the Credit Facility through December 2018 and on and after January 2019, in each case unless we maintain certain minimum cash levels with the lender in an amount equal to or greater than six times the sum of the average six-month trailing operating cash flow net outlay plus the average monthly principal due and payable in the immediately succeeding three-month period. The Credit Facility places various restrictions on our company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens and selling assets and permitted assets to be held at foreign subsidiaries above specified caps, in each case subject to certain exceptions. A failure to comply with these covenants could permit the lender to exercise remedies against us and the collateral securing the Credit Facility, including foreclosure of our properties securing the Credit Facilities and our cash. At December 31, 2018, we were in compliance with the covenants for the Credit Facility.
As further discussed in Note 16, “Subsequent Events”, in February 2019, we entered into the eighth lease amendment of our business premises (the “Eighth Amendment”). Pursuant to the terms of the Eighth Amendment, we exercised an option to deliver a $1.1 million letter of credit to the lessor in lieu of a security deposit. In January 2019, we entered into the Fifth Amendment to the Credit Facility, which amended certain restrictive covenants with respect to letters of credit made in connection with the leasing of real property.
Legal Proceedings
We are not currently a party to any material pending litigation or other material legal proceedings.
In February 2018, we and EnzymeWorks, Inc. (U.S.), Suzhou Hanmei Biotechnology Co. Ltd, d/b/a EnzymeWorks, Inc. (China) (collectively, "EnzymeWorks"), Junhua Tao, and Andrew Tao reached a settlement concerning the lawsuit filed by us in February 2016 against EnzymeWorks, Junhua Tao, and Andrew Tao in the United States District Court for the Northern District of California. The parties have entered into a settlement agreement, the terms of which are confidential. The parties have also stipulated to a judgment of patent infringement of all asserted patents against EnzymeWorks, and a permanent injunction barring any future infringement. The remaining claims against EnzymeWorks, and all claims against Junhua Tao, and Andrew Tao including trade secret misappropriation, breach of contract and voidable transfer have been dismissed with prejudice. EnzymeWorks appealed the sanctions levied against them by Judge Orrick to the Federal Circuit and filed its opening brief on May 30, 2018. On July 9, 2018, Codexis filed its response brief, and EnzymeWorks filed its reply on July 30, 2018. On February 8, 2019, the Federal Circuit panel of judges assigned to the case issued an opinion affirming the lower court’s ruling and remanding the case to the lower court on jurisdictional grounds to vacate the order to which the parties had earlier stipulated.
Indemnifications
We are required to recognize a liability for the fair value of any obligations we assume upon the issuance of a guarantee. We have certain agreements with licensors, licensees and collaborators that contain indemnification provisions. In such provisions, we typically agree to indemnify the licensor, licensee and collaborator against certain types of third party claims. The maximum amount of the indemnifications is not limited. We accrue for known indemnification issues when a loss is probable and can be reasonably estimated. There were no accruals for expenses related to indemnification issues for any periods presented.
XML 41 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions
12 Months Ended
Dec. 31, 2018
Related Party Transaction, Due from (to) Related Party [Abstract]  
Related Party Transactions
Related Party Transactions
Exela PharmSci, Inc. (“Exela”)
We entered into a commercialization agreement with Exela in 2007. Under the license agreement, as amended, we and Exela cross-licensed certain technology relating to the manufacture of argatroban, an API, in exchange for rights to certain sublicensing fees or development payments and profit sharing. The revenue sharing arrangement was terminated in December 2017.
Thomas R. Baruch, one of our directors, serves on the board of directors of Exela, and is a retired general partner in Presidio Partners 2007, L.P., which owns over 10% of Exela’s outstanding capital stock. As such, Mr. Baruch has an indirect pecuniary interest in the shares of Exela held by Presidio Partners 2007, L.P.
We had no revenue from transactions with Exela in 2018. We recognized $2.6 million in 2017 and $2.2 million in 2016 as research and development revenue from transactions with Exela. We had no receivables at December 31, 2018 and $1.6 million of receivables due from Exela at December 31, 2017.
AstraZeneca PLC
Pam P. Cheng, a member of our board of directors, joined AstraZeneca PLC as Executive Vice President, Operations and Information Technology in June 2015. We sell biocatalyst products to AstraZeneca PLC, to Alfa Aesar, which is a purchasing agent of AstraZeneca PLC, and also to Asymchem Life Science Co, Ltd, which is a contract manufacturer for AstraZeneca PLC.
We recognized product revenue of $0.6 million in 2018, $0.1 million in 2017 and de minimis revenue in 2016 from transactions with AstraZeneca PLC. We recognized no revenue from transactions with Alfa Aesar in 2018 and 2017 and $0.4 million of product revenue in 2016. We recognized de minimis revenue from Asymchem Life Science Co, Ltd in 2018, $75 thousand in 2017, and de minimis revenue in 2016. At December 31, 2018, we had $0.2 million of receivables and at December 31, 2017, we had $0.1 million of receivables due from AstraZeneca, PLC. At December 31, 2018, we had no receivables and at December 31, 2017, we had $0.1 million of receivables due from Asymchem Life Science Co, Ltd. At December 31, 2018 and 2017, we had no receivables due from Alfa Aesar.
XML 42 R24.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information
12 Months Ended
Dec. 31, 2018
Segment Reporting Information, Operating Income (Loss) [Abstract]  
Segment, Geographical and Other Revenue Information
Segment, Geographical and Other Revenue Information
Segment Information

As discussed in Note 2, "Basis of Presentation and Summary of Significant Accounting Policies," beginning in 2018, we identified our biotherapeutics business as a standalone business segment. Our two reportable business segments as of January 1, 2018, consisted of Performance Enzymes and Novel Biotherapeutics.
We report corporate-related expenses such as legal, accounting, information technology, and other costs that are not otherwise included in our reportable business segments as "Corporate costs." All items not included in income (loss) from operations are excluded from the business segments.
We manage our assets on a total company basis, not by business segment, as the majority of our operating assets are shared or commingled. Our CODM does not review asset information by business segment in assessing performance or allocating resources, and accordingly, we do not report asset information by business segment.

Performance Enzymes
We initially commercialized our CodeEvolver® protein engineering technology platform and products in the pharmaceuticals market, and to date this continues to be our largest market served. Our customers, which include many large global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development. We have also used the technology to develop customized enzymes for use in other industrial markets. These markets consist of several large industrial verticals, including food and food ingredients, animal feed, flavors, fragrances, and agricultural chemicals. We also use our technology to develop enzymes for customers using NGS and PCR/qPCR for in vitro molecular diagnostic and molecular biology research applications.

Novel Biotherapeutics
We are also targeting new opportunities in the pharmaceutical industry to discover, improve, and/or develop biotherapeutic drug candidates. We believe that our CodeEvolver® protein engineering platform technology can be used to discover novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability or immunogenicity. Most notable is our lead program for the potential treatment of PKU in humans. PKU is an inherited metabolic disorder in which the enzyme that converts the essential amino acid phenylalanine into tyrosine is deficient. In October 2017, we announced a strategic collaboration with Nestlé Health Science to advance CDX-6114, our own novel orally administrable enzyme therapeutic candidate for the potential treatment of PKU. In July 2018, we announced that we had dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, which was conducted in Australia. In November 2018, we announced top-line results from the Phase 1a study in healthy volunteers with CDX-6114. In December 2018, Nestlé Health Science became obligated to pay us an additional $1.0 million within 60 days after the achievement of a milestone relating to formulation of CDX-6114. In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States. In February 2019, Nestlé Health Science exercised its option to obtain an exclusive license for the global development and commercialization of CDX-6114 for the management of PKU. The exercise of the option triggers a $3 million milestone payment. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019. See Note 16, “Subsequent Events” in the notes to the Consolidated Financial Statements set forth in Item 8 of this Annual Report on Form 10-K for details.
We have also developed a pipeline of other biotherapeutic drug candidates in which we expect to continue to make additional investments with the aim of advancing additional product candidates targeting other therapeutic areas.
For the year ended December 31, 2018, primarily all revenues related to the Novel Biotherapeutics segment were generated from our collaboration with customer projects. There was no revenue related to the Novel Biotherapeutics segment in the year ended December 31, 2017. Novel Biotherapeutics had no operational activity in the year ended December 31, 2016.
Our CODM regularly reviews our segments and the approach provided by management for performance evaluation and resource allocation.
Operating expenses that directly support the segment activity are allocated based on segment headcount, revenue contribution or activity of the business units within the segments, based on the corporate activity type provided to the segment. The expense allocation excludes certain corporate costs that are separately managed from the segments. This provides the CODM with more meaningful segment profitability reporting to support operating decisions and allocate resources.
The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


Year Ended December 31, 2018

Year Ended December 31, 2017


Performance Enzymes

Novel Biotherapeutics

Total

Performance Enzymes

Novel Biotherapeutics

Total
Revenues:












Product revenue

$
25,590


$


$
25,590


$
26,685


$


$
26,685

Research and development revenue

21,483


13,521


35,004


15,648


7,691


23,339

Total revenues

47,073


13,521


60,594


42,333


7,691


50,024

Costs and operating expenses:












Cost of product revenue

12,620




12,620


14,327




14,327

Research and development(1)

18,924


10,185


29,109


16,847


12,107


28,954

Selling, general and administrative

7,538


771


8,309


7,371




7,371

Total segment costs and operating expenses

39,082


10,956


50,038


38,545


12,107


50,652

Income (loss) from operations

$
7,991


$
2,565


$
10,556


$
3,788


$
(4,416
)

$
(628
)
Corporate costs (2)





(20,324
)





(21,245
)
Depreciation





(1,147
)





(1,042
)
Loss before income taxes





$
(10,915
)





$
(22,915
)
(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):
 
 
2018
 
2017
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Stock-based compensation
 
$
2,591

 
$
338

 
$
2,929

 
$
2,306

 
$
208

 
$
2,514


Significant Customers
Customers that each contributed 10% or more of our total revenues were as follows:
 
Percentage of Total Revenues
For The Years Ended December 31,
 
2018
 
2017
 
2016
Merck
29
%
 
28
%
 
47
%
Nestlé Health Science
22
%
 
15
%
 
*

Tate & Lyle
13
%
 
11
%
 
*

Novartis
*

 
14
%
 
*

GSK
*

 
*

 
22
%



Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:
 
Percentage of Accounts Receivables
As Of December 31,
 
2018
 
2017
Merck
37
%
 
31
%
Nestlé Health Science
17
%
 
*

Tate & Lyle
*

 
16
%
Novartis
11
%
 
15
%
Kyorin Pharmaceutical Co Ltd
16
%
 
*

Exela PharmaSci, Inc.
*

 
14
%
* Percentage was less than 10%
Geographic Information
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Revenues
 
 
 
 
 
Americas
$
15,370

 
$
15,575

 
$
23,126

EMEA
22,361

 
19,610

 
17,138

APAC
22,863

 
14,839

 
8,573

Total revenues
$
60,594

 
$
50,024

 
$
48,837



Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets
 
 
 
United States
$
4,759

 
$
2,815



 
 
 
December 31, 2018
 
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
 
 
 
 
 
 
 
Goodwill
 
 
$
2,463

 
$
778

 
$
3,241

XML 43 R25.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events
12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
Subsequent Events
Subsequent Events
Operating Leases
In February 2019, we entered into the eighth lease amendment ("Eighth Amendment") with MetLife to extend the lease term for the Penobscot Space, the Building 2 Space and the 501 Chesapeake Space for another 88 months. The various terms for these properties have expiration dates that range from May 2027 to May 2029. The terms include an optional renewal period of 5 years after the expiration date based on fair market rates for comparable transactions in the geographic area described in the Eighth Amendment. The Eighth Amendment requires us to install certain improvements to the buildings. On completion of the improvements to the building, the landlord will reimburse us up to a contractually specified amount and the landlord will become the owner of the improvements. Pursuant to the terms of the Eighth Amendment, we exercised our right to deliver a letter of credit in lieu of a security deposit. The letters of credit are collateralized by deposit balances held by the bank in the amount of $1.1 million in 2019. These deposits will be recorded as restricted cash on the consolidated balance sheets. Total future minimum lease payments under the Eighth Amendment is $32.9 million.
FDA Approval and Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114
In January 2019, we received notice from the U.S. Food and Drug Administration (the “FDA”) that it had completed its review of our investigational new drug application (“IND”) for CDX-6114 and concluded that we may proceed with the proposed Phase 1b multiple ascending dose study in healthy volunteers in the United States.
In February 2019, Nestlé Health Science exercised its option to obtain an exclusive, worldwide, royalty-bearing, sublicensable license to develop and commercialize certain products based on the our novel, orally delivered enzyme IND for the management of phenylketonuria. Nestlé Health Science was granted this option under the Development, Option and Licensing Agreement with Codexis announced in October 2017. The exercise of the option triggered a $3 million milestone payment from Nestlé Health Science to Codexis. Upon exercising its option, Nestlé Health Science has assumed all responsibilities for future clinical development and commercialization of CDX-6114, with the exception of the completion of an extension study, CDX - 6114-004, which is expected to be completed in the second quarter of 2019.
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Basis of Presentation and Principles of Consolidation
Basis of Presentation and Principles of Consolidation
The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and the applicable rules and regulations of the Securities and Exchange Commission (“SEC”) and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated in consolidation.
Comprehensive income or loss
Comprehensive income or loss
Comprehensive loss is equivalent to net loss in 2018 because after adopting Accounting Standards Update No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." (“Subtopic 825-10”), we do not have any other transactions recorded under comprehensive loss. Prior to our adoption of Subtopic 825-10, and for the year ended in December 31, 2017 and 2016, comprehensive loss included unrealized gains and unrealized losses from our equity investment in equity securities. See “Recently adopted accounting pronouncements below for additional information.
Certain prior year amounts have been reclassified to conform to 2018 presentation. These changes and reclassifications did not impact net loss or comprehensive loss.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of equity securities, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.
Segment Reporting
Segment Reporting

We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker ("CODM"), or decision making group, in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for our company. We do not allocate or evaluate assets by segment.
Previously, we had only one business segment. As our biotherapeutics business has emerged as a significant opportunity for us, effective in 2018, we formed Novel Biotherapeutics as a new business segment. The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. The Performance Enzymes segment consists of the existing protein catalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.
Foreign Currency Translation
Foreign Currency Translation
The United States dollar is the functional currency for our operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in United States dollars at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-U.S. dollar transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s functional currency are included in other expense in the accompanying consolidated statements of operations.
Revenue Recognition
Revenue Recognition
Policy from January 1, 2018
On January 1, 2018, we adopted the provisions of Accounting Standards Update (ASU) 2014-09, "Revenue from Contracts with Customers (Topic 606) and the related amendments (“ASC 606”). The guidance provides a unified model to determine how revenue is recognized.
Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and services. We account for individual products and services separately if they are distinct-that is, if a product or service is separately identifiable from other items in the contract and if a customer can benefit from it on its own or with other resources that are readily available to the customer.
In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our product revenue and collaborative research and development agreements, we perform the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) we satisfy each performance obligation.
The majority of our collaborative contracts contain multiple revenue streams such as up-front and/or annual license fees, fees for full time employee ("FTE") research and development services, contingent milestone payments upon achievement of contractual criteria, and royalty fees based on the licensees' product revenue or usage, among others. We determine the stand-alone selling price ("SSP") and allocate consideration to distinct performance obligations. Typically, we base our SSPs on our historical sales. If an SSP is not directly observable, then we estimate the SSP taking into consideration market conditions, forecasted sales, entity-specific factors and available information about the customer. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
We account for a contract with a customer when there is approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. Non-cancellable purchase orders received from customers to deliver a specific quantity of product, when combined with our order confirmation, in exchange for future consideration, create enforceable rights and obligations on both parties and constitute a contract with a customer.
We measure revenue based on the consideration specified in the contract with each customer, net of any sales incentives and taxes collected on behalf of government authorities. We recognize revenue in a manner that best depicts the transfer of promised goods or services to the customer, when control of the product or service is transferred to a customer. We make significant judgments when determining the appropriate timing of revenue recognition.
The following is a description of principal activities from which we generate revenue:
Product Revenue
Product revenue consist of sales of protein catalysts, pharmaceutical intermediates and Codex® Biocatalyst Panels and Kits. A majority of our product revenue is made pursuant to purchase orders or supply agreements and is recognized at a point in time when the control of the product has been transferred to the customer typically upon shipment. For some of the products that we develop, we recognize revenue over time as the product is manufactured because we have a right to payment from the customer under a binding, non-cancellable purchase order, and there is no alternate use of the product for us as it is specifically made for the customer’s use.
Certain of our agreements provide options to customers which they can exercise at a future date, such as the option to purchase our product during the contract duration at discounted prices and an option to extend their contract, among others. In accounting for customer options, we determine whether an option is a material right and this requires us to exercise significant judgment. If a contract provides the customer an option to acquire additional goods or services at a discount that exceeds the range of discounts that we typically give for that product or service for the same class of customer, or if the option provides the customer certain additional goods or services for free, the option may be considered a material right. If the contract gives the customer the option to acquire additional goods or services at their normal SSPs, we would likely determine that the option is not a material right and, therefore, account for it as a separate performance obligation when the customer exercises the option. We primarily account for options which provide material rights using the alternative approach available under ASC 606, as we concluded we meet the criteria for using the alternative approach. Therefore, the transaction price is calculated as the expected consideration to be received for all the goods and services we expect to provide under the contract. We update the transaction price for expected consideration, subject to constraint, each reporting period if our estimate of future goods to be ordered by customers change.
Research and Development Revenues
We perform research and development activities as specified in each respective customer agreement. We identify each performance obligation in our research and development agreements at contract inception. We allocate the consideration to each distinct performance obligation based on the estimated SSP of each performance obligation. Performance obligations included in our research and services agreements typically include research and development services for a specified term, periodic reports and small samples of enzyme produced.
The majority of our research and development agreements are based on a contractual rate per FTE working on the project. The underlying product that we develop for customers does not create an asset with an alternative use to us and the customer receives benefits as we perform the work towards completion. Thus, our performance obligations are generally satisfied over time as the service is performed. We utilize an appropriate method of measuring progress towards the completion of our performance obligations to determine the timing of revenue recognition. For each performance obligation that is satisfied over time, we recognize revenue using a single measure of progress, typically based on FTE hours incurred.
Our contracts frequently provide customers with rights to use or access our products or technology, along with other promises or performance obligations. Under ASC 606, we must first determine whether the license is distinct from other promises, such as our promise to manufacture a product. If we determine that the customer cannot benefit from the license without our manufacturing capability, the license will be accounted for as combined with the other performance obligations. If we determine that a license is distinct and has significant standalone functionality, we would recognize revenues from a functional license at a point in time when the license is transferred to the customer, and the customer can use and benefit from it. We estimate the SSP for license rights by using a discounted cash flow method which includes the following key assumptions: the development timelines, revenue forecasts, commercialization expenses, discount rate, and the probability of technical and regulatory success. For licenses that have been previously sold to other customers, we use historical information to determine SSP.
At the inception of each arrangement that includes variable consideration such as development milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment.
Our CodeEvolver® platform technology transfer collaboration agreements typically include license fees, upfront fees, and variable consideration in the form of milestone payments, and sales or usage-based royalties. We have recognized revenues from our platform technology transfer agreements over time as our customer learns to use our technology.
We also have an agreement under which we have granted a functional license to some elements of our biocatalyst technology. We recognize revenues for the functional license at a point in time when the control of the license and technology transfers to the customer.
For agreements that include sales or usage-based royalty payments to us, we do not recognize revenue until the underlying sales of the product or usage has occurred. At the end of each reporting period, we estimate the royalty amount. We recognize revenue at the later of (i) when the related sale of the product occurs, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied, or partially satisfied.
Contract Assets
Contract assets include amounts related to our contractual right to consideration for completed performance obligations not yet invoiced. The contract assets are reclassified to receivables when the rights become unconditional.
Contract Liabilities
Contract liabilities are recorded as deferred revenues and include payments received in advance of performance under the contract. Contract liabilities are realized when the development services are provided to the customer or control of the products has been transferred to the customer. A portion of our contract liabilities relate to supply arrangements that contain material rights that are recognized using the alternative method, under which the aggregate amount invoiced to the customer for shipped products, including annual fees, is higher than the amount of revenue recognized based on the transaction price allocated to the shipped products.
Contract Costs
ASC 606 requires the recognition of an asset for the incremental costs of obtaining a contract with a customer if the entity expects to recover such costs. Incremental costs are costs that would not have been incurred if the contract had not been obtained. Examples of contract costs are commissions paid to sales personnel. We do not typically incur significant incremental costs because the compensation of our salespeople are not based on contracts closed but on a mixture of company goals, individual goals, and sales goals. If a commission paid is directly related to obtaining a specific contract, our policy is to capitalize and amortize such costs on a systematic basis, consistent with the pattern of transfer of the good or service to which the asset relates.
Contract costs are reported in other non-current assets.
Revenue Recognition Policy before January 1, 2018
We recognize revenue from the sale of our products, collaborative research and development agreements and revenue sharing arrangements. Revenue is recognized when the related costs are incurred and the four basic criteria of revenue recognition are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Where the revenue recognition criteria are not met, we defer the recognition of revenue by recording deferred revenue until such time that all criteria of revenue recognition are met.
We account for revenues from multiple element arrangements, such as license and platform technology transfer agreements in which a licensee may purchase several deliverables, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Subtopic 605-25, “Multiple Element Arrangements.” For new or materially amended multiple element arrangements, we identify the deliverables at the inception of the arrangement and each deliverable within a multiple deliverable revenue arrangement is accounted for as a separate unit of accounting if both of the following criteria are met: (1) the delivered item or items have value to the customer on a standalone basis and (2) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. Revenue allocated to each element is then recognized based on when the basic four revenue recognition criteria are met for each element.
Where a portion of non-refundable up-front fees or other payments received are allocated to continuing performance obligations under the terms of a collaborative arrangement, they are recorded as deferred revenue and recognized as revenue ratably over the term of our estimated performance period under the agreement or using the proportional performance method based on the ratio of the level of effort incurred to date compared to the total estimated level of effort required to complete our performance obligations under the agreement. Determining the total estimated level of effort required to complete all performance obligations requires management judgment and estimation including assumptions regarding the number of internal hours required to complete the project and external effort incurred. We determine the estimated performance periods, and they are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period and, therefore, to revenue recognized, would occur on a prospective basis in the period that the change was made.
Product Sales
Product sales consist of sales of protein catalysts, pharmaceutical intermediates, and Codex® Biocatalyst Panels and Kits. Product sales are recognized once passage of title and risk of loss has occurred and contractually specified acceptance criteria, if any, have been met, provided all other revenue recognition criteria have also been met. Shipping and handling costs charged to customers are recorded as revenue.
Research and Development Revenues
Collaborative research and development agreements typically provide us with multiple revenue streams, including: research services fees for full time employee (“FTE”) research services, up-front license fees, technology access, contingent payments upon achievement of contractual criteria, and royalty fees based on the licensee’s product sales or cost savings achieved by our customers.
We perform collaborative research and development activities as specified in each respective customer agreement. Payments for services received are not refundable. Certain research agreements are based on a contractual reimbursement rate per FTE working on the project. We recognize revenue from research services as those services are performed over the contractual performance periods. When up-front payments are combined with FTE services in a single unit of accounting, we recognize the up-front payments using the proportionate performance method of revenue recognition based upon the actual amount of research labor hours incurred relative to the amount of the total expected labor hours to be incurred by us, up to the amount of cash received. In cases where the planned levels of research services fluctuate substantially over the research term, we are required to make estimates of the total hours required to perform our obligations.
We recognize research and development revenues from non-refundable, up-front license fees or technology access payments that are not dependent on any future performance by us when such amounts are earned. If we have continuing obligations to perform under the arrangement, such fees are recorded as deferred revenues and recognized over the estimated period of continuing performance. Estimated performance periods are periodically reviewed based on the progress of the related program. The effect of any change made to an estimated performance period, and therefore to revenue recognized, would occur on a prospective basis in the period that the change was made.
A payment that is contingent upon the achievement of a substantive milestone is recognized in its entirety in the period in which the milestone is achieved. A milestone is an event (i) that can only be achieved based in whole or in part on either our performance or on the occurrence of a specific outcome resulting from our performance, (ii) for which there is, as of the date the arrangement is entered into, substantive uncertainty that the event will be achieved and (iii) results in additional payments being due to us. Milestones are considered substantive when the consideration earned from the achievement of the milestone (i) is commensurate with either our performance to achieve the milestone or the enhancement of the value of the item delivered as a result of a specific outcome resulting from its performance, (ii) relates solely to past performance and (iii) is reasonable relative to all deliverable and payment terms in the arrangement.
We recognize revenue from other contingent payments based on passage of time or when earned as the result of a customer’s performance in accordance with the contractual terms and when such payments can be reasonably estimated and collectability of such payments is reasonably assured.
We recognize revenue from royalties based on licensees’ sales of our products or products using our technologies. Royalties are recognized as earned in accordance with the contract terms when royalties from licensees can be reasonably estimated and collectability is reasonably assured. For the majority of our royalty revenue, estimates are made using notification of the sale of licensed products from the licensees.
Cost of Product Revenue
Cost of product revenue comprises both internal and third party fixed and variable costs including materials and supplies, labor, facilities, and other overhead costs associated with our product sales. Shipping costs are included in our cost of product revenue. Such charges were not significant in any of the periods presented.
Fulfillment costs, such as shipping and handling, are recognized at a point in time and are included in cost of product sales.
Unbilled receivable
Pursuant to ASC 606, the timing of revenue recognition may differ from the timing of invoicing to our customers. When we satisfy (or partially satisfy) a performance obligation, prior to being able to invoice the customer, we recognize an unbilled receivable when the right to consideration is unconditional.
Cost of Research and Development Services and Research and Development Expense
Cost of Research and Development Services
Cost of research and development services related to FTE services under research and development agreements approximate the research funding over the term of the respective agreements and is included in research and development expense. Costs of services provided under license and platform technology transfer agreements are included in research and development expenses and are expensed in the periods in which such costs are incurred.
Research and Development Expenses
Research and development expenses consist of costs incurred for internal projects and partner-funded collaborative research and development activities, as well as license and platform technology transfer agreements, as mentioned above. These costs include our direct and research-related overhead expenses, which include salaries and other personnel-related expenses (including stock-based compensation), occupancy-related costs, supplies, and depreciation of facilities and laboratory equipment, as well as external costs, and are expensed as incurred. Costs to acquire technologies that are utilized in research and development and that have no alternative future use are expensed when incurred.
Advertising
Advertising
Advertising costs are expensed as incurred and included in selling, general and administrative expenses in the consolidated statements of operations.
Stock-Based Compensation
Stock-Based Compensation
We use the Black-Scholes-Merton option pricing model to estimate the fair value of options granted under our equity incentive plans. The Black-Scholes-Merton option pricing model requires the use of assumptions, including the expected term of the award and the expected stock price volatility. The expected term is based on historical exercise behavior on similar awards, giving consideration to the contractual terms, vesting schedules and expectations of future employee behavior. We use historical volatility to estimate expected stock price volatility. The risk-free rate assumption is based on United States Treasury instruments whose terms are consistent with the expected term of the stock options. The expected dividend assumption is based on our history and expectation of dividend payouts.
Restricted Stock Units ("RSUs") and Restricted Stock Awards ("RSAs") are measured based on the fair market values of the underlying stock on the dates of grant. Performance based options ("PBOs") and performance-contingent restricted stock units ("PSUs") are measured using Black-Scholes-Merton option pricing model. The vesting of PBOs and PSUs awarded is conditioned upon the attainment of one or more performance objectives over a specified period and upon continued employment through the applicable vesting date. At the end of the performance period, shares of stock subject to the PBOs and PSUs vest based upon both the level of achievement of performance objectives within the performance period and continued employment through the applicable vesting date.
Stock-based compensation expense is calculated based on awards ultimately expected to vest and is reduced for estimated forfeitures at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The estimated annual forfeiture rates for stock options, RSUs, PSUs, PBOs, and RSAs are based on historical forfeiture experience.
The estimated fair value of stock options, RSUs and RSAs are expensed on a straight-line basis over the vesting term of the grant and the estimated fair value of PSUs and PBOs are expensed using an accelerated method over the term of the award once management has determined that it is probable that the performance objective will be achieved. Compensation expense is recorded over the requisite service period based on management's best estimate as to whether it is probable that the shares awarded are expected to vest. Management assesses the probability of the performance milestones being met on a continuous basis.
Cash and Cash Equivalents
Cash and Cash Equivalents
We consider all highly liquid investments with maturity dates of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market funds. The majority of cash and cash equivalents is maintained with major financial institutions in the United States. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits.
Restricted Cash
Restricted Cash
In 2016, we began the process of liquidating our Indian subsidiary. The local legal requirements for liquidation required us to maintain our subsidiary's cash balance in an account managed by a legal trustee to satisfy our financial obligations.
Equity Securities
Equity Securities
We invest in equity securities that are carried at estimated fair value with changes in fair value recognized within earnings. Equity securities with remaining maturities of greater than one year or which we currently do not intend to sell are classified as long-term. See Note 6, “Cash Equivalents and Equity Securities.”
Unrealized holding gains and losses (the adjustment to fair value) and realized gains and losses are included in other income (expense) in the consolidated statement of operations subsequent to the adoption of ASU 2016-01 starting on January 1, 2018.
Fair Value Measurements
Fair Value Measurements
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, we utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and we consider counterparty credit risk in our assessment of fair value. Carrying amounts of financial instruments, including cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair values as of the balance sheet dates because of their short maturities.
The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.
Level 2: Inputs that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and which reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.
See Note 7, “Fair Value Measurements” for additional details.
Concentrations of Credit Risk
Concentrations of Credit Risk
Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, contract assets, equity securities, and restricted cash. Cash that is not required for immediate operating needs is invested principally in money market funds. Cash and cash equivalents are invested through banks and other financial institutions in the United States, India, and the Netherlands. Such deposits in those countries may be in excess of insured limits.
Accounts Receivable and Allowance for Doubtful Accounts
Accounts Receivable and Allowance for Doubtful Accounts
We currently sell primarily to pharmaceutical and fine chemicals companies throughout the world by the extension of trade credit terms based on an assessment of each customer's financial condition. Trade credit terms are generally offered without collateral and may include an insignificant discount for prompt payment for specific customers. To manage our credit exposure, we perform ongoing evaluations of our customers' financial conditions. In addition, accounts receivable includes amounts owed to us under our collaborative research and development agreements. We recognize accounts receivable at invoiced amounts and we maintain a valuation allowance for doubtful accounts.

The allowances for doubtful accounts reflect our best estimates of probable losses inherent in the accounts receivable and contract assets’ balances. We determine the allowances based on known troubled accounts, historical experience, and other currently available evidence. Uncollectible accounts receivables and contract assets are written off against the allowance for doubtful accounts when all efforts to collect them have been exhausted. Recoveries are recognized when they are received. Actual collection losses may differ from our estimates and could be material to our consolidated financial position, results of operations, and cash flows.
Inventories
Inventories
Inventories are stated at the lower of cost or net realizable value. Cost is determined using a weighted-average approach, assuming full absorption of direct and indirect manufacturing costs, or based on cost of purchasing from our vendors. If inventory costs exceed expected net realizable value due to obsolescence or lack of demand, valuation adjustments are recorded for the difference between the cost and the expected net realizable value.
Concentrations of Supply Risk
Concentrations of Supply Risk
We rely on a limited number of suppliers for our products. We believe that other vendors would be able to provide similar products; however, the qualification of such vendors may require substantial start-up time. In order to mitigate any adverse impacts from a disruption of supply, we attempt to maintain an adequate supply of critical single-sourced materials. For certain materials, our vendors maintain a supply for us. We outsource the large scale manufacturing of our products to contract manufacturers with facilities in Austria and Italy.
Property and Equipment
Property and equipment classified as construction in process includes equipment that has been received but not yet placed in service. Normal repairs and maintenance costs are expensed as incurred.
Impairment of Long-Lived Assets
Impairment of Long-Lived Assets
Our tangible long-lived assets consist primarily of property and equipment.
In the first quarter of 2018, we determined that we operate in two segments. We have not identified property and equipment by segment since these assets are shared or commingled. We evaluate the carrying value of long-lived assets, including property and equipment, whenever events, changes in business circumstances or our planned use of long-lived assets indicate that their carrying amounts may not be fully recoverable or that their useful lives are no longer appropriate. If these facts and circumstances exist, we assess for recovery by comparing the carrying values of long-lived assets with their future net undiscounted cash flows. If the comparison indicates that impairment exists, long-lived assets are written down to their respective fair values based on discounted cash flows. Significant management judgment is required in the forecast of future operating results that are used in the preparation of unexpected undiscounted cash flows.
Goodwill
Goodwill
Goodwill represents the excess of the consideration transferred over the fair value of net assets of businesses acquired and is assigned to reporting units. We test goodwill for impairment considering amongst other things, whether there have been sustained declines in our share price. If we conclude it is more likely than not that the fair value of a reporting unit is less than its carrying amount, a quantitative fair value test is performed. In the first quarter of 2018, we determined that we operate in two segments and accordingly we re-evaluated our assessment of the number of reporting units. We concluded that we have two reporting units that reflect our operating segments and accordingly, we tested goodwill for impairment at the reporting unit level. Historically, assets are jointly used by the segments, are not separable, and are not identified by reporting unit. In order to assign the amount of goodwill to the two reporting units, we used a relative fair value allocation methodology that primarily relied on our estimates of revenue and future earnings for each reporting units. Using the relative fair value allocation methodology, we have determined that approximately 76% of goodwill is allocated to the Performance Enzymes segment and 24% is allocated to the Novel Biotherapeutics segment. As a result of the calculation, $2.4 million of the goodwill was assigned to the Performance Enzymes segment and $0.8 million was assigned to the Novel Biotherapeutics segment. There were no changes in the amount of goodwill assigned to each reporting unit at the end of the year.
The goodwill impairment test consists of a two-step process. The first step of the goodwill impairment test, used to identify potential impairment, compares the fair value of each reporting unit to its carrying value. Using the relative fair value allocation methodology, we compared the allocated carrying amount of each reporting unit’s net assets and the assigned goodwill to its fair value. If the fair value of the reporting unit exceeds its carrying amount, goodwill of the reporting unit is considered not impaired, and the second step of the impairment test is not required. The second step, if required, compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. Implied fair value is the excess of the fair value of the reporting unit over the fair value of all identified or allocated assets and liabilities. Any excess of the reporting unit’s carrying amount goodwill over the respective implied fair value is recognized as an impairment. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
We test goodwill for impairment on an annual basis on the last day of the fourth fiscal quarter and, when specific circumstances dictate, between annual tests by first assessing qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. During 2018, 2017 and 2016, we did not record impairment charges related to goodwill.
Income Taxes
Income Taxes
We use the liability method of accounting for income taxes, whereby deferred tax asset or liability account balances are calculated at the balance sheet date using current tax laws and rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are provided when necessary to reduce deferred tax assets to the amount that will more likely than not be realized.
We make certain estimates and judgments in determining income tax expense for financial statement purposes. These estimates and judgments occur in the calculation of tax credits, benefits and deductions and in the calculation of certain tax assets and liabilities, which arise from differences in the timing of recognition of revenues and expenses for tax and financial statement purposes. Significant changes to these estimates may result in an increase or decrease to our tax provision in a subsequent period.
In assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will be realized on a jurisdiction by jurisdiction basis. The ultimate realization of deferred tax assets is dependent upon the generation of taxable income in the future. We have recorded a valuation allowance against these deferred tax assets in jurisdictions where ultimate realization of deferred tax assets is more likely than not to occur. As of December 31, 2018, we maintain a full valuation allowance in all jurisdictions against the net deferred tax assets as we believe that it is more likely than not that the majority of deferred tax assets will not be realized.
We make estimates and judgments about our future taxable income that are based on assumptions that are consistent with our plans and estimates. Should the actual amounts differ from our estimates, the amount of our valuation allowance may be materially impacted. Any adjustment to the deferred tax asset valuation allowance would be recorded in the statements of operations for the periods in which the adjustment is determined to be required.
We account for uncertainty in income taxes as required by the provisions of ASU 2009-06, Income Taxes (Topic 740) ”Implementation Guidance on Accounting for Uncertainty in Income Taxes and Disclosure Amendments for Nonpublic Entities”, which clarifies the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to estimate and measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. It is inherently difficult and subjective to estimate such amounts, as this requires us to determine the probability of various possible outcomes. We consider many factors when evaluating and estimating our tax positions and tax benefits, which may require periodic adjustments and may not accurately anticipate actual outcomes.
The Tax Reform Act of 1986 and similar state provisions limit the use of net operating loss (“NOL”) carryforwards in certain situations where equity transactions result in a change of ownership as defined by Internal Revenue Code Section 382. In the event we should experience such a change of ownership, utilization of our federal and state NOL carryforwards could be limited.
The adoption of ASC 606 primarily resulted in less revenue recognized as of January 1, 2018, which in turn generated an increase in net deferred tax assets. As we fully reserve our net deferred tax assets in the jurisdictions impacted by the adoption of ASC 606, this impact was offset by a corresponding increase to the valuation allowance.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently adopted accounting pronouncement

In May 2014, the FASB issued ASU 2014-09, "Revenue from Contracts with Customers (Topic 606)" , (“ASC 606”), amending revenue recognition guidance and requiring more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers is effective for annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted for public companies effective for annual and interim reporting periods beginning after December 15, 2016. We have adopted the provisions of ASC 606 and the related amendments, effective January 1, 2018, using the modified retrospective transition method. We recognized the cumulative effect of applying the new revenue standard and recognized a $4.1 million increase to the opening balance of the accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the period presented. See Note 3, "Revenue Recognition" for more details.

In January 2016, the FASB issued ASU No. 2016-01, "Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities" (“Subtopic 825-10”). This guidance principally affects accounting standards for equity investments, financial liabilities where the fair value option has been elected, and the presentation and disclosure requirements for financial instruments. Upon the effective date of this new guidance, all equity investments in unconsolidated entities, other than those accounted for using the equity method of accounting, will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification and therefore no changes in fair value will be reported in other comprehensive income (loss) for equity securities with readily determinable fair values. This new guidance primarily impacts our accounting for equity investments. In February 2018, the FASB issued ASU 2018-03, "Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities, that clarifies the guidance in ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10)." Prior to the adoption of ASC 825, we recognized unrealized holding gains and losses from our equity investment in CO2 Solutions in other comprehensive loss. We adopted ASC 825 in the first quarter of 2018 using a modified retrospective approach by means of a cumulative-effect adjustment to accumulated deficit. Upon adoption of ASC 825, we reclassified $0.5 million of unrealized loss (net of $0.6 million tax) from other accumulated comprehensive loss to beginning accumulated deficit. Any changes in the fair value of our equity investments, except those accounted for under the equity method, will be recognized in earnings on a prospective basis.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments" (“ASC 230”), which provides the FASB's guidance on certain cash flow statements items. ASC 230 is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. We adopted ASC 230 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In November 2016, the FASB issued ASU No. 2016-18, "Statement of Cash Flows (Topic 230) Restricted Cash a consensus of the FASB Emerging Issues Task Force” (“ASC 230”). The standard requires restricted cash and restricted cash equivalents to be included with cash and cash equivalents on the statement of cash flows. We adopted ASU 2016-18 in the first quarter of 2018 and the adoption had no material impact on our annual consolidated financial statements. The effect of the adoption of ASC 230 on our consolidated statements of cash flows was to include restricted cash balances in the beginning and end of period balances of cash and cash equivalents and restricted cash. The change in restricted cash was previously disclosed in operating and investing activities in the consolidated statements of cash flows.

In January 2017, the FASB issued ASU No. 2017-01 "Business Combinations (Topic 805): Clarifying the Definition of a Business” (“ASC 805”). The guidance requires the use of a framework to determine whether a set of assets and activities constitutes an acquired or a sold business. The guidance is effective for fiscal reporting periods beginning after December 15, 2017, including interim periods within those fiscal years. The amendments should be applied prospectively as of the beginning of the period of adoption. We adopted ASC 805 in the first quarter of 2018, and the adoption had no impact on our annual consolidated financial statements.

In May 2017, the FASB issued ASU No. 2017-09, "Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting” (“ASC 718”). The amendments provide guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. The new standard is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted. We adopted ASC 718 in the first quarter of 2018 and the adoption had no impact on our annual consolidated financial statements.

In March 2018, the FASB issued ASU 2018-05, "Income Taxes (Topic 740): Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 118" (“ASC 740”) which amends Topic 740 by incorporating the SEC Staff Accounting Bulletin No. 118 (SAB 118) issued on December 22, 2017. SAB 118 provides guidance on accounting for the effects of the Tax Cuts and Jobs Act (Tax Reform) and allows a company to record provisional amounts during a measurement period not to extend beyond one year from the enactment date. See Income Taxes section above for additional information.
Recently issued accounting pronouncements not yet adopted
From time to time, new accounting pronouncements are issued by the FASB or other standards setting bodies that are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our consolidated financial statements upon adoption.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASC 842”), which replaces prior lease guidance (“ASC 840”). This guidance establishes a right-of-use ("ROU") model that requires a lessee to record a ROU asset and lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the Consolidated Statement of Operations. The guidance also eliminates today’s real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. Entities have the option to use certain practical expedients. Full retrospective application is prohibited. ASC 842 is effective for public business entities for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. In July 2018, the FASB issued ASU 2018-10, "Codification Improvements to ASC 842, Leases." These amendments affect narrow aspects of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases under ASC 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases under ASC 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions. For entities that have not adopted ASC 842, the effective date and transition requirements will be the same as the effective date and transition requirements in ASC 842. The FASB also issued ASU 2018-11, "Leases (Topic 842): Targeted Improvements." These amendments provide entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity’s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). The amendments also provide lessors with a practical expedient, by class of underlying asset, to not separate nonlease components from the associated lease component and, instead, to account for those components as a single component if the nonlease components otherwise would be accounted for under ASC 606 and certain criteria are met. If the nonlease component or components associated with the lease component are the predominant component of the combined component, an entity is required to account for the combined component in accordance with ASC 606. Otherwise, the entity must account for the combined component as an operating lease in accordance with ASC 842. For entities that have not adopted ASC 842 before the issuance of ASU No. 2018-11, the effective date and transition requirements for the amendments related to separating components of a contract are the same as the effective date and transition requirements in ASU No. 2016-02. We plan to adopt ASC 842 on January 1, 2019 using a modified retrospective approach and effective date method per adoption of ASU 2018-11. We will recognize and measure all leases within the scope of the standard that exist as of January 1, 2017, beginning of the earliest period, as if the standard had always been applied, subject to the practical expedients and transition relief in “Practical Expedients” section. In the current period, we evaluated the practical expedients elections and on adoption, and may apply a practical expedient in which an entity need not reassess whether any expired or existing contracts are or contain leases; An entity need not reassess the lease classification for any expired or existing leases (for example, all existing leases that were classified as operating leases in accordance with ASC 840 will be classified as operating leases, and all existing leases that were classified as capital leases in accordance with ASC 840 will be classified as finance leases); An entity need not reassess initial direct costs for any existing leases. We started the transition plan in the third quarter of 2018 and continued to perform the scoping work in the fourth quarter of 2018. We identified a total of 13 lease agreements that are subject to ASC 842 and seven of them meet the short-term lease exception. We completed the full analysis by January, 2019 and we evaluated the right-of-use (ROU) assets and lease liability using the incremental borrowing rate (IBR) at December 31, 2018 because the implicit rate is not readily determinable in the lease agreement. Upon adoption of ASC 842, all existing leases will be classified as either operating lease or finance lease. We expect to record a range from $20 million to $30 million of ROU assets and liabilities for operating leases and a range from $0.1 million to $0.8 million of ROU assets and liabilities for finance leases in the balance sheet during the first quarter of 2019. This analysis was inclusive of the eighth amendment to the lease agreement disclosed in Note 16, “Subsequent Events.”
In June 2016, the FASB issued ASU 2016-13, "Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments," which amends the FASB's guidance on the impairment of financial instruments. The standard adds a new impairment model (known as the "current expected credit loss model") that is based on expected losses rather than incurred losses. ASU 2016-13 is effective for annual reporting periods ending after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. We are currently evaluating the impact of adopting ASU 2016-13 on our consolidated financial statements and related disclosures.
In January 2017, the FASB issued ASU No. 2017-04, "Intangibles - Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The amendments eliminate Step 2 from the goodwill impairment test. The annual, or interim, goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. In addition, income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit should be considered when measuring the goodwill impairment loss, if applicable. The amendments also eliminate the requirements for any reporting unit with a zero or negative carrying amount to perform a qualitative assessment and, if it fails that qualitative test, to perform Step 2 of the goodwill impairment test. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new standard is effective for fiscal years beginning after December 15, 2019, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In February 2018, the FASB issued ASU No. 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220) - Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income”. This standard allows a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act and requires certain disclosures about stranded tax effects and will be effective for us beginning January 1, 2019 and should be applied either in the period of adoption or retrospectively. Early adoption is permitted. We do not expect this standard to have any impact on our consolidated financial statements.

In June 2018, the FASB issued ASU 2018-07, "Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting," which expands the scope of Topic 718, Compensation—Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity—Equity-Based Payments to Non-Employees. The new standard is effective for fiscal years beginning after December 15, 2018, with early adoption permitted. We do not expect the adoption of this standard to have a material impact on our consolidated financial statements and related disclosures.

In July 2018, the FASB issued ASU 2018-09, "Codification Improvements”, which represent changes to clarify, correct errors in, or make minor improvements to the Codification, eliminating inconsistencies and providing clarifications in current guidance. The amendments in this ASU include those made to: Subtopic 220-10, Income Statement-Reporting Comprehensive Income-Overall; Subtopic 470-50, Debt-Modifications and Extinguishments; Subtopic 480-10, Distinguishing Liabilities from Equity-Overall; Subtopic 718-740, Compensation-Stock Compensation-Income Taxes; Subtopic 805-740, Business Combinations-Income Taxes; Subtopic 815-10, Derivatives and Hedging-Overall; Subtopic 820-10, Fair Value Measurement-Overall; Subtopic 940-405, Financial Services-Brokers and Dealers-Liabilities; and Subtopic 962-325, Plan Accounting-Defined Contribution Pension Plans-Investments-Other. The transition and effective date guidance is based on the facts and circumstances of each amendment. Some of the amendments do not require transition guidance and will be effective upon issuance. However, many of the amendments do have transition guidance with effective dates for annual periods beginning after December 15, 2018, for public business entities. We do not expect this standard to have any material impact on our consolidated financial statements.

In August 2018, the FASB issued ASU 2018-13, "Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement." The primary focus of ASU 2018-13 is to improve the effectiveness of the disclosure requirements for fair value measurements. The changes affect all companies that are required to include fair value measurement disclosures. In general, the amendments in this standard are effective for all entities for fiscal years and interim periods within those fiscal years, beginning after December 15, 2019. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.

In November 2018, the FASB issued ASU 2018-18, "Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606." ASU 2018-18 provides guidance on how to assess whether certain transactions between collaborative arrangement participants should be accounted for within the revenue recognition standard. The ASU also provides more comparability in the presentation of revenue for certain transactions between collaborative arrangement participants. In general, for public companies, the amendments in this standard are effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. We do not expect this standard to have any material impact on our consolidated financial statements.

In November 2018, the FASB issued ASU 2018-19, "Codification Improvements to Topic 326, Financial Instruments—Credit Losses." ASU 2018-19 clarifies that receivables arising from operating leases are not within the scope of the credit losses standard, but rather, should be accounted for in accordance with the leases standard. In general, the amendments in this standard are effective for public business entities that meet the definition of a SEC filer for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. We do not expect this standard to have any material impact on our consolidated financial statements.
XML 45 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2018
Accounting Policies [Abstract]  
Schedule of estimated ranges of useful lives of property and equipment
Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:
 
Asset classification
Estimated useful life
 
Laboratory equipment
5 years
 
Computer equipment and software
3 to 5 years
 
Office equipment and furniture
5 years
 
Leasehold improvements
Lesser of useful life or lease term
Property and equipment, net consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Laboratory equipment (1)
$
21,328

 
$
19,777

Leasehold improvements
10,359

 
10,327

Computer equipment and software
3,954

 
3,695

Office equipment and furniture
1,272

 
1,185

Construction in progress (2)
939

 
85

Property and equipment
37,852

 
35,069

Less: accumulated depreciation and amortization
(33,093
)
 
(32,254
)
Property and equipment, net
$
4,759

 
$
2,815

(1) Fully depreciated laboratory equipment with a cost of $0.3 million and $0.2 million were retired during 2018 and 2017, respectively.
(2) Construction in progress includes equipment received but not yet placed into service pending installation.
XML 46 R28.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2018
Revenue from Contract with Customer [Abstract]  
Disaggregation of revenue
Segment information for fiscal year 2018 is as follows (in thousands):
 
Year Ended December 31, 2018
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
25,590

 
$

 
$
25,590

Research and development revenue
21,483

 
13,521

 
35,004

Total revenues
$
47,073

 
$
13,521

 
$
60,594

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,332

 
$
38

 
$
15,370

EMEA
8,878

 
13,483

 
22,361

APAC
22,863

 

 
22,863

Total revenues
$
47,073

 
$
13,521

 
$
60,594


Segment information for fiscal year 2017 is as follows (in thousands):
 
Year Ended December 31, 2017
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Major products and service:
 
 
 
 
 
       Product Revenue
$
26,685

 
$

 
$
26,685

Research and development revenue
15,648

 
7,691

 
23,339

Total revenues
$
42,333

 
$
7,691

 
$
50,024

 
 
 
 
 
 
Primary geographical markets:
 
 
 
 
 
Americas
$
15,575

 
$

 
$
15,575

EMEA
11,919

 
7,691

 
19,610

APAC
14,839

 

 
14,839

Total revenues
$
42,333

 
$
7,691

 
$
50,024

Contract with customer
The following table presents changes in the contract assets, unbilled receivable, contract costs, and contract liabilities (in thousands):
 
January 1, 2018 balance
 
Additions
 
Deductions (1)
 
December 31, 2018
Contract Assets
$

 
8,934

 
(8,899
)
 
$
35

Unbilled receivables, current
$

 
2,908

 
(992
)
 
$
1,916

Unbilled receivables, non-current
$

 
786

 

 
$
786

Contract Costs
$
239

 

 
(197
)
 
$
42

Contract Liabilities: Deferred Revenue
$
18,966

 
6,446

 
(17,124
)
 
$
8,288

(1) The asset or liability balances are presented as a net position per contract and accordingly the deductions column includes the netting effect of presenting each contract on a net position basis as either a net liability or asset.
During the year ended December 31, 2018, we recognized the following revenues (in thousands):
Revenue recognized in the period for:
Year Ended December 31, 2018
Amounts included in contract liabilities at the beginning of the period:
 
     Performance obligations satisfied
$
13,615

Changes in the period:
 
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods
374

Performance obligations satisfied from new activities in the period - contract revenue
46,605

Total revenue
$
60,594

The following table shows the reconciliation of contract liabilities from what was disclosed in the Form 10-K for the year ended December 31, 2017 and gives effect to the modified retrospective adoption of the revenue guidance on January 1, 2018 (in thousands):

 
Balance
Deferred Revenue, balance at December 31, 2017
$
13,793

Changes in estimated consideration

Unsatisfied performance obligations
$
5,173

Deferred Revenue, balance at January 1, 2018
$
18,966

Performance obligation, expected timing of satisfaction
The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts (in thousands):
 
2019
 
2020
 
2021
 
2022 and Thereafter
 
Total
Product Revenue
$
2,201

 
$
1,729

 
$
1,623

 
$

 
$
5,553

Research and development revenue
2,735

 

 

 

 
2,735

Total revenues
$
4,936

 
$
1,729

 
$
1,623

 
$

 
$
8,288

Impact of adoption on financial statements
In accordance with ASC 606, the disclosure of the impact of adoption to our consolidated statements of operations and balance sheets was as follows (in thousands, except per share amounts):
 
Year Ended December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Revenues:





Product revenue
$
25,590


$
(3,422
)

$
22,168

Research and development revenue
35,004


(1,609
)

33,395

Total revenues
60,594


(5,031
)

55,563

Costs and operating expenses:





Cost of product revenue
12,620


(285
)

12,335

Research and development
29,978


(196
)

29,782

Selling, general and administrative
29,291




29,291

Total costs and operating expenses
71,889


(481
)

71,408

Loss from operations
(11,295
)

(4,550
)

(15,845
)
Interest income
671




671

Other expenses
(291
)



(291
)
Loss before income taxes
(10,915
)

(4,550
)

(15,465
)
Provision for (benefit from) income taxes
(37
)



(37
)
Net loss
$
(10,878
)

$
(4,550
)

$
(15,428
)









Net loss per share, basic and diluted
$
(0.21
)

$
(0.09
)

$
(0.30
)
Weighted average common shares used in computing net loss per share, basic and diluted
52,205




52,205


 
December 31, 2018
 
As reported

Adjustments

Balances without adoption of
ASC 606
Assets





Accounts receivable
$
11,551


$
(1,253
)

$
10,298

Unbilled receivables, current
1,916


(1,916
)


Contract assets
35


(35
)


Inventories
589


1


590

Unbilled receivables, non-current
786

 
(786
)
 

Other non-current assets
265


(42
)

223

Liabilities





Other accrued liabilities
4,855


(520
)

4,335

Deferred revenue - current
4,936


(1,574
)

3,362

Deferred revenue - non-current
3,352


(1,445
)

1,907

Stockholders' equity








Accumulated deficit
(330,474
)

(492
)

(330,966
)
XML 47 R29.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share (Tables)
12 Months Ended
Dec. 31, 2018
Earnings Per Share [Abstract]  
Shares not included in computation of diluted net loss per share
The following shares were not included in the computation of diluted net loss per share (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Shares issuable under Equity Incentive Plan
6,339

 
6,882

 
5,567

Shares issuable upon the conversion of warrants

 

 
73

Total anti-dilutive securities
6,339

 
6,882

 
5,640

XML 48 R30.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Equity Securities (Tables)
12 Months Ended
Dec. 31, 2018
Debt Securities, Available-for-sale [Abstract]  
Schedule of cash equivalents and marketable securities
Cash equivalents and equity securities at December 31, 2018 and 2017 consisted of the following (in thousands): 
 
December 31, 2018
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
31,225

 
$

 
$

 
$
31,225

 
n/a
Common shares of CO2 Solutions (2)
563

 
25

 

 
588

 
n/a
Total
$
31,788

 
$
25

 
$

 
$
31,813

 
 

 
December 31, 2017
 
Adjusted Cost
 
Gross Unrealized Gains (3)
 
Gross Unrealized Losses (3)
 
Estimated
Fair Value
 
Average
Contractual
Maturities
 
 
 
(in days)
Money market funds (1)
$
6,778

 
$

 
$

 
$
6,778

 
n/a
Common shares of CO2 Solutions (2)
563

 
108

 

 
671

 
n/a
Total
$
7,341

 
$
108

 
$

 
$
7,449

 
 

(1) Money market funds are classified in cash and cash equivalents on our consolidated balance sheets.
(2) Common shares of CO2 Solutions are classified in equity securities on our consolidated balance sheets.
(3) As a result of adopting ASU 2016-01, in 2018 and thereafter gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recognized in other expense, in the consolidated statements of operations. Prior to 2018 gross unrealized gains and gross unrealized losses related to our investment in CO2 Solutions were recorded in accumulated other comprehensive loss on the balance sheet.
XML 49 R31.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2018
Fair Value Disclosures [Abstract]  
Summary of financial instruments measured at fair value on a recurring basis
The following tables present the financial instruments that were measured at fair value on a recurring basis at December 31, 2018 and 2017 by level within the fair value hierarchy (in thousands): 
 
December 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
31,225

 
$

 
$

 
$
31,225

Common shares of CO2 Solutions
588

 

 

 
588

Total
$
31,813

 
$

 
$

 
$
31,813

 
December 31, 2017
 
Level 1
 
Level 2
 
Level 3
 
Total
Money market funds
$
6,778

 
$

 
$


$
6,778

Common shares of CO2 Solutions


671

 

 
671

Total
$
6,778

 
$
671

 
$

 
$
7,449


XML 50 R32.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details (Tables)
12 Months Ended
Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]  
Allowance for doubtful accounts
The following is a summary of activity in our allowance for doubtful accounts for the periods presented (in thousands):
 
December 31,
 
2018
 
2017
 
2016
Allowance - beginning of period
$
(34
)
 
$
(421
)
 
$
(421
)
Write-offs and other (1)

 
387

 

Allowance - end of period
$
(34
)
 
$
(34
)
 
$
(421
)

(1) The change in allowance for doubtful accounts was mainly related to the write-off of receivables from a foreign customer.
Schedule of inventory components
Inventories consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Raw materials
$
165

 
$
158

Work in process
47

 
53

Finished goods
377

 
825

Inventories
$
589

 
$
1,036


Property and equipment, net
Property, equipment and leasehold improvements are stated at cost less accumulated depreciation and amortization and depreciated using the straight-line method over their estimated useful lives as follows:
 
Asset classification
Estimated useful life
 
Laboratory equipment
5 years
 
Computer equipment and software
3 to 5 years
 
Office equipment and furniture
5 years
 
Leasehold improvements
Lesser of useful life or lease term
Property and equipment, net consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Laboratory equipment (1)
$
21,328

 
$
19,777

Leasehold improvements
10,359

 
10,327

Computer equipment and software
3,954

 
3,695

Office equipment and furniture
1,272

 
1,185

Construction in progress (2)
939

 
85

Property and equipment
37,852

 
35,069

Less: accumulated depreciation and amortization
(33,093
)
 
(32,254
)
Property and equipment, net
$
4,759

 
$
2,815

(1) Fully depreciated laboratory equipment with a cost of $0.3 million and $0.2 million were retired during 2018 and 2017, respectively.
(2) Construction in progress includes equipment received but not yet placed into service pending installation.
Schedule of accrued liabilities
Other accrued liabilities consisted of the following (in thousands): 
 
December 31,
 
2018
 
2017
Accrued purchases
$
1,492

 
$
941

Accrued professional and outside service fees
2,020

 
2,393

Deferred rent
343

 
258

Lease incentive obligation
425

 
425

Other
575

 
345

Total
$
4,855

 
$
4,362



XML 51 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation (Tables)
12 Months Ended
Dec. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of stock-based compensation expense
Stock-based compensation expense is included in the consolidated statements of operations as follows (in thousands):
 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Research and development
$
2,055

 
$
1,444

 
$
1,033

Selling, general and administrative
5,834

 
5,647

 
4,640

Total
$
7,889

 
$
7,091

 
$
5,673



The following table presents total stock-based compensation expense by security type included in the consolidated statements of operations (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Stock options
$
1,975

 
$
1,554

 
$
1,102

RSUs and RSAs
1,770

 
1,888

 
2,043

PSUs
1,511

 
1,792

 
2,528

PBOs
2,633

 
1,857

 

Total
$
7,889

 
$
7,091

 
$
5,673

Assumptions used to estimate the fair value of option grants
The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.6

 
5.4

 
5.3

Volatility
60.0
%
 
62.2
%
 
64.2
%
Risk-free interest rate
2.7
%
 
2.0
%
 
1.3
%
Expected dividend yield
0.0
%
 
0.0
%
 
0.0
%
Schedule of share-based compensation, stock options, activity
The following tables summarizes stock option activities:
 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
(In Thousands)
 
 
Outstanding at December 31, 2015
3,918

 
$
4.49

Granted
971

 
$
4.16

Exercised
(398
)
 
$
2.60

Forfeited/Expired
(601
)
 
$
5.76

Outstanding at December 31, 2016
3,890

 
$
4.40

Granted
856

 
$
4.57

Exercised
(86
)
 
$
3.10

Forfeited/Expired
(81
)
 
$
7.72

Outstanding at December 31, 2017
4,579

 
$
4.40

Granted
645

 
$
9.56

Exercised
(772
)
 
$
5.56

Forfeited/Expired
(340
)
 
$
6.66

Outstanding at December 31, 2018
4,112

 
$
4.81

 
 
 
 
Exercisable at December 31, 2018
2,876

 
$
3.83

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Outstanding at December 31, 2018
4,112

 
$
4.81

 
6.23
 
$
48,927

Exercisable at December 31, 2018
2,876

 
$
3.83

 
5.25
 
$
37,005

Vested and expected to vest at December 31, 2018
3,954

 
$
4.69

 
6.13
 
$
47,503

Schedule of share-based compensation, RSA activity
The following table summarizes RSA activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at December 31, 2015
480

 
$
3.29

Granted
185

 
$
4.21

Vested
(435
)
 
$
3.40

Non-vested balance at December 31, 2016
230

 
$
3.82

Granted
143

 
$
4.75

Vested
(214
)
 
$
3.81

Non-vested balance at December 31, 2017
159

 
$
4.68

Granted
47

 
$
14.35

Vested
(151
)
 
$
4.71

Non-vested balance at December 31, 2018
55

 
$
12.83

Schedule of share-based compensation, RSU activity
The following table summarizes RSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
545

 
$
3.15

Granted
330

 
$
4.10

Vested
(243
)
 
$
3.11

Forfeited/Expired
(15
)
 
$
2.74

Non-vested balance at December 31, 2016
617

 
$
3.69

Granted
275

 
$
4.22

Vested
(302
)
 
$
3.40

Forfeited/Expired
(30
)
 
$
4.12

Non-vested balance at December 31, 2017
560

 
$
4.08

Granted
86

 
$
10.56

Vested
(290
)
 
$
4.09

Forfeited/Expired
(8
)
 
$
4.73

Non-vested balance at December 31, 2018
348

 
$
5.66

Share-based compensation, performance shares sward outstanding activity
The following table summarizes PBO activities in 2018:
 
Number of Shares
 
Weighted Average Grant Date Fair Value Per Share
 
(in thousands)
 
 
Outstanding at December 31, 2016

 
$

Granted
1,720

 
$
2.54

Outstanding at December 31, 2017
1,720

 
$
2.54

Granted
1,200

 
$
5.02

Exercised
(84
)
 
$
2.54

Forfeited
(1,254
)
 
$
3.73

Outstanding at December 31, 2018
1,582

 
$
3.47


 
Number
of
Shares
 
Weighted
Average
Exercise Price Per Share
 
Weighted
Average
Remaining
Contractual Term
 
Aggregate Intrinsic
Value
 
(In Thousands)
 
 
 
(In Years)
 
(In Thousands)
Exercisable at December 31, 2018
493

 
$
4.60

 
5.60
 
$
5,968

Vested and expected to vest at December 31, 2018
1,582

 
$
6.24

 
5.44
 
$
16,553

The following table summarizes PSU activities:
 
Number
of
Shares
 
Weighted Average
Grant Date
Fair Value
Per Share
 
(In Thousands)
 
 
Non-vested balance at January 1, 2016
989

 
$
2.94

Granted
629

 
$
4.10

Vested
(482
)
 
$
2.89

Forfeited/Expired
(305
)
 
$
2.82

Non-vested balance at January 1, 2017
831

 
$
3.88

Granted
276

 
$
4.25

Vested
(651
)
 
$
3.84

Forfeited/Expired
(27
)
 
$
3.65

Non-vested balance at January 1, 2018
429

 
$
4.20

Granted
306

 
$
6.71

Vested
(495
)
 
$
4.16

Non-vested balance at December 31, 2018
240

 
$
7.48

Schedule of assumptions used
The following summarize the ranges of weighted-average assumptions used to estimate the fair value of employee stock options granted:
 
Year Ended December 31,
 
2018
 
2017
 
2016
Expected life (years)
5.63

 
5.33

 

Volatility
60.3
%
 
62.3
%
 

Risk-free interest rate
5.6
%
 
5.3
%
 

Expected dividend yield
0.0
%
 
0.0
%
 

XML 52 R34.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2018
Income Tax Disclosure [Abstract]  
Schedule of loss before income taxes, domestic and foreign
Our loss before provision for income taxes was as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
United States
$
(10,653
)
 
$
(22,994
)
 
$
(8,174
)
Foreign
(262
)
 
79

 
(424
)
Loss before provision for income taxes
$
(10,915
)
 
$
(22,915
)
 
$
(8,598
)
Components of provision for income taxes
The components of the provision for income taxes are as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Current provision (benefit):
 
 
 
 
 
Federal
$

 
$

 
$

State
5

 
5

 
5

Foreign
(13
)
 
64

 
(14
)
Total current provision (benefit)
(8
)
 
69

 
(9
)
Deferred provision (benefit):
 
 
 
 
 
Federal

 

 

State

 

 

Foreign
(29
)
 
12

 
(31
)
Total deferred provision (benefit)
(29
)
 
12

 
(31
)
Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)
Reconciliation of provision for income taxes calculated at the statutory rate to provision for income taxes
Reconciliation of the provision for income taxes calculated at the statutory rate to our provision for (benefit from) income taxes is as follows (in thousands): 
 
Year Ended December 31,
 
2018
 
2017
 
2016
Tax benefit at federal statutory rate
$
(2,292
)
 
$
(7,791
)
 
$
(2,924
)
State taxes
222

 
48

 
127

Research and development credits
(499
)
 
(399
)
 
(161
)
Foreign operations taxed at different rates
(17
)
 
(2
)
 
30

Stock-based compensation
(2,587
)
 
(216
)
 
327

Other nondeductible items
(3
)
 
326

 
405

Executive compensation
838

 
73

 
255

Change in valuation allowance
4,301

 
(26,058
)
 
1,901

Change in statutory tax rate

 
34,100

 

Provision for (benefit from) income taxes
$
(37
)
 
$
81

 
$
(40
)
Significant components of our deferred tax assets and liabilities
Significant components of our deferred tax assets and liabilities are as follows (in thousands): 
 
December 31,
 
2018
 
2017
Deferred tax assets:
 
 
 
Net operating losses
$
60,455

 
$
53,901

Credits
7,174

 
6,221

Deferred revenues
1,879

 
3,334

Stock-based compensation
2,967

 
2,872

Reserves and accruals
1,876

 
2,028

Depreciation
1,376

 
1,573

Intangible assets
2,557

 
3,172

Capital losses
576

 
576

Unrealized gain/loss
297

 
295

Other assets
83

 
78

Total deferred tax assets:
79,240

 
74,050

Deferred tax liabilities:
 
 
 
Other
(64
)
 
(115
)
Total deferred tax liabilities:
(64
)
 
(115
)
Valuation allowance
(79,222
)
 
(74,010
)
Net deferred tax liabilities
$
(46
)
 
$
(75
)
Summary of federal, state and foreign NOL carryforwards and federal research and development tax credits
The following table sets forth our federal, state and foreign NOL carryforwards and federal research and development tax credits as of December 31, 2018 (in thousands): 
 
December 31, 2018
 
Amount
 
Expiration
Years
Net operating losses, federal
$
254,208

 
2022-2038
Net operating losses, state
115,420

 
2018-2038
Tax credits, federal
7,430

 
2022-2038
Tax credits, state
9,121

 
Do not expire
Net operating losses, foreign
383

 
Various
Reconciliation of the beginning and ending amount of unrecognized tax benefits
A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows (in thousands): 
 
Rollforward Table (at Gross): As of
 
December 31,
 
2018
 
2017
 
2016
Balance at beginning of year
$
9,422

 
$
8,566

 
$
8,152

Additions based on tax positions related to current year
1,087

 
880

 
459

Reductions to tax provision of prior years
(529
)
 
(24
)
 
(45
)
Balance at end of year
$
9,980

 
$
9,422

 
$
8,566

XML 53 R35.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies (Tables)
12 Months Ended
Dec. 31, 2018
Loss Contingency [Abstract]  
Schedule of future minimum payments under non-cancellable operating leases
Future minimum payments under non-cancellable capital and operating leases at December 31, 2018 are as follows (in thousands): 
Years ending December 31,
Capital Leases
 
Operating Leases
2019
$
252

 
$
3,280

2020
61

 
712

2021

 
490

2022

 
41

2023

 

Total minimum lease payments (1)
313

 
$
4,523

Less: amount representing interest
(10
)
 
 
Present value of capital lease obligations
303

 
 
Less: current portion
(242
)
 
 
Long-term portion of capital leases
$
61

 
 

(1) 
Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
uture minimum lease payments under the Eighth Amendment is $32.9 million.
Schedule of future minimum lease payments for capital leases
Future minimum payments under non-cancellable capital and operating leases at December 31, 2018 are as follows (in thousands): 
Years ending December 31,
Capital Leases
 
Operating Leases
2019
$
252

 
$
3,280

2020
61

 
712

2021

 
490

2022

 
41

2023

 

Total minimum lease payments (1)
313

 
$
4,523

Less: amount representing interest
(10
)
 
 
Present value of capital lease obligations
303

 
 
Less: current portion
(242
)
 
 
Long-term portion of capital leases
$
61

 
 

(1) 
Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
Schedule of supply commitment
The following table provides quantitative data regarding our other commitments. Future minimum payments reflect amounts that we expect to pay including potential obligations under services agreements subject to risk of cancellation by us (in thousands):
Other Commitment Agreement Type
Agreement Date
 
Future Minimum Payment
Manufacture and supply agreement with expected future payment date of December, 2022
April 2016
 
$
1,458

Service agreement for stability study
July 2017
 
331

Service agreement for clinical trial
December 2017
 
1,258

Total other commitments

 
$
3,047

Schedule of credit facility prepayment terms
Prepayments of Term Debt and early termination of the Revolving Line of Credit are subject to prepayment and final payment fees are as follows:
 
Term Debt
 
Revolving Line of Credit
Through and including the first anniversary of the funding date of the first Term Debt drawn
2.0%
 
 
After the first anniversary of the funding date of the first Term Debt drawn and before the maturity date
1.0%
 
 
On the earliest to occur of the maturity date, the acceleration of Term Debt drawn or prepayment of Term Debt drawn
5.5%
 
 
Through and including the first anniversary of the closing date
 
 
3.0%
After the first anniversary of the closing date through and including the second anniversary of the closing date
 
 
2.0%
After the second anniversary of the closing date through and including the third anniversary of the closing date
 
 
1.0%
XML 54 R36.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information (Tables)
12 Months Ended
Dec. 31, 2018
Segment Reporting Information, Operating Income (Loss) [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):


Year Ended December 31, 2018

Year Ended December 31, 2017


Performance Enzymes

Novel Biotherapeutics

Total

Performance Enzymes

Novel Biotherapeutics

Total
Revenues:












Product revenue

$
25,590


$


$
25,590


$
26,685


$


$
26,685

Research and development revenue

21,483


13,521


35,004


15,648


7,691


23,339

Total revenues

47,073


13,521


60,594


42,333


7,691


50,024

Costs and operating expenses:












Cost of product revenue

12,620




12,620


14,327




14,327

Research and development(1)

18,924


10,185


29,109


16,847


12,107


28,954

Selling, general and administrative

7,538


771


8,309


7,371




7,371

Total segment costs and operating expenses

39,082


10,956


50,038


38,545


12,107


50,652

Income (loss) from operations

$
7,991


$
2,565


$
10,556


$
3,788


$
(4,416
)

$
(628
)
Corporate costs (2)





(20,324
)





(21,245
)
Depreciation





(1,147
)





(1,042
)
Loss before income taxes





$
(10,915
)





$
(22,915
)
(1) Research and development expenses and Selling, general and administrative expenses exclude depreciation.
(2) Corporate costs include unallocated selling, general and administrative expense, interest income, and other income and expenses.

The following table provides stock-based compensation expense included in income (loss) from operations by segment (in thousands):
 
 
2018
 
2017
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
Stock-based compensation
 
$
2,591

 
$
338

 
$
2,929

 
$
2,306

 
$
208

 
$
2,514

Schedules of Concentration of Risk
Customers that each contributed 10% or more of our total revenues were as follows:
 
Percentage of Total Revenues
For The Years Ended December 31,
 
2018
 
2017
 
2016
Merck
29
%
 
28
%
 
47
%
Nestlé Health Science
22
%
 
15
%
 
*

Tate & Lyle
13
%
 
11
%
 
*

Novartis
*

 
14
%
 
*

GSK
*

 
*

 
22
%



Customers that each accounted for 10% or more of our accounts receivable balance for the period presented were as follows:
 
Percentage of Accounts Receivables
As Of December 31,
 
2018
 
2017
Merck
37
%
 
31
%
Nestlé Health Science
17
%
 
*

Tate & Lyle
*

 
16
%
Novartis
11
%
 
15
%
Kyorin Pharmaceutical Co Ltd
16
%
 
*

Exela PharmaSci, Inc.
*

 
14
%
* Percentage was less than 10%
Schedule of Revenues by Geographical Area
Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
 
Year Ended December 31,
 
2018
 
2017
 
2016
Revenues
 
 
 
 
 
Americas
$
15,370

 
$
15,575

 
$
23,126

EMEA
22,361

 
19,610

 
17,138

APAC
22,863

 
14,839

 
8,573

Total revenues
$
60,594

 
$
50,024

 
$
48,837

Schedule of Long-lived Assets by Geographical Area
Identifiable long-lived assets by location and goodwill by reporting unit as of year-end were as follows (in thousands):
 
December 31,
 
2018
 
2017
Long-lived assets
 
 
 
United States
$
4,759

 
$
2,815

Schedule of Goodwill
 
 
 
December 31, 2018
 
 
 
Performance Enzymes
 
Novel Biotherapeutics
 
Total
 
 
 
 
 
 
 
 
Goodwill
 
 
$
2,463

 
$
778

 
$
3,241

XML 55 R37.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events (Tables)
12 Months Ended
Dec. 31, 2018
Subsequent Events [Abstract]  
Schedule of future minimum payments under non-cancellable operating leases
Future minimum payments under non-cancellable capital and operating leases at December 31, 2018 are as follows (in thousands): 
Years ending December 31,
Capital Leases
 
Operating Leases
2019
$
252

 
$
3,280

2020
61

 
712

2021

 
490

2022

 
41

2023

 

Total minimum lease payments (1)
313

 
$
4,523

Less: amount representing interest
(10
)
 
 
Present value of capital lease obligations
303

 
 
Less: current portion
(242
)
 
 
Long-term portion of capital leases
$
61

 
 

(1) 
Minimum payments have not been reduced by future minimum sublease rentals of $0.9 million to be received under non-cancellable subleases.
uture minimum lease payments under the Eighth Amendment is $32.9 million.
XML 56 R38.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business Description of Business (Details) - CDX-6114 - Nestec Ltd. (Nestle Health Sciences) - Collaborative Arrangement - USD ($)
$ in Millions
1 Months Ended
Feb. 28, 2019
Dec. 31, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Milestone payment amount   $ 1.0
Duration to pay after milestone achievement   60 days
Subsequent Event    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Amount from exercising alternative option $ 3.0  
Duration to pay after license effective date 60 days  
Threshold to achieve aggregate milestone amount $ 1,000.0  
Subsequent Event | Development and Approval    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum milestone receivable 86.0  
Subsequent Event | Sales-based Milestone    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]    
Maximum milestone receivable $ 250.0  
XML 57 R39.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Jan. 01, 2018
USD ($)
Dec. 31, 2018
USD ($)
segment
Dec. 31, 2017
USD ($)
segment
Dec. 31, 2016
USD ($)
Feb. 28, 2019
USD ($)
Jan. 01, 2019
USD ($)
Restricted Cash and Cash Equivalents Items [Line Items]            
Number of reportable segments | segment   2        
Number of operating segments | segment   2 1      
Advertising expense   $ 500,000 $ 700,000 $ 500,000    
Cash and cash equivalents   53,039,000 31,219,000 19,240,000    
Cash   21,800,000 24,400,000      
Money market funds   31,200,000 6,800,000      
Unbilled receivables, not billable   2,700,000        
Impairment of long-lived assets held-for-use   0 0 0    
Goodwill   3,241,000 3,241,000      
Goodwill impairment   0 0 0    
Provision for (benefit from) income taxes   (37,000) 81,000 $ (40,000)    
Provisional income tax expense valuation   34,100,000        
Cumulative effect of change in accounting principles   (4,059,000)        
Accounting Standards Update 2014-09            
Restricted Cash and Cash Equivalents Items [Line Items]            
Cumulative effect of change on equity or net assets   4,100,000        
Accounting Standards Update 2016-01            
Restricted Cash and Cash Equivalents Items [Line Items]            
Cumulative effect of change on equity or net assets   $ 500,000        
Cumulative effect of change in accounting principles $ 500,000          
Reclassification from AOCI, current period, tax $ 600,000          
Performance Enzymes            
Restricted Cash and Cash Equivalents Items [Line Items]            
Goodwill, allocation percent   76.00%        
Goodwill   $ 2,400,000        
Novel Biotherapeutics            
Restricted Cash and Cash Equivalents Items [Line Items]            
Goodwill, allocation percent   24.00%        
Goodwill   $ 800,000        
Subsequent Event            
Restricted Cash and Cash Equivalents Items [Line Items]            
Operating lease, right-of-use asset           $ 20,000,000
Operating lease, liability           30,000,000
Finance lease, right-of-use asset           100,000
Finance lease, liability           $ 800,000
Eighth Lease Amendment | Subsequent Event            
Restricted Cash and Cash Equivalents Items [Line Items]            
Letters of credit         $ 1,100,000  
Trustee Deposit            
Restricted Cash and Cash Equivalents Items [Line Items]            
Restricted cash and investments, noncurrent   700,000 800,000      
Demand Deposits [Member]            
Restricted Cash and Cash Equivalents Items [Line Items]            
Restricted cash and investments, noncurrent     700,000      
Letter of Credit | Demand Deposits [Member]            
Restricted Cash and Cash Equivalents Items [Line Items]            
Restricted cash and investments, noncurrent   $ 700,000 $ 800,000      
XML 58 R40.htm IDEA: XBRL DOCUMENT v3.10.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Plant, Property, and Equipment (Details)
12 Months Ended
Dec. 31, 2018
Laboratory equipment  
Property, Plant and Equipment [Line Items]  
Estimated useful life (years) 5 years
Computer equipment and software | Minimum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (years) 3 years
Computer equipment and software | Maximum  
Property, Plant and Equipment [Line Items]  
Estimated useful life (years) 5 years
Office equipment and furniture  
Property, Plant and Equipment [Line Items]  
Estimated useful life (years) 5 years
XML 59 R41.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Additional Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total revenues $ 60,594,000 $ 50,024,000 $ 48,837,000
Impairment charges related to contract assets $ 0    
Minimum      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Payment terms 30 days    
Maximum      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Payment terms 90 days    
Accounting Standards Update 2014-09      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Cumulative effect of change on equity or net assets $ 4,100,000    
Accounting Standards Update 2014-09 | Difference between Revenue Guidance in Effect before and after Topic 606      
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]      
Total revenues $ (5,031,000)    
XML 60 R42.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Disaggregation of Revenue [Line Items]      
Total revenues $ 60,594 $ 50,024 $ 48,837
Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 15,370 15,575  
EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 22,361 19,610  
APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 22,863 14,839  
Product Sales      
Disaggregation of Revenue [Line Items]      
Total revenues 25,590 26,685 $ 15,321
Research and Development Revenues      
Disaggregation of Revenue [Line Items]      
Total revenues 35,004 23,339  
Performance Enzymes      
Disaggregation of Revenue [Line Items]      
Total revenues 47,073 42,333  
Performance Enzymes | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 15,332 15,575  
Performance Enzymes | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 8,878 11,919  
Performance Enzymes | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues 22,863 14,839  
Novel Biotherapeutics      
Disaggregation of Revenue [Line Items]      
Total revenues 13,521 7,691  
Novel Biotherapeutics | Americas      
Disaggregation of Revenue [Line Items]      
Total revenues 38 0  
Novel Biotherapeutics | EMEA      
Disaggregation of Revenue [Line Items]      
Total revenues 13,483 7,691  
Novel Biotherapeutics | APAC      
Disaggregation of Revenue [Line Items]      
Total revenues $ 0 $ 0  
XML 61 R43.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Reconciliation of Contract Revenues (Details)
$ in Thousands
Jan. 01, 2018
USD ($)
Movement in Deferred Revenue [Roll Forward]  
Ending balance $ 18,966
Balances without adoption of Topic 606  
Movement in Deferred Revenue [Roll Forward]  
Beginning balance 13,793
Difference between Revenue Guidance in Effect before and after Topic 606  
Movement in Deferred Revenue [Roll Forward]  
Changes in estimated consideration 0
Unsatisfied performance obligations $ 5,173
XML 62 R44.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Contracts with Customer (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2018
Contract Assets    
Beginning balance $ 0 $ 0
Additions 8,934  
Deductions (8,899)  
Ending balance 35 35
Unbilled receivables, current    
Beginning balance 0 353
Additions 2,908  
Deductions (992)  
Ending balance 1,916 1,916
Unbilled receivables, non-current    
Beginning balance 0  
Additions 786  
Deductions 0  
Ending balance 786 786
Contract Costs    
Beginning balance 239  
Additions 0  
Deductions (197)  
Ending balance 42 42
Contract Liabilities: Deferred Revenue    
Beginning balance 18,966  
Additions 6,446  
Deductions (17,124)  
Ending balance $ 8,288 8,288
Change in Contract with Customer, Liability [Abstract]    
Performance obligations satisfied   13,615
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods   374
Performance obligations satisfied from new activities in the period - contract revenue   46,605
Total revenue   $ 60,594
XML 63 R45.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Performance Obligation (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 4,936
Expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 1,729
Expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 1,623
Expected timing of satisfaction, period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 0
Expected timing of satisfaction, period
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 8,288
Product Sales | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 2,201
Expected timing of satisfaction, period 1 year
Product Sales | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 1,729
Expected timing of satisfaction, period 1 year
Product Sales | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 1,623
Expected timing of satisfaction, period 1 year
Product Sales | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 0
Expected timing of satisfaction, period
Product Sales | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 5,553
Research and Development Revenues | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 2,735
Expected timing of satisfaction, period 1 year
Research and Development Revenues | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 0
Expected timing of satisfaction, period 1 year
Research and Development Revenues | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 0
Expected timing of satisfaction, period 1 year
Research and Development Revenues | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 0
Expected timing of satisfaction, period
Research and Development Revenues | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: (nil)  
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]  
Performance obligation $ 2,735
XML 64 R46.htm IDEA: XBRL DOCUMENT v3.10.0.1
Revenue Recognition - Impact to Financial Statements (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Revenues:        
Total revenues $ 60,594 $ 50,024 $ 48,837  
Cumulative effect of change in accounting principles (4,059)      
Costs and operating expenses:        
Cost of product revenue 12,620 14,327 9,753  
Research and development 29,978 29,659 22,229  
Selling, general and administrative 29,291 29,008 25,419  
Total costs and operating expenses 71,889 72,994 57,401  
Loss from operations (11,295) (22,970) (8,564)  
Interest income 671 147 60  
Other expenses, net (291) (92) (94)  
Loss before income taxes (10,915) (22,915) (8,598)  
Provision for (benefit from) income taxes (37) 81 (40)  
Net loss $ (10,878) $ (22,996) $ (8,558)  
Net loss per share, basic and diluted (usd per share) $ (0.21) $ (0.50) $ (0.21)  
Weighted average common stock shares used in computing net loss per share, basic and diluted (shares) 52,205 46,228 40,629  
Assets        
Accounts receivable $ 11,551 $ 11,447    
Unbilled receivables, current 1,916 353   $ 0
Contract assets 35 0   0
Inventories 589 1,036    
Unbilled receivables, non-current 786     $ 0
Other non-current assets 265      
Liabilities        
Other accrued liabilities 4,855 4,362    
Deferred revenue - current 4,936 12,292    
Deferred revenue - non-current 3,352 1,501    
Stockholders’ equity:        
Accumulated deficit (330,474) (315,065)    
Product Sales        
Revenues:        
Total revenues 25,590 26,685 $ 15,321  
Research and Development Revenues        
Revenues:        
Total revenues 35,004 $ 23,339    
Balances without adoption of Topic 606        
Revenues:        
Total revenues 55,563      
Costs and operating expenses:        
Cost of product revenue 12,335      
Research and development 29,782      
Selling, general and administrative 29,291      
Total costs and operating expenses 71,408      
Loss from operations (15,845)      
Interest income 671      
Other expenses, net (291)      
Loss before income taxes (15,465)      
Provision for (benefit from) income taxes (37)      
Net loss $ (15,428)      
Net loss per share, basic and diluted (usd per share) $ (0.30)      
Weighted average common stock shares used in computing net loss per share, basic and diluted (shares) 52,205      
Assets        
Accounts receivable $ 10,298      
Unbilled receivables, current 0      
Contract assets 0      
Inventories 590      
Unbilled receivables, non-current 0      
Other non-current assets 223      
Liabilities        
Other accrued liabilities 4,335      
Deferred revenue - current 3,362      
Deferred revenue - non-current 1,907      
Stockholders’ equity:        
Accumulated deficit (330,966)      
Balances without adoption of Topic 606 | Product Sales        
Revenues:        
Total revenues 22,168      
Balances without adoption of Topic 606 | Research and Development Revenues        
Revenues:        
Total revenues 33,395      
Accounting Standards Update 2014-09 | Adjustments        
Revenues:        
Total revenues (5,031)      
Costs and operating expenses:        
Cost of product revenue (285)      
Research and development (196)      
Selling, general and administrative 0      
Total costs and operating expenses (481)      
Loss from operations (4,550)      
Interest income 0      
Other expenses, net 0      
Loss before income taxes (4,550)      
Provision for (benefit from) income taxes 0      
Net loss $ (4,550)      
Net loss per share, basic and diluted (usd per share) $ (0.09)      
Assets        
Accounts receivable $ (1,253)      
Unbilled receivables, current (1,916)      
Contract assets (35)      
Inventories 1      
Unbilled receivables, non-current (786)      
Other non-current assets (42)      
Liabilities        
Other accrued liabilities (520)      
Deferred revenue - current (1,574)      
Deferred revenue - non-current (1,445)      
Stockholders’ equity:        
Accumulated deficit (492)      
Accounting Standards Update 2014-09 | Adjustments | Product Sales        
Revenues:        
Total revenues (3,422)      
Accounting Standards Update 2014-09 | Adjustments | Research and Development Revenues        
Revenues:        
Total revenues $ (1,609)      
XML 65 R47.htm IDEA: XBRL DOCUMENT v3.10.0.1
Net Loss per Share (Details) - shares
shares in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total anti-dilutive securities 6,339 6,882 5,640
Shares issuable under Equity Incentive Plan      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total anti-dilutive securities 6,339 6,882 5,567
Shares issuable upon the conversion of warrants      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Total anti-dilutive securities 0 0 73
XML 66 R48.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaborative Arrangements (Details) - USD ($)
1 Months Ended 12 Months Ended
Feb. 28, 2019
Jan. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Apr. 30, 2018
Oct. 31, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Aug. 31, 2015
Feb. 29, 2012
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Sales revenue, goods                       $ 60,594,000 $ 50,024,000 $ 48,837,000  
Contract with customer, liability     $ 8,288,000                 8,288,000     $ 18,966,000
Deferred revenue - current     4,936,000                 4,936,000 12,292,000    
Liability, revenue recognized                       60,594,000      
Research and Development Revenues                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Sales revenue, goods                       35,004,000 23,339,000    
Supply Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront milestone payment                 $ 800,000            
Supply Agreement | Merck                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Term of milestone agreement                     5 years        
Term of agreement extension                     5 years        
Supply Agreement | License and Service | Merck                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Sales revenue, goods             $ 300,000         1,300,000 1,300,000 1,300,000  
GSK Platform | Minimum | Technology Transfer and License Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contingent receivables       $ 5,750,000                      
GSK Platform | Maximum | Technology Transfer and License Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contingent receivables       38,500,000                      
Merck                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Sales revenue, goods                       12,300,000 9,000,000 5,900,000  
Merck | Collaborative Arrangement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Proceeds from license fees received                   $ 5,000,000          
Merck | Collaborative Arrangement | Research and Development Revenues                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Sales revenue, goods                       4,100,000 3,600,000 $ 3,000,000  
Merck | Technology Transfer and License Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Maximum milestone receivable                   $ 15,000,000          
Merck | Supply Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contract with customer, liability     3,600,000                 3,600,000 1,500,000    
Customer | Supply Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contract with customer, liability     2,000,000                 2,000,000 700,000    
Fine Chemical Customer | Research and Development Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contract with customer, liability     0                 0 3,100,000    
Upfront milestone payment               $ 3,000,000              
Term of collaborative research and development agreement               21 months              
Research and development revenues                       7,100,000 3,200,000    
Nestec Ltd. (Nestle Health Sciences) | CDX-6114 | Subsequent Event                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Progress payment eligible after commencement of Phase 1a clinical trial   $ 3,000,000                          
Nestec Ltd. (Nestle Health Sciences) | Collaborative Arrangement | Global Development, Option and License Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront milestone payment           $ 14,000,000                  
Research and development revenues                       9,900,000 7,200,000    
Progress payment eligible after commencement of Phase 1a clinical trial       4,000,000                 $ 4,000,000    
Duration to pay after license effective date                         60 days    
Nestec Ltd. (Nestle Health Sciences) | Collaborative Arrangement | Global Development, Option and License Agreement | Transferred over Time                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Contract with customer, liability     1,900,000                 1,900,000 $ 6,800,000    
Nestec Ltd. (Nestle Health Sciences) | Collaborative Arrangement | CDX-6114                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Milestone payment amount     $ 1,000,000                        
Duration to pay after milestone achievement     60 days                        
Nestec Ltd. (Nestle Health Sciences) | Collaborative Arrangement | CDX-6114 | Subsequent Event                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Duration to pay after license effective date 60 days                            
Amount from exercising alternative option $ 3,000,000                            
Threshold to achieve aggregate milestone amount 1,000,000,000                            
Nestec Ltd. (Nestle Health Sciences) | Collaborative Arrangement | Strategic Collaboration Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront milestone payment       $ 600,000                      
Research and development revenues                         1,200,000    
Deferred revenue - current     $ 800,000                 800,000 1,100,000    
Liability, revenue recognized                       3,600,000 $ 500,000    
Nestec Ltd. (Nestle Health Sciences) | Development and Approval | Collaborative Arrangement | CDX-6114 | Subsequent Event                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Maximum milestone receivable 86,000,000                            
Nestec Ltd. (Nestle Health Sciences) | Sales-based Milestone | Collaborative Arrangement | CDX-6114 | Subsequent Event                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Maximum milestone receivable $ 250,000,000                            
Porton | Porton Agreement                              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                              
Upfront milestone payment         $ 500,000                    
Research and development revenues                       $ 2,800,000      
Number of days for payment         30 days                    
XML 67 R49.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Equity Securities - Components of Cash Equivalents and Equity Securities (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Equity Securities, Available-for-sale [Line Items]      
Cash and cash equivalents $ 53,039 $ 31,219 $ 19,240
Equity securities, adjusted cost basis 563    
Equity securities, gross unrealized gains 25    
Equity securities, gross unrealized losses 0    
Equity securities, estimated fair value 588    
Equity securities, adjusted cost 31,788    
Equity securities, adjusted cost   563  
Equity securities, gross unrealized gains   108  
Equity securities, gross unrealized losses   0  
Equity securities, estimated fair value   671  
Adjusted Cost   7,341  
Gross unrealized gains   108  
Gross unrealized losses   0  
Estimated Fair Value 31,813 7,449  
Money market funds      
Equity Securities, Available-for-sale [Line Items]      
Cash and cash equivalents $ 31,225 $ 6,778  
XML 68 R50.htm IDEA: XBRL DOCUMENT v3.10.0.1
Cash Equivalents and Equity Securities - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2009
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Jan. 01, 2018
Equity Securities, Available-for-sale [Line Items]          
Cash and cash equivalents   $ 53,039 $ 31,219 $ 19,240  
Money market funds   31,200 6,800    
Cash   21,800 24,400    
Initial ownership percentage at the time of investment 16.60%        
Statutory resale restriction expiry period 4 months        
Gross unrealized gains     108    
Cumulative effect of change in accounting principles   (4,059)      
Unrealized loss on investments   (83) $ 0 $ 0  
Accounting Standards Update 2016-01          
Equity Securities, Available-for-sale [Line Items]          
Cumulative effect of change in accounting principles         $ 500
Common shares of CO2 Solutions          
Equity Securities, Available-for-sale [Line Items]          
Number of CO2 Solutions common shares we invested in (shares) 10,000,000        
Unrealized loss on investments   $ (84)      
XML 69 R51.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Financial Assets measured at Fair Value on a Recurring Basis (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and cash equivalents $ 53,039 $ 31,219 $ 19,240
Total 31,813 7,449  
Money market funds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and cash equivalents 31,225 6,778  
Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total 31,813 6,778  
Level 1 | Money market funds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and cash equivalents 31,225 6,778  
Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total 0 671  
Level 2 | Money market funds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and cash equivalents 0 0  
Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Total 0 0  
Level 3 | Money market funds      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Cash and cash equivalents 0 0  
Available-for-sale Securities [Member]      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities 588 671  
Available-for-sale Securities [Member] | Level 1      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities 588 0  
Available-for-sale Securities [Member] | Level 2      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities 0 671  
Available-for-sale Securities [Member] | Level 3      
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]      
Available-for-sale Securities $ 0 $ 0  
XML 70 R52.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Measurements - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Common shares of CO2 Solutions | Fair Value, Inputs, Level 2    
Investment [Line Items]    
Fair value of common shares (in shares) 10,000,000  
Available-for-sale Securities [Member]    
Investment [Line Items]    
Available-for-sale Securities $ 588 $ 671
Available-for-sale Securities [Member] | Fair Value, Inputs, Level 2    
Investment [Line Items]    
Available-for-sale Securities $ 0 $ 671
XML 71 R53.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details - Allowance for Doubtful Accounts Receivable (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Allowance for Doubtful Accounts Receivable [Roll Forward]      
Allowance - beginning of period $ (34) $ (421) $ (421)
Write-offs and other 0 387 0
Allowance - end of period $ (34) $ (34) $ (421)
XML 72 R54.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details - Schedule of Inventory Components (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Schedule of Inventory Components    
Raw materials $ 165 $ 158
Work in process 47 53
Finished goods 377 825
Inventories $ 589 $ 1,036
XML 73 R55.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details - Property and Equipment, net (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment $ 37,852 $ 35,069
Less: accumulated depreciation and amortization (33,093) (32,254)
Property and equipment, net 4,759 2,815
Laboratory equipment    
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment 21,328 19,777
Equipment retired during period 300 200
Leasehold improvements    
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment 10,359 10,327
Computer equipment and software    
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment 3,954 3,695
Office equipment and furniture    
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment 1,272 1,185
Construction in progress    
Property, Plant and Equipment, Net, by Type [Abstract]    
Property and equipment $ 939 $ 85
XML 74 R56.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details - Narrative (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]    
Goodwill $ 3,241 $ 3,241
XML 75 R57.htm IDEA: XBRL DOCUMENT v3.10.0.1
Balance Sheets Details - Accrued Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Balance Sheet Related Disclosures [Abstract]    
Accrued purchases $ 1,492 $ 941
Accrued professional and outside service fees 2,020 2,393
Deferred rent 343 258
Lease incentive obligation 425 425
Other 575 345
Total $ 4,855 $ 4,362
XML 76 R58.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation - Narrative (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2017
USD ($)
shares
Mar. 31, 2010
shares
Dec. 31, 2018
USD ($)
installment
$ / shares
shares
Dec. 31, 2017
USD ($)
$ / shares
shares
Dec. 31, 2016
USD ($)
$ / shares
shares
Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Total shares remaining available for issuance (shares) | shares     7,897,144      
Number of installments | installment     2      
Weighted average grant date fair value (usd per share) | $ / shares     $ 5.34 $ 2.51 $ 2.32  
Aggregate intrinsic value of options exercised     $ 7,600,000 $ 200,000 $ 600,000  
Unrecognized compensation cost, options     $ 3,500,000      
Incentive Stock Options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Option price as a percent of common stock   100.00%        
Non-Statutory Stock Options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Option price as a percent of common stock   85.00%        
Stock options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Percent of voting interests   10.00%        
Purchase price of common stock when voting percent is above minimum threshold   110.00%        
Expiration period   10 years        
Vesting period of units granted 6 months 4 years        
Award vesting rights percentage 16.67%          
Nonemployee services transaction, quantity of securities issued (shares) | shares 11,100   0   0  
Nonemployee services transaction, value of securities issued $ 48,000          
Volatility 60.60%   60.00% 62.20% 64.20%  
Risk-free interest rate 2.40%   2.70% 2.00% 1.30%  
Weighted-average remaining amortization period (years)     2 years 6 months      
Stock options | Tranche One            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Award vesting rights percentage   25.00%        
Stock options | Tranche Two            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Award vesting rights percentage   75.00%        
RSUs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Granted (shares) | shares     86,000 275,000 330,000  
Weighted-average remaining amortization period (years)     1 year 1 month      
Weighted average grant date fair value (usd per share) | $ / shares     $ 10.56 $ 4.22 $ 4.10  
Equity instruments other than options, aggregate intrinsic value, vested     $ 2,900,000 $ 1,300,000 $ 1,000,000  
Unrecognized compensation cost, awards other than options     $ 1,000,000      
RSUs | Tranche One            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period of units granted   3 years        
Award vesting rights percentage   33.33333%        
RSUs | Tranche Two            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Vesting period of units granted   4 years        
Award vesting rights percentage   25.00%        
RSAs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Granted (shares) | shares     47,000 143,000 185,000  
Weighted-average remaining amortization period (years)     4 months 24 days      
Weighted average grant date fair value (usd per share) | $ / shares     $ 14.35 $ 4.75 $ 4.21  
Equity instruments other than options, aggregate intrinsic value, vested     $ 2,100,000 $ 1,000,000 $ 1,800,000  
Unrecognized compensation cost, awards other than options     $ 300,000      
PBOs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Threshold level multiplier     0      
Granted (shares) | shares     1,200,000 1,720,000    
Volatility     60.30% 62.30% 0.00%  
Risk-free interest rate     5.60% 5.30% 0.00%  
Weighted-average remaining amortization period (years)     10 months 24 days      
Weighted average grant date fair value (usd per share) | $ / shares     $ 5.02 $ 2.54    
Unrecognized compensation cost, awards other than options     $ 1,200,000      
Exercises in period, intrinsic value     $ 200,000 $ 0 $ 0  
PBOs | Tranche One            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Future vesting rights, percentage           50.00%
PBOs | Tranche Two            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Future vesting rights, percentage           50.00%
PSUs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Granted (shares) | shares     306,000 276,000 629,000  
Weighted-average remaining amortization period (years)     6 months      
Weighted average grant date fair value (usd per share) | $ / shares     $ 6.71 $ 4.25 $ 4.10  
Equity instruments other than options, aggregate intrinsic value, vested     $ 5,400,000 $ 2,700,000 $ 1,800,000  
Unrecognized compensation cost, awards other than options     $ 600,000      
2010 Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares initially available for future issuance (shares) | shares   1,100,000        
Reduction of share reserve for each share granted (shares) | shares   1        
2018 PSU and PBO Plan | PBOs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Estimated performance goal achievement rate     118.00%      
2017 PSU and PBO Plan | PBOs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Estimated performance goal achievement rate       134.20%    
2016 PSU Plan | PBOs            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Estimated performance goal achievement rate         142.30%  
Granted (shares) | shares         0  
XML 77 R59.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Schedule of stock-based compensation expense      
Stock-based compensation $ 7,889 $ 7,091 $ 5,673
Stock options      
Schedule of stock-based compensation expense      
Stock-based compensation 1,975 1,554 1,102
RSUs and RSAs      
Schedule of stock-based compensation expense      
Stock-based compensation 1,770 1,888 2,043
PSUs      
Schedule of stock-based compensation expense      
Stock-based compensation 1,511 1,792 2,528
PBOs      
Schedule of stock-based compensation expense      
Stock-based compensation 2,633 1,857 0
Research and development      
Schedule of stock-based compensation expense      
Stock-based compensation 2,055 1,444 1,033
Selling, general and administrative      
Schedule of stock-based compensation expense      
Stock-based compensation $ 5,834 $ 5,647 $ 4,640
XML 78 R60.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation - Assumptions Used (Details)
1 Months Ended 12 Months Ended
Oct. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Stock options        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life (years)   5 years 6 months 28 days 5 years 4 months 28 days 5 years 3 months 29 days
Volatility 60.60% 60.00% 62.20% 64.20%
Risk-free interest rate 2.40% 2.70% 2.00% 1.30%
Expected dividend yield   0.00% 0.00% 0.00%
PBOs        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Expected life (years)   5 years 7 months 17 days 5 years 3 months 29 days  
Volatility   60.30% 62.30% 0.00%
Risk-free interest rate   5.60% 5.30% 0.00%
Expected dividend yield   0.00% 0.00% 0.00%
XML 79 R61.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation - Option Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Number of Shares Subject to Outstanding Options      
Outstanding, beginning of period (shares) 4,579 3,890 3,918
Granted (shares) 645 856 971
Exercised (shares) (772) (86) (398)
Forfeited/Expired (shares) (340) (81) (601)
Outstanding, end of period (shares) 4,112 4,579 3,890
Options exercisable (shares) 2,876    
Options vested and expected to vest (shares) 3,954    
Weighted-average Exercise Price of Outstanding Options      
Outstanding, beginning of period (usd per share) $ 4.40 $ 4.40 $ 4.49
Granted (usd per share) 9.56 4.57 4.16
Exercised (usd per share) 5.56 3.10 2.60
Forfeited/Expired (usd per share) 6.66 7.72 5.76
Outstanding, end of period (usd per share) 4.81 $ 4.40 $ 4.40
Options exercisable (usd per share) 3.83    
Options vested and expected to vest (usd per share) $ 4.69    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]      
Weighted average remaining contractual terms 6 years 2 months 23 days    
Weighted average remaining contractual terms, exercisable options 5 years 3 months    
Weighted average remaining contractual terms, vested and expected to vest options 6 years 1 month 17 days    
Aggregate intrinsic value, outstanding $ 48,927    
Aggregate intrinsic value, exercisable options 37,005    
Aggregate intrinsic value, options vested and expected to vest $ 47,503    
XML 80 R62.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stock-based Compensation - Award Activity (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Number of Shares      
Forfeited/expired (shares)   (27) (305)
Weighted-average Grant Date Fair Value per Share      
Forfeited/Expired, weighted average exercise price per share (usd per share)   $ 3.65 $ 2.82
Exercisable and Expected to Vest      
Options exercisable (shares) 2,876    
Options vested and expected to vest (shares) 3,954    
Options exercisable (usd per share) $ 3.83    
Options vested and expected to vest (usd per share) $ 4.69    
Weighted average remaining contractual terms, exercisable options 5 years 3 months    
Weighted average remaining contractual terms, vested and expected to vest options 6 years 1 month 17 days    
Aggregate intrinsic value, exercisable options $ 37,005    
Aggregate intrinsic value, options vested and expected to vest $ 47,503    
RSAs      
Number of Shares      
Non-vested, beginning of period (shares) 159 230 480
Granted (shares) 47 143 185
Vested (shares) (151) (214) (435)
Non-vested, end of period (shares) 55 159 230
Weighted-average Grant Date Fair Value per Share      
Non-vested, beginning of period (usd per share) $ 4.68 $ 3.82 $ 3.29
Granted, weighted average grant date fair value (usd per share) 14.35 4.75 4.21
Vested, weighted average grant date fair value (usd per share) 4.71 3.81 3.40
Non-vested, end of period (usd per share) $ 12.83 $ 4.68 $ 3.82
RSUs      
Number of Shares      
Non-vested, beginning of period (shares) 560 617 545
Granted (shares) 86 275 330
Vested (shares) (290) (302) (243)
Forfeited/expired (shares) (8) (30) (15)
Non-vested, end of period (shares) 348 560 617
Weighted-average Grant Date Fair Value per Share      
Non-vested, beginning of period (usd per share) $ 4.08 $ 3.69 $ 3.15
Granted, weighted average grant date fair value (usd per share) 10.56 4.22 4.10
Vested, weighted average grant date fair value (usd per share) 4.09 3.40 3.11
Forfeited/Expired, weighted average exercise price per share (usd per share) 4.73 4.12 2.74
Non-vested, end of period (usd per share) $ 5.66 $ 4.08 $ 3.69
PSUs      
Number of Shares      
Non-vested, beginning of period (shares) 429 831 989
Granted (shares) 306 276 629
Vested (shares) (495) (651) (482)
Non-vested, end of period (shares) 240 429 831
Weighted-average Grant Date Fair Value per Share      
Non-vested, beginning of period (usd per share) $ 4.20 $ 3.88 $ 2.94
Granted, weighted average grant date fair value (usd per share) 6.71 4.25 4.10
Vested, weighted average grant date fair value (usd per share) 4.16 3.84 2.89
Non-vested, end of period (usd per share) $ 7.48 $ 4.20 $ 3.88
PBOs      
Number of Shares      
Non-vested, beginning of period (shares) 1,720 0  
Granted (shares) 1,200 1,720  
Exercised (shares) (84)    
Forfeited/expired (shares) (1,254)    
Non-vested, end of period (shares) 1,582 1,720 0
Weighted-average Grant Date Fair Value per Share      
Non-vested, beginning of period (usd per share) $ 2.54 $ 0.00  
Granted, weighted average grant date fair value (usd per share) 5.02 2.54  
Exercised, weighted average grant date fair value (usd per share) 2.54    
Forfeited/Expired, weighted average exercise price per share (usd per share) 3.73    
Non-vested, end of period (usd per share) $ 3.47 $ 2.54 $ 0.00
Exercisable and Expected to Vest      
Options exercisable (shares) 493    
Options vested and expected to vest (shares) 1,582    
Options exercisable (usd per share) $ 4.60    
Options vested and expected to vest (usd per share) $ 6.24    
Weighted average remaining contractual terms, exercisable options 5 years 7 months 7 days    
Weighted average remaining contractual terms, vested and expected to vest options 5 years 5 months 8 days    
Aggregate intrinsic value, exercisable options $ 5,968    
Aggregate intrinsic value, options vested and expected to vest $ 16,553    
XML 81 R63.htm IDEA: XBRL DOCUMENT v3.10.0.1
Capital Stock (Details)
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 30, 2018
USD ($)
$ / shares
shares
Class of Stock [Line Items]  
Price per share issued (usd per share) | $ / shares $ 9.25
Proceeds from public offering | $ $ 37.3
Underwritten Public Offering  
Class of Stock [Line Items]  
Issuance of common stock, net of issuance costs (shares) 4,312,500
Over-Allotment Option  
Class of Stock [Line Items]  
Issuance of common stock, net of issuance costs (shares) 562,500
XML 82 R64.htm IDEA: XBRL DOCUMENT v3.10.0.1
401(k) Plan (Details) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Retirement Benefits [Abstract]      
Employer matching contribution amount $ 0.6 $ 0.6 $ 0.4
XML 83 R65.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Components of Loss Before Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax Disclosure [Abstract]      
United States $ (10,653) $ (22,994) $ (8,174)
Foreign (262) 79 (424)
Loss before income taxes $ (10,915) $ (22,915) $ (8,598)
XML 84 R66.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Components of Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Current provision (benefit):      
Federal $ 0 $ 0 $ 0
State 5 5 5
Foreign (13) 64 (14)
Total current provision (benefit) (8) 69 (9)
Deferred provision (benefit):      
Federal 0 0 0
State 0 0 0
Foreign (29) 12 (31)
Total deferred provision (benefit) (29) 12 (31)
Provision for (benefit from) income taxes $ (37) $ 81 $ (40)
XML 85 R67.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Tax Rate Reconciliation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Tax Rate Reconciliation      
Tax benefit at federal statutory rate $ (2,292) $ (7,791) $ (2,924)
State taxes 222 48 127
Research and development credits (499) (399) (161)
Foreign operations taxed at different rates (17) (2) 30
Stock-based compensation (2,587) (216) 327
Other nondeductible items (3) 326 405
Executive compensation 838 73 255
Change in valuation allowance 4,301 (26,058) 1,901
Change in statutory tax rate 0 34,100 0
Provision for (benefit from) income taxes $ (37) $ 81 $ (40)
XML 86 R68.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Deferred tax assets:    
Net operating losses $ 60,455 $ 53,901
Credits 7,174 6,221
Deferred revenues 1,879 3,334
Stock-based compensation 2,967 2,872
Reserves and accruals 1,876 2,028
Depreciation 1,376 1,573
Intangible assets 2,557 3,172
Capital losses 576 576
Unrealized gain/loss 297 295
Other assets 83 78
Total deferred tax assets: 79,240 74,050
Deferred tax liabilities:    
Other (64) (115)
Total deferred tax liabilities: (64) (115)
Valuation allowance (79,222) (74,010)
Net deferred tax liabilities $ (46) $ (75)
XML 87 R69.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Narrative (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Income Taxes [Line Items]      
Cumulative effect of change in accounting principles $ 4,059    
Increase (decrease) in deferred tax asset valuation allowance 5,200 $ (20,400) $ 1,900
Interest and penalties recognize in income tax expense 37 31 $ 35
Interest and penalties recognized on the balance sheet 400 300  
Unrecognized tax benefits that would impact effective tax rate 300 $ 400  
India      
Income Taxes [Line Items]      
Deferred tax liability from undistributed foreign earnings 100    
Accumulated Deficit      
Income Taxes [Line Items]      
Cumulative effect of change in accounting principles 4,531    
Accumulated Deficit | Accounting Standards Update 2014-09      
Income Taxes [Line Items]      
Cumulative effect of change in accounting principles $ 900    
XML 88 R70.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - NOL Carryforwards and Federal Research and Development Tax Credits (Details)
$ in Thousands
Dec. 31, 2018
USD ($)
Federal  
Net Operating Losses and Tax Credit Carryforwards  
Net operating losses, amount $ 254,208
Tax credits, amount 7,430
State  
Net Operating Losses and Tax Credit Carryforwards  
Net operating losses, amount 115,420
Tax credits, amount 9,121
Foreign Tax Authority [Member]  
Net Operating Losses and Tax Credit Carryforwards  
Net operating losses, amount $ 383
XML 89 R71.htm IDEA: XBRL DOCUMENT v3.10.0.1
Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]      
Balance at beginning of year $ 9,422 $ 8,566 $ 8,152
Additions based on tax positions related to current year 1,087 880 459
Reductions to tax provision of prior years (529) (24) (45)
Balance at end of year $ 9,980 $ 9,422 $ 8,566
XML 90 R72.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Narrative (Details)
1 Months Ended 12 Months Ended 24 Months Ended
Jun. 30, 2017
USD ($)
Apr. 30, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2018
USD ($)
ft²
multiplier
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2012
USD ($)
Mar. 01, 2019
Feb. 28, 2019
USD ($)
Long-term Purchase Commitment [Line Items]                    
Lease area space occupancy | ft²       107,200            
Payments for capital improvements   $ 300,000 $ 400,000              
Rent expense       $ 3,200,000 $ 3,200,000 $ 2,900,000        
Sublease rentals       1,100,000 1,400,000 $ 1,200,000        
Term of contract   3 years 3 years     3 years        
Indemnification agreement                    
Long-term Purchase Commitment [Line Items]                    
Accruals for expenses related to indemnification issues       $ 0            
Term Debt                    
Long-term Purchase Commitment [Line Items]                    
Current borrowing capacity $ 10,000,000.0                  
Term Debt | London Interbank Offered Rate (LIBOR)                    
Long-term Purchase Commitment [Line Items]                    
Basis spread on variable rate 3.60%                  
Revolving Line of Credit                    
Long-term Purchase Commitment [Line Items]                    
Current borrowing capacity $ 5,000,000.0                  
Accounts receivable borrowing base percentage 80.00%                  
Interest rate, stated percentage 5.00%                  
Minimum cash multiplier | multiplier       6            
Revolving Line of Credit | Prime Rate [Member]                    
Long-term Purchase Commitment [Line Items]                    
Basis spread on variable rate 1.00%                  
Demand Deposits [Member]                    
Long-term Purchase Commitment [Line Items]                    
Restricted cash and investments, noncurrent         700,000          
Eighth Lease Amendment | Subsequent Event                    
Long-term Purchase Commitment [Line Items]                    
Renewal term                 5 years 88 months
Letters of credit                   $ 1,100,000
Fifth Amendment                    
Long-term Purchase Commitment [Line Items]                    
Payments for capital improvements             $ 3,600,000      
Payments for (proceeds from) tenant allowance               $ (3,100,000)    
Amendment 7                    
Long-term Purchase Commitment [Line Items]                    
Incentive from lessor       $ 500,000 900,000          
Redwood City, California, Penobscot Space                    
Long-term Purchase Commitment [Line Items]                    
Lease area space occupancy | ft²       28,200            
Redwood City, California, Building 2 Space                    
Long-term Purchase Commitment [Line Items]                    
Lease area space occupancy | ft²       37,900            
Redwood City, California, 501 Chesapeake Space                    
Long-term Purchase Commitment [Line Items]                    
Lease area space occupancy | ft²       11,200            
Redwood City, California, Saginaw Space                    
Long-term Purchase Commitment [Line Items]                    
Lease area space occupancy | ft²       29,900            
Headquarters Redwood City                    
Long-term Purchase Commitment [Line Items]                    
Asset retirement obligations       $ 200,000 $ 200,000          
XML 91 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Future Minimum Payments Under Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Capital Leases    
2019 $ 252  
2020 61  
2021 0  
2022 0  
2023 0  
Total minimum lease payments 313  
Less: amount representing interest (10)  
Present value of capital lease obligations 303  
Less: current portion (242)  
Long-term portion of capital leases 61 $ 302
Operating leases    
2019 3,280  
2020 712  
2021 490  
2022 41  
2023 0  
Total minimum lease payments 4,523  
Total future minimum sublease rentals to be received under noncancellable subleases $ 900  
XML 92 R74.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Other Commitments (Details) - Supply Commitment
$ in Thousands
Dec. 31, 2018
USD ($)
Loss Contingencies [Line Items]  
Future Minimum Payment $ 3,047
April 2016  
Loss Contingencies [Line Items]  
Future Minimum Payment 1,458
July 2017  
Loss Contingencies [Line Items]  
Future Minimum Payment 331
December 2017  
Loss Contingencies [Line Items]  
Future Minimum Payment $ 1,258
XML 93 R75.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Credit Facility (Details)
Jun. 30, 2017
Term Debt | Repayment Period 1  
Debt Instrument [Line Items]  
Prepayment fee percentage 2.00%
Term Debt | Repayment Period 2  
Debt Instrument [Line Items]  
Prepayment fee percentage 1.00%
Term Debt | Repayment Period 3  
Debt Instrument [Line Items]  
Prepayment fee percentage 5.50%
Revolving Line of Credit | Repayment Period 4  
Debt Instrument [Line Items]  
Prepayment fee percentage 3.00%
Revolving Line of Credit | Repayment Period 5  
Debt Instrument [Line Items]  
Prepayment fee percentage 2.00%
Revolving Line of Credit | Repayment Period 6  
Debt Instrument [Line Items]  
Prepayment fee percentage 1.00%
XML 94 R76.htm IDEA: XBRL DOCUMENT v3.10.0.1
Related Party Transactions (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Related Party Transaction [Line Items]      
Total revenues $ 60,594,000 $ 50,024,000 $ 48,837,000
Exela      
Related Party Transaction [Line Items]      
Accounts receivable, related parties 0 1,600,000  
Exela | Revenue sharing arrangement      
Related Party Transaction [Line Items]      
Total revenues 0 2,600,000 2,200,000
Alfa Aesar      
Related Party Transaction [Line Items]      
Accounts receivable, related parties 0 0 400,000
AstraZeneca      
Related Party Transaction [Line Items]      
Accounts receivable, related parties 200,000 100,000  
Revenue from related parties 600,000 100,000 0
Asymchem      
Related Party Transaction [Line Items]      
Accounts receivable, related parties 0 100,000  
Revenue from related parties $ 0 $ 75,000 $ 0
Exela | Presidio Partners 2007, L.P.      
Related Party Transaction [Line Items]      
Investment, ownership percentage 10.00%    
XML 95 R77.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information - Narrative (Details)
$ in Millions
1 Months Ended 12 Months Ended
Feb. 28, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
segment
Dec. 31, 2017
segment
Segment Reporting Information [Line Items]        
Number of operating segments | segment     2 1
Collaborative Arrangement | CDX-6114 | Nestec Ltd. (Nestle Health Sciences)        
Segment Reporting Information [Line Items]        
Milestone payment amount   $ 1.0    
Duration to pay after milestone achievement   60 days    
Collaborative Arrangement | CDX-6114 | Nestec Ltd. (Nestle Health Sciences) | Subsequent Event        
Segment Reporting Information [Line Items]        
Amount from exercising alternative option $ 3.0      
XML 96 R78.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Segment Reporting Information [Line Items]      
Total revenues $ 60,594 $ 50,024 $ 48,837
Cost of product revenue 12,620 14,327 9,753
Research and development 29,978 29,659 22,229
Selling, general and administrative 29,291 29,008 25,419
Total costs and operating expenses 71,889 72,994 57,401
Loss from operations (11,295) (22,970) (8,564)
Depreciation (1,147) (1,042) (1,734)
Loss before income taxes (10,915) (22,915) (8,598)
Share-based compensation 7,889 7,091 5,673
Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 60,594 50,024  
Cost of product revenue 12,620 14,327  
Research and development 29,109 28,954  
Selling, general and administrative 8,309 7,371  
Total costs and operating expenses 50,038 50,652  
Loss from operations 10,556 (628)  
Share-based compensation 2,929 2,514  
Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 47,073 42,333  
Cost of product revenue 12,620 14,327  
Research and development 18,924 16,847  
Selling, general and administrative 7,538 7,371  
Total costs and operating expenses 39,082 38,545  
Loss from operations 7,991 3,788  
Share-based compensation 2,591 2,306  
Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 13,521 7,691  
Cost of product revenue 0 0  
Research and development 10,185 12,107  
Selling, general and administrative 771 0  
Total costs and operating expenses 10,956 12,107  
Loss from operations 2,565 (4,416)  
Share-based compensation 338 208  
Corporate, Non-Segment      
Segment Reporting Information [Line Items]      
Total costs and operating expenses (20,324) (21,245)  
Depreciation 1,147 1,042  
Product Sales      
Segment Reporting Information [Line Items]      
Total revenues 25,590 26,685 $ 15,321
Product Sales | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 25,590 26,685  
Product Sales | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 25,590 26,685  
Product Sales | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues 0 0  
Research and Development Revenues      
Segment Reporting Information [Line Items]      
Total revenues 35,004 23,339  
Research and Development Revenues | Operating Segments      
Segment Reporting Information [Line Items]      
Total revenues 35,004 23,339  
Research and Development Revenues | Operating Segments | Performance Enzymes      
Segment Reporting Information [Line Items]      
Total revenues 21,483 15,648  
Research and Development Revenues | Operating Segments | Novel Biotherapeutics      
Segment Reporting Information [Line Items]      
Total revenues $ 13,521 $ 7,691  
XML 97 R79.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information - Concentration Risk (Details)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Merck | Sales | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 29.00% 28.00% 47.00%
Merck | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 37.00% 31.00%  
Nestle Health Science | Sales | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 22.00% 15.00%  
Nestle Health Science | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 17.00%    
Tate & Lyle | Sales | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 13.00% 11.00%  
Tate & Lyle | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage   16.00%  
Novartis | Sales | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage   14.00%  
Novartis | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 11.00% 15.00%  
GSK | Sales | Customer Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage     22.00%
Kyorin Pharmaceutical Co Ltd | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage 16.00%    
Exela PharmSci, Inc | Accounts Receivable | Credit Concentration Risk      
Concentration Risk [Line Items]      
Concentration risk, percentage   14.00%  
XML 98 R80.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information - Revenues (Details) - USD ($)
12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Schedule of revenues by geographical area      
Revenues $ 60,594,000 $ 50,024,000 $ 48,837,000
Americas      
Schedule of revenues by geographical area      
Revenues 15,370,000 15,575,000 23,126,000
EMEA      
Schedule of revenues by geographical area      
Revenues 22,361,000 19,610,000 17,138,000
APAC      
Schedule of revenues by geographical area      
Revenues 22,863,000 14,839,000 $ 8,573,000
United States      
Schedule of revenues by geographical area      
Long-lived assets $ 4,759,000 $ 2,815,000  
XML 99 R81.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segment, Geographical and Other Revenue Information - Goodwill (Details) - USD ($)
$ in Thousands
Dec. 31, 2018
Dec. 31, 2017
Segment Reporting Information [Line Items]    
Goodwill $ 3,241 $ 3,241
Performance Enzymes    
Segment Reporting Information [Line Items]    
Goodwill 2,400  
Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Goodwill 800  
Operating Segments    
Segment Reporting Information [Line Items]    
Goodwill 3,241  
Operating Segments | Performance Enzymes    
Segment Reporting Information [Line Items]    
Goodwill 2,463  
Operating Segments | Novel Biotherapeutics    
Segment Reporting Information [Line Items]    
Goodwill $ 778  
XML 100 R82.htm IDEA: XBRL DOCUMENT v3.10.0.1
Subsequent Events - Additional Information (Details) - USD ($)
1 Months Ended
Jan. 31, 2019
Mar. 01, 2019
Feb. 28, 2019
Dec. 31, 2018
Subsequent Event [Line Items]        
Total minimum lease payments       $ 4,523,000
Subsequent Event | Nestec Ltd. (Nestle Health Sciences) | CDX-6114        
Subsequent Event [Line Items]        
Progress payment eligible after exercise $ 3,000,000      
Eighth Lease Amendment | Subsequent Event        
Subsequent Event [Line Items]        
Lease, term of contract   88 months    
Renewal term   5 years 88 months  
Letters of credit     $ 1,100,000  
Total minimum lease payments     $ 32,900,000  
EXCEL 101 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

3O!G:" M4. K.%VY62[",LD2](Q%0<=2OU$K,/*'7^%4THMBM;+%6M%*I!QP-)^YSW8: MNY?O0'WSIA-JE3>/?J4@O5Q[PD3C63098

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end XML 102 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 103 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 105 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 358 420 1 true 126 0 false 8 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.codexis.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated Balance Sheets Sheet http://www.codexis.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1001501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.codexis.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Consolidated Statements of Operations Sheet http://www.codexis.com/role/ConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 1003000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.codexis.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 1003001 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) Sheet http://www.codexis.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical Consolidated Statements of Comprehensive Loss (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements Stockholders' Equity Sheet http://www.codexis.com/role/ConsolidatedStatementsStockholdersEquity Consolidated Statements Stockholders' Equity Statements 7 false false R8.htm 1004001 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.codexis.com/role/ConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) Statements 8 false false R9.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.codexis.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 9 false false R10.htm 2101100 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 10 false false R11.htm 2101100 - Disclosure - Description of Business Sheet http://www.codexis.com/role/DescriptionOfBusiness Description of Business Notes 11 false false R12.htm 2102100 - Disclosure - Revenue Recognition Sheet http://www.codexis.com/role/RevenueRecognition Revenue Recognition Notes 12 false false R13.htm 2103100 - Disclosure - Net Loss per Share Sheet http://www.codexis.com/role/NetLossPerShare Net Loss per Share Notes 13 false false R14.htm 2104100 - Disclosure - Collaborative Arrangements Sheet http://www.codexis.com/role/CollaborativeArrangements Collaborative Arrangements Notes 14 false false R15.htm 2106100 - Disclosure - Cash Equivalents and Equity Securities Sheet http://www.codexis.com/role/CashEquivalentsAndEquitySecurities Cash Equivalents and Equity Securities Notes 15 false false R16.htm 2107100 - Disclosure - Fair Value Measurements Sheet http://www.codexis.com/role/FairValueMeasurements Fair Value Measurements Notes 16 false false R17.htm 2108100 - Disclosure - Balance Sheets Details Sheet http://www.codexis.com/role/BalanceSheetsDetails Balance Sheets Details Notes 17 false false R18.htm 2111100 - Disclosure - Stock-based Compensation Sheet http://www.codexis.com/role/StockBasedCompensation Stock-based Compensation Notes 18 false false R19.htm 2112100 - Disclosure - Capital Stock Sheet http://www.codexis.com/role/CapitalStock Capital Stock Notes 19 false false R20.htm 2113100 - Disclosure - 401(k) Plan Sheet http://www.codexis.com/role/A401KPlan 401(k) Plan Notes 20 false false R21.htm 2114100 - Disclosure - Income Taxes Sheet http://www.codexis.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2115100 - Disclosure - Commitments and Contingencies Sheet http://www.codexis.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 22 false false R23.htm 2116100 - Disclosure - Related Party Transactions Sheet http://www.codexis.com/role/RelatedPartyTransactions Related Party Transactions Notes 23 false false R24.htm 2117100 - Disclosure - Segment, Geographical and Other Revenue Information Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformation Segment, Geographical and Other Revenue Information Notes 24 false false R25.htm 2120100 - Disclosure - Subsequent Events Sheet http://www.codexis.com/role/SubsequentEvents Subsequent Events Notes 25 false false R26.htm 2201201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 26 false false R27.htm 2301302 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPolicies 27 false false R28.htm 2302301 - Disclosure - Revenue Recognition (Tables) Sheet http://www.codexis.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.codexis.com/role/RevenueRecognition 28 false false R29.htm 2303301 - Disclosure - Net Loss per Share (Tables) Sheet http://www.codexis.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://www.codexis.com/role/NetLossPerShare 29 false false R30.htm 2306301 - Disclosure - Cash Equivalents and Equity Securities (Tables) Sheet http://www.codexis.com/role/CashEquivalentsAndEquitySecuritiesTables Cash Equivalents and Equity Securities (Tables) Tables http://www.codexis.com/role/CashEquivalentsAndEquitySecurities 30 false false R31.htm 2307301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.codexis.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.codexis.com/role/FairValueMeasurements 31 false false R32.htm 2308301 - Disclosure - Balance Sheets Details (Tables) Sheet http://www.codexis.com/role/BalanceSheetsDetailsTables Balance Sheets Details (Tables) Tables http://www.codexis.com/role/BalanceSheetsDetails 32 false false R33.htm 2311301 - Disclosure - Stock-based Compensation (Tables) Sheet http://www.codexis.com/role/StockBasedCompensationTables Stock-based Compensation (Tables) Tables http://www.codexis.com/role/StockBasedCompensation 33 false false R34.htm 2314301 - Disclosure - Income Taxes (Tables) Sheet http://www.codexis.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.codexis.com/role/IncomeTaxes 34 false false R35.htm 2315301 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.codexis.com/role/CommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.codexis.com/role/CommitmentsAndContingencies 35 false false R36.htm 2317301 - Disclosure - Segment, Geographical and Other Revenue Information (Tables) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationTables Segment, Geographical and Other Revenue Information (Tables) Tables http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformation 36 false false R37.htm 2320301 - Disclosure - Subsequent Events (Tables) Sheet http://www.codexis.com/role/SubsequentEventsTables Subsequent Events (Tables) Tables http://www.codexis.com/role/SubsequentEvents 37 false false R38.htm 2401401 - Disclosure - Description of Business Description of Business (Details) Sheet http://www.codexis.com/role/DescriptionOfBusinessDescriptionOfBusinessDetails Description of Business Description of Business (Details) Details 38 false false R39.htm 2401403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables 39 false false R40.htm 2401404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Plant, Property, and Equipment (Details) Sheet http://www.codexis.com/role/BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPlantPropertyAndEquipmentDetails Basis of Presentation and Summary of Significant Accounting Policies - Plant, Property, and Equipment (Details) Details 40 false false R41.htm 2402402 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.codexis.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 41 false false R42.htm 2402403 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.codexis.com/role/RevenueRecognitionDisaggregationOfRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 42 false false R43.htm 2402404 - Disclosure - Revenue Recognition - Reconciliation of Contract Revenues (Details) Sheet http://www.codexis.com/role/RevenueRecognitionReconciliationOfContractRevenuesDetails Revenue Recognition - Reconciliation of Contract Revenues (Details) Details 43 false false R44.htm 2402405 - Disclosure - Revenue Recognition - Contracts with Customer (Details) Sheet http://www.codexis.com/role/RevenueRecognitionContractsWithCustomerDetails Revenue Recognition - Contracts with Customer (Details) Details 44 false false R45.htm 2402406 - Disclosure - Revenue Recognition - Performance Obligation (Details) Sheet http://www.codexis.com/role/RevenueRecognitionPerformanceObligationDetails Revenue Recognition - Performance Obligation (Details) Details 45 false false R46.htm 2402407 - Disclosure - Revenue Recognition - Impact to Financial Statements (Details) Sheet http://www.codexis.com/role/RevenueRecognitionImpactToFinancialStatementsDetails Revenue Recognition - Impact to Financial Statements (Details) Details 46 false false R47.htm 2403402 - Disclosure - Net Loss per Share (Details) Sheet http://www.codexis.com/role/NetLossPerShareDetails Net Loss per Share (Details) Details http://www.codexis.com/role/NetLossPerShareTables 47 false false R48.htm 2404401 - Disclosure - Collaborative Arrangements (Details) Sheet http://www.codexis.com/role/CollaborativeArrangementsDetails Collaborative Arrangements (Details) Details http://www.codexis.com/role/CollaborativeArrangements 48 false false R49.htm 2406402 - Disclosure - Cash Equivalents and Equity Securities - Components of Cash Equivalents and Equity Securities (Details) Sheet http://www.codexis.com/role/CashEquivalentsAndEquitySecuritiesComponentsOfCashEquivalentsAndEquitySecuritiesDetails Cash Equivalents and Equity Securities - Components of Cash Equivalents and Equity Securities (Details) Details 49 false false R50.htm 2406403 - Disclosure - Cash Equivalents and Equity Securities - Narrative (Details) Sheet http://www.codexis.com/role/CashEquivalentsAndEquitySecuritiesNarrativeDetails Cash Equivalents and Equity Securities - Narrative (Details) Details 50 false false R51.htm 2407403 - Disclosure - Fair Value Measurements - Financial Assets measured at Fair Value on a Recurring Basis (Details) Sheet http://www.codexis.com/role/FairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisDetails Fair Value Measurements - Financial Assets measured at Fair Value on a Recurring Basis (Details) Details 51 false false R52.htm 2407404 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.codexis.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 52 false false R53.htm 2408402 - Disclosure - Balance Sheets Details - Allowance for Doubtful Accounts Receivable (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsAllowanceForDoubtfulAccountsReceivableDetails Balance Sheets Details - Allowance for Doubtful Accounts Receivable (Details) Details 53 false false R54.htm 2408403 - Disclosure - Balance Sheets Details - Schedule of Inventory Components (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsScheduleOfInventoryComponentsDetails Balance Sheets Details - Schedule of Inventory Components (Details) Details 54 false false R55.htm 2408404 - Disclosure - Balance Sheets Details - Property and Equipment, net (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsPropertyAndEquipmentNetDetails Balance Sheets Details - Property and Equipment, net (Details) Details 55 false false R56.htm 2408406 - Disclosure - Balance Sheets Details - Narrative (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsNarrativeDetails Balance Sheets Details - Narrative (Details) Details 56 false false R57.htm 2408407 - Disclosure - Balance Sheets Details - Accrued Liabilities (Details) Sheet http://www.codexis.com/role/BalanceSheetsDetailsAccruedLiabilitiesDetails Balance Sheets Details - Accrued Liabilities (Details) Details 57 false false R58.htm 2411402 - Disclosure - Stock-based Compensation - Narrative (Details) Sheet http://www.codexis.com/role/StockBasedCompensationNarrativeDetails Stock-based Compensation - Narrative (Details) Details 58 false false R59.htm 2411403 - Disclosure - Stock-based Compensation - Stock-Based Compensation Expense (Details) Sheet http://www.codexis.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails Stock-based Compensation - Stock-Based Compensation Expense (Details) Details 59 false false R60.htm 2411404 - Disclosure - Stock-based Compensation - Assumptions Used (Details) Sheet http://www.codexis.com/role/StockBasedCompensationAssumptionsUsedDetails Stock-based Compensation - Assumptions Used (Details) Details 60 false false R61.htm 2411405 - Disclosure - Stock-based Compensation - Option Activity (Details) Sheet http://www.codexis.com/role/StockBasedCompensationOptionActivityDetails Stock-based Compensation - Option Activity (Details) Details 61 false false R62.htm 2411406 - Disclosure - Stock-based Compensation - Award Activity (Details) Sheet http://www.codexis.com/role/StockBasedCompensationAwardActivityDetails Stock-based Compensation - Award Activity (Details) Details 62 false false R63.htm 2412401 - Disclosure - Capital Stock (Details) Sheet http://www.codexis.com/role/CapitalStockDetails Capital Stock (Details) Details http://www.codexis.com/role/CapitalStock 63 false false R64.htm 2413401 - Disclosure - 401(k) Plan (Details) Sheet http://www.codexis.com/role/A401KPlanDetails 401(k) Plan (Details) Details http://www.codexis.com/role/A401KPlan 64 false false R65.htm 2414402 - Disclosure - Income Taxes - Components of Loss Before Provision for Income Taxes (Details) Sheet http://www.codexis.com/role/IncomeTaxesComponentsOfLossBeforeProvisionForIncomeTaxesDetails Income Taxes - Components of Loss Before Provision for Income Taxes (Details) Details 65 false false R66.htm 2414403 - Disclosure - Income Taxes - Components of Provision for Income Taxes (Details) Sheet http://www.codexis.com/role/IncomeTaxesComponentsOfProvisionForIncomeTaxesDetails Income Taxes - Components of Provision for Income Taxes (Details) Details 66 false false R67.htm 2414404 - Disclosure - Income Taxes - Tax Rate Reconciliation (Details) Sheet http://www.codexis.com/role/IncomeTaxesTaxRateReconciliationDetails Income Taxes - Tax Rate Reconciliation (Details) Details 67 false false R68.htm 2414405 - Disclosure - Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Sheet http://www.codexis.com/role/IncomeTaxesComponentsOfDeferredTaxAssetsAndLiabilitiesDetails Income Taxes - Components of Deferred Tax Assets and Liabilities (Details) Details 68 false false R69.htm 2414406 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.codexis.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 69 false false R70.htm 2414407 - Disclosure - Income Taxes - NOL Carryforwards and Federal Research and Development Tax Credits (Details) Sheet http://www.codexis.com/role/IncomeTaxesNolCarryforwardsAndFederalResearchAndDevelopmentTaxCreditsDetails Income Taxes - NOL Carryforwards and Federal Research and Development Tax Credits (Details) Details 70 false false R71.htm 2414408 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Sheet http://www.codexis.com/role/IncomeTaxesReconciliationOfUnrecognizedTaxBenefitsDetails Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) Details 71 false false R72.htm 2415402 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.codexis.com/role/CommitmentsAndContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 72 false false R73.htm 2415403 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Leases (Details) Sheet http://www.codexis.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderLeasesDetails Commitments and Contingencies - Future Minimum Payments Under Leases (Details) Details 73 false false R74.htm 2415404 - Disclosure - Commitments and Contingencies - Other Commitments (Details) Sheet http://www.codexis.com/role/CommitmentsAndContingenciesOtherCommitmentsDetails Commitments and Contingencies - Other Commitments (Details) Details 74 false false R75.htm 2415405 - Disclosure - Commitments and Contingencies - Credit Facility (Details) Sheet http://www.codexis.com/role/CommitmentsAndContingenciesCreditFacilityDetails Commitments and Contingencies - Credit Facility (Details) Details 75 false false R76.htm 2416401 - Disclosure - Related Party Transactions (Details) Sheet http://www.codexis.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.codexis.com/role/RelatedPartyTransactions 76 false false R77.htm 2417402 - Disclosure - Segment, Geographical and Other Revenue Information - Narrative (Details) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationNarrativeDetails Segment, Geographical and Other Revenue Information - Narrative (Details) Details http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationTables 77 false false R78.htm 2417403 - Disclosure - Segment, Geographical and Other Revenue Information - Segment Reporting (Details) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationSegmentReportingDetails Segment, Geographical and Other Revenue Information - Segment Reporting (Details) Details 78 false false R79.htm 2417404 - Disclosure - Segment, Geographical and Other Revenue Information - Concentration Risk (Details) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationConcentrationRiskDetails Segment, Geographical and Other Revenue Information - Concentration Risk (Details) Details 79 false false R80.htm 2417405 - Disclosure - Segment, Geographical and Other Revenue Information - Revenues (Details) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationRevenuesDetails Segment, Geographical and Other Revenue Information - Revenues (Details) Details http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationTables 80 false false R81.htm 2417406 - Disclosure - Segment, Geographical and Other Revenue Information - Goodwill (Details) Sheet http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationGoodwillDetails Segment, Geographical and Other Revenue Information - Goodwill (Details) Details http://www.codexis.com/role/SegmentGeographicalAndOtherRevenueInformationTables 81 false false R82.htm 2420402 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.codexis.com/role/SubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 82 false false All Reports Book All Reports cdxs-20181231.xml cdxs-20181231.xsd cdxs-20181231_cal.xml cdxs-20181231_def.xml cdxs-20181231_lab.xml cdxs-20181231_pre.xml http://fasb.org/us-gaap/2018-01-31 http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 107 0001200375-19-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001200375-19-000005-xbrl.zip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end

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